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ABSTRACT 
 
Ovarian cancer is called the “Silent Killer” as it is often diagnosed in advanced stages of the 
disease or misdiagnosed which ends with a poor prognostic outcome for the patient. A high 
rate of disease relapse, a high incidence-to-mortality ratio as well as acquired multidrug 
resistance makes it necessary to find alternative diagnostic- and therapeutic tools for ovarian 
cancer. Nanotechnology describes molecular devices with at least one dimension in the sub-
1μm scale and has been suggested as a possible solution for overcoming challenges in cancer 
multidrug resistance as well as early diagnosis of the disease. One-pot synthesized gold 
nanoparticles were used to demonstrate in vitro drug delivery of doxorubicin in a manner 
which overcame the cytoprotective mechanisms of a multidrug resistant ovarian carcinoma 
cell line (A2780cis) by inducing apoptosis mediated by caspase-3 within 3h of treatment. The 
gold nanoparticles were further functionalized with nitrilotriacetic acid and displayed specific 
interaction with a 6xHis-tagged cancer targeting peptide, chlorotoxin. Proprietary indium 
based quantum dots were functionalized with the same surface chemistry used for gold 
nanoparticles and bioconjugated with chlorotoxin. Wide field fluorescence studies showed 
the peptide-quantum dot construct specifically targeted enhanced green fluorescent tagged 
matrix metalloproteinase-2 transfected A2780cis cells in a specific manner. The 
cytoprotective multidrug resistant mechanisms of the ovarian carcinoma was overcome 
successfully with a single dose of doxorubicin loaded gold nanoparticles and tumour specific 
targeting was demonstrated using quantum dots with a similar surface chemistry used for the 
gold nanoparticles.   
 
Chapter 1 is a literature overview of ovarian cancer with regards to statistics, therapeutic 
strategies, metastasis and mechanisms of acquired drug resistance. A cancer specific protease 
enzyme associated with metastasis, matrix metalloprotease-2 (MMP-2), and the highly 
specific interaction with a small venom peptide, chlorotoxin, was discussed with focus on 
cancer diagnostics as well as therapeutic targeting. The topic of nanotechnology was also 
discussed with a more topical review of gold nanoparticles and quantum dots. Applications of 
nanotechnology as proposed anti-cancer theranostic tools were also highlighted. 
 
Chapter 2 describes the materials and methods used for this study. 
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Chapter 3 focused on the cloning, bacterial expression as well as the purification of the small 
venom peptide, chlorotoxin (CTX). A truncated C-terminal enhanced green fluorescent 
protein (EGFP) tagged MMP2 vector was transfected into A2780 cells for stable expression 
of the tMMP2-EGFP product. Quantum dot functionalized CTX demonstrated specific co-
localization with tMMP2-EGFP during wide field fluorescence microscopy studies. The CTX 
interaction with recombinant MMP2 was investigated by enzyme kinetics which suggested an 
uncompetitive inhibition mechanism. Both experiments confirmed the interaction between 
CTX and MMP2, where the interaction was questioned in a recent publication. 
 
Chapter 4 described the synthesis, functionalization and physicochemical characterization of 
ligands as well as nanoparticles utilized in this study. The gold nanoparticles were evaluated 
for colloidal stability in solution, with and without doxorubicin covalently loaded bound to 
the nanoparticle surface. The drug loading capacity of the gold nanoparticles were evaluated. 
Techniques used in this chapter included UV-Vis spectroscopy, high resolution transmission 
electron microscopy, energy-dispersive X-ray dispersive spectroscopy and fluorescence 
emission spectroscopy. 
 
Chapter 5 focused on the in vitro drug delivery of gold nanoparticles surface functionalized 
with doxorubicin. A possible mechanism for the induced cell death was investigated and 
proposed to be caspase-3 mediated in response to oxidative stress within 3h of treatment. The 
sub-cellular localization of the gold nanoparticles was investigated by transmission electron 
microscopy and demonstrated peri-nuclear as well as cytoplasmic loci. Techniques used in 
this chapter included immunoblotting, luminescence- and colorimetric detection assays. 
 
Chapter 6 is the overall discussion of the research conducted, followed by a conclusion and 
suggested future work. 
 
Keywords: ovarian cancer, matrix metalloproteinase-2, multidrug resistance, gold 
nanoparticles, quantum dots, doxorubicin, synthesis, polyethyleneimine 
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Chapter 1: Literature   Review 
1.1 Introduction 
1.1.1 Cancer: Overview of the Collective Noun 
Cancer, as a disease, is a collective noun for a group of related diseases where normal cellular 
proliferation and division becomes abnormal. Altered molecular events prevent the cell from 
responding to inhibitory signals during the cell cycle checkpoints [1, 2]. Cellular 
immortalization takes place with loss of original cellular function and the cell will continue to 
proliferate, divide and confer the same ability to daughter cells which developed further 
abnormalities, resulting in tumour formation or tumourigenesis [1, 2].  If a tumour is not 
invasive to other tissues it is a benign tumour. If a tumour is invasive to nearby tissues or 
organs, the tumour is classified as malignant. Tumourigenesis should not be confused with 
carcinogenesis, in which the origin of a tumour can be traced directly to a relationship with a 
specific carcinogen [2].  Cancer has no specific identified individual cause where prevention 
is unlikely, but it has been suggested that altering lifestyle can act as a preventative measure 
[3-5]. Genetic inheritance can predispose an individual to developing certain types of cancer. 
Should a proto-oncogene or tumour suppressor gene be affected by a mutation, the risk of 
cancer can increase [1, 3-5]. The following non-inherited factors have been found to also play 
a role in tumour initiation:  
(i) Lifestyle factors – viral sexually transmitted disease, diet, alcohol consumption 
and smoking tobacco products [2, 4, 5];  
(ii) Gender – hormone specific cancers, e.g. testosterone or oestrogen dependant 
cancers and [1, 2];  
(iii) Environmental factors – biological toxins, chemical carcinogens or ultraviolet 
irradiation [2, 4, 5].  
 
The traditional theory of somatic mutation being the only origin of cancer has fallen out of 
favour, as genetic events alone cannot explain the inherent complexity of cancer as shown by 
the genetic diversity of cells within the same tumour [1, 2, 6]. This paradigm shift is slowly 
replacing traditional views of cancer molecular biology. 
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1.1.2 The Statistics of Cancer 
Global cancer statistics (GLOBOCAN) aim to consolidate data generated in different 
countries as well as the World Health Organization (WHO) to represent a uniform dataset. By 
time of going to press, the most recent worldwide consolidated published and peer reviewed 
cancer data set was for 2008. In 2008 12.7 million new cases of cancer were diagnosed 
globally and 7.6 million deaths were attributed to cancer in that same year, with 70% of these 
deaths in middle- to low income countries [7]. An estimated cancer related death toll of 13.1 
million is being expected in 2030 according to the WHO [8]. The three cancers with the 
highest incidence of mortality for all ethnic groups and genders in 2008, expressed as 
percentage of total cancer deaths, were lung (18%); stomach (9.6%) and liver cancer (9.1%) 
[7, 8]. Breast cancer had the highest incidence of mortality in developing countries (Africa, 
Asia and South America) [7, 8]. Global incidence of cancer diagnosis as a collective disease 
for 2008 can be seen in Figure 1.1. North America, Western Europe and South-Central Asia 
had the highest diagnosis rates. Southern Africa and Middle Africa had comparative low 
incidences of cancer when compared to the developed countries. 
 
Figure 1.1: Incidence of new cases of cancer worldwide in 2008 (Global Cancer Facts and Figures, 2
nd
 Ed). 
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1.2  Ovarian Cancer: A Model for Therapeutics Development and Multi-
drug Resistance Studies 
1.2.1 A Statistical Perspective on Ovarian Cancer 
At the end of 2011, ovarian cancer was the 8
th
 most common diagnosed cancer in women 
(±250 000) in the North America with ±140 000 deaths reported, and ±24 000 new cases each 
year since 2008 [7, 8]. Also in 2011, it was the 5
th
 most common diagnosed cancer in women 
in Europe with ±41 500 deaths reported in 2008 [7, 8]. 
 
Ovarian cancer presents with a high cancer dormancy rate post-treatment and presents with 
disease relapse within 15 months of initial diagnosis [9-12]. The North American 5 year 
survival rate of 30-45% for ovarian cancer is comparatively a low survival rate compared to 
the 5 year survival rate for breast cancer which is 89%, which is attributed to ovarian cancer 
being detected only in advanced stages [7, 9-12]. Survival rates for ovarian cancer may be 
higher in cases where diagnosis occurs in the early stages of the cancer [10-12]. In 
examination of Figure 1.4, it becomes clear that the mortality-to-diagnosis rate (per 100 000 
population) of ovarian cancer is higher than the same ratio for breast cancer in North 
America, with women from Caucasian and African decent being most effected. Ovarian 
cancer has been identified by the WHO as the “Silent Killer”. 
 
Reliable statistical data of ovarian cancers relevant to the diverse multicultural South African 
population was not available. The statistical information was either outdated or non-
informative. North America is a multi-cultural society and an argument can be made for data 
extrapolation to South Africa. If the socio-economic environment, traditional cultural beliefs 
as well as accessibility to proficient medical care are taken into consideration it begs to raise 
the question how many cases of ovarian cancer remains misdiagnosed or not diagnosed at all. 
Further, affordable medical care in the case of a cancer diagnosis is not available to the 
majority of South Africans. In the next sections, aspects of ovarian cancer will be discussed. 
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Figure 1.2: Comparative ovarian cancer and breast cancer diagnosis incidence and mortality rates for 
different ethnicities in North America. The diagnosis rate (per 100 000 population) for breast cancer (c) is 
higher than for ovarian cancer (a). When a comparison is drawn between the two cancers regarding 
mortality rates (per 100 000 population) in b) and d) it becomes clear that ovarian cancer has a higher 
mortality to diagnosis ratio than breast cancer, even across different ethnicities. (White – Caucasians; 
Black – African Americans; AI/AN – American Indian and Alaskan Native and Asian/PI – Asian and 
Pacific Islander). Figure obtained and modified from the North American Centre for Disease Control [9]. 
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1.2.2 The Ovaries and Ovarian Cancer: Epidemiology and Pathology 
Two ovaries (Figure 1.3) form part of the female reproductive system and are responsible for 
female sex hormone production, ovum production and regulation of the menstrual cycle. 
Ovary based hormone production will decrease with an increase in age until cessation of the 
menstrual cycle takes place. Ovum formation and release involves the formation of cysts on 
either ovary where physical rupture of the cysts releases the ovum into the fallopian tubes and 
the ruptures heal [10]. When cysts are present post-menstruation, have abnormal size or 
texture, or found in post-menopausal women a high risk for developing ovarian cancer is 
probable [10-14]. Further risks factors that may indicate an increased risk are: human 
papilloma virus (HPV) infections [10, 11], endometriosis [10, 11, 13], being overweight or 
above average height [10, 11], early-onset menstruation [10, 11, 13], late-onset menopause 
[10, 13], advanced age [10, 13] and smoking tobacco [10]. 
                                                   
Figure 1.3: The female pelvic reproductive anatomy depicting the location of the ovaries (Image adapted 
from http://cancerhelp.cancerresearchuk.org). 
 
In 1971, Fathalla and co-workers [15] hypothesized that accumulated repeated ovulation 
during a lifetime increased the risk for developing ovarian cancer. Selective apoptosis 
combined with cellular/DNA repair can increase the risk of developing chance mutations in 
the localized genome. This can be exacerbated by hormonal therapy, hyper ovulation and 
even diurnal disturbances. This hypothesis gained some evidence with observations by 
Fathalla et al, where hens developed peritoneal cancers under various hormonal treatments 
[15]. A familial history of ovarian cancer or breast cancer in two or more relatives indicates 
an increased risk of developing ovarian cancer [10-12, 16]. Mutations in the oncogenes 
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BRCA1 or BRCA2 are prognostic for a 23-54% increased chance of developing ovarian 
cancer [10-12, 14, 16]. 
 
Tumours can develop on the surface (epithelial cells) of the ovaries or the inside of the 
ovaries (germ cells and stromal cells).  One or both ovaries can be affected. There are two 
main classifications of ovarian cancer, namely ovarian cancer of epithelial origin that makes 
up 90% of cases and the other 10% of ovarian cancer cases include germ cell cancer and 
sarcomas [10-12]. Only 5% of epithelial cancers are attributed to inheritance of a penetrative 
allele [10, 16]. Epithelial ovarian cancers (EOC) are further classified into serous; mucinous; 
endometrioid; clear cell; undifferentiated and unclassifiable cancers [10-12]. Epidemiological 
data suggests that the overwhelming majority of EOCs are serous in nature and defy the 
multistep model of tumourigenesis and are all treated as the same disease [10-12]. For the 
purposes of this review, the same assumption will be made regarding EOC.  
 
Early stage symptoms of EOC are vague and ambiguous. The ovaries are located in the 
abdomen and as such any associated pain or discomfort can be mistaken for a benign 
condition, e.g.: pain in the lower abdomen, lower back pain and feeling bloated. Late stage 
symptoms are equally non-specific where abdominal pains, nausea, lower back pain, 
bloating, urinary tract symptoms, constipation, painful sexual intercourse, irregular periods 
and post-menopausal vaginal bleeding is predominant [10-14]. Cancer antigen 125 (CA-125), 
a surface glycosylated-protein, can be used as a disease biomarker, but unfortunately elevated 
serum levels of CA-125 do not always present in all cases of ovarian cancer with 
epidemiological data suggesting that detection is only significant in very late disease stages 
(III and IV) [10-12, 17]. CA-125 serum levels are more pronounced in late stages of the 
disease or for disease relapse, even if it was not present during initial diagnosis [10, 17]. 
Some findings demonstrated that CA-125 can present up to 9 months before macroscopic 
evidence of relapse is detectable [10, 17]. Other karyotyping techniques are less specific than 
CA-125 [10, 17]. Computerized Axial Tomography (CAT) scan [10, 14], ultrasound [10], x-
ray imaging [10, ] and explorative surgery (laparotomy) [10, 11, 18, 19] are the most reliable 
diagnostics tools for late stage detection but are still prone to a very high rate of 
misdiagnosis. All these techniques rely on how well a clinician can interpret the data. The 
same techniques are employed in determining the success of treatment and the rate of relapse, 
in which case the disease has become incurable [10-12, 17, 18]. Successful diagnosis 
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typically detects 70% of women in stage III or IV which leaves a poor prognosis for the 
patient [9-14, 18]. 
 
Ambiguous symptoms, ineffective screening technologies, invasive medical examinations, a 
high rate of misdiagnosis and a high incidence of disease relapse all accumulate into a poor 
prognosis for the patient. It becomes clear why ovarian cancer has such a comparative high 
mortality rate and a poor survival rate. In the next paragraph focus will be given to the current 
treatment strategies for EOC. 
 
1.2.3 Current Treatment Strategies for Epithelial Ovarian Cancer (EOC) 
Several factors play a crucial role when a clinician determines treatment strategies for ovarian 
cancer. Surgery is utilized for tumour debulking and complemented post-surgery with 
chemotherapy [18]. This is not always successful and neo-adjuvant strategies (chemotherapy 
pre-surgery) facilitate tumour shrinkage for ease of surgical excision [19]. Treatment should 
aim to improve the quality of life, delay the onset of symptoms related to disease progression 
and improve the survival rate of patients [10, 17-19]. Treatment strategies depend on: 
(i) Tumour size [10, 18, 19]: The grade and stage of the tumour is under 
consideration. Early stage tumours can be treated without surgery if adequate 
chemotherapy strategies available. A tumour 5 cm in diameter is considered 
advanced. A malignant (invasive) tumour will typically be surgically excised. 
(ii) Tumour position [10, 18, 19]: Metastasis, vascularity and accessibility of the 
tumour to excision will be evaluated. If the tumour is surgically inaccessible or 
excessive bleeding will follow as a result, chemotherapy and radiotherapy are the 
only options.  
(iii) The physical condition of the patient [10, 18, 19]: The clinician will evaluate the 
patient’s chance of surviving the surgery as well as recuperation ability. If the 
tumour is too far advanced, the clinician will only provide pain management 
measures. 
 
It is feasible that the physician would also consider the mental and emotional condition of the 
patient as well as the wishes of the patient. It remains the prerogative of the patient to refuse 
treatment.  The treatment options with regards to surgery and selected chemotherapies will be 
discussed in the following paragraphs. 
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1.2.3.1 Surgery 
The physician will recommend that both ovaries and the uterus be removed (hysterectomy) 
unless childbirth is desired. Both ovaries will be removed, even if only one presents with a 
tumour growth, in a procedure termed a bilateral oophorectomy [18, 19]. Hormone 
replacement therapy will be recommended by most clinicians, post-chemotherapy [10, 18-
20]. Excision of the tumour mass can lead to spontaneous metastasis which necessitates 
follow-up treatments with chemotherapeutics [10, 18-20]. Various internet-based ovarian 
cancer support groups suggest psychological counselling in the case of surgery. The 
hysterectomy and oophorectomy procedures are traumatic events which can exert a severe 
emotional and psychological stress on an individual.     
 
1.2.3.2 Chemotherapy: Traditional Clinical Compounds 
Chemotherapy is the utilization of small molecule-compounds that are administered orally, 
topically, intravenously or intra-peritoneal for the treatment of cancerous tissue [10, 20, 21]. 
Cancerous as well as non-cancerous cells are affected equally and even with tumour-specific 
targeting healthy tissue can still be affected presenting with side-effect symptoms such as 
nausea; vomiting; hair and nail loss; weight loss; cardiac complications; renal failure; hepatic 
failure and a compromised immune system [10, 20, 21]. Selected classes of anti-cancer 
compounds as applicable to this project will be briefly discussed in the following paragraphs. 
 
1.2.3.2.1 Platinum-(IV) Compounds 
Platinum-(IV) complexes have been used in combination therapy with alkylating agents as 
primary treatment for ovarian cancer and other epithelial cancers since the mid 1980’s [20, 
21]. Administration is intravenous or intra-peritoneal with systemic circulation time and half-
life times being formulation specific [10, 20, 21]. These compounds all show poor aqueous 
solubility, poor cellular uptake which is also associated with neurotoxicity and nephrotoxicity 
[10, 22-24]. Modern analogues of these compounds show improvement of the aqueous 
solubility, lipophilic character and incorporate targeted delivery of these compounds to 
cancerous tissue [22, 24, 25].  
 
Platinum-(IV) is reduced to platinum-(II) in the cellular milieu, activating the anti-cancer 
activity. The cis-position (Figure 1.4) of the chlorine atoms (electron withdrawing atoms) and 
primary amine molecules (electron donating molecules) facilitate the bio-reduction. Cell 
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ular uptake of compounds with a lipophilic character is optimal where there are sufficient 
electron donating groups for bio-reduction, such as primary amines (NH2) and their 
derivatives [22]. 
                         
Figure 1.4: Examples of platinum-(IV) compounds used as chemotherapy agents. A motif shared by all 
molecules are the chlorine atoms (Cl) and primary amine molecules (NH2) being in cis-positions. Figure is 
taken from [22]. 
 
Platinum-(II) forms cross-strand adducts with DNA, specifically on the adenine and guanine 
residues. This effectively destabilizes the double helix structure and acts as a steric hindrance 
to DNA-associated proteins [10, 22, 24]. Sulfhydryl (-SH) containing biomolecules have a 
high reactivity towards platinum-(II) and will form a covalent bond, nullifying the anti-cancer 
activity of the platinum-(II) compound [22, 24, 25]. EOC readily acquire drug resistance to 
treatment with platinum compounds, in some instances developing cross resistance [10, 18-
21, 24, 25] and will be discussed in Section 2.4. 
 
1.2.3.2.2 Anthracycline Anticancer Antibiotics: Adriamycin (Doxorubicin, 
DOX)  
Doxorubicin (Adriamycin, 14-OH Daunomycin, DOX) is a potent anticancer antibiotic from 
the anthracycline class of molecules (Figure 1.5), produced by the fungus Streptomyces 
peucius [26]. DOX is used in the treatment of a variety of cancers: epithelial, endothelial and 
leukaemia [10, 26]. Mono- and combination therapy of DOX have been utilized for ovarian 
cancers since 1995 and was found to cause a lowered rate of disease relapse [10, 20-22, 26]. 
Currently all approved DOX formulations approved by the North American Food and Drug 
Administration (FDA) are under patent by Pfizer. Tissue distribution of the active metabolite 
indicates 50% bio-availability with systemic spread to all major organs and tissues with 
inactive doxorubicin excreted in the biliary system [26]. 
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Figure 1.5: The structure of anthracycline anti-tumour antibiotics. Each analogue has a similar 
mechanism of anticancer activity, with carminomycin having the lowest systemic toxicity (A – cyclo-
hexane ring; B – hydroquinone ring; C – semiquinone ring; D – phenyl ring). Figure is taken from [27]. 
 
There are two routes of administration according to the Pfizer CCO formulatory for 
physicians [26]:  
(i) Intravenous as a bolus, at a dosage between 10 mg/m2 to 75 mg/m2 and a half-life 
of 20 - 48 hours. The treatment frequency is dependent on the patients’ physical 
condition, but not more than once a week as a recovery period is required.  
(ii) Intravesicle by bladder instillation, 50-100 mL, at a dosage of 50-80 mg/m2 with 
subsequent bladder voiding after two hours. Frequency of administration is 
dependent on similar criteria as in (i). 
 
Suggested mechanisms for DOX anti-cancer activity based on in vitro and in vivo models are: 
(1) DNA-intercalation (guanine and cytosine residues) and induction of single and double 
strand breaks [27, 30, 31]; (2) hydrogen-peroxide (H2O2) and / or superoxide (O2
·-
) induced 
generation of oxygen- and nitrate free radicals [27, 28, 29]; (3) oxidative stress induced DNA 
mutagenesis [28, 30, 31]; (4) loss of mitochondria inner membrane potential [28, 30] and (5) 
inhibition of topoisomerase II [27, 31]. Patients have presented with side-effects related to 
cardiotoxicity, nephrotoxicity and hepatotoxicity as well as contact necrosis at site of 
administration [26]. Various in vitro and in vivo studies suggested that co-administration with 
reduced glutathione (GSH) [32], propionyl-L-carnitine [33] and L-carnitine [34] prevented 
cardiotoxicity and nephrotoxicity. In vitro genetics studies found that overexpression of 
peptides from the metallothionein family negates overall DOX associated toxicity [35]. 
Cross-reactivity with a host of other medications, food related compounds and bio-molecules 
have been extensively reported [34]. Ovarian epithelial cancers develop acquired drug 
resistance to DOX treatment [10, 21, 31] and will be discussed in section 2.4. Doxil
®
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(Caelyx) is a pharmaceutical grade nanoparticle based liposomal formulation with a 
decreased systemic toxicity and enhanced anti-cancer efficacy which has replaced traditional 
DOX therapy for ovarian- and other cancers [10, 11, 21, 36, 37]. 
 
1.2.3.3 Alternative Chemotherapeutics Treatment Strategies 
No single treatment or specific combinations of treatments are equally effective in cancer 
therapy and as such adaptive strategies should be adopted for successful cancer therapeutics. 
There are many classes of chemotherapy agents available to physicians to treat ovarian 
cancers. They are typically used in combination therapy based on the required pharmacology 
effect required by physicians. A few will be briefly mentioned: 
(i) Taxanes (e.g. Paclitaxel/Taxol): Alkylating reagents that target microtubules and 
polarizes tubulin, interfering with mitosis [10, 11, 38, 39]. 
(ii) Anti-angeogenics (e.g. Avastatin): Compounds that prevent or inhibit the 
formation of new tumour vasculature. Subsequently this induces tumour hypoxia 
and nutrient starvation [10, 20, 21, 39]. 
(iii) Anti-oestrogenics (e.g. Tamoxifen): This class of compounds bind to oestrogen 
receptors and prevent hormone dependent signalling. Growth and survival signals 
are thus inhibited [13, 20, 21, 23, 39]. 
 
1.2.4 Mechanism of Disease Progression: Metastasis and Acquired Multidrug 
Resistance of Epithelial Ovarian Cancer 
1.2.4.1 Metastasis of Epithelial Ovarian Cancer (EOC) 
The multi-step hypothesis of tumourigenesis doesn’t fully explain the disease development 
and progression of ovarian cancer. Evidence points to a cancerous stem cell as the origin of 
the disease [1, 6, 40, 41, 43, 44]. Support for this theory is strengthened by the various 
histologically distinct subtypes of EOC (see section 2.2) as well as the pattern of disease 
progression to metastases having no set course as opposed to other types of non-ovarian 
cancers. This suggests a distinct early cellular differentiation event in tumour development 
[40-42, 44]. 
 
Metastasis (Figure 1.6A) describes the spread of a single tumour cell from the site of origin to 
a secondary adjacent locus in the body. Current understanding of metastasis is based on 
studies done in murine models with subsequent ex vivo immuno-histological examination of 
the tissues [40, 42-44]. In humans only the final stage of metastasis is observed, where the 
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degree of metastasis is directly associated with prognosis and survival [40-44]. Disease 
progression is divided into four stages according to the Federation Internationale de 
Ginecologie et d'Obstetrique (FIGO, http://www.figo.org): 
(i) Stage I – The cancerous tissue is confined to one or both ovaries and is treatable 
with chemotherapy.  
(ii) Stage II – The tumour has grown in size and proceeded to invade nearby tissues in 
the peritoneal cavity. Combination therapy is recommended. 
(iii) Stage III – The grade of the tumour has become aggressive with metastasis to the 
majority of the abdominal cavity and the lymphatic system. Combination therapy 
is recommended but prognostic outcome is poor with potential disease relapse.  
(iv) Stage IV – The final stage. Secondary tumour formation is found at distant organs 
not associated with the peritoneum.  
 
Feki et al demonstrated in a murine model the aggressive metastasis of ovarian cancer into 
the peritoneal cavity via the lymphatic system by using a lentiviral-green fluorescent protein 
(GFP) reporter construct with ex vivo analysis of fluorescence tissue distribution [45]. Based 
on murine models, metastasis occurs in three main stages (Figure 1.6, A and B) where the 
tumour cell has to (1) invade the vascular system, (2) survive extracellular pro-apoptotic 
signals and evade the immune system and (3) colonize a new secondary site by tissue 
invasion [45, 46]. The first and last steps of metastasis are dependent on the metastatic 
potential or invasiveness of tumour cells. Metastatic potential is determined by suppressors or 
inducers in signalling pathways, where the cumulative effect will determine how invasive a 
tumour will be [40, 43, 44]. Various suppressors have been identified e.g.: cadherin on the 
cell membrane, members of the Rho-family of proteins in the cytoskeleton or caspase-8 in the 
mitochondria [40, 43, 44, 47]. Altered gene expression patterns, epigenetic gene 
modifications as well as chance mutations have been implicated in the metastatic potential of 
ovarian tumours, being demonstrated in both in vitro and in vivo studies [40, 44, 45, 47]. 
Induction of metastasis in EOC is associated with extensive extracellular matrix (ECM) 
remodelling, where matrix metalloproteinase-2 (MMP2) was identified as being a crucial 
protease with a prognostic link to disease progression, increased tissue invasion and 
metastasis [47, 48]. MMP2 will be discussed more in-depth in 1.3. 
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Figure 1.6: Metastasis of EOC from the primary tumour to a new site. New paradigms suggest that 
tumour spheroids have a higher success rate of metastasis than single suspension cells (A). Spheroids will 
disassociate and spread along the mesothelial surface, eventually leading to tissue invasion and formation 
of a secondary tumour (B). Figure is taken and adapted from [46]. 
 
The second step of metastasis requires the tumour cell to evade the immune system 
(macrophages and natural killer cells) successfully by suppression of gene expression for 
antigens or death-ligand receptors [46, 49]. Figure 1.6A gives a graphical representation of 
the traditional view on metastasis and the new hypothesis of tumour spheroid migration. 
During detachment and migration, single cells in suspension are vulnerable to the immune 
system as well as chemotherapy. A spheroid structure provides the cancer cells protection in 
multilayer cocoon. This increases the survival rate of the cancer cells during progression of 
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metastasis significantly. The chance that cells at the core of the spheroid survive to invade 
new sites is enhanced. Multiple cells which express tissue invasion proteins have a higher 
success rate of establishing a secondary tumour. This is proposed to be a potential 
explanation for the aggressive and invasive nature of EOC [45]. A 2009 review by Shield and 
colleagues provided significant evidence to suggest that in the case of ovarian carcinomas, 
the tumour cells metastasize in a spheroid [46]. In 2003, Zhang et al applied immune-
histological techniques to examine tumour tissue isolated from cancer patients and came to 
the conclusion that tumour spheroids had a lower intra-tumour T-cell content than the rest of 
the cancerous tissue [48]. The outer layer of cells in the spheroid will be exposed to the 
immune system of chemotherapeutics. Based on the reported literature, it is feasible that the 
outer layer of tumour cells act as a protective layer for cells within the spheroid, effectively 
enhancing the survival and metastasis of the tumour.  
 
Acquired multidrug resistance as a tumour survival mechanism will be the focus of the next 
few paragraphs. 
 
1.2.4.2 Acquired Multidrug Resistance (MDR) in Epithelial Ovarian Cancer 
(EOC) 
Tumour acquired multidrug resistance is considered to be multifactorial in origin and 
associated with primary tumours with possible causes being (1) increased resistance to DNA 
damage [50-53], (2) increased DNA repair mechanisms [50-53], (3) direct inactivation of 
cytotoxic compounds [52, 53], (4) decreased cellular accumulation of cytotoxic compounds 
[50, 52, 53], (5) sequestration of cytotoxic compounds in intracellular vesicles [50, 52] and 
(6) avoidance of pro-apoptotic signals [50-53]. This will be discussed with the focus on 
platinum based compounds and doxorubicin. The main focuses of these studies are all based 
on in vitro models. The full complement of acquired multidrug resistance mechanisms 
mentioned above has been identified in EOC.  
 
1.2.4.2.1 DNA Repair Mechanisms and Gene Mutations 
MutL homologue-1 (MLH1) is a mismatch repair (MMR) protein and has been found to be 
epigenetic silenced in various in vitro EOC models of acquired drug resistance [54, 55]. A 
reduced ability to repair DNA strand breaks at 3' loci induces microsatellite instability and 
has been shown to increase drug resistance [54, 55] as well as impairment of apoptosis 
induction [54-56]. In contrast, in a 2006 study no correlation was found between inactivated 
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MLH1 and increased drug resistance. This study made use of quantitative real-time 
polymerase chain reaction (qRT-PCR) experiments on tissue obtained from 75 ovarian cancer 
patients on cisplatin treatment [56]. DNA alkylation and strand breaks are proposed 
mechanisms for platinum-compounds and doxorubicin (see 1.2.3). The overexpression of 
pro-apoptotic and inhibition of anti-apoptotic proteins failed to induce apoptosis in drug 
resistant MLH1 deficient A2780 cells [54, 55, 63]. Increased nucleotide excision repair 
(NER) has been shown to be the predominant DNA repair mechanism in drug resistant 
cancers and with NER inhibition the cells displayed increased sensitivity to cisplatin [55, 57].  
 
Mutations in essential and diverse cellular homeostasis genes and their protein products have 
also been linked to acquired multi drug resistance. Genes which have been found mutated in 
acquired MDR in EOC reported in the literature include DNA-topoisomerase II [51], Bcl-2 
protein family [58, 59] and caspases [60].  The regulators of caspase gene expression have 
been reported to inhibit apoptosis in cancer as well as lead to acquired multidrug resistance 
[61, 62]. In the case of acquired drug resistance for alkylating chemotherapeutics it was found 
that the levels of pro- and anti-apoptotic proteins did not play a role in the tumour cell 
survival [63], suggesting a re-evaluation of current dogmas. Mutations in the tumour 
suppressor p53 have been directly linked to multidrug resistance in EOC [64, 65].  In a 2001 
publication Reles et al identified through genetic studies that 110 of 178 (62%) EOC patients 
had several mutations in the exons as well as introns for p53 [65]. 
 
1.2.4.2.2 The Glutathione Pathway and Antioxidant Response to 
Cytotoxicity of Anti-cancer Compounds 
Glutathione (GSH) is the main cellular antioxidant defence molecule. It has a thiol (-SH) 
moiety with a strong nucleophilic character. Aqueous solubility is conferred by the 
carboxylic acid (-COOH) and primary amine (-NH2) groups. Glutathione pathways can be 
seen in Figure 1.7, where consumption and synthesis is depicted. Xenobiotic compounds, 
hydrophobic molecules and cytotoxic compounds can be glutathiolated [66]. This can be by 
direct nucleophilic substitution of the thiol moiety on reactive electrophilic centres or by 
enzymatic bioconjugation catalysed by glutathione-S-transferase (GST) [66]. The 
glutathiolated compounds will undergo exocytosis from the cell, either by passive means or 
facilitated in an ATP-dependent process by drug efflux pumps (Figure 1.8). Feedback 
inhibition determines glutathione metabolism and regulates the tempo of de novo synthesis, 
salvage and bio-conjugation (Figure 1.7). The role of glutathione synthesis and glutathione-S-
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transferase activity was implicated in the early 1990’s in the development of acquired drug 
resistance in ovarian cancers [67, 68]. The glutathione pathway plays a role in a larger 
antioxidant defence pathway which includes cytochrome p450, phase II detoxification 
enzymes, membrane transport proteins and cytoskeleton associated proteins.  
 
The whole antioxidant defence pathway is regulated by a transcription factor nuclear factor-
erythroid 2-related factor 2 (NRF2) [69, 70]. A study done in 2005 by Cho and colleagues on 
a murine model identified 446 genes directly associated with the transcription factor NRF2 
[69]. The antioxidant response element (ARE) is a DNA sequence on the promotor region of 
cyto-protective genes to which NRF2 will bind in response to oxidative stress. NRF2 was 
assumed to be induced by a chemo-preventative pathway. The assumption regarding NRF2 
has been called into question recently. In an invited review Lau et al proposed very strong 
evidence that indicates NRF2 may promote cancer disease progression, especially in response 
to chemotherapeutic compounds [71, 72]. This was supportive evidence for a 2009 
publication where Hayes et al found that somatic mutations in nrf2 as well as its inhibitor 
gene, keap1, may predispose an adaptive response to chemotherapy in the form of acquired 
drug resistance [70]. 
 
Evidence emerged for acquired doxorubicin resistance in ovarian carcinomas in 2009 when 
Shim et al demonstrated involvement of the NRF2 pathway. Increased antioxidant capacity 
paired with increased drug efflux was identified in the A2780 cell when it became drug 
resistant to doxorubicin. When NRF2 was knocked down using siRNA, the cells were 
sensitive to doxorubicin treatment again [72]. Nrf-2 regulates glutathione biosynthesis and 
glutathione redox-cycling independently [73], where up-regulation of both pathways is 
associated with increased- and acquired multidrug resistance [51, 66-68]. The result is a very 
active antioxidant defence mechanism which has an adaptive response to oxidative stress. 
 
The glutathione pathways are well characterized and form an essential part of any oxidative 
stress study. This makes the glutathione pathways an essential tool to investigate drug 
resistance as well as antioxidant capacity of cells. Glutathione is one of the many 
biomolecules which is involved in drug efflux (Figure 1.8), which will be the focus of the 
following section. 
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Figure 1.7: Glutathione metabolism and its role in the antioxidant defence of the cell (GSH – Reduced 
glutathione; GSSG – Oxidised glutathione). Figure is taken and adapted from [66]. 
 
 
1.2.4.2.3 Internalization, Transport and Efflux of Chemotherapeutic 
Compounds 
Efficacy of treatment with anticancer compounds requires adequate intracellular drug 
accumulation. Cellular membrane bound influx proteins such as copper transporter protein-1 
(CPR1) [74, 77] and the family of organic cation transporters (OCTs) [75, 77] were shown to 
facilitate cisplatin influx in the A2780 ovarian carcinoma cell line. With acquired drug 
resistance, these transporters will be internalized or inhibited at a translational level, 
effectively preventing cisplatin cellular internalization and accumulation [74-77]. Vacuole-
like structures (Figure 1.8) and other vesicles are used to sequester cytotoxic compounds and 
exocytose their contents, in an ATP-dependent manner, from the cell [75, 77]. The ATP-
binding cassette (ABC) transport protein family are ATP-dependent trans-membrane proteins 
which have been shown to decrease cellular drug accumulation for various anti-cancer 
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compounds [76, 77]. All members of this family can be induced by NRF2 in a tissue specific 
manner [69].  
 
Sensitivity to liposomal doxorubicin treatment was enhanced in an in vitro A2780 cell line by 
using antisense oligonucleotides targeted to MRP1-mRNA and Bcl-2-mRNA. Western 
blotting and fluorescence microscopy confirmed decreased protein expression, enhanced 
cellular doxorubicin accumulation and apoptosis induction [78]. Annexin A3 was identified 
as a new biomarker for multidrug resistant ovarian cancer when Yan and colleagues found 
elevated mRNA and protein in various models: in vitro, in vivo murine and in cancer patient 
tissue samples [79]. Decreased cellular accumulation of cisplatin was associated with 
increased expression of Annexin A3, suggesting a drug efflux role for this protein. It was 
reported to be present in the urine of prostate cancer patients, but no study has yet 
investigated if similar findings have been found for ovarian cancer. 
         
          
Figure 1.8: A simplified schematic representation of the fate of chemotherapeutic compounds in a MDR 
cancer cell. A drug (green sphere) internalize passively by diffusion, endocytosis or active transport. In 
multidrug resistant cancer cells the drug will be either sequestered in vesicles to be shielded away from 
the cytoplasm or the drug will be inactivated. The inactivation will be either enzymatic or by 
bioconjugation (blue rectangle). Exocytosis or active transport will be the mechanisms by which the 
drug will be transported out of the system. 
 
Ovarian cancers adapt with consecutive treatments to obtain acquired multidrug resistance. 
This is true especially for disease relapse, such as with EOC. Mortality is directly correlated 
to acquired multidrug resistance and late stage initial disease diagnosis. Socio-economic 
factors are implicated to play a significant role in timely cancer diagnosis. If the disease 
cannot be diagnosed in an early stage, improvement of treatment strategies should be an 
alternate focus area.      
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1.3 The Role of Matrix Metalloproteinase-2 (MMP2) in Epithelial 
Ovarian Cancer 
1.3.1 Matrix metalloproteinase-2: Nomenclature, Structure and Function 
 Matrix metalloproteinase-2 (Gelatinase A / Collagenase IV, EC 3.4.24.24) is a soluble 
72kDa enzyme which is part of a family of zinc-dependent proteases [80, 81, 86]. This 
endopeptidase is secreted as an inactive pro-enzyme (zymogen, Figure 1.9) in mesenchymal 
and epithelial cells during tissue development and extracellular matrix remodelling [80, 81]. 
MMP2 recognises the following amino acid motif: Pro-Gln-Gly-/-Ile-Ala-Gly-Gln [81,82]. 
Cleavage takes place between the glycine (Gly) and isoleucine (Ile) residues in the above mentioned 
motif. Substrates which have been identified for MMP2 include collagen type IV [80-82, 92], 
collagen type V [82, 83, 92], gelatin [80-83, 92], fibronectin [82, 83, 92] and elastin [82, 83, 
92]. Collagen type IV forms part of the basement membrane of the extracellular matrix 
(Figure 1.8). Serum- and tissue MMP2 activity appears to be directly correlated to a poor 
prognosis for cancer patients [47, 48, 84, 86] and MMP2 has been identified as a key role-
player in extracellular matrix remodelling [80, 81, 83, 92], cell detachment from the primary 
tumour [84, 86, 92], angiogenesis [83, 84, 86, 92], tissue invasion [83, 84, 86, 92] and 
avoidance of apoptosis [84, 92]. Solid tumours of epithelial origin are particularly associated 
with MMP2 dependent disease progression [84, 86, 92]. A range of solid and metastatic 
tumours in which MMP2 mRNA and MMP2 protein were reported can be seen in Table 1. 
Cardiovascular disease [96, 97] and HIV-associated neuroencephalopathy [98, 99] have 
shown to have a direct correlation between MMP2 activity and a poor prognostic outcome as 
well.    
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Figure 1.9: The structure of pro-MMP2. The catalytic domain (magenta) has two zinc cations (red) and 
two calcium cations (purple) bound. The C-terminal hemopexin domain (yellow) has one calcium cation 
(purple) bound and is exposed to the cytoplasm when the protein is in a transmembrane position. Figure is 
taken from [80]. 
 
 
Table 1.1: Matrix metalloproteinase-2 expression in solid- and metastatic tumours  
Cancer Type Tissue Type mRNA Protein Reference 
Ovarian Human Biopsy; in vitro ⬆ ⬆ [85, 86] 
Melanomas In vitro; in vivo ⬆ ⬆ [87, 88] 
Brain Human Biopsy; in vitro ⬆ ⬆ [88, 90, 95] 
Breast Human Biopsy; in vitro ⬆ ⬆ [86, 90, 91, 95] 
Cervix Human Biopsy; in vitro ⬆ ⬆ [86, 90] 
Prostate Human Biopsy; in vitro ⬆ ⬆ [86, 90, 92, 95] 
Renal And Bladder Human Biopsy; in vitro ⬆ ⬆ [86] 
Lung Human Biopsy; in vitro ⬆ ⬆ [86, 95] 
Head And Neck Human Biopsy; in vitro ⬆ ⬆ [86, 90] 
Gastrointestinal Human Biopsy; in vitro ⬆ ⬆ [86, 93, 94, 95] 
Testes In vitro ⬆ - [90] 
Bone In vitro ⬆ - [90, 95] 
Eye In vitro ⬆ - [90] 
Thyroid In vitro ⬆ - [95] 
Leukemia In vitro ⬆ - [95] 
*⬆ indicates an increase in the respective intracellular level  
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During protease activation (Figure 1.10) the signalling peptide and pro-domain will be 
cleaved, yielding a mature protease of ~62kDa [85, 93]. It has been shown that autolytic 
cleaved variants of MMP2 (68kDa [99], 58kDa [90, 93], 54kDa [90], 50kDa [99] and 44kDa 
[99]) still retain catalytic activity. Three fibronectin domains are embedded in the catalytic 
domain which allow for substrate binding [80]. In the pro-enzyme the cysteine residues are 
bound covalently to the Zn
2+
-binding sites to prevent autocatalytic activation [80, 82]. A C-
terminal hemopexin-like domain contains a Ca
2+
-binding site and is linked to the catalytic 
domain by a hinge region [80, 82]. The hemopexin domain structure is speculated to 
determine the substrate specificity and is cytoplasmic orientated in the event that MMP2 is in 
a transmembrane position [80]. MMP2 activity is optimal at physiological pH to mildly basic 
conditions at 37 
 
 C [82, 98].  
 
 
Figure 1.10: The activation of pro-MMP2 by MT1-MMP on the cell plasma membrane. Active MMP2 will 
degrade collagen and gelatin in the extracellular matrix. Figure is taken from [86]. 
 
There is discrepancy as to where pro-MMP2 is sequestered within the cell, as it can be 
activated by various cytosolic proteases [86, 100]. MMP2 has been implicated in PARP-
cleavage during apoptosis which implies nuclear translocation and catalytic activation 
[97].The natural inhibitor of MMP2 is tissue inhibitor of MMP2 (TIMP-2) which binds to the 
protease in the hemopexin domain [80, 82, 101]. The pro-enzyme and mature enzyme can 
also be found as part of a trans-membrane protein complex with TIMP-2 and membrane type 
1 matrix metalloproteinase (MT1-MMP) in close proximity to the integrin αVβ3 (Figure 1.10) 
[85-87, 102-104].The trans-membrane complex bound pro-enzyme will stay inactive in a 
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stoichiometric ratio of 1:1 with TIMP-2 [86, 101]. Overexpression of pro-MMP2 or 
decreased expression of TIMP-2 will facilitate MMP2 catalytic activation by MT1-MMP 
[102-104]. Mature MMP2 can be secreted into the extracellular matrix or be internalized into 
the intracellular environment [86, 102-104]. Proteolytic activity of MMP2 is delicately 
regulated on transcriptional- and post-translational level. Phosphorylation has been identified 
to play regulatory roles in zymogen transcription and translational activation [105] where 
ERK1/2 and p38-MAPK have also been implicated [106]. Increased superoxide dismutase 
transcription and translation increased MMP2 mRNA levels [107]. Non-enzymatic activation 
of MMP2 can be induced by organomercurial compounds [80] and sulfhydryl (SH) 
containing molecules [80]. 
 
The substrate specificity of MMP2 has allowed for the development of colorimetric- [81] and 
fluorometric [82] peptide-based probes as well as various inhibitors [108, 109], which has 
been utilized in in vitro-based diagnostics as well as in vivo tumour imaging. These probes all 
employ variations on the fluorescence resonance energy transfer (FRET) technique. MMP2 
synthetic inhibitors showed promise in vitro but were less effective for in vivo models and 
clinical trials and were less effective in cases where the disease was in advanced stages [108-
110]. Similarly antibody-based therapeutic targeting was promising by using anti-MMP2 
drug delivery systems but has yielded disappointing results in vivo [109, 110]. In the above 
mentioned studies the respective authors did not venture to provide reasons for the 
disappointing results. Radio-labelled inhibitor peptides have gained some success in MMP2 
imaging with techniques such as positron emission tomography (PET) and magnetic 
resonance imaging (MRI) in cancer patients [108, 109]. Confirmation of MMP2 activity in 
tissues and biopsy samples still has to be routinely done with laborious zymography 
techniques [110-112]. Currently the use of MMP2 specific ligands and inhibitors are being 
utilized to target nanoparticle liposomal formulations to cancer cells [113, 114]. 
 
1.3.2  The Role of MMP2 in Epithelial Ovarian Cancer 
Davidson et al utilized in situ colorimetric RNA hybridization techniques on tissue biopsy 
samples from ovarian cancer patients in various disease stages to determine mRNA 
expression patterns of MMP2, MT1-MMP, TIMP2 and MMP9 [115]. The data suggested a 
poor prognosis in direct correlation to high MMP2 mRNA expression levels. This 
relationship was even more evident for cases of late stage disease or disease relapse. 
Davidson et al reported similar results were observed for corresponding protein levels but 
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results were not published. In a 2009 in vitro study on ovarian carcinoma cells, Roomi and 
co-workers found that phorbol myristate acetate (PMA) induced MMP2 protein activation 
[90]. Preferential expression of active MMP2 was observed for ovarian carcinoma cells and 
not MMP9. The converse was true for some cervical cell lines. A 2006 study by Shen et al 
found that PMA and lipopolysaccharide induction of MMP2 in glioma cells was inhibited by 
dietary flavonoid compounds [116]. Although this study was not done on ovarian cancer cells 
it is feasible that a similar effect could be expected for dietary flavonoids which may indicate 
potential therapeutic applications. These results appear to add merit to the theory of 
metastasis-to-evade-apoptosis and as such, MMP2 could be an early stage indicator of 
development of acquired multidrug resistance. This idea receives additional support if it is 
considered that superoxide dismutase is regulated by NRF2. A recent study on the role of 
NRF2 in epithelial ovarian cancer found a strong link between acquired drug resistance and 
mutations in the inhibitor of NRF2, Keap1 [117]. A diagnostic test which predicts the 
development of acquired multidrug resistance can give clinicians a foot in the door. 
Preventative measures can be taken to alter the combinatorial treatment strategy before full 
blown drug resistance sets in. 
 
 
1.4 Chlorotoxin: A Matrix Metalloproteinase-2 Targeting Venom Peptide 
from the Deathstalker Scorpion 
1.4.1 Origins and Biochemistry 
Chlorotoxin (CTX) is a 4.3kDa, 36 amino acid residue peptide that was first isolated from the 
venom of the “Deathstalker” scorpion (Leiurus quinquestriatus) by Debin et al in 1991 [118]. 
There are 8 cysteine residues which contribute to 4 disulphide bridge formations in this small 
peptide [119, 120] and can be seen in Figure 1.11. The cysteine residues are thought to play a 
role in stabilizing the structure of the peptide [121]. This peptide is a potent invertebrate 
neurotoxin and has been shown to bind to chlorine channels [118]. Deshane et al were the 
first to find that CTX inhibits glioma progression, metastasis and angiogenesis [122]. 
Deshane and colleagues filed for and obtained a patent on the CTX-MMP2 interaction as 
treatment for glioma in 2003. In mammals histological [122, 123] as well as in vivo studies 
[123] implicated CTX as having a high affinity to the majority of glioma subtypes where this 
association was directly associated with MMP2 activity in these tumours. Zymography 
studies determined that the IC50 value of CTX for inhibition with MMP2 was 100nM [119]. 
The exact nature of the interaction between CTX and MMP2 has not yet been fully described 
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in the literature. CTX itself will enter the cell through a chlathrin mediated endocytotic 
pathway in the absence of membrane bound proteins to interact with [124]. No systemic 
toxicity towards vertebrates and no cytotoxic effects to mammalian cells have been reported 
[122, 123]. The typical RGD-motif is not present in the sequence of CTX as for other cancer 
targeting peptides, but the 3 lysine residues have been shown to play a direct role in CTX 
affinity for glioma cells [125]. With alteration of the lysines (K) to alanines (A), a decreased 
affinity to target glioma was observed in murine magnetic resonance imaging (MRI) studies. 
This study did not investigate the direct CTX-MMP2 mechanistic interactions. 
 
CTX is commercially available from various distributors. It can also be obtained by direct 
purification from the venom gland of the scorpion or it can be produced by using molecular 
biology methods. The strategy most researchers employ is to introduce an affinity tag onto 
the peptide for ease of purification [126]. Undirected chemical conjugation techniques, e.g.: 
carbodiimide chemistry [127], are typically utilized to attach CTX to various types of 
molecules. 
  
1.4.2 Current Research and Therapeutic Strategies Exploiting the CTX-MMP2 
Interaction 
The therapeutic and diagnostic applications of CTX have been explored by various cancer 
researchers. Veiseh et al developed a Cy5.5-CTX tumour contrast dye which can 
fluorescently label the tumour and facilitate surgeons to image cancer cells in a realtime bi-
photonic imaging system during surgery [128]. Conjugation of dyes or other molecules to 
CTX has not been reported to affect the affinity of CTX for glioma cells. It is to be expected 
that this holds true for other solid tumours as well. Mamelak and colleagues developed an 
iodine-131 labelled synthetic version of CTX, TM601, as an intravenous glioma treatment in 
2006 for Phase-I clinical trials [129]. The cross application to other tumours was investigated 
by Lyons et al, with his research group confirming that normal non-cancerous tissues showed 
no traces of TM-601 [130]. A group under the leadership of Douglas Jacoby found that TM-
601 has potent anti-angiogenic, anti-metastasis and growth inhibitory effects on various types 
of cancers [131]. As of 2010, TM-601 was in phase II clinical trials. TM-601 is retained up to 
8 days at the tumour site and excreted in the urine, with significant tumour shrinkage taking 
place in the said duration of treatment [131]. Recently, in 2010, the CTX-MMP2 interaction 
was called into question by a study done on TM601 which identified Annexin A2 as the 
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molecular target [132]. The authors however did not indicate if this altered molecular target 
may be an effect of the modification of the peptide. Also, the authors did not include 
contrasting experimental data with MMP2 included in the study. The question arises whether 
there is a conserved sequence homology between MMP2 and Annexin A2.  
 
CTX itself has been identified as a viable targeting vector for various nanoparticle based 
strategies in the past decade. Magnetic nanoparticles have been functionalized with CTX to 
act either as diagnostic agents, multimodal imaging-drug delivery agents or gene delivery 
agents [133, 134, 136]. Fluorescent nanoparticle-CTX conjugations have also been employed 
effectively in in vitro and in vivo fluorescent imaging applications [126, 137].  
 
The application of CTX as a diagnostic tool [136, 137] or an anticancer targeting moiety 
becomes more apparent if one considers the expression of MMP2 in cancer cells (1.3, Table 
1.1). The range of cancers that can be investigated makes this peptide a very important 
investigative tool. Further application goes above and beyond cancer treatment. Any disease 
where MMP2 levels are elevated (e.g. cardiovascular disease or HIV) can be targeted in a 
CTX based strategy to achieve either a diagnosis or to facilitate therapy. The diagnostics as 
well as therapeutic potential of CTX becomes more evident if the ability of said peptide to 
cross the blood-brain-barrier is considered. There may be an application for CTX in 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease. In all 
these diseases some variant of tissue remodelling and breakdown occur. 
 
 
1.5 Current Therapeutic and Diagnostic (Theranostic) Applications of 
gold nanoparticles (AuNPs) and semiconductor nanocrystals quantum 
dots (QDs) 
A trend in peer reviewed literature as well as international conferences seems to indicate that 
AuNPs are losing favour as drug delivery vehicles with soft nanoparticles, such as liposomes 
and polymer nanoparticles, are seen to be more suited for diagnostics. AuNPs and other 
metallic based nanoparticles were still favoured for diagnostic as well as biosensor 
applications. The Gordon’s Conference Noble Metal Nanoparticles 2012 as well as the 
Elsevier-Oxford Journals Colloids and Nanomedicine 2012 conference confirmed this shift in 
nanoparticle applications. In the next few paragraphs some applications of nanoparticles, in 
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particular gold nanoparticles and fluorescent quantum dots, will be highlighted. 
Terminologies as well as applicable in-depth aspects of nanoparticles will be discussed in 
section 1.6. 
 
Frank Caruso’s research group demonstrated at the Colloids and Nanomedicine conference 
the use of capsosomes [138]. A capsosomes is a “Russian doll” liposomal or polymer 
nanoparticle in which each liposomal layer can be systematically stripped away to release a 
chemotherapeutic or chromophore payload. Each liposomal layer can be engineered to have a 
pH or protease dependent release. In such a way a multimodal theranostic nanoparticle is 
created. Molly Steven’s group demonstrated an in situ gold nanoparticle based diagnostic for 
prostate specific antigen (PSA) [139] at the Gordon’s Research Conference Noble Metal 
Nanoparticles 2012. Glucose oxidase (Gox) is covalently immobilized on the AuNP surface, 
where the AuNP-Gox nanoconstructs are suspended in an aqueous hydrogen peroxide (H2O2) 
solution with a predetermined concentration of silver nitrate (AgNO3). In the presence of 
glucose, silver nanoparticles will be synthesized in the reducing environment facilitated by 
the enzymatic action of glucose oxidase and its cofactor H2O2. The UV-Vis spectra as well as 
surface plasmon band of the newly formed silver nanoparticles will be proportionate to the 
amount of analyte present.   
 
Gold nanoparticles (AuNPs) have been used as drug delivery vehicles in vitro and in vivo 
(Table 1.2).  The chemotherapeutic compounds are immobilized on the AuNP surface and as 
such will be exposed to the surrounding environment which can have unwanted side 
reactions. These concerns will be highlighted and discussed in Sections 1.6 and 1.7. The 
utilization of metallic nanoparticles as drug delivery systems is still a novel tool which is 
being developed as most studies are in vitro based as seen in Table 1.2. The surface plasmon 
resonance (SPR) of AuNPs makes them ideal for colorimetric based diagnostics [140-142]. 
Antibody functionalized AuNPs have been successfully applied as high contrast stains for 
immunohistology darkfield microscopy [141]. Further, the physicochemical character of 
AuNPs make them ideal candidates for in vivo imaging techniques such as X-ray imaging 
[140, 141, 145] and surface enhanced Raman spectroscopy (SERS) [140-144]. In such a 
manner the AuNPs can act as multimodal drug delivery vehicles as well as high contrast 
imaging reagents, creating theranostic nanoparticles. Unfortunately the equipment needed for 
the above mentioned in vivo imaging techniques are expensive and using animal models for 
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research requires ethics approval, which discourages some researchers from developing the 
field.   
 
Table 1.2: Gold nanoparticles in nanomedicine: Drug delivery, imaging, diagnostics and 
multipurpose applications 
Compound Model 
Imaging / 
Diagnostic 
Other 
Applications 
Reference 
Doxorubicin In vitro Fluorescence Drug delivery [146], [147] 
Bombesin 
In vitro; 
in vivo 
- Drug delivery [148] 
Pthalocyanines In vivo - 
Drug delivery,  
Photothermal therapy 
[149] 
5-Fluorouracil In vitro - UV-drug release [150] 
Paclitaxel In situ - Drug delivery [151] 
Collagen-Cy5.5 
In vitro; 
in vivo 
FRET MMP2 Activity [152] 
Cisplatin In situ - Drug delivery [153] 
Oxaliplatin In vitro - Drug delivery [154] 
Modified platinum(IV) 
drugs 
In vitro Fluorescence Drug delivery [155] 
Coumarin In vitro Fluorescence Drug delivery [156] 
Alexa647 
In vivo, 
ex vivo 
Fluorescence,  
SERS 
Drug delivery [157] 
Heparin In vivo - Drug delivery [158] 
DNA In vitro - Gene delivery [159] 
DNA In vitro Fluorescence Gene therapy [160] 
 
The intrinsic toxicity of quantum dots (QDs) (Section 1.6.3) restricts the in vivo applications 
but they still remain as very useful as sensitive fluorescence diagnostics tools [161-163]. QDs 
have been labelled with antibodies [162, 163, 164, 174], peptides [162, 163] and 
oligonucleotides [162, 163]. The most common applications for QDs are for immuno-staining 
techniques such as Western blotting [164], ELISA [162] and immuno-histology [162, 164, 
165]. QDs have also been successfully utilized in multiplexed multi-chromatic flow 
cytometry experiments [166], cellular tracking [173, 180] as well as for single molecule 
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imaging in vitro [167, 174]. In vivo murine studies have also shown that QDs gave a very 
high signal-to-noise ratio over tissue auto-fluorescence, even at a similar wavelength where 
tissue auto-fluorescence occurs [162, 165, 168-170]. A new generation of near-infra red non-
toxic QDs are showing great potential in deep tissue diagnostics due to light penetration 
depth [170-172] as well as avoiding tissue auto-fluorescence completely by exploiting the 
near-infrared optical window for in vivo imaging [170, 174]. 
   
The currently approved FDA (2012) nanoparticle formulations can be seen in Table 1.3. A 
specific colloidal gold device has been approved for use as an in vitro assay. The only FDA 
accepted gold nanoparticle formulation is targeted towards solid tumours by exploiting an 
interaction with tumour necrosis factor (TNF) and is currently in Phase-II clinical trials [174]. 
This is a PEGylated TNF passivated 27nm diameter gold nanoparticle which exploits the 
leaky tumour vasculature (passive targeting) to induce cell death in tumour masses and was 
reported to have an 85% response rate in cancer patients. This is a proprietary commercial 
preparation with the trade name Aurimune™ (CYT-6091). The manufacturer, Cytimmune 
Sciences Inc., aims to use this AuNP formulation to treat solid tumours such as ovarian-, 
breast- and pancreatic cancer. Multimodal theranostic nanoparticles which are currently 
under investigation by the FDA can be seen in Table 1.4. Currently there is no gold 
nanoparticle based therapeutic or diagnostic formulation under investigation. A gold 
nanoshell (Auroshell™) nanoparticle is currently being investigated for the use of near 
infrared laser technology to selectively destroy cancer cells [175]. The gold shell 
encapsulates a silica core. Nanospectra Biosciences developed this nanoparticle system to 
exploit the leaky vasculature of tumours and as such utilizes a passive targeting system. 
 
It is clear from Table 1.4 that the FDA currently accepts QDs for in vitro use only which 
limits the QDs to be used as high contrast fluorescence imaging reagents for molecular 
biology- and histology techniques. However, with advances in QD synthesis techniques 
acceptable levels of in vivo QD toxicity may be attained. The toxicity of QDs begs to raise 
the question “Why would the toxicity of nanoparticles matter if the application is for cancer 
treatment or cancer diagnostics?”. At the risk of controversy, if a toxic nanoparticle can be 
specifically targeted towards a cancer cell it may negate the need for chemotherapeutics 
which are known to induce systemic toxicity.  
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Table 1.3: Actively targeted nanoparticle therapeutic and diagnostic devices currently 
being investigated by the FDA (2012), taken from [176] 
 
 
Table 1.4: Actively targeted multimodal nanoparticle therapeutic and diagnostic devices 
currently being investigated by the FDA (2012), taken from [176] 
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Currently, liposomes and magnetic nanoparticles are favoured for drug delivery and 
multimodal applications (Table 1.4). Liposomes can be engineered to have biodegradable 
components [25, 176, 177] and iron based magnetic nanoparticles will be oxidised in the 
biological milieu and incorporated in metabolism [176, 178]. The use of liposomes and 
magnetic nanoparticles has had the most success up to date to create a multimodal 
nanoparticle system which can act simultaneously as a diagnostic as well as a therapeutic 
platform. The FDA is investigating targeted single- and multimodal nanoparticle 
formulations (Table 1.4) which are in various phases of human clinical trials. 
 
In the next section some background information will be given on nanotechnology with the 
focus on gold nanoparticles and quantum dots. This will include synthesis and some unique 
physicochemical phenomena of these nanoparticles as well as some considerations that need 
to be taken into account for applications in biological systems. 
 
 
1.6 Nanotechnology: A Brief Review 
Cancer therapeutics and diagnostics have developed into a very complex multidisciplinary 
field of research. Nanotechnology is a rapidly expanding multidisciplinary field that has 
emerged as an important contributor to theranostics of cancer. Theranostics describes the 
multimodal applications of nanoparticles as therapeutic (thera-) and diagnostic (-nostic) 
agents. The terminology “theranostics” has been introduced recently at international 
conferences and publications [179-182]. Due to the complex nature and numerous 
permutations of the various nanotechnology sub-disciplines which has developed, a basic and 
then applied discussion of nanoparticles applicable to this project will follow. 
 
1.6.1 Overview: Big Implications of a Small Science 
Nanotechnology describes the study of devices and materials where at least one of the 
dimensions is on the “nano” (10-9 meter) scale [178, 183, 186, 187]. If Figure 1.11 is 
examined it becomes clear that nanotechnology deals with devices so small they are 
magnitudes smaller than cells and in the same size category as biomolecules. These devices 
can be created by a bottom-up or top-down approach [184, 186, 187]. The former is based on 
synthesis from the atomic scale to the required size, and the latter is based on using existing 
templates with nano-dimensions, such as membranes or thin-films, to create nanostructures. 
The nanoparticles can be varied in size, shape and elemental composition [184, 186, 187]. 
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The physicochemical properties of nanoparticles vary considerably when compared to the 
elemental atomic and the elemental bulk scale [178, 186, 187], e.g. gold nanoparticles have a 
red hue in solution where atomic and bulk gold will have a yellow colour [185, 187]. Further, 
the physicochemical properties of nanoparticles are size-dependent, called the quantum 
confinement effect [184, 186, 187]. The increased surface area-to-volume ratio creates a 
highly reactive surface with unique chemistry or optical phenomena [184, 187]. This can be 
exploited for catalysis [187], disease therapeutics [184-187] and in medical diagnostics [185-
187].  
                     
 
Figure 1.11: A comparative size scale putting nanoparticles in perspective to known structures and 
biological molecules. (Encyclopedia Britannica, 2005) 
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There are currently many permutations on nanoparticle classifications. For ease of 
explanation, 3 groupings will be made:  
 
(i) Hard nanoparticles: 
Metallic nanoparticles have at least one metallic element in their composition and include 
noble metal-, magnetic- and semiconductor fluorescent nanoparticles. Typical applications 
include but are not limited to: (bio-) chemical sensors [186-188, 190], medical optical 
diagnostics [186, 187, 189, 190], drug delivery vehicles [186, 187, 189, 190] and magnetic 
contrast reagents [186, 187, 191]. The noble metal nanoparticles (Pd, Pt, Au, Au) are 
expensive to produce and other than for gold these noble metal nanoparticles have been 
reported to pose potential health [192, 193]- and environmental risks [163, 193]. The toxicity 
of selected types of nanoparticles will be discussed in Section 1.6.4. 
 
(ii) Soft nanoparticles: 
Polymers, dendrimers, carbon nanotubes, micelles and liposomes are the main types of 
nanoparticles in this category [179, 186, 194]. They mainly consist of synthetic organic 
molecules which are to a certain extent bio-degradable. Applications of these nanoparticles 
include water/air differentially permeable purification membranes [195] and drug-
encapsulation vehicles [186, 194]. An example of a bio-degradable liposomal therapeutic 
formulation is Doxil
®
 (Section 1.2.3.2). 
 
(iii) Ultrafine particles:  
These are nanoparticles that are mostly the by-products of combustive processes in industry 
[193, 196], fossil fuel combustion engines [193, 196], asbestos [193], biomass burning [196] 
and even tobacco smoking [196]. The composition of these nanoparticles is a complex 
mixture of organic compounds and metal impurities, displaying a wide range of physical 
morphologies and sizes [193, 196-198]. These nanoparticles are inhaled, ingested or absorbed 
on a daily basis [198]. Ultrafine nanoparticles pose personal health well as environmental 
risks and have been linked to increased incidence of pulmonary diseases [193, 196, 198] as 
well as variety of cancers [193, 198]. 
 
In the next few paragraphs attention will be given to gold nanoparticles and fluorescent semi-
conductor quantum dots. 
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1.6.2 Gold Nanoparticles (AuNPs) 
Gold nanoparticles (AuNPs) or gold colloids have been around long before Turkevich 
rediscovered the synthetic route in 1951 [190]. The use of colloidal gold dates back to 
2500BC in ancient Egypt and China where it was used in health elixirs, paint for urns and 
dyes for clothes [141, 185]. Medieval Christians used gold nanoparticles to give the red tint 
to stained glass windows in their cathedrals and churches [141, 185].  
 
1.6.2.1 Synthesis and Functionalization 
In the Turkevich method an aqueous gold salt (Au
3+
) solution is brought to near boiling point 
and a citric acid solution is added [141, 199, 200, 202]. The solution colour will change 
within a few minutes from yellow, to black and then finally a shade of red [141, 199, 200, 
202]. Mechanistic studies determined this colour shift corresponds to the various steps of 
nanoparticle formation. Addition of the reducing agent leads to nucleation seeding [141, 200, 
203], nanoparticle growth and maturation (Ostwaldt ripening [141, 200, 203]) to the desired 
AuNP size [141, 200, 201, 203]. This mechanism is represented in Figure 1.12. 
               
       
Figure 1.12: The stepwise synthesis of AuNPs. After addition of the reducing agent nucleation of gold 
clusters will occur where the solution will go from yellow to brown or black. A red colour indicates 
nanoparticle growth is occurring with maturation leaving AuNPs of the desired size. 
 
The nanoparticles would aggregate if the surfaces weren’t shielded from direct collision 
interactions with one another [140, 141, 190, 202]. The citrate is electrostatically adsorbed 
onto the AuNP surface [199, 202]. Citrate has a dual role in this synthesis technique by acting 
as an inducer/controller to growth (reducing agent) [202] as well as surface protectant 
(capping agent) [141, 187, 202]. Frens later expanded this synthesis to the Frens-Turkevich 
(seed-mediated synthesis) method. Pre-synthesized AuNPs are added to additional gold salt 
to the solution and the Turkevich method is applied [204]. Larger and more size 
monodisperse AuNPs with increased colloidal stability are produced in this way [185, 204]. 
The ratio of citrate to gold in solution is the determining factor for the final size distribution 
of the nanoparticles in solution for the Turkevich [199] as well as the Frens-Turkevich 
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methods [204]. Colloidal stable spherical gold nanoparticles of 5-40nm in diameter (ᴓ) can be 
prepared this way. Ascorbic acid [205, 206], cetyltrimethyl ammonium bromide (CTAB) 
[141, 205-207], and polyvinyl-(pyrrolidone) (PVP) [141, 207] in combination with citrate can 
be utilized in permutations of the Turkevich- and Frens-Turkevich methods to synthesize 
AuNPs of different shapes and sizes.  
 
Ligand exchange (Figure 1.13) is the process used to prepare AuNPs prepared by the 
Turkevich method for biological applications [141, 185, 190]. This can be done in a binary or 
in an analogue solvent system [141, 185, 189, 208, 209]. The solvent system is dependent on 
the desired solubility of the final AuNP surface functionalization where the solubility of the 
AuNPs will be dictated by the solubility of the molecule (ligand) found on the AuNP surface. 
A hydrophobic molecule will confer organic solvent solubility and a hydrophilic molecule 
will confer aqueous solubility. A molecule that has a higher affinity for the AuNP surface 
would displace the citrate [141, 194, 208, 209]. Depending on the functional group it can be a 
chelation (-COOH) [141, 184, 194], a covalent bond (-SH, -NH2) [141, 184, 194, 209] or an 
electrostatic interaction with an electron rich molecule like a phenyl compound [209, 210]. 
The most stable capping ligands are those with a thiol (-SH) moiety [141, 185, 187, 189, 
209]. Addition of a chaotropic salt will enhance the bond between the AuNP surface and the 
new ligand but this is not essential for successful ligand exchange [189, 194, 209]. 
Biomolecules can be proteins [141, 186, 189, 194, 209], peptides [141, 186, 189, 194, 209], 
oligonucleotides (DNA and RNA) [141, 186, 189, 194, 209, 210], carbohydrates [189, 194, 
209] and polymers [189, 194, 209]. This can be a laborious and time consuming process as 
each biomolecule will require the ligand exchange reaction conditions to be refined. In the 
case of siRNA or novel proteins/peptides, this can be an expensive experiment. Additional 
modification of the AuNP surface can be done using self-assembly techniques, such as layer-
by-layer hydrophobic- [209, 210] or electrostatic interactions [209, 210], as well as 
bioconjugation techniques [194, 210]. 
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Figure 1.13: Schematic representation of ligand exchange or place exchange. In this example a biphasic 
system is used for illustration of how the solubility chemistry can change using this reversible method. The 
AuNPs will be in the phase containing the ligand which has a higher affinity for the AuNP surface. The 
biphasic system can readily be adapted to an aqueous system, the principle remains the same: molecules 
that preferentially bind to the AuNP surface will confer corresponding solubility to the AuNPs. 
 
The Brust-Schiffren method introduced a facile one-pot method for the production of 
thioalkane capped AuNPs in a binary solvent system [141, 212]. The gold salt is dissolved in 
the aqueous layer and the thioalkane capping agent(s) in a toluene solution. It is possible to 
use more than one capping ligand. Sodium borohydride (NaBH4), the reducing agent, is 
added to the rapidly stirring solution. Spherical thioalkane capped nanoparticles with good 
monodispersity are produced, ranging from 6nm ≤ ᴓ ≤ 10nm [212]. Brust et al further 
speculated that the thiolate ligand will contribute to size- and shape control of the AuNPs 
under different experimental conditions [212]. The mechanism of nanoparticle formation is 
the same as for the Turkevich method with the exception that the gold salt (Au
3+
) will 
complex with the thioalkane ligand beforehand to make an Au
1
-thioalkane precursor which 
may facilitate the formation of a more narrow size dispersion of nanoparticles due to slower 
nanoparticle growth [212, 213]. In a permutation of this one-pot synthesis Brinas et al  
demonstrated the stepwise reduction of the aurate salt by glutathione and how the final shape 
of the AuNP was dependent on the size of the thioalkane-Au(I) precursor polymer size [213]. 
The thioalkane will reduce Au
3+
 to Au
+1
, reducing the chemical reactivity of the gold cations 
slightly and that the pH of the reaction solution influenced the size of the AuNPs [213]. 
Mayes et al reported that the AuNP size can be manipulated by altering the ratio of thiol to 
aurate salt where a large thiol:aurate ratio will favour smaller AuNPs and a small thiol:aurate 
ratio will favour larger AuNPs [214]. Mayes et al also demonstrated in this same study that 
variation in the temperature influenced the size and shape of the AuNPs [214]. 
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There are many more synthetic routes to produce gold nanoparticles of various shapes 
(triangles, cubes, rods, etc.) and sizes (2nm ≤ ᴓ ≤ 100nm) and functionalities [141, 187, 204-
214]. The desired characteristics of the AuNPs would be dependent on the downstream 
applications. 
 
1.6.2.2 Physicochemical Properties 
The surface reactivity of AuNPs differs distinctly from the atomic or bulk scale [186, 187]. 
Bulk gold is chemically inert and does not oxidize. The d and f orbitals of the gold atoms on 
the surface of the nanoparticle (Au
0
) overlap [141, 187, 190] and the absorption of 
electromagnetic radiation can be monitored at 450nm where the electromagnetic radiation 
absorption facilitates electron transitions between the d and f orbitals [141, 187, 190]. These 
are high energy orbitals with the electrons delocalizing across the increased surface area and 
creates an electron density cloud or electron conduction band over the whole AuNP surface 
[141, 187, 216]. The observed red colour of AuNPs in solution are size, shape and size-
distribution dependent [141, 187, 190, 216]. The visible part of the electromagnetic spectrum 
(photons), have wave properties as well as particle properties. If radiation from the visible 
range of the electromagnetic spectrum (Figure 1.14) floods across the surface of the AuNPs it 
will excite and polarize the delocalized electrons creating an electron cloud which will absorb 
wavelengths of the light of the same frequency. The wavelength(s) that are not absorbed are 
transmitted through the solution being dictated by the size of the AuNP [141, 187, 190, 215]. 
The absorbed radiation will result in the electrons oscillating continuously across the AuNP 
surface (Figure 1.15). This oscillating of the electrons at the same frequency as the incident 
electromagnetic radiation is called surface plasmon resonance (SPR) [140, 141, 187, 190]. 
 
SPR associated with spherical AuNPs is the result of short wavelength light (green, yellow 
and blue) being absorbed and red light being transmitted [140, 187, 190]. The 
electromagnetic radiation doesn’t reach the AuNP surface due to the density of the electron 
cloud and as such the yellow colour of bulk gold will not be reflected [140, 187, 190]. Light 
scattering will still be observed [187, 190]. 
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Figure 1.14: The electromagnetic spectrum. Visible light ranges from 400nm to 700nm. The absorption 
and transmittance is determined by size and shape of the nanoparticle (Image obtained from 
http://chemed.chem.purdue.edu/genchem/topicreview/bp/ch6/atom_emr.html). 
 
 
 
                                        
Figure 1.15: A graphical representation of the surface plasmon resonance effect. Electrons will flood or 
oscillate across the AuNP surface in response to an incident light wave passing close to the surface. This 
causes a resultant redshift in the electromagnetic spectrum from yellow to red. 
 
Larger AuNPs will have an increased surface area for the plasmons to oscillate across than 
for smaller AuNPs, the former displaying rosé red colour and the latter a red-purple colour 
[140, 141, 187, 217]. The amount of light that is absorbed by the SPR-effect is described by 
the molar extinction coefficient (ε; 106 Mol-1.L.cm-1 < ε < 1012 Mol-1.L.cm-1) [141, 187, 190]. 
The molar extinction coefficient is directly proportional to gold nanoparticle size and as such 
would be dependent on the mean diameter of all the AuNPs in solution [140, 141, 190]. 
Turkevich obtained UV-Vis spectra of the citrate capped AuNPs and discovered that the 
nanoparticles in solution obeyed the Beer-Lambert law [140, 141, 199]. The optical density 
of the AuNP solution is directly proportional to the concentration as well as the average size 
dispersion of the nanoparticles (Figure 1.16). There is however a bathochromic shift where 
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the linearity of this relationship does not hold true for nanoparticles 15nm < ᴓ < 25nm [140, 
141, 217]. To mathematically compensate for this phenomenon Haiss et al determined that 
the ratio of the optical density at the plasmon peak (λSPR) to the optical density at 450nm 
(λ450) is directly proportional to the AuNP diameter [218]. Haiss et al however only evaluated 
this mathematical compensation for AuNPs produced by the Turkevich and Frens-Turkevich 
method with citrate as capping agent [218].  This mathematical compensation provides a 
more accurate estimation of the extinction coefficient, translating into a more accurate 
determination of the AuNP concentration.  
 
The SPR band peak is the value where the optical density of the solution is at its maximum, 
corresponding to the size and shape of the AuNP [140, 153, 187, 190, 199]. This can be seen 
in Figure 1.16 where the maximum peak absorption shifts according to the size of the AuNPs. 
Molecules which are electron rich (e.g. biomolecules and polymers) will have a more 
pronounced effect on the surface properties of AuNPs than citrate and alter the SPR band 
[140, 187, 215]. In such a manner the SPR effect can be exploited for molecule-molecule 
interaction studies on the AuNP surface. Surface functionalization during ligand exchange 
affects the SPR and as such a blueshift or a redshift of a few nanometres in the 
electromagnetic spectrum can be observed with UV-Vis spectroscopy. This change in the 
SPR band is attributed to the change in the energy levels of the electron conduction band 
which occur on the AuNP surface [140, 141, 187, 216]. Other factors that can affect the SPR 
band are temperature [140, 210, 215, 219], pH [140, 210], ionic strength [140, 210] and the 
type of solvent (dielectric constant) [140, 210, 215, 216]. 
 
                        
Figure 1.16: The UV-Vis spectra of spherical AuNPs. The spectrum is dependent on the average size 
distribution of the nanoparticles in the sample. The image was obtained and adapted from 
http://www.grin.com/en/doc/247330/surface-engineering-of-gold-nanoparticles-and-their-applications. 
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1.6.3 Quantum Dots (QDs) 
These fluorescent semi-conductor nano-crystals have acquired popularity in biomedical 
research in the past few years due to the applications in (bio-)chemical sensors [172, 220, 
221], in vitro diagnostics [172, 222, 223] and potential in vivo diagnostic applications [224-
226]. These spherical nanoparticles typically have diameters which range between 4nm and 
25nm [170]. 
 
1.6.3.1 Synthesis and  Functionalization 
The synthesis of QDs is a fairly complex and intricate process being conducted at high 
temperatures in organic solutions under inert atmospheres [172, 174, 227, 228]. Initially an 
organometallic precursor is injected into a hot organic solution where the temperature will be 
incrementally increased to induce crystal growth of the metallic component [170, 227, 228]. 
Accurate temperature control is crucial for uniform crystal growth [172, 227, 228]. This is 
termed core-formation (Figure 1.17) with typical elements being cadmium (Cd) [163, 170, 
227, 228], selenium (Se) [163, 170, 227, 228], tellurium (Te) [163, 170, 229], indium (In) 
[163, 170], arsenic (As) [163, 170] and gallium (Ga) [163, 170, 227]. Other elements can be 
used for core formation where the limiting factor determined by similarity in crystal lattice 
structure [171, 227, 228]. To prevent auto-oxidation the core is capped with a shell (shell-
formation) [170, 227, 228]. This typically is a combination of zinc (Zn) [170, 227, 228] and 
sulphur (S) [170, 228] or selenium (Se) [170, 227]. The crystal structure of the shell element 
components should be complementary to each other as well as the core elements [171, 227, 
228]. A typical core-shell QD can be seen in Figure 1.17. QDs display quantum containment 
effects regarding surface reactivity and physico-chemical properties [162, 170]. Nanoparticle 
surface passivation is done with a capping ligand, such as tri-n-octyl phosphine oxide 
(TOPO) [174, 227-229], which is usually incorporated into the reaction mixture from the start 
of synthesis [171, 174, 227-229]. Various research groups have reported the synthesis of 
noble metal (gold) fluorescent quantum dots [230, 231]. 
                                                        
Figure 1.17: The structure of spherical semiconductor nanocrystals QDs. The core and shell both consist 
of semiconductor elements. The restriction on elements that can be used is cubic crystal lattice 
compatibility. 
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Ligand exchange [162, 170, 210, 233] is once again the preferred method of facilitating bio-
functionalization of the QDs and would be a biphasic place exchange reaction, similar as for 
AuNPs (Figure 1.13, 1.6.2.1). Ligands which have a thiol moiety show a high affinity for the 
cadmium (Cd) in the core and the zinc (Zn) in the shell of the QD [171, 174, 230, 233]. One-
pot synthesis of water-soluble ligand passivated QDs without shells have been reported [170, 
228].  
 
1.6.3.2 Physicochemical Properties 
The cubic crystal lattice compatibility of the different substituents in the QD core and shell 
contributes to the unique optical properties resulting from the quantum confinement effects 
for these colloids [170, 171, 174, 227-229, 234, 235]. The Bohr radius can be defined for 
three variables for the electron (ae), electron hole (ah) and the exciton (aexc) [234, 235]. When 
a nanoparticle has a radius (a) smaller than the Bohr radius the quantum confinement 
associated phenomena will be observed [234, 235]. The bandgap energy is defined as the 
minimum energy necessary to excite an electron from a relaxed state to a higher energy level 
[170, 234, 235]. The relaxation of the electron to the ground state will release energy in the 
form of fluorescence. Each individual semiconductor or semiconductor alloys will have 
unique bandgap energy [170, 234, 235]. In layman’s terms, the emission wavelength of QDs 
is dependent on the diameter of the sphere, with small diameters displaying blue emission 
and larger diameters displaying increasing redshift emission (Figure 1.18b).  
 
Fluorescence excitation can be achieved with any wavelength of light with a shorter 
wavelength than the emission wavelength providing the excitation energy exceeds the 
bandgap energy [170, 174, 234-236] and this can be seen in Figure 1.18a where the excitation 
and emission spectra of different QDs are displayed. In a mixed QD sample, simultaneous 
fluorescence emission can be achieved by using a single light source [234-237]. Compared to 
organic fluorophores, QDs have a high resistance to photobleaching [227-229, 234-237] with 
highly symmetrical emission spectra [227-229, 234-237] presenting relative narrow half-peak 
width (HPW) and full peak-width (FPW) emission profiles (Figure 1.18a). For large QDs the 
HPW and FPW broaden significantly, especially for the case of QDs that emit in the near-
infrared part of the electromagnetic spectrum (Figure1.18a) [227-229, 236, 237]. QDs have a 
fluorescence intensity that is 1000 – 10 000 fold higher than most typical organic 
fluorophores [170, 174, 234-237].                            
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Figure 1.18: The quantum confined effect optical properties of QDs. Symmetrical emission spectra with 
excitation by any wavelength of light below the emission maximum can be seen in a). The fluorescence 
emission profile can be fine-tuned based on the QD size as seen in b). Image was taken and adapted from 
Invitrogen Qdot® Nanocrystal catalogue (http://www.invitrogen.com).  
 
 
1.6.4 Current Challenges in Nanoparticle Based Therapeutic Strategies 
For any therapeutic drug to be cleared for clinical trials and ultimately FDA approval, it 
needs to adhere to stringent conditions [36, 186, 238]. A few points will be raised which 
should be taken into consideration and are proving to be quite challenging. This is even more 
so in the case of nanoparticles, as the inherent toxicity (1.6.5) of these emerging medical 
devices still needs to be sufficiently studied.  
 
1.6.4.1 Administration Route 
Oral administration involves the acidity of the stomach and various digestive enzymes. Also, 
the formulation has to undergo first pass metabolism before systemic spread. Intravenous 
administration delivers formulations directly into systemic circulation, bypassing first pass 
metabolism [186, 198, 238]. This however can cause site-injection accumulation of the 
formulation resulting in sub-effective dosages reaching the site of action and even an immune 
response paired with inflammation [36, 198, 238]. Topical application would require 
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sufficient diffusion through the skin, but once again site specific irritation can occur and 
contact necrosis has been reported [239]. 
 
1.6.4.2 Tumour Specific Targeting 
The aim of any anticancer treatment is to only affect the cancerous tissue and not healthy 
tissue. Due to the complexity of cancer there exists no universal cancer targeting system. 
Folate receptor targeting is a viable route as most cancer cells will up-regulate this receptor 
for the increased metabolism in the cells and a nanoparticle-folic acid conjugate will then 
preferentially accumulate in these cells [160, 186, 238, 240]. Similarly ferritin assisted 
targeting have been employed [160, 241, 250]. Healthy non-cancerous cells also express 
folate- and ferritin receptors as these form part of normal cellular metabolism. Thiamine 
[186] and transferrin [241] assisted targeting to cancer cells has also been reported. More 
attention has been given to peptide and antibody assisted tumour targeting. Novel cancer 
targeting peptides are identified either by phage-display techniques [241-243] or synthetically 
produced by combinatorial chemistry methods [244-247]. The peptides have good specificity 
and usually have the RGD (arginine-glycine-aspartic acid)-motif [186, 248] but can be 
difficult to produce and purify, whether by recombinant or protein chemistry methods. 
Antibodies (monoclonal) display a high specificity [186, 238, 249] but are costly to produce 
or purchase commercially. General drawbacks for peptides as well as antibodies are that they 
are not produced in a human host and as such evoke an immune response with subsequent 
sequestration in the lymphatic system decreasing the efficacy for drug delivery [238, 240] 
 
Tumour specific targeting received a fair amount of criticism at the Gordon’s Noble Metal 
Nanoparticle Research Conference 2012. The majority of researchers where in favour of 
passive tumour targeting claiming antibodies as well as other targeting molecules do not 
enhance the ability of drug loaded nanoparticles to localize and internalize to tumours. This is 
in direct contrast with the current paradigm in the literature.      
 
1.6.4.3 Avoidance of the Immune System and Prevention of  Biomolecule 
Interaction 
The immune system will sequester any foreign body in the lymphatic system leading to the 
excretion of the foreign body. A potential solution for this problem is to humanize [251] 
peptides, proteins and antibodies to be used for therapeutics, however this is expensive. 
Another complication is non-specific interaction with serum proteins and biomolecules such 
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as albumin [160, 185, 186, 238, 240]. Polyethylene glycol (PEG) conjugate-versions of the 
drug or nanoparticles improve circulation half-life [151, 153, 156, 160, 186], minimizes non-
specific interactions with biomolecules [142, 151, 153, 156, 160, 186] as well as assists in 
avoidance of the immune system [151, 153, 156, 160, 186]. Polyethylene glycol is FDA 
approved [185, 186]. The majority of liposomal anticancer formulations utilize polyethylene 
glycol incorporation in their structure [113, 114, 169, 186, 238]. 
 
1.6.4.4 Tumour Penetration, Cellular Penetration and Overcoming Multidrug 
Resistance 
The enhanced perfusion and retention effect (EPR) is a controversial topic currently in 
nanomedicine. The EPR describes the potential of a therapeutic formulation to penetrate the 
tumour epicentre and destroy the tumour radially outward from the epicentre [160, 182, 185, 
186, 238, 240]. The tumour penetrating potential of the therapeutic formulation is dependent 
on the circulation half-life, the interstitial radial outward tumour pressure, the size of the 
formulation as well as the extent of the leaky tumour vasculature [160, 182, 185, 186, 238, 
240]. At two recent conferences, Gordon Research Noble Metal Nanoparticles 2012 and 
Elsevier Colloids and Nanomedicine 2012, various speakers contended EPR. The consensus 
was that to effectively treat cancer, systematic radial inward decrease in tumour size has to 
take place with consecutive treatments. This is the converse to the traditional view on EPR.  
 
Tumour cell membrane physiology differs from non-tumour cells due to increased expression 
of specific proteins and other bio-molecules on the surface. Annexin A2 is an example of a 
protein that confers a more negative charge to the cancer cell membrane and has been 
identified as a prognostic marker in ovarian carcinomas [132, 252, 253]. The proton sponge 
effect can be exploited if the nanoparticle has a cationic detergent surface coating which can 
facilitate internalization into the cell [160, 254, 255].  The cationic nature is due to a primary 
amine (-:NH2) or secondary amine (-:NH-) the lone pair electrons on the nitrogen will act as 
proton acceptors during endosome sequestration. The endosomes will attempt to maintain pH 
homeostasis through osmosis [160, 241, 254, 255]. Adequate cationic character will cause 
osmotic rupture of the endosomes and release the contents into the cytoplasm.  
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1.6.5 Nanotoxicology: The Need to Investigate the Uncertainty 
The unique physicochemical properties of nanoparticles raises the question of how safe are 
these materials [186, 192, 193, 198, 238-240]. Carbon is the atom of life being biologically 
inert and carbon nanotubes have been utilized in in vitro therapeutics [256, 257]. The 
assumption was made that carbon nanotubes would be equally biologically inert. Typical 
biochemical based toxicity assays showed favourable cell viability and mechanistic studies 
indicated no oxidative stress [198, 256]. High resolution microscopy studies told another 
story: the carbon nanotubes have sharp edges which pierced the cell membranes, similar to a 
needle piercing a balloon, causing lesions which can lead to mesothelioma [193, 198]. The 
stiff structures of the carbon nanotubes are also associated with chronic inflammation [193, 
198, 256, 257]. The nanotube surface was not as chemically inert and displayed direct 
chemical interaction with the substituents of the biochemical assays [192. 238], inducing 
DNA strand breaks [192], inducing platelet aggregation [36] as well as generating reactive 
oxygen species [193, 198, 239]. A controversial question arises regarding carbon nanotubes 
as drug delivery vehicles [258]: How sure are the authors that the in vivo results for 
overcoming multidrug resistance is not an artefact? 
  
Magnetic nanoparticles (MNPs) are currently one of the most acceptable nanoparticles, next 
to liposomes, for being chosen for FDA clinical trials as multimodal drug delivery vehicles 
and imaging agents (section 1.5, Table 1.3 and Table 1.4). MNPs consist mainly of ferric 
(Fe
2+
) or ferrous (Fe
3+
) ions, where the iron will eventually be biodegraded by oxidation and 
will either be absorbed and used for cellular processes or excreted [238]. The in vivo stability 
and safety of iron magnetic nanoparticles was brought into question when it was reported that 
biological oxidation induced nanoparticle aggregation, even with biomolecule surface 
coatings [192, 238]. In a recommended review by McNeil et al in 2009 it was reported that 
iron containing nanoparticles showed significant differences in tumour uptake as well as 
biological clearance dependent on tumour- and organism types [238]. Pisanic and co-workers 
reported in 2007 that iron nanoparticles induced dose-dependent disturbances in the PC12 rat 
neural cell line: cytoskeletal disruptions; decreased intracellular contact and unresponsive to 
stimuli by nerve growth factor (NGF) [259]. It is not known how MNPs would affect 
individuals that have genetic defects in iron metabolism or even severe liver and kidney 
damage. Cobalt (Co) doped magnetic nanoparticles showed significant toxicity in vitro [192, 
198] and outcompeted magnesium (Mg) for DNA binding [192]. It is possible that doping 
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magnetic nanoparticles with other heavy metals such as nickel (Ni) and manganese (Mn) 
should show similar toxic effects in vitro and in vivo. 
 
Various studies claim that citrate capped AuNPs are biologically inert [140, 141, 185, 192, 
194]. If biologically inert means “to have no interactions with biological molecules”, one 
would dispute these findings. A more accurate definition would be “have no cytotoxic effects 
under specific conditions”. Aqueous ligand exchange (1.6.2.1) specifically exchanges citrate 
on the AuNP surface with biomolecules. In the cell there are many molecules in the 
biological milieu that have carboxylic acids (-COOH), primary amines (-NH2), thiols (-SH) 
and electron rich phenolic compounds. This also holds true for whole blood and serum 
proteins [36, 260]. Citrate capped AuNPs have also been reported to induce oxidative stress 
and interact with DNA repair genes such as BRCA1 [261]. Essential transcription factors with 
cysteine residues can also potentially react with AuNPs and have been reported for activator 
protein (AP)-1 [192]. AuNPs may interact with and deplete intracellular glutathione (GSH) 
and have been demonstrated in situ by Su Deep et al [262]. Gao and co-workers 
demonstrated in vitro GSH depletion, 48h after treatment with AuNPs, which subsequently 
leads to increased intracellular H2O2 production and cell death [263]. The chemical reactivity 
and spectroscopic properties of AuNPs have led to speculation that biochemical assays were 
prone to interference from AuNPs. The propidium iodide absorbs to the surface of the AuNP 
and the fluorescence of the dye is quenched which leads to altered results when determining 
cellular necrosis [238]. Similar concerns have been raised for the 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide, a tetrazolium (MTT) assay where there is significant 
spectral overlap for the tetrazolium dye and AuNPs [264, 265]. MTT can also be absorbed 
onto the AuNP surface [264, 265]. Bio-impedance in vitro assays have been suggested as a 
solution to determining cellular responses to AuNPs [266]. The consensus in peer reviewed 
literature is that the cellular distribution of AuNPs is directly related to the size and shape 
although endocytosis appears to be the main internalization method reported [185, 267, 268]. 
Small AuNPs are localized in peri-nuclear or intra-nuclear regions [267, 268]. Larger AuNPs 
are found in the cytoplasm or plasma membrane bound [267, 268]. The cellular distribution is 
further also dependent on the surface functionality of the AuNPs [267-269, 271, 272] as well 
as the cell type [269-271]. Cationic functionalities appear to be more readily sequestered in 
endosomes than anionic functionalities [271-275]. An anionic nanoparticle will be repulsed 
from the membrane and may have decreased cellular internalization. This may be the reason 
why anionic nanoparticles display a lesser degree of toxicity than their cationic counterparts. 
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It has been reported that cationic nanoparticles are intrinsically toxic [271-275]. Whole 
animal imaging studies elucidated organ specific distribution of AuNPs [269, 273, 274]. 
Citrate capped AuNPs would be sequestered in the lymphatic system, liver or kidneys [269, 
273] but larger AuNPs may be found in the lungs as well [269, 273]. AuNPs will be 
gradually degraded in the biological milieu [275] and diameters smaller than 5nm are readily 
excreted through the kidneys [275]. 
 
The elements which make up the core of the QDs are toxic and induce severe oxidative stress 
[161-163, 170, 275, 276]. Oxidation of the QDs in the biological environment releases the 
toxic elements from the nanocrytal structure [161-163, 170, 276]. Non-genomic [162, 170, 
269, 276], genomic [162, 170, 269, 276] as well as epigenetic [162, 269, 276] changes in 
vitro have also been reported with the use of QDs and as such live cell imaging using QDs 
proves to be a challenge since toxicity from the QD may affect the cellular event being 
studied [162, 276]. It has been reported that if the capping ligand on the QD surface is 
sufficiently dense it can prevent or decrease the leakage of the QD-core elements to the 
biological environment [170, 275, 276]. It is speculated that polymers, dendrimers as well as 
liposomal ligands are the best suited for in vivo QD applications as these ligands resist 
biological oxidation and desorption from the QDs surface more readily than smaller ligands 
[168-170, 223, 276, 277]. In vivo models have shown that untargeted QDs will eventually be 
sequestered in the lymphatic system, the kidneys, liver as well as bone marrow for up to 4 
months after administration [277, 278]. Renal- and hepatic failure can be induced by 
micromolar quantities of cadmium [161, 269, 275, 276]. In all these QD toxicity reports the 
consensus is that toxicity is time- and dose-dependent. 
 
It is clear that the toxicity of various nanoparticles is called into question. This is especially 
important for nanoparticles which have traditionally been seen as “bio-inert” where the 
chemical- as well as mechanical stress mechanisms still have to be fully elucidated. Care 
should be taken when considering which biochemical toxicity assays to use for nanoparticle 
types. Biochemical- and microscopy toxicity assays can experience (bio-)chemical-, 
fluorescence quenching- or fluorescence superposition interference which is dependent on the 
size, shape or composition of the nanoparticle. 
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1.7 Problem Statement and Objectives 
1.7.1 Problem statement 
Early as well as accurate diagnosis of ovarian cancer is a challenge where diagnosis occurs 
when the disease is an advanced stage with a poor prognosis for the patient (Sections 1.2.1 
and 1.2.2). Ambiguity of the symptoms as well as the lack of specific molecular biomarkers 
exacerbates the difficulty of a correct and early diagnosis (Section 1.2.2). Successful 
diagnosis and treatment still requires the patient to have regular invasive examinations to 
monitor the potential disease relapse (Section 1.2.2). Ovarian cancer has a higher mortality-
to-incidence ratio than breast cancer or any other gynaecological cancer (Section 1.2.1). 
Surgery is typically used to reduce overall tumour mass, but may cause metastasis of the 
cancer, with chemotherapy as follow-up treatment (Section 1.2.3). Successive chemotherapy 
administration is required, over a time frame of weeks or months, for ovarian cancers which 
leads acquired multidrug resistance. In cases of disease relapse, epithelial ovarian cancer will 
be non-responsive to chemotherapy and incurable (Sections 1.2.2 and 1.2.3). The adverse 
side-effects of chemotherapy include physical- as well as psychological symptoms (Sections 
1.2.2 and 1.2.3). From a personal perspective and experience, some individuals would rather 
suffer the effects of the disease than suffer the effects of treatment. In a South African 
context, where the majority of the population lives in rural areas without adequate health care 
or access to a physician, ovarian cancer proves even more challenging. If the specific 
diagnosis cannot be improved, attempts should be made to improve the treatment of the 
disease.  
 
MMP2 has been identified as a non-specific prognostic marker for solid- and metastatic 
tumours, where the levels of MMP2 are directly correlated to how aggressive and advanced 
the tumour is (Table 1.1, Section 1.3.1). CTX is a small venom peptide which has been 
identified to specifically bind to MMP2 in glioma cells and has been shown to bind to MMP2 
in other cancers as well (Sections 1.4.1 and 1.4.2). Various diagnostic- and therapeutic 
strategies have utilized the CTX-MMP2 interaction with success (Section 1.4.2). The 
interaction of CTX-MMP2 can thus be utilized to develop a targeted nanoparticle drug 
delivery vehicle and has been shown to be feasible (Section 1.4.2). Delivery of a therapeutic 
payload still has cellular internalization, intracellular accumulation and intracellular retention 
to contend with. Multidrug resistance involves the ability of a cancer cell to inactivate, export 
or evade a chemotherapeutic treatment.  
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The cellular internalization and intracellular localization of gold nanoparticles (AuNPs) is 
dependent on nanoparticle size as well as surface functionalization. Cationic nanoparticles 
proved to be superior for internalization but also proved to be more toxic to the cell (Section 
1.6.5). Small AuNPs would in theory deliver a chemotherapeutic payload to peri-nuclear 
regions and larger AuNPs would deliver a chemotherapeutic payload to the cytoplasm and 
plasma membrane (Section 1.6.5). However, endosome sequestration and cellular efflux is 
the typical fate of AuNPs (Section 1.6.5). In vitro imaging of AuNPs can be done with 
techniques such as dark field microscopy [178] and SERS- and X-ray imaging for in vivo 
(Section 1.5). A successful drug delivery vehicle will need to overcome cellular drug efflux, 
display increased intracellular accumulation as well as deliver the chemotherapeutic payload 
to the site of action. A chemotherapeutic drug like doxorubicin (DOX) has multiple sites of 
action within the cell, with the nucleus, mitochondria and cytoplasm being the most 
prominent targets (1.2.3.2.2). Monodisperse AuNPs have been used to deliver DOX and other 
chemotherapeutics to cancer cells in vitro and in vivo with varying degrees of success (Table 
1.2, 1.5). 
 
Shuming Nie and co-workers described an approach where quantum dots (QDs) were 
functionalized with hyper branched polyethyleneimine (PEI) and were successfully used as 
gene delivery vectors, showing an increased transfection efficiency of the genetic payload 
which was attributed to the increased cellular retention [226, 255, 279]. This event was 
monitored with fluorescence based techniques such as fluorescence microscopy as well as 
flow cytometry. The success of these studies mentioned above was attributed to the 
exploitation of the enhanced perfusion and retention (EPR) effect as well as endosomal 
escape due to the proton sponge effect [226, 255, 279]. A similar use of PEI on silica 
nanoparticles to transfect cells in vitro for effective siRNA delivery has been reported [280]. 
In a similar manner, gold nanoparticles were functionalized with PEI and acted as siRNA 
delivery agents but have not yet been reported as drug delivery vectors. PEI has been shown 
to be biodegradable in co-block polymer formulations which included polyethylene glycol 
(PEG) and is a superior transfection reagent [280-283].  
 
Utilizing PEI as a surface functionalization for size polydisperse AuNPs has the potential as a 
drug delivery vehicle which can deliver its therapeutic payload (DOX) to multiple sites in the 
cell with enhanced drug accumulation and retention. Further modification of the surface of 
the PEI-functionalized AuNPs (AuNP-PEI) with PEG can enhance the cellular retention of 
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the formulation. Increased cellular retention of nanoparticles will enable not only enhanced 
drug delivery within the cell, but also enable more specific and sensitive diagnostics. In such 
a manner a multimodal theranostic AuNP can be developed. 
 
1.7.2 Aims and Objectives 
The primary aim of this study is to synthesize and functionalize a multimodal theranostic 
gold nanoparticle for the in vitro drug delivery to a multidrug resistant ovarian carcinoma cell 
line in an attempt to overcome the cellular drug resistance and induce significant 
programmed cell death.  
 
The primary objectives of the study are the following: 
 Synthesize, bio-functionalize and physicochemically characterize gold nanoparticles; 
 Evaluate the biomolecular interactions of the gold nanoparticles 
 Refine the surface chemistry and colloidal stability of the gold nanoparticles to act as 
drug delivery vehicles for doxorubicin 
 Evaluate if the doxorubicin functionalized gold nanoparticles could overcome 
multidrug resistance in a multidrug resistant ovarian carcinoma cell line (A2780cis) 
 Suggest a mechanism for cell death induced by the doxorubicin functionalized gold 
nanoparticles 
 
The secondary aims of this study are to evaluate if the above mentioned drug delivery 
platform can be transferred to fluorescent nanoparticles (quantum dots) to evaluate in vitro 
tumour-specific targeting by exploiting the matrix metalloproteinase-2 interaction with the 
venom peptide chlorotoxin. 
 
The secondary objectives of the study are: 
 Generate a stable transfected A2780cis cell line which expresses enhanced green 
fluorescent (EGFP) tagged full length pro-MMP2  
 Clone, produce and purify a recombinant variant of chlorotoxin with a 6xHis-tag 
 Biofunctionalize nitrilotriacetic acid (NTA) functionalized gold nanoparticles and 
quantum dots with CTX 
 Investigate the in vitro co-localization of chlorotoxin and matrix metalloproteinase-2 
with the use of wide field fluorescence microscopy 
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Chapter 2: Materials and Methods 
 
2.1 Materials and Stock Solutions 
2.1.1 Materials and Suppliers 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide  
hydrochloride, (EDC.HCl)       Sigma 
12-O-tetradecanoylphorbol-13-acetate, (PMA)    Sigma 
12-well Flat bottom clear plates      Greiner 
2000 MWCO concentrator tubes, 15mL     Millipore 
2-(N-morpholino) ethanesulfonic acid, (MES)    Sigma 
(2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxy-3-phenyl- 
propionamide, (BiPS)        Merck 
24-well Flat bottom clear plates      Greiner 
3-(N-Morpholino)-propanesulfonic acid, (MOPS)    Sigma 
40% 37.5:1 acrylamide:bisacrylamide     Promega 
5,5'-Dithiobis(-2-nitrobenzoic acid), (DTNB)    Sigma 
6x Green DNA loading buffer      Fermentas 
6-well Flat bottom clear plates      Greiner 
96-well Flat bottom (F) clear microplates     Greiner 
96-well Round bottom (U) black microplates    Merck 
10 000 MWCO concentrator tubes, 50mL     Millipore 
β-actin mouse anti-human monoclonal antibody,  
HRP conjugated        Santa Cruz 
β-mercaptoethanol        Sigma 
γ-thiobutyrolactone        Sigma 
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Acetone         Merck 
Acetonitrile         Sigma 
Agarose          Promega 
Ammonium persulphate        Merck 
Ampicillin         Roche 
ApoPercentage™ Assay Kit       Biocolor 
Aurotetrachloro trihydrate (HAuCl4.3H2O)     Sigma / Merck 
BamHI FastDigest® restriction enzyme     Fermentas 
BCA Protein quantification kit      Pierce 
BcglII FastDigest® restriction enzyme     Fermentas 
Boric acid (Ortho boric acid)       Merck 
Bovine serum albumin, (BSA)      Roche 
Bromoacetic acid, (BrCH2COOH)      Sigma 
Bugbuster™ GST Bind Purification Kit     Novagen 
Calcium chloride, (CaCl2)       Merck 
CD27L, mouse anti-human monoclonal antibody, 
FITC conjugated         Santa Cruz  
FluoroShield® with DAPI       Sigma 
Chloramphenicol        Sigma 
Chloroform-D1, (CDCl3)       Sigma 
Chloroform         Merck 
Cis-diammineplatinum-(II) chloride (cisplatin)    Sigma 
Coomassie Brilliant Blue R-250      Sigma 
Coverslips, 22 x 22 mm       Lasec 
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Cysteine hydrochloride       Sigma 
Cytobuster™ Protein Extraction Reagent     Novagen 
Dansyl chloride        Sigma 
Di-deuterium oxide (D2O, 99.5%)      Sigma 
Di-sodium hydrogen phosphate      Merck 
Doxorubicin (Adriamycin)       Wuhan-Sunrise 
          Tech. Dev. Ltd. 
DreamTaq® Green PCR master mix      Fermentas 
Ethanol         Merck 
Ethylene diamine tetra acetic acid, (EDTA)      Merck 
FastDigest® x10 restriction digest green buffer    Fermentas 
G418 hydrochloride        Sigma 
G418 Solution         Roche 
GelRed™         Biotium 
Glacial acetic acid        Merck 
Glutathione, reduced (GSH)       Sigma 
Glutaraldehyde solution       Sigma 
Glycerol         Merck 
Glycine hydrochloride       Merck 
Goat anti-mouse polyclonal antibody, HRP conjugated   Santa Cruz 
GSH/GSSG-Glo™ Assay       Promega 
HiFi™ Hotstart Taq master mix      Kapa Biosystems 
Holey carbon film, 400 mesh Cu (50)     Agar Scientific 
Hydrochloric acid        Merck 
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HSP60 mouse anti-human monoclonal antibody    Santa Cruz  
Immersion oil, mineral       Zeiss 
Iodine (I2 crystals)        Merck 
Isopropanol         Merck 
Isopropyl-β-D-thiogalactopyranoside, (IPTG)    Roche 
Kanamycin mono-phosphate       Roche  
Lipopolysaccharide         Sigma 
Magnesium chloride, (MgCl2)      Merck 
Metafectene®Pro        Biontex 
Methanol         Merck 
Microscope slides        Lasec 
MLH1 mouse anti-human monoclonal antibody    Santa Cruz  
MMP2 goat anti-human polyclonal antibody     Pierce  
MMP Chromogenic substrate, thiopeptolide     Enzo Life Science 
N
6
-Cbz-L-Lysine        Sigma 
N-(2-Hydroxyethyl)-piperazine-N’-ethanesulfonic acid, (HEPES)  Sigma 
N-hydroxysulfosuccinimidyl ester, (Sulfo-NHS)    Sigma 
N, N, N’, N’-Tetra methylethylene-diamine, (TEMED)   Sigma 
Nickel sulphate, (NiSO4)       Sigma 
Ninhydrin         Merck 
Nutrient agar         Merck 
O’GeneRuler™ DNA 100bp ladder      Fermentas 
p-Aminophenylmercuric acetate, (APMA)     Sigma 
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p-Anisaldehyde        Sigma 
PageRuler™ unstained protein ladder     Pierce 
Palladium/Carbon (5% Pd/C)       Sigma 
Parafilm         Lasec 
Paraformaldehyde        Sigma 
Polyethyleneimine 2kDa (PEI)      Sigma 
Potassium acetate (CH3COOK)      Merck 
Potassium chloride (KCl)       Merck 
Potassium di-hydrogen phosphate      Merck 
Procaspase-3 mouse anti-human monoclonal antibody   Santa Cruz 
Pro-Matrix metalloproteinase-2, recombinant    Merck 
QIAquick® Gel Extraction Kit      Qiagen 
RPMI-1640 with 1mM glutamine      Lonza 
SalI FastDigest® restriction enzyme      Fermentas 
SM-PEG6 bifunctional crosslinker, 100mg     Pierce  
Sodium borohydride, (NaBH4)      Sigma / Merck 
Sodium chloride, (NaCl)       Merck 
Sodium dodecyl sulphate, (SDS)      Sigma 
Sodium hydroxide (NaOH)       Merck 
SuperSignal® West Pico chemiluminescent kit    Pierce  
T4 ligase         Fermentas 
TLC plates, silica gel on aluminium, F254     Merck 
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Tetrabutyl-ammonium hydroxide      Sigma 
Tetrahydrofuran, (THF)       Sigma 
Trifluoroacetic acid        Sigma 
Tris-[hydroxymethyl]-aminomethane     Merck 
Trisodium citrate        Merck 
Triton X-100         Fluka 
Tryptone         Merck 
Tween-20         Fluka 
Wizard® SV DNA preparation kit      Promega 
WST-1 Cell viability / Cytotoxicity Reagent     Roche 
Yeast extract         Merck 
XhoI FastDigest® restriction enzyme      Fermentas 
 
 
2.1.2 Stock Solutions and Buffers 
3C Protease buffer: 50mM Tris, pH 8.0, 200mM NaCl, 20mM β-mercaptoethanol in dH2O. 
 
4% Paraformaldehyde solution: 4% paraformaldehyde was dissolved in dH2O at 60°C in a 
fume hood and the pH was adjusted to pH 8. The solution was kept at 4°C. Do not autoclave. 
 
4X SDS gel sample buffer: 8% SDS, 0.25M Tris pH 6.8, 30% glycerol, 2 mg/mL 
bromophenol blue and 20% β-mercaptoethanol in dH2O. This buffer was stored in in 2mL 
portions at -20°C. 
 
10X PBS (1L): 80g NaCl, 2g KCl, 14.4g Na2HPO4 and 2.4g KH2PO4 dissolved in dH2O. The 
pH was adjusted to pH 7.4 and autoclaved. The stock solution was stored at room temperature 
and diluted 10-fold as needed. 
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10X TBE: 0.9M Tris (pH 8.3), 0.89M boric acid and 25mM EDTA dissolved in dH2O. The 
solution pH was adjusted to pH 8.3 with NaOH and then autoclaved. The stock solution was 
stored at room temperature and diluted ten-fold when needed. 
 
10X SDS: 10% SDS in in dH2O. The stock solution was stored at room temperature. 
 
10X SDS electrophoresis buffer: 50mM Tris, 0.2% SDS and 500mM glycine, pH 8.3. 
 
Ampicillin: A 200mg/mL solution was made in dH2O, filter-sterilised and stored at -20 
°
C. 
 
APMA Buffer (MMP2 Activation Reagent): 1mM p-Aminophenylmercuric acetate 
(APMA) and 80mM NaOH in 1mL dH2O. This solution as kept at -20°C. 
 
Aurotetrachloro trihydrate solution, methanolic: 50mM aurotetrachloro trihydrate was 
made in 10mL methanol, 0.2μm filter purified, wrapped in aluminium foil and stored at room 
temperature. 
 
BiPS Solution: 1mg/mL (2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxy-3-phenyl-propion-
amide (BiPS) was dissolved in MMP2 assay buffer and the solution was stored at -20°C. 
 
Coomassie gel staining solution: 40% EtOH, 10% acetic acid and 0.1% Coomassie Brilliant 
Blue R-250 in dH2O. The solution was kept at room temperature. 
 
Coomassie destaining solution: 40% EtOH and 10% acetic acid in dH2O. The solution was 
kept at room temperature. 
 
Ellman’s Reagent: 2mM DTNB, 50mM Sodium acetate in dH2O and kept at 4°C. Do not 
autoclave. 
  
G418 (Gentamycin): A 50mg/mL stock solution was prepared in dH2O and stored at -20°C. 
 
HEPES buffer: 20mM N-(2-Hydroxyethyl)-piperazine-N’-ethanesulfonic acid in dH2O. The 
pH was adjusted to pH 8 and stored at room temperature. 
IPTG: A 1.0M stock solution was prepared in dH2O, filter-sterilised and stored at -20 
°
C. 
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Kanamycin: A 50mg/mL stock solution was prepared in dH2O and stored at -20 
°
C. 
 
Luria broth (LB): 1% Tryptone, 0.5% yeast extract and 0.5% NaCl in dH2O. The solution 
was autoclaved and kept at room temperature. 
 
MES Buffer: 20mM 2-(N-morpholino) ethanesulfonic acid (MES) in dH2O and adjusted to 
pH 6. Do not autoclave. 
 
MMP2 Assay Buffer: 50mM Tris, 200mM NaCl, 4mM CaCl2, 0.007% ZnCl2 and 0.2% 
NaN3 in dH2O with pH adjusted to pH 7.5. The solution was kept at 4°C. 
 
Nickel Binding Buffer: 50mM NaH2PO4, 500mM NaCl, 10mM imidazole, 0.1% Triton X-
100 and 10% glycerol in dH2O. The solution pH was adjusted to pH 8 and stored at room 
temperature. 
 
Ninhydrin solution: 1.5g Ninhydrin and 3mL glacial acetic acid in 300mL n-BuOH. The 
solution was stored at room temperature. Do not autoclave. 
 
p-Anisaldehyde solution: 3.5mL p-Anisaldehyde, 15mL glacial acetic acid and 50mL 
H2SO4(C)  in 350mL ice cold EtOH. The solution was stored at 0°C. Do not autoclave. 
 
Permeation buffer: 0.2% Triton-X100 dissolved in PBS (pH 7.4) and kept at 4°C until 
needed. Do not autoclave. 
 
Transfer buffer 1 (Tbf1): 30mM potassium acetate, 50mM MnCl2, 0.1M KCl, 10mM CaCl2 
and 15% glycerol (v/v) in dH2O. Do not autoclave. 
                           
Transfer buffer 2 (Tbf2): 9mM MOPS, 50mM CaCl2, 10mM KCl and 15% glycerol (v/v) in 
dH2O. Do not autoclave. 
 
Transfer buffer, immunoblotting: 25mM Tris base, 0.2M glycine and 20% methanol (v/v) 
in dH2O. Do not autoclave. 
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Tris-buffered saline with Tween-20 (TBS-T20): 17.6g NaCl, 0.4g KCl, 6g Tris and 500μL 
Tween-20 per 1L dH2O. The solution pH was adjusted to pH 7 and kept at 4°C until needed. 
Do not autoclave. 
 
TYM broth: 20% Tryptone, 0.5% yeast extract, 0.1M NaCl, 0.2% glucose and 10mM MgCl2 
in dH2O. Autoclave and store at room temperature. 
 
 
2.2 Chemistry and Nanotechnology Methods 
2.2.1 Characterization Techniques and Assays 
2.2.1.1 Ellman’s Assay for Reduced Thiols 
The reaction mixture for Ellman’s assay was set up as follows: 840μL ddH2O, 100μL 1M 
Tris (pH 8), 50μL DTNB and 10μL of the sample [284]. A standard series was prepared with 
cysteine hydrochloride of reduced glutathione (GSH), ranging from 0.001mM to 100mM. 
The reaction mixture was vortexed for 30sec then left to incubate at room temperature for 30-
60min. The formation of a yellow colour indicated a positive for reduced thiol content and 
200μL of the reaction mixture was transferred to a 96-well flat bottom microplate (Greiner) 
with the optical density determined at 412nm (OD412) on a Omega® POLARStar (BMG 
Labtech) multimodal plate reader. Data capture was done with Omega™ Reader Control 
software package and data analysis was done with Microsoft® Excel™ 2010. The 
concentration of the unknown thiol, in molar (M), can be determined using the Beer-Lambert 
law (εDTNB = 13 600M
-1
cm
-1
) [285]. 
 
2.2.1.2 Nuclear Magnetic Resonance (NMR) Spectroscopy 
1-D proton (
1
H) nuclear resonance spectroscopy characterization was done at the Central 
Analytical Facility (CAF) at Stellenbosch University (Stellenbosch, Western Cape, South 
Africa). The experiments were conducted on a 600MHz Varian Inova Spectrometer (Varian 
Inc.). The samples were dissolved in 750µL deuterium oxide (D2O) or 750µL deuterated 
chloroform (CDCl3) in 5mm NMR tubes. Data deconvolution was done with SpinWorks© 
V3.1.8.1. 
 
2.2.1.3 Attenuated Total Reflectance (ATR) Infrared Spectroscopy 
ATR infrared spectroscopy experiments were carried out with a Nexus (Thermo Scientific) 
spectrometer with a Smart Golden Gate Accessory (Thermo Scientific) equipped with a zinc 
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selenide (ZnSe) lens. Solid- and liquid state samples were readily analysed by deposition on 
the optic sample window. Data acquisition was done with Omnic® for a spectral range of 
600-4000cm
-1
 with 32 scans read per sample and automated refractive index correction for 
the ZnSe crystal (refractive index = 2.1). Background acquisition was done for 32 scans with 
background gain 8, set for automated compensation for ambient atmospheric CO2 and H2O 
content. Data analysis was done with Essential FTIR® V3.00.00.19. 
 
2.2.1.4 High Resolution Transmission Electron Microscopy (HR-TEM) and 
Qualitative Energy Dispersive X-ray Spectroscopy (EDX) 
a) Sample Preparation 
A sterile dust free surface was prepared and a holey carbon film (400 mesh Cu) was placed 
with the reflective side facing upward. The nanoparticle samples were suspended in dH2O at 
5mg/mL and 3 drops were dropped onto the holey copper film with a stub-nosed Pasteur 
pipette. The sample prepared copper grids were allowed to dry at room temperature before 
being placed in a sample cartridge. The cartridge was dried in vacuo for at least 24h before 
analysis.   
  
b) High Resolution Transmission Electron Microscopy (HR-TEM) and 
Qualitative Energy Dispersive X-Ray Spectroscopy (EDX) 
Sample analysis was conducted by Dr S. Botha with a Tecnai F20 high resolution Field 
Emission Transimission Electron Microscope (TEM) equipped with modules for EDS, STEM 
(Scanning TEM), EELS (Electron Energy Loss Spectroscopy) and a HAADF (High Angle 
Angular Dark Field) detector. The obtained micrographs were analysed with ImageJ V1.46r. 
 
2.2.1.5 Quantitative Energy Dispersive X-Ray Spectroscopy (EDX) 
Synthesized gold nanoparticles were lyophilized and 30-50mg of the appropriate sample was 
transferred to a 15mL polypropylene tube and sealed with parafilm. The samples were sent 
for quantitative EDX analysis by Dr J.D. Painter at the Department of Engineering and 
Applied Materials Science, Cranfield University, Cranfield, Bedfordshire, United Kingdom. 
  
2.2.1.6 Ultra Violet-Visible (UV-Vis) Spectroscopy, UV-Vis Spectrometry and 
Luminescence 
UV-Vis spectroscopy and luminescence assays were conducted on an Omega® POLARStar 
(BMG Labtech, Offenburg) multimodal plate reader. The plate reader has an absorbance 
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spectrometer, preselected fluorescence excitation/emission filter wheels and luminescence 
modules. Data acquisition can be done for endpoint- as well as kinetic analysis for all above 
mentioned spectral functions and was done with the Omega® Reader Control software 
package with acquired data exported in Microsoft® Excel™ 2010 format. Acquisition 
parameters which were typically used are given below. 
 
(a) UV-Vis spectroscopy and UV-Vis Spectrometry 
An absorbance spectrometer with a xenon flash-lamp was used for spectral- and absorbance 
acquisition. Spectral acquisition was in the range 220-850nm with a resolution of 1nm. 
Absorbance data acquisition was done with up to 8 different specified discrete wavelengths 
simultaneously, dependent on the assay requirements. Both data acquisition modes utilized 
200 scans per well with the THERMOStar™ incubator pre-set at 25°C and 6-well to 96-well 
clear microplates were read with the bottom optic. Assay specifics will be discussed in the 
appropriate sections. 
 
(b) Luminescence 
The luminescence module was installed as required and the THERMOStar™ incubator pre-
set at the required assay temperature. The fluorescence emission filter wheels were set to 
“lens” and the integration time was set at 0.5sec per well with data normalized to 0.1sec. 
Luminescent samples were prepared in 96-well U-bottom black plates (Merck) and read with 
the top optic. 
 
2.2.1.7 Fluorescence Emission Spectroscopy 
Fluorescent quantum dots samples were prepared in the appropriate buffer solutions at equal 
concentrations and 400μL was transferred to precision cell Quarzglas SUPRASIL® cuvettes 
(Hellma Analytics, Mullheim, Germany). Fluorescence emission spectra were obtained using 
a Nanolog
TM 
3-22-TRIAX (Horiba, USA) fitted with double grating excitation and emission 
monochromators (slit width of 5nm) for a spectral range of 400-800nm. 
.  
2.2.1.8 High Pressure Liquid Chromatography Electron Spray Ionization 
Mass Spectrometry (HPLC-ESI-MS) 
The protocol was utilized for accurate mass determination of small molecules by Dr T. 
Kudanga (Biocatalysis and Technical Biology, Cape Peninsula University of Technology, 
Cape Town, South Africa). LC-MS was performed on an Ultimate 3000 Dionex HPLC 
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system (Dionex Softron, Germering, Germany) equipped with a binary solvent manager and 
autosampler and coupled to a Brucker ESI Q-TOF mass spectrometer (Bruker Daltonik 
GmbH, Germany). The products were separated by reversed phase chromatography, on a 
Waters Sunfire C18-column (5μm; 4.6×150mm; Dublin Ireland). Methanol, water and 
trifluoroacetic acid (30:70:0.1 v/v/v) was used as solvent with isocratic elution for 20min at a 
flow rate of 1mL.min
−1
 with an oven temperature of 30°C. MS spectra were acquired in 
positive mode using the full scan and auto MS/MS (collision energy 25eV) scan modes with 
dual spray for reference mass solution. Electrospray voltage was set to -4500V. Dry gas flow 
was set to 9L.min
−1
 with a temperature of 300°C and nebulizer gas pressure was set to 35psi. 
 
2.2.1.9 Agarose Gel Electrophoresis of Gold Nanoparticles 
Gold nanoparticles were resolved by agarose gel electrophoresis on 0.25-0.5% gels and 
electrophoresed in 1x TBE buffer. The loading sample was prepared by mixing gold 
nanoparticles with 30% glycerol in a ratio of 1:1 and loaded into the wells at a volume of 15-
20µL. The samples were electrophoresed at 40V for 30-45min. Agarose gels were visualized 
and photographed with the UVP BioSpectrum® Imaging System. 
 
 
2.2.2 Synthesis of Ligands to be used in Gold Nanoparticle Functionalization 
Glassware and magnetic stirrer bars were stripped with 5M NaOH, rinsed with ultrapure 
water (18.2MΩ), treated with high purity acetone (Merck) and over dried at 90°C. Solvents 
and chemicals of highest purity were used in the synthesis. Reactions were monitored with 
thin layer chromatography on silica coated aluminium foil plates (Merck). The TLC analysis 
was done by using functional group specific staining solutions (p-anisaldehyde and 
ninhydrin), ultraviolet (254nm) staining and iodine staining. Inert reaction atmospheres were 
not used. 
 
2.2.2.1 Synthesis of 6-N-2-(N-bis(carboxymethyl))-hexanoic acid (NH2-NTA) 
This synthesis is adapted from the literature [286]. Bromoacetic acid (30.2mM) was dissolved 
in 15mL of ice cold 1.5N NaOH aqueous solution and kept at 0°C while stirring. N
ε
-Z-L-
lysine (0.5eq) was dissolved in 25mL ice cold 1.5M NaOH solution and added drop wise to 
the bromoacetic acid solution. The solution was heated to 50°C with stirring for 2h and left to 
cool to ambient room temperature string overnight. To this stirring solution 45mL of 1M HCl 
was added drop wise with the immediate formation of a white precipitate (N
ε
-Z-NTA). The 
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reaction was allowed to go to completion for 2h (monitored by TLC) and the precipitate was 
washed with ultrapure water (18.2MΩ) three times on a Buchner funnel. The precipitate was 
dissolved 50mL methanol:H2O (20:1) with the addition of a spatula tip of 5% Pd/C under 
stirring at room temperature and atmospheric pressure. The hydrogenation reaction reached 
completion within 5 days, monitored with TLC. The catalyst was filtered off with a Buchner 
funnel and the solvent was then removed in vacuo. The white-yellow precipitate was 
dissolved in 200mL ethanol:dH2O (97.5:2.5) and left to crystallize at 0°C for 2-4 days. The 
crystals were washed with ethanol (Merck), oven dried and analysed by proton NMR 
spectroscopy (Section 2.2.1.2).   
 
2.2.2.2 Synthesis of 6-N-Thiobutyro-2-(N-bis(carboxymethyl))-hexanoic acid 
(SH-NTA) 
The 6-N-2-(N-bis(carboxymethyl))-hexanoic acid (NH2-NTA) crystals (Section 2.2.2.1) were 
dissolved in 50mL 20mM MES buffer (pH 6) at room temperature with rapid stirring. 
Thiobutyrolactone (5eq) was added to the stirring solution and allowed to reach completion 
within 16h, confirmed by TLC. The whole reaction solution was freeze-dried (Section 2.3.4) 
and the lyophilized powder was resuspended in 200mL ethanol:dH2O (97.5:2.5) and left to 
crystallize at 0°C for 2-4 days. The crystals were washed with ethanol (Merck), oven dried 
and analysed by proton NMR spectroscopy (Section 2.2.1.2). 
 
2.2.2.3 Synthesis of thiolated Hyperbranched High Molecular Weight 
Polyethyleneimine (SH-PEI) 
Hyperbranched polyethyleneimine (~15.4kDa, PEI) was dissolved in 50mL 20mM MES 
buffer (pH 6) at room temperature with rapid stirring. Thiobutyrolactone (1.1eq) was added 
to the stirring solution and reached completion after 24h, monitored with TLC. The whole 
reaction solution was freeze-dried (Section 2.3.4) and suspended in 5mL ultrapure water 
(18.2MΩ). The 5mL solution was dialyzed with a 3500 MWCO dialysis cartridge (Pierce 
Biotechnology) against ultrapure water (18.2MΩ) for 2 days with the addition of fresh buffer 
twice daily. The contents of the dialysis cartridge were transferred to a 50mL polypropylene 
tube.  The product was confirmed to be thiolated and quantified with Ellman’s assay (Section 
2.2.1.1). 
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2.2.3 One-pot Synthesis and Bio-functionalization of Gold Nanoparticles (AuNPs) 
2.2.3.1 Synthesis  
Glassware and magnetic stirrer bars were stripped with 5M NaOH, rinsed with ultrapure 
water (18.2MΩ), treated with high purity acetone (Merck) and over dried at 90°C. Solvents of 
highest purity were used in the synthesis. The one-pot synthesis is adapted from Zheng at al 
[287]. 600μL of a methanolic aurotetrachloro trihydrate solution was dissolved in 55mL 
methanol:acetic acid (0.73:0.27) stirring at room temperature. The desired surface ligand was 
prepared in ultrapure water (18.2MΩ) and added all at once at a predetermined ratio to aurate 
ions in solution, Ligand:Au
3+, ranging from 0.25:1 → 1:1. The solution was left to stir for 5-
20min and aqueous sodium borohydride (NaBH4) was added drop wise at a predetermined 
ratio to aurate ions in solution, NaBH4:Au
3+, ranging from 0.25:1 → 1.1. The reaction 
solution turned brown, black then a hue of red. The reaction was monitored, by taking 500μL 
aliquots at 30min intervals, using UV-Vis spectroscopy (Section 2.2.1.6) for the formation of 
gold nanoparticles (AuNPs). The reaction was complete after 5h when no further change was 
observed for the UV-Vis spectra. The one-pot functionalized AuNPs were sedimented by 
centrifugation at 8000g for 45min in a Beckman Coulter centrifuge (SX4750A swing rotor). 
The AuNP sediment was resuspended and washed 5 times with 10mL PBS (pH 7.4) by 
centrifugation at 8000g for 45min in a Beckman Coulter centrifuge (SX4750A swing rotor). 
The AuNPs were transferred to a 10 000MWCO dialysis cartridge (Pierce Biotechnology) 
and dialysed against PBS (pH 7.4) for 2 days with fresh buffer added twice daily. The AuNPs 
were freeze-dried (Section 2.3.4) and the lyophilized powder was kept at room temperature in 
the dark. The lyophilized AuNP powder was grey to black in colour and was readily 
resuspended in ultrapure water (18.2MΩ) at 5mg/mL-100mg/mL without loss in optical 
density for up to 1 year after synthesis.   
 
2.2.3.2 Evaluation of Gold Nanoparticle (AuNP) Aqueous Stability 
The lyophilized AuNPs (2.2.4.1) were suspended in ultrapure water (18.2MΩ) at 5mg/mL-
50mg/mL. The AuNP samples were adjusted to an optical density (OD) ~1.6 and 25μL was 
transferred to a 96-well flat bottom clear microplate (Greiner). The appropriate buffer was 
pipetted to the corresponding wells to a final volume of 200μL with the AuNPs final OD 
~0.2. The UV-Vis spectrum of each well was determined (Section 2.2.1.6a) and monitored at 
different time intervals for the following parameters: ionic strength, pH and biomolecule 
interactions. Citrate (pH 5 and pH 6) was used from 0.001M to 1M; sodium chloride (NaCl) 
was used from 0.001M to 1M and β-mercaptoethanol was used from 0.25mM to 25mM. 
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Biomolecule interactions were done with bovine serum albumin (BSA), at a final 
concentration of 1mg/mL, as well as tissue culture media, with and without foetal bovine 
serum supplemented. 
 
2.2.3.3 Bioconjugation to Functionalize Gold Nanoparticle Surfaces 
2.2.3.3.1 Differential Functionalization of the Gold Nanoparticle Surface 
with Commercial Crosslinker SM-PEG6 
Quantitative EDX analysis (Section 2.2.1.5) was used to determine the nitrogen content of the 
lyophilized AuNP samples. The assumption was made that nitrogen contributing to the 
elemental composition of the AuNP samples were from the surface ligand. PBS does not 
contain nitrogen and atmospheric nitrogen was discounted as the EDX analysis was 
conducted in vacuo. The estimated amount of primary- (149mol), secondary- (90mol) and 
tertiary amines (120mol) cumulatively delivers 359mol nitrogen for 1mol PEI-SH on the 
surface of the AuNPs. As an example, if EDX indicated an average nitrogen content of 10% 
for 5mg/mL AuNPs, this would mean:  
                     
                   
 x 10% x 5mg/mL = 0.21mg/mL 
primary amines (-NH2) for 5mg/mL AuNPs. The SM-PEG6 bifunctional crosslinker (Pierce 
Biotechnology) utilizes carbodiimide and maleimide bioconjugation chemistry to crosslink 
primary amines (NH2) and thiols (SH) [288]. The SM-PEG6 was attached to the primary 
amines of PEI-SH on the AuNP surface in the following manner: 10% (0.02mg/mL primary 
amines), 20% (0.04mg/mL primary amines) and 30% (0.06mg/mL primary amines) SM-
PEG6 to total primary amines. 
 
The crosslinking reaction times were conducted for the maximum time recommended by the 
manufacturer. The AuNPs (5mg/mL) was dissolved in 20mL 20mM HEPES buffer (pH 8) 
stirring at room temperature. SM-PEG6 (1.1eq) was added to the calculated amount of 
primary amines and the reaction was left to proceed for 40-60min. A 500μL aliquot was 
taken for UV-Vis spectroscopy analysis of the surface plasmon band (λSPR). Equimolar 
amounts of SH-NTA (Section 2.2.2.2) to SM-PEG6 were added to the solution and the 
reaction was left to proceed for 60-80min. A 500μL aliquot was taken for UV-Vis 
spectroscopy analysis of the surface plasmon band (λSPR). The surface modified AuNPs were 
sedimented and washed three times with 10mL PBS (pH 7.4) by centrifugation at 8000g for 
45min in a Beckman Coulter centrifuge (SX4750A swing rotor). Colloidal stability of the 
surface modified AuNPs was determined as in Section 2.2.3.2. 
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2.2.3.3.2 Glutaraldehyde Mediated Amine-to-Amine Crosslinking of 
Doxorubicin to the Gold Nanoparticle (AuNP) Surface 
The glutaraldehyde crosslinking of primary amines is from known drug loading [289] and 
protein crosslinking protocols [290]. Surface modified AuNPs (2.2.4.3.1) were suspended at 
5mg/mL in a rapidly stirring 50mL 20mM HEPES (pH 8) which contained 45mg doxorubicin 
(0.9mg/mL). The reaction vessel was protected from direct ambient light by aluminium foil 
and the mixture was stirred for 15-20min. A freshly prepared 2.5% glutaraldehyde solution 
(20mM HEPES, pH 8) was added to the stirring solution in four equal 250μL portions over 
10min. The solution colour slowly changed from bright clear red to a turbid orange colour. 
The reaction was quenched with 500μL 1M Tris (pH 8). The doxorubicin loaded AuNPs 
were sedimented and washed (5x) with PBS (pH 7.4) by centrifugation at 8000g for 10min in 
a Beckman Coulter centrifuge (SX4750A swing rotor) precooled to 4°C. The doxorubicin 
loaded AuNPs were freeze-dried and kept protected from light at -20°C. 
 
2.2.3.3.3 Quantification of the Doxorubicin on the Surface of Gold 
Nanoparticles 
(a) Acid hydrolysis drug release 
Acid hydrolysis of doxorubicin release is typically done with 1M HCl [291] but was adapted 
to a lower concentration to determine if doxorubicin was gradually released from the AuNP 
surface. The amine-sugar which is attached by an ether linkage to the anthracine-like 
structure of doxorubicin (Figure 1.5, Section 1.2.3.2.2) is labile in acidic environments and 
will facilitate doxorubicin release without the need for a pH-sensitive linker. The doxorubicin 
loaded AuNPs (100pM) were suspended in dH2O at and aliquotted into different 1.5mL 
Eppendorf tubes containing 750μL 0.1N HCl. The contents of the tubes were mixed by gentle 
inversion and left to incubate at room temperature for different time intervals to determine 
acid hydrolysis facilitated drug release of doxorubicin from the AuNP surface. At the 
appropriate time interval the AuNPs were sedimented by centrifugation at 16 000g in an 
Eppendorf 5415D bench top centrifuge (Rotor: F45-24-11). The doxorubicin containing 
supernatant was snap frozen in liquid nitrogen and stored at -20°C.   
 
(b) High pressure liquid chromatography (HPLC) quantification 
High pressure liquid chromatography was performed on an Ultimate 3000 Dionex HPLC 
system (Dionex Softron, Germering, Germany) equipped with a binary solvent manager, an 
autosampler and a coupled photodiode array. The acid hydrolyzed supernatants (Section 
 
 
 
 
66 
 
2.2.3.3.3a) were separated by reversed phase chromatography on a Hypersil Gold C18-
column (5μm; 4.6×250mm; Thermo). The mobile phase was a mixture of methanol, 
acetonitrile, water and trifluoroacetic acid (25:15:60:0.1 v/v/v) with isocratic elution for 
20min at a flow rate of 0.8mL.min
−1
 and an oven temperature of 40°C. UV detection of 
doxorubicin was done at 272nm and confirmed with corresponding UV-Vis spectra which 
showed doxorubicin absorbance maxima at 495nm. Quantification of doxorubicin was done 
with a doxorubicin standard series ranging from 0.001μg/mL to 1μg/mL. 
 
 
2.2.4 Ligand Exchange and Bio-functionalization of Indium Phosphide Quantum 
Dots 
Surface changes on the quantum dot surface were monitored with fluorescence spectrometry 
(Section 2.2.1.7). 
 
 
2.2.4.1 Ligand Exchange of Indium Phosphide Quantum Dots 
The following protocol is an adaptive amalgation of various protocols [223, 292-294]. A 
methanolic solution of 1μM palmitic acid passivated indium phosphide quantum dots with a 
maximum emission wavelength at 625nm (QD625) were obtained from Mr Paul Mushonga 
[388] (Chemistry Department, University of the Western Cape, Cape Town, South Africa). 
The QD625 was sedimented and washed three times with 1mL methanol by centrifugation at 
16 000g in an Eppendorf 5415D bench top centrifuge (Rotor: F45-24-11) and suspended in 
500μL chloroform in a 1.5mL Eppendorf tube. In a separate Eppendorf tube a 500μL aqueous 
solution containing 1mM thiolated polyethyleneimine (PEI-SH, Section 2.2.2.3) and 1mM 
tetrabutyl-ammonium hydroxide (Sigma) was incubated at room temperature for 30min. The 
contents of the tubes were mixed together and vortexed for 2-4h at room temperature. Ligand 
exchange was completed when the red QD625 exchanged from the chloroform layer to the 
aqueous layer. The water soluble PEI-SH functionalized QD625 was sedimented by 
centrifugation at 16 000g in an Eppendorf 5415D bench top centrifuge (Rotor: F45-24-11) 
and suspended in 500μL ultrapure water (18.2MΩ). Fluorescence spectroscopy indicated no 
fluorescence signal was left in the organic layer and it was assumed that all QD625 were 
successfully ligand exchanged with PEI-SH into the aqueous layer. The PEI-SH 
functionalized quantum dots were kept at 4°C until needed. 
 
 
 
 
 
 
67 
 
2.2.4.2 Bio-functionalization of Indium Phosphide Quantum Dots  
(a) Differential Functionalization of the Quantum Dot Surface with Commercial 
Crosslinker SM-PEG6 
The assumption was made that the quantum dots were of the same size range as the gold 
nanoparticles used in this study. A further assumption was made that the amount of the PEI-
SH on the surface of QD625 would have the same packing density as on the surface of AuNP. 
The quantum dots (Section 2.2.4.1) were lyophilized (Section 2.4.3) then resuspended in 
dH2O at 5mg/mL with the appropriate amount of SM-PEG6 (10%, 20% and 30%) and SH-
NTA added. The reaction conditions and purification were as described in Section 2.2.3.3.1. 
    
(b) Carbodiimide Crosslinking of Chlorotoxin to the Quantum Dot Surface 
The modified quantum dots (Section 2.2.4.2a) were suspended in 20mL HEPES buffer 
(20mM, pH 8) stirring at room temperature and recombinant chlorotoxin (Section 2.3.3) was 
added at a final concentration of 1μg/mL. The reaction mixture was left to stir for 5-10min 
and 1.5 equivalents of freshly prepared 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
HCl (EDC) was added and the reaction was left to proceed for 40-60min. The peptide 
functionalized quantum dots were sedimented and washed three times with 10mL PBS by 
centrifugation at 6000g for 10min in a Beckman Coulter centrifuge (SX4750A swing rotor) 
precooled to 4°C and suspended in ultrapure water (18.2MΩ) to a final concentration of 
10nM. The peptide functionalized quantum dots were protected from light kept at 4°C. 
 
 
2.3 Molecular Biology Techniques 
2.3.1 Bacterial Cell Culture 
2.3.1.1 Bacterial Strains 
Escherichia coli strain DH5α:  
 F
–
 Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 
λ– thi-1 gyrA96 relA1. This strain was used to produce plasmid DNA. 
 
Escherichia coli strain ArcticExpress™ (DE3): 
B F
–
 ompT hsdS(rB
–
 mB
–
) dcm
+
 Tet
r
 gal λ(DE3) endA Hte [cpn10 cpn60 Gentr]. This strain 
was used to produce recombinant peptides. 
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2.3.1.2 Antibiotic Selection 
Transformed E. coli containing ampicillin or kanamycin (G418) resistant plasmids were 
plated on nutrient agar with the appropriate concentration of antibiotics. Ampicillin was used 
at 200µg/mL and kanamycin (G418) was used at 35µg/mL. Antibiotic specific selection was 
maintained for bacterial growth in liquid culture by inclusion of the appropriate antibiotic at 
similar concentration as was used for nutrient agar growth. 
 
2.3.1.3 Preparation of Competent Bacterial Strains for Transformation 
Nutrient agar plates with were used to streak a desired bacterial strain onto with incubation 
overnight at 37°C. A single colony was picked and inoculated into 20mL TYM broth. The 
liquid culture was put on a shaker (200rpm) at 37°C and monitored until the optical density 
(OD550) was ~0.2. This liquid culture was then transferred to 100mL TYM broth and grown 
at 37°C until OD550 reached 0.2. To this culture 400mL fresh TYM broth was added and 
grown until OD550 was between 0.4-0.6. The cells were rapidly cooled on ice water by 
swirling and then transferred to 250mL centrifuge tubes. The cells were pelleted by 
centrifugation at 6000g for 10min in a Beckman Coulter centrifuge (SX4750A swing rotor) 
precooled to 4°C. The cell pellet was resuspended in ice cold 250mL Tfb1 and left to 
equilibrate for 30min. The cells were then pelleted by centrifugation. The cell pellet was 
resuspended in 30mL Tfb2. The cells were snap frozen in 300µL portions with liquid 
nitrogen and stored at -80°C. 
 
2.3.1.4 Bacterial Transformations 
Competent cells (Section 2.3.1.3) were thawed on ice for 30min. A 100µL of the competent 
cells were transferred to two autoclaved Eppendorf tubes and kept on ice. A negative control 
was setup by adding 1µL water to the competent cells and treating the control identical as the 
plasmid DNA experiment.  Plasmid DNA, 1µL of 100-300ng DNA, was added and gently 
mixed by inversion of the tube and incubated on ice for 30min. ells were then heat shocked at 
37°C for 5min and cooled on ice for 5min with immediate addition of 500µL pre-warmed LB 
without antibiotics. The mixture was incubated at 37°C for 1h. The cells (50µL) were then 
plated with glass beads onto nutrient agar plates containing the appropriate antibiotic(s) and 
grown overnight at 37°C. 
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2.3.2 Acquisition, Preparation and Manipulation of DNA 
2.3.2.1 Acquisition of Template DNA 
A synthetic variant of chlorotoxin gene was designed based on the published amino acid 
sequence [118] and commercially synthesized by GenScript (GenScript Inc., New Jersey, 
USA) to be subcloned into a pGEX-6P-2 expression construct. The construct obtained was 
named pGEX-6P-2-CTX. A pGEM-T-Easy cDNA clone of MMP2 was prepared from MCF-
7 breast cancer cells by Miss C Dodgen (Biotechnology Department, University of the 
Western Cape, Bellville, Cape Town, South Africa). The sequence was confirmed to be a 
perfect match for wild type MMP2 and was named pGEM-T-MMP2. 
 
2.3.2.2 Isolation of plasmid DNA 
A single colony of transformed (2.3.1.4) E. coli was picked at random from an overnight 
nutrient agar plate and inoculated into 10mL LB containing the appropriate antibiotic(s). The 
inoculated culture was incubated at 37°C with shaking for 16h. The cells were harvested by 
centrifugation at 6000g for 10min in a Beckman Coulter centrifuge (SX4750A swing rotor). 
The plasmid DNA was isolated with the Promega Wizard® SV plasmid isolation kit. The 
protocol was completed according to the manufacturer’s instructions. 
 
2.3.2.3 PCR Amplification of Gene Fragments 
PCR reactions were done at a final volume of 25µL. The amount of template DNA used was 
concentration dependent. The composition typical for a PCR reaction can be seen in Table 
2.1. 
 
Table 2.1: PCR reaction composition 
 Volume (µL) Final [ ] 
HiFi hotstart Taq 
Mastermix (x2) 
12.5 x1 
Forward primer 
(10µM stock) 
1.0 0.4µM 
Reverse primer 
(10µM stock) 
1.0 0.4µM 
Template DNA 1.0 – 2.0 1-5ng/µL 
ddH2O 8.5 – 9.5 - 
Total 25.0 - 
 
Oligonucleotide melting temperatures (Tm) was provided by the supplier (IDT Technologies) 
and was confirmed by using an online tool OligoCalc (www.basic.northwestern.edu/biotools 
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/oligocalc.html). Thermal cycling conditions used for the different templates are given in (a) 
and (b), respectively. PCR products were analysed by electrophoresis on 1% agarose gels 
with 1x TBE as electrophoresis buffer. 
 
(a) Thermal cycling conditions for amplification of pGEX-6P-2-CTX 
94
o
C for 2min (Initial denaturation) 
94
o
C for 1min (Denaturation) 
98
o
C for 20sec (Hotstart Taq activation) 
60
o
C for 15sec (Annealing) 
72
o
C for 30sec min (Extension) 
72
o
C for 5 min (Final extension) 
 
(b) Thermal cycling conditions for amplification of pGEM-T-MMP2 
94
o
C for 2min (Initial denaturation) 
94
o
C for 1min (Denaturation) 
98
o
C for 20sec (Hotstart Taq activation) 
65
o
C for 45sec (Annealing) 
72
o
C for 30sec min (Extension) 
72
o
C for 5 min (Final extension) 
 
2.3.2.4 Gel Extraction and Purification of PCR Products and DNA 
DNA bands of the desired size were excised from the agarose gel under brief UV-assisted 
visualization and purified with the QIAquick® gel extraction kit (Qiagen). The protocol was 
completed according to the manufacturer’s recommendations. The purified amplicons were 
used immediately or stored at 4°C until needed. Plasmid DNA was purified in a similar 
manner. 
 
2.3.2.5 Restriction Enzyme Digestion of PCR Products and Plasmids 
Restriction enzymes were used and inactivated as recommended by the manufacturer 
(Fermentas). Typically, restriction enzyme digestion reaction final volume was 50μL where 
the reaction constituents were as follows: 5μL FastDigest® 10x green buffer; 4-6μL for the 
appropriate combination of FastDigest® double digestion restriction enzymes; 2-10μL DNA 
with the remainder of the volume made up with nuclease free water. The reaction mixtures 
were mixed by gentle pipetting or inversion and incubated at 37°C for 90min. The restriction 
25 cycles 
20 cycles 
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enzymes were inactivated by the addition of 1μL 0.2M EDTA (pH 8) or by heating the 
reaction mixture at 80°C for 5min, dependent on the manufacturer’s recommendations. The 
reaction mixtures were resolved on an agarose gel and purified with QIAquick® gel 
extraction kit (Qiagen) as per manufacturer’s recommendations. 
 
PCR amplicons (Sections 2.3.2.3a and 2.3.2.3b) were purified as described in Section 2.3.2.4 
and were double digested with BamHI and XhoI. Plasmid DNA (pGEX-6P-2) obtained as 
described in 2.3.2.2 was also double digested with BamHI and XhoI. This enabled insertion of 
the PCR amplicon sequence in the correct 5' to 3' orientation in the multiple cloning site 
(MCS) of the pGEX-6P-2 plasmid. The restriction enzymes left the pGEX-6P-2 with non-
complementary ends which prevented self-ligation. The pGEX-6P-2 vector enabled the 
recombinant fusion of an N-terminal glutathione-S-transferase (GST) which allows for 
specific fusion protein purification downstream.  
 
Figure 2.1: Circular vector map of pGEX-6P-2 
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The pEGFP-N3 plasmid was double digested with SalI and BglII, isoschizomers for BamHI 
and XhoI, respectively. The restriction enzymes left the pEGFP-N3 construct with non-
complementary ends, preventing self-ligation. This enabled the insertion of PCR amplicons 
(Sections 2.3.2.3a and 2.3.2.3b), digested with BamHI (5') and XhoI (3'), in the correct 5' to 3' 
orientation. Ligation into this vector would destroy the respective restriction sites, making it 
impossible to release the inserted DNA sequence. The pEGFP-N3 vector enabled the fusion 
of enhanced green fluorescent protein (EGFP) to the C-terminal of recombinant proteins. 
 
  
Figure 2.2: Circular vector map of pEGFP-N3 
 
 
 
 
73 
 
2.3.2.6 Ligation of DNA 
PCR amplicons and plasmid DNA, prepared as in Sections 2.3.2.4 and 2.3.2.5, was used in 
ligation reactions. Typically, the ratio of PCR amplicon insert DNA to plasmid DNA was 
calculated at a ratio of 3:1 to 6:1 depending on the amount of DNA. The following equation 
was used for the above mentioned calculation: 
 
(
(                          ) (                    )
(                     )
)  (                          )  
 
A typical ligation reaction can be seen in Table 2.2. The ligation was left to proceed at 4°C 
for 16h and then used to transform competent E. coli (Section 2.3.1.4). 
 
Table 2.2: The composition for a typical ligation reaction 
 Volume (µL) Final [ ] (ng/μL) 
*PCR Amplicon 12-24 24-72 
*Plasmid 2-6 4-12 
T4 ligase 2 - 
ddH2O 24-8 - 
Total 40  
*Purified and restriction enzyme digested 
 
2.3.2.7 Colony PCR to Screen for Positive Bacterial Transformants 
Transformed E. coli (Section 2.3.1.4) was plated onto nutrient agar and left to grown 
overnight at 37°C. Colonies were picked at random with a sterile pipette tip and gently mixed 
into the appropriate PCR tube containing the PCR reaction mixture by pipetting the mix ten 
times. The composition for a typical colony PCR reaction can be seen in Table 2.3. Gene 
specific primers were used. Thermal cycling conditions used for colony PCR were:  
 
94
o
C for 2min (Initial denaturation) 
94
o
C for 1min (Denaturation) 
Tm-5
o
C for 1min (Annealing) 
72
o
C for 45sec (Extension) 
72
o
C for 5 min (Final extension) 
 
30 cycles 
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  Table 2.3: colony PCR reaction composition 
 Volume (µL) Final [ ] 
DreamTaq Mastermix (x2) 12.5 x1 
Forward primer 
(10µM stock) 
1.0 0.4µM 
Reverse primer 
(10µM stock) 
1.0 0.4µM 
ddH2O 10.5 - 
Total 25.0 - 
 
PCR products were analysed by electrophoresis on 1% agarose gels with 1x TBE as 
electrophoresis buffer. 
 
2.3.2.8 Agarose Gel Electrophoresis of DNA 
DNA was resolved by agarose gel electrophoresis on 1% gels with GelRed (20µL per 100mL 
agarose) and electrophoresed in 1x TBE buffer. The loading sample was prepared by mixing 
sample DNA with commercial loading buffer (Fermentas) in a ratio of 5:1 and loaded into the 
wells at a volume of 5-10µL. A DNA molecular marker, O’GeneRuler™ DNA 100bp ladder 
(Fermentas) was utilized to estimate DNA fragment sizes and was loaded at a volume of 
2.5µL. The samples were electrophoresed at 100V for 45-60min. Agarose gels were 
visualized and photographed with the UVP BioSpectrum® Imaging System. 
 
2.3.2.9 Quantification of DNA 
DNA content of samples were analysed using the Nanodrop-1000 spectrophotometer. The 
sample pedestal was wiped clean and the spectrophotometer was blanked with 1µL ddH2O. 
The appropriate sample was loaded onto the sample pedestal at 1µL. This was repeated three 
times and the average value was the estimated DNA content in ng/μL. 
 
2.3.2.10 Sequence Analysis of Clones 
The desired clones identified by colony PCR (Section 2.3.2.7) were streaked onto nutrient 
agar plates and left to grow overnight at 37°C. The plates were sealed with parafilm and sent 
for sequencing at Inqaba Biotechnologies. The sequencing was done for all clones with the 
following: 
(i) Plasmid specific primers in both directions (5' → ,3' ←) 
(ii) Gene specific primers flanking the restriction enzyme sites of sequence insertion 
(5' → ,3' ←) 
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(iii) Internal sequence primers, reading the gene sequence from the centre of the gene 
towards the ends (3' ←, 5' →) 
Sequencing data obtained was analysed with various programs. FinchTV© (V1.4.0) was used 
to determine sequence chromatogram quality. BioEdit© Sequence Alignment editor was used 
to do multiple sequence alignments as well as generate a consensus sequence. The BLAST® 
(GenBank) algorithm was used to align the consensus sequence with the wild type 
oligonucleotide sequences. 
 
2.3.3 Recombinant Protein Production, Extraction and Purification 
2.3.3.1 Protein Expression 
Expression construct (pGEX-6P-2) transformed ArcticExpress™ E. coli were gown 
overnight at 37°C on nutrient agar plates with the appropriate antibiotics. Single colonies 
were picked and used to inoculate 100mL LB agar containing the appropriate antibiotics and 
grown overnight at 37°C on a rotary shaker (200rpm). Fresh 900mL LB with appropriate 
antibiotics was inoculated with the 100mL overnight culture and grown at 37°C on a rotary 
shaker until an optical density (OD) of 0.8 was reached. The incubation temperature was 
decreased to 10°C and Isopropyl-b-D-thiogalactopyranoside (IPTG) was added to the liquid 
culture to a final concentration of 2mM to induce protein production. The culture was left to 
grow for 48h at 10°C and the cells were harvested. The cell suspension was transferred to 
250mL centrifuge tubes and centrifuged at 6000g for 10min in a Beckman Coulter centrifuge 
(SX4750A swing rotor) precooled to 4°C. The cell pellets were stored at -20°C. 
  
2.3.3.2 Protein Extraction 
Cell pellets were thawed on ice and resuspended in BugBuster™ (Bugbuster™ GST Bind 
Purification Kit, Novagen) bacterial cell lysis reagent, 5mL BugBuster™ per 1g wet cell 
paste, by pipette mixing the cell paste with the lysis reagent. Benzoase™ Nuclease 
(Bugbuster™ GST Bind Purification Kit, Novagen) was added to the cell suspension, 1µL 
Benzoase™ Nuclease per 1mL BugBuster™, and thoroughly mixed by pipetting. The cell 
suspension mixture was incubated at 37°C for 30min. The lysates were cleared from cellular 
debris by centrifugation at 10 000g for 10min in a Beckman Coulter centrifuge (SX4750A 
swing rotor) precooled to 4°C. The lysates was kept at -20°C until needed. 
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2.3.3.3 Recombinant Protein Purification 
The chromatography columns, glutathione agarose as well as buffers used in this section are 
all components of the Bugbuster™ GST Bind Purification Kit (Novagen) unless mentioned 
otherwise. 
 
(a) Column Preparation 
A glutathione agarose chromatography column was packed under gravity flow according to 
the manufacturer’s recommendations. The column was equilibrated with 30 column volumes 
of 1x GST Bind/Wash buffer prepared from 10x GST Bind/Wash buffer. This column was 
used for the purification of GST tagged fusion proteins. 
 
(b) Purification of Crude Cell Lysate 
The cell lysate prepared as described in Sections 2.3.3.2 was loaded onto the column 
prepared in Section 2.3.3.3a and collected for reloading onto the column. This was repeated 
twice and the flow through was collected. The column was washed with 40 column volumes 
of 1x GST Bind/Wash buffer and then eluted with 15 volumes 1x GST Elute buffer. The 
column was washed with 40 column volumes of 5M NaCl and stored in 20% ethanol (aq) for 
future use. The flow through-, wash- and elute fractions were resolved on a 16% SDS-PAGE 
gel with 1x SDS electrophoresis buffer. 
 
(c) Cleavage of Recombinant Proteins 
The GST fusion proteins were cleaved by recombinant 3C Protease™ which was obtained 
from Mr F. Hassem. The elute fractions (Section 2.3.3.3b) were pooled then suspended in an 
equal volume of 3C Protease buffer with the addition of 10U 3C Protease per mg total GST 
fusion protein in a 50mL polypropylene tube and left at 4°C with gentle agitation overnight.  
 
(d) Buffer Exchange, Fractionation and Concentrating of Protein Samples 
The protein mixture obtained in Section 2.3.3.3c was concentrated and buffer exchanged 
using a 2000 MWCO concentrator tube (Millipore) into 1x PBS (pH 7.4) by centrifugation at 
6000g for in a Beckman Coulter centrifuge (SX4750A swing rotor) precooled to 4°C. The 3C 
Protease™ (46kDa) and GST (26kDa) was fractionated from the recombinant peptide (< 
10 000kDa) with a 10 000 MWCO concentrator tubes (Millipore) by centrifugation as above 
and 1x PBS (pH 7.4) as the buffer. The fractionated samples were individually concentrated 
with 2000 MWCO concentrator tubes. The samples were kept at -20°C until needed. 
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(e) Determination of Protein Concentration 
Protein samples were quantified with the BCA assay kit (Pierce) in Greiner 96-well 
microplates. A bovine serum albumin (BSA) standard series was used with a concentration 
range from 0.02-2.0mg/mL. The assay was conducted as recommended by the manufacturer’s 
recommendations and the optical density was read at 562nm on a BMG Labtech Omega® 
POLARStar multimodal plate reader. Data acquisition was done with Omega® Control 
software and analysis was done with Microsoft® Excel™ 2010. 
 
2.3.3.4 SDS-PAGE Analysis of Recombinant Proteins 
Samples were prepared for polyacrylamide gel electrophoresis by mixing the 20-100µL of 
the appropriate sample with 4x SDS gel sample buffer in a ratio of 1:2. The samples were 
vortexed for 30sec then heated at 95°C for 5min and centrifuged at 16 000g for 5min in 
Eppendorf 5415D bench top centrifuge (Rotor: F45-24-11). The samples were kept on ice 
until loaded onto the SDS-PAGE gels. 14-16% SDS-PAGE gels were prepared from an 
established lab protocol and the typical composition of the preparation mixtures can be seen 
in Table 2.4.  
 
The separating gel was poured between glass plates to a final volume of 4mL and covered 
with isopropanol until the gel had solidified. The isopropanol was decanted and the stacking 
gel mixture was poured on top of the solidified separating gel and the well combs were 
inserted. Samples were loaded at equal concentrations (determined in Section 2.3.3.3e) up to 
a final volume of 20µL a well. The sample loaded SDS-PAGE gels were electrophoresed in 
1x SDS electrophoresis buffer at 120-140V for 70-90min. Gels were incubated post-
electrophoresis in Coomassie gel staining solution overnight with gently agitation. Destaining 
solution was used to remove excess Coomassie gel stain from the gel. Destained SDS-PAGE 
gels were photographed using the UVP BioSpectrum® Imaging System (Cambridge). 
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Table 2.4: Composition of 14-16% SDS-PAGE gels 
 Stacking gel (8%) Separating gel (14-16%) 
 Volumes (mL) Volumes (mL) 
dH2O 1.449 1.895 – 1.645 
40% acrylamide:bis-acrylamide 0.375 1.750 – 2.000 
Tris (0.5M, pH 6.8) 0.625 0 
Tris (1.5M, pH 8.8) 0 1.250 
10% Ammonium persulphate 0.025 0.050 
10% SDS 0.025 0.050 
TEMED 0.001 0.005 
Total 2.500 5.000 
 
 
2.3.3.5 Recombinant Peptide Sequence Analysis 
The recombinant proteins were resolved on a 16% SDS-PAGE gel (2.3.3.4) and gel slices 
containing the appropriate band were excised. Protein sequence analysis was done at the 
Mass Spectrometry Unit (Proteomics Laboratory, Central Analytical Facility (CAF)) at 
Tygerberg Campus Stellenbosch University (Stellenbosch, Cape Town, South Africa). The 
gel slices were trypsin digested in-gel and then analysed liquid chromatography mass 
spectrometry. The protocols were supplied by the analyst, Dr S. Smit. 
 
(a) In-gel trypsin digestion 
All gel pieces were cut into smaller cubes and washed twice with water followed by 50% 
(v/v) acetonitrile for 10min. The acetonitrile was replaced with 50mM ammonium 
bicarbonate and incubated for 10min, and repeated two more times. All the gel pieces were 
then incubated in 100% acetonitrile until they turned white, after which the gel pieces were 
dried in vacuo. Proteins were reduced with 10mM DTT for 1h at 57°C. This was followed by 
brief washing steps of ammonium bicarbonate followed by 50% acetonitrile before proteins 
were alkylated with 55mM iodoacetamide for 1h in the dark. Following alkylation the gel 
pieces were washed with ammonium bicarbonate for 10 min followed by 50% acetonitrile for 
20 min, before being dried in vacuo. The gel pieces were digested with 20μL of a 10ng/μL 
trypsin solution at 37⁰C overnight. The resulting peptides were extracted twice with 70% 
acetonitrile in 0.1% formic acid for 30min, and then dried and stored at -20⁰C. Dried peptides 
were dissolved in 5% acetonitrile in 0.1% formic acid and 10μL injections were made for 
nano-LC chromatography. 
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(b) Liquid Chromatography Mass Spectrometry (LC-MS) 
 All experiments were performed on a Thermo Scientific EASY-nLC II connected to a LTQ 
Orbitrap Velos mass spectrometer (Thermo Scientific, Bremen, Germany) equipped with a 
nano-electron spray source. For liquid chromatography, separation was performed on an 
EASY-Column (2cm, ID 100μm, 5μm, C18) pre-column followed by an EASY-column 
(10cm, ID 75μm, 3μm, C18) column with a flow rate of 300nL/min. The gradient used was 
from 5-40 % B in 20 min, 40-80% B in 5 min and kept at 80% B for 10 min. Solvent A was 
100% water in 0.1 % formic acid, and solvent B was 100 % acetonitrile in 0.1% formic acid. 
 
The mass spectrometer was operated in data-dependent mode to automatically switch 
between Orbitrap-MS and LTQ-MS/MS acquisition. Data were acquired using the Xcaliber 
software package. The precursor ion scan MS spectra (m/z 400–2000) were acquired in the 
Orbitrap with resolution R = 60000 with the number of accumulated ions being 1 x 106. The 
20 most intense ions were isolated and fragmented in linear ion trap (number of accumulated 
ions 1.5x10
4
) using collision induced dissociation. The lock mass option 
(polydimethylcyclosiloxane; m/z 445.120025) enabled accurate mass measurement in both 
the MS and MS/MS modes. In data-dependent LC-MS/MS experiments, dynamic exclusion 
was used with 60 s exclusion duration. Mass spectrometry conditions were 1.5 kV, capillary 
temperature of 200 °C, with no sheath and auxiliary gas flow. The ion selection threshold was 
500 counts for MS/MS and an activation Q-value of 0.25 and activation time of 10ms were 
also applied for MS/MS. 
 
(c) Data Analysis 
Thermo Proteome Discoverer 1.3 (Thermo Scientific, Bremen, Germany) were used to 
identify proteins via automated database searching (Mascot, Matrix Science, London, UK) of 
all tandem mass spectra against the sequence provided by you. Carbamidomethyl cysteine 
was set as fixed modification, and oxidized methionine, N-acetylation and deamidation (NQ) 
was used as variable modifications. The precursor mass tolerance was set to 10 ppm, and 
fragment mass tolerance set to 0.8Da. Two missed tryptic cleavages were allowed. Proteins 
were considered positively identified when they were identified with at least 2 tryptic 
peptides per proteins, a Mascot or Sequest score of more that p < 0.05 as determined by 
Proteome Discoverer 1.3. Percolator was also used for validation of search results. In 
Percolator a decoy database was searched with a FDR (strict) of 0.02 and FDR (relaxed) of 
0.05 with validation based on the q-value. 
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2.3.3.6 UV-Vis Spectroscopy Surface Plasmon Resonance Interactions of 
Affinity Tagged Recombinant Proteins with Nitrilotriacetic acid 
Functionalized Gold Nanoparticles 
Nitrilotriacetic acid (NTA) functionalized gold nanoparticles (AuNP-NTA) was diluted to 
and optical density ~0.4 and transferred in 100μL aliquots to the wells of a 96-well clear flat 
bottom microplate (Greiner). A 1mM nickel sulphate (NiSO4) solution was made in nickel 
binding buffer and used for titrating Ni
2+
 into the appropriate wells, at a final concentration of 
0-500μM Ni2+ for a final volume of 200μL per well. The plate was carefully agitated to mix 
the constituents and incubated at room temperature for 10-15min followed by UV-Vis 
spectroscopy (Section 2.2.1.6a) to monitor the change in the surface plasmon resonance band 
(λSPR) with increased Ni
2+
 addition. An optimized nickel concentration of nickel ions was 
used for titrating proteins, with and without a recombinant 6xHis tag, at a concentration range 
of 0.1-50μg/mL. The plate was gently agitated and incubated at room temperature for 40-
60min followed by UV-Vis spectroscopy (Section 2.2.1.6a) to monitor the change in the 
surface plasmon resonance band (λSPR). The acquired data was analysed with Microsoft® 
Excel™ 2010. 
 
2.3.4 Lyophilization 
Samples were snap-frozen in liquid nitrogen or gradually frozen at -20°C then lyophilized 
overnight on a Virtis Sentry (Virtis Company Inc.) freeze-drier. All lyophilized samples were 
kept at -20°C. 
 
 
2.4 Mammalian Cell Culture 
2.4.1 Cell Line and Tissue Culture Media 
A2780cis ovarian carcinoma cells were used in this project. The cells were purchased from 
the European Collection of Cell Cultures (ECACC) through Sigma and received at passage 4 
(p4). This is an adherent monolayer epithelial cell line cultured in RPMI1640 (with 1mM 
glutamine, Lonza) was supplemented with 10% foetal bovine serum (FBS, Gibco) and 10x 
penicillin-streptomycin (PS, Gibco). Working solutions of 10x PS and 2x trypsin (Gibco) was 
prepared in sterile phosphate buffered saline (PBS pH 7.0, Gibco). All other reagents used for 
tissue culture was prepared in sterile PBS. All media and reagents were allowed to equilibrate 
to 37°C before being used. 
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2.4.2 Propagation of Cell Lines 
Cells were grown in the appropriate complete media (PS and FBS supplemented) in a 37°C 
incubator with 5% CO2 atmosphere until the desired confluency was reached. Cells were 
gently rinsed with sterile PBS then trypsinized with 2x trypsin for 5min at 37°C. Trypsin was 
inactivated by the addition of 2 volumes of appropriate complete media. Cells were pelleted 
by centrifugation at 2000g with a Sorval TC (Du Pont) bench top centrifuge. The cells were 
resuspended in 5mL fresh appropriate complete media and cell density was determined with 
the Countess Automated Cell Counter (Life Technologies) as recommended by the 
manufacturer’s instructions. The cell density for different culture vessels can be seen in Table 
2.5. Seeding density of cells was done at 10%, 20% and 50% of the maximum seeding 
density for the appropriate culture vessel. 
 
Table 2.5: Seeding densities for cell culture vessels (Data obtained from ATCC) 
 Cell Density 
Type of 
Culture Vessel 
Surface Area 
(mm
2
) 
Confluency 
10% 
Confluency 
20% 
Confluency 
50% 
Confluency 
6-well 962 1.2 x10
6
 0.12 x10
6
 0.24 x10
6
 0.6 x10
6
 
12-well 401 0.4 x 10
6
 0.04 x 10
6
 0.08 x 10
6
 0.2 x 10
6
 
24-well 200 0.2 x 10
6
 0.02 x 10
6
 0.04 x 10
6
 0.1 x 10
6
 
96-well 63 0.06 x 10
6
 0.006 x 10
6
 0.012 x 10
6
 0.03 x 10
6
 
T25 2500 2.8 x 10
6
 0.28 x 10
6
 0.56 x 10
6
 1.4 x 10
6
 
T75 7500 8.4 x 10
6
 0.84 x 10
6
 1.68 x 10
6
 4.2 x 10
6
 
 
 
2.4.3 Reversion of Cell Line from Drug Resistant to Drug Responsive 
2.4.3.1 Differential Exposure of Cells to Cisplatin 
A solution of 400µM cisplatin (Sigma) was prepared in sterile PBS. Dimethyl sulfoxide 
(DMSO) was not used to prepare cisplatin as it has been reported that adduct formation 
occurs between the former and latter compounds, which alters the pharmacologic activity of 
cisplatin [295]. Culture media was prepared by the addition of cisplatin to complete media to 
a final concentration of 2µM. Culture media with an equal volume of sterile PBS 
corresponding to the amount of used for cisplatin addition was prepared. A2780cis cells were 
seeded at p4 in T25 flasks as described in Section 2.4.2 and divided in two groups.  The first 
group was cultured in 2µM cisplatin supplemented complete media and the second group was 
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cultured in complete media containing vehicle (PBS) only. The cells were propagated 
(Section 2.4.2) until p10. 
  
2.4.3.2 Protein Extraction and Immunodetection of Biomarkers 
Cells were grown until ~80% confluency for each passage (Section 2.4.3.1). The cells were 
rinsed with sterile PBS followed by covering the adherent cells in 500µL Cytobuster™ 
Protein Extraction Reagent (Novagen) with careful agitation at room temperature for 5min. A 
cell scraper (Greiner) was used to pool cell debris which was transferred to a 1.5mL 
Eppendorf tube. The lysate was separated from the cell debris by centrifugation at 16 000g 
for 5min in an Eppendorf 5415D bench top centrifuge (Rotor: F45-24-11). The protein 
content was quantified as described in Section 2.3.3.3e and proteins were resolved on a 14% 
SDS-PAGE gel (Section 2.3.3.4). 
 
Proteins were transferred to PVDF membranes using immunoblotting transfer buffer with a 
BioRAD® Electro blotter at 110V for 90min on ice. Following the transfer, the membranes 
were blocked with 3% BSA in TBS-T20 for 2h. The membranes were washed three times 
with 5mL TBS-T20 for 5min followed by incubation with the appropriate primary antibodies 
(Table 2.6), diluted in 3% BSA in TBS-T20, overnight at 4°C. The membranes were washed 
three times with 5mL TBS-T20 for 5min and incubated with the appropriate secondary 
antibody (Table 2.6), diluted in 3% BSA in TBS-T20, for 1h at room temperature. A final 
wash step wash step was done as described above followed by immunodetection with 
SuperSignal®West Pico chemiluminescent substrate solution (Pierce). The chemiluminescent 
signal was detected and captured with the UVP BioSpectrum® Imaging System (Cambridge). 
Densiometric analysis was done with ImageJ V1.46r. 
 
Table 2.6: Antibodies and Dilutions used for Immunodetection 
 Primary Antibody Secondary Antibody (HRP conjugated) 
Biomarker Origin Dilution Origin Dilution 
MLH1 
Mouse anti-human, 
monoclonal 
1:500 Goat anti-mouse, polyclonal 1:5000 
HSP60 
Mouse anti-human, 
monoclonal 
1:500 Goat anti-mouse, polyclonal 1:5000 
β-actin 
Mouse antihuman, 
monoclonal 
(HRP conjugated) 
1:500 - - 
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2.4.3.3 Flow Cytometry for the Detection of Biomarkers 
Cells were grown to ~80% confluency (Section 2.4.3.1) and treated with trypsin for 5min at 
37°C. The cells were pelleted at 2000g with a Sorval TC (Du Pont) bench top centrifuge and 
resuspended in 5mL complete media. The cell density was determined (Section 2.4.2) and the 
cell suspension was divided into two 2.5mL aliquots in flow cytometer sample tubes. A 
fluoroisothiocyanite (FITC) conjugated CD27L monoclonal antibody (Santa Crux 
Biotechnology) was added to one sample tube at 1μg per 1 x 106 cells, as per manufacturer’s 
recommendations. The other tube served as a negative control. The samples were mixed by 
gentle inversion of the sample tubes and left to incubate in the dark for 30min at 37°C. The 
cell suspension was analysed utilizing the green channel fluorescence channel and front 
scatter with subsequent data capture on a BD Biosciences FACScan® flow cytometer. 
 
2.4.4 Transfection of A2780 Cell Line with pEGFP-N3-MMP2 
Cells were allowed to reach ~80% confluency in a T25 flask, trypsinized (Section2.4.2) then 
grown to 50-60% confluency (Table 2.5, Section 2.4.2) into 6-well clear plates (Greiner) and 
left to adhere overnight in a 37°C incubator with a 5% CO2 atmosphere. Transfections were 
done with Metafectene®Pro (Biontex) as per manufacturer’s recommendations. Two 
solutions were prepared, solution A and solution B. Solution A contained 1-2μg plasmid 
DNA in serum free media made to a final volume of 50μL. A control was setup with sterile 
PBS instead of plasmid DNA as described above. Solution B contained 2-8μL 
Metafectene®Pro in serum free media to a final volume of 50μL. Solution A was mixed with 
solution B and left to incubate at room temperature for 20-30min to allow the DNA to 
complex with the transfection reagent. The cells were washed twice with sterile PBS and 
1mL fresh serum free media was added to each well. The mixed solution (A+B) was added 
drop wise to the plate with constant gentle agitation and thereafter incubated at 37°C with 5% 
CO2 atmosphere for 3h. The plate was removed from the incubator and 1mL complete media 
was added to each well and the cells were further incubated for 48h at 37°C with 5% CO2. 
Selection of transfected cells was initiated by preparing appropriate complete media that 
contained 100-800μg/mL G418 antibiotic. The old media was removed from the cells and 
freshly prepared 2mL complete media with the appropriate concentration of G418 was added 
to each well. Antibiotic selection was done for 8-12 days after which selection was stopped 
and the cells were then grown in complete media without antibiotic. The cells were allowed 
to reach 80-90% confluency before being propagated. 
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2.4.5 In vitro Assessment of Gold Nanoparticle Toxicity 
2.4.5.1 WST-1 Cytotoxicity Assay 
Cells were allowed to reach ~80% confluency in a T25 flask, trypsinized (Section 2.4.2) and 
seeded into 96-well clear microplates (Greiner) at ~70-80% confluency (Table 2.5, Section 
2.4.2) per well and left to adhere overnight in a 37°C incubator with 5% CO2 atmosphere. 
The spent media was removed and 100μL fresh complete tissue media was added per well. 
The different gold nanoparticle preparations were added at a concentration range of 32-
1000pM (0.013 ≤ optical density (OD) ≤ 0.4) in sterile PBS to a final total volume of 200μL 
per well. The untreated control was PBS only. The microplate was gently agitated to ensure 
mixing of the well contents and incubated for 24h at 37°C in a 5% CO2 atmosphere. After 
24h the media in the wells was gently removed and the cells were gently washed twice with 
sterile PBS. Fresh complete media was added to each well to a final volume of 100μL and 
10μL WST-1 reagent (Roche) was added per well, as per manufacturer’s recommendations, 
and the plate was gently agitated and incubated at 37°C for 30-240min to allow for colour 
development. The optical density was read at 450nm (OD450) with a reference wavelength at 
620nm using the Omega® POLARStar multimodal plate reader (Section 2.2.1.6a). Acquired 
data was background as well as reference wavelength corrected. Data analysis was done with 
Microsoft® Excel™ 2010.   
 
2.4.5.2 ApoPercentage™ Assay 
The ApoPercentage™ assay was adapted to accommodate shorter assay duration as it was 
found that the result did not differ. Cells were allowed to reach ~80% confluency in a T25 
flask, trypsinized (Section 2.4.2) and propagated into 24-well clear microplates (Greiner) at 
70-80% confluency (Table 2.5, Section 2.4.2) per well and left to adhere overnight in a 37°C 
incubator with 5% CO2 atmosphere. The spent media was removed and 300μL complete 
media was added per well. The different gold nanoparticle preparations were added at LD50 
values (Sections 2.4.5.1, 5.2.2.2 and 5.2.3.2) in sterile PBS to a final total volume of 600μL 
per well. The untreated control was PBS only. After 24h the media in the wells was gently 
removed and the cells were gently washed twice with 600μL sterile PBS. Fresh complete 
media was added to each well to a final volume of 570μL and 30μL (5% v/v) 
ApoPercentage™ (Biocolor) dye was added to each well and the plate was incubated at 37°C 
for 30min as per manufacturer’s recommendations. The cells were washed twice with 600μL 
sterile PBS to remove unbound dye with a final volume of 300μL PBS per well. Micrographs 
were obtained with a Leica EC3 Firecam (Leica Microsystems) camera attached to a Nikon 
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(TMS) inverted light microscope. After micrographs were obtained, the PBS was removed 
and 300μL Dye Release Agent was added to each well and the plate was incubated at 37°C 
with gentle agitation for 10min. The optical density was read at 550nm (OD550) on the 
Omega® POLARStar multimodal plate reader (2.2.1.6a). Acquired data was analysed with 
Microsoft® Excel™ 2010.   
  
2.4.5.3 Immunodetection of Procaspase-3 
The dose-response as well as time-dose response was determined for procaspase-3. Cells 
were grown until ~80% confluency in T25 (Table 2.5, Section 2.4.2) flasks for each 
treatment. The spent media was decanted and 2.5mL fresh complete media was added. Gold 
nanoparticles were added at the LD50 values (Sections 2.4.5.1, 5.2.2.2 and 5.2.3.2) suspended 
in sterile PBS to a total final volume of 5mL and incubated at 37°C with 5% CO2 atmosphere 
for 24h. The spent media was kept for the respective flasks. The cells were subsequently 
washed twice with 2mL sterile PBS where the PBS was added to the corresponding flask’s 
spent media. The spent media-PBS mixture was centrifuged at 2000g for 5min and the 
supernatant was decanted. The cell pellets were resuspended in 500µL Cytobuster™ Protein 
Extraction Reagent (Novagen) and added to the corresponding T25 flasks. The flasks were 
incubated at room temperature for 5min with gentle agitation. A cell scraper (Greiner) was 
used to pool cell debris which was transferred to a 1.5mL Eppendorf tube. The lysate was 
separated from the cell debris by centrifugation at 16 000g for 5min in an Eppendorf 5415D 
bench top centrifuge (Rotor: F45-24-11). The protein content was quantified as described in 
Section 2.3.3.3e and proteins were resolved on a 14% SDS-PAGE gel (Section 2.3.3.4). 
Immunodetection of procaspase-3 (Santa Cruz) was done as described in Section 2.4.3.2. 
 
2.4.5.4 GSH/GSSG-Glo™ (Promega) Total Glutathione Assay 
Cells were allowed to reach ~80% confluency in a T25 flask, trypsinized (Section 2.4.2) and 
seeded into 96-well black microplates (Merck) at ~70-80% confluency (Table 2.5, Section 
2.4.2) per well and left to adhere overnight in a 37°C incubator with a 5% CO2 atmosphere. 
The spent media was removed and 100μL fresh complete tissue media was added per well. 
The different gold nanoparticle preparations were added at LD50 values (Section 2.4.5.1, 
5.2.2.2 and 5.2.3.2) in sterile PBS to a final total volume of 200μL per well. The untreated 
control was PBS only. The microplate was gently agitated to ensure mixing of the well 
contents and incubated for 24h at 37°C in 5% CO2 atmosphere. The assay kit was used as per 
manufacturer’s recommendations to determine reduced glutathione (GSH) as well as oxidised 
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glutathione (GSSG). The luminescence signal which is generated is based on the well-known 
luciferrin-luciferase bioluminescence reaction. Addition of the kit reagents was followed by 
15-20min incubation of the microplate at 37°C and the luminescence signal was quantified 
with the Omega® POLARStar multimodal plate reader (Section 2.2.1.6b). Acquired data was 
analysed with Microsoft® Excel™ 2010. 
 
2.4.5.5 Transmission Electron Microscopy 
Cells were grown to ~80% confluency in T25 (Table 2.5, Section 2.4.2) flasks for each 
treatment. The cells were washed twice with 2mL sterile PBS and fresh 2.5mL complete 
media was added to the flasks. The gold nanoparticles were added at the LD50 values 
(Sections 2.4.5.1, 5.2.2.2 and 5.2.3.2) suspended in sterile PBS to a total final volume of 5mL 
and incubated at 37°C with a 5% CO2 atmosphere for 24h. The spent media was kept for the 
respective flasks. The cells were subsequently washed twice with 2mL sterile PBS where the 
PBS was added to the corresponding flask’s spent media. The spent media-PBS mixture was 
centrifuged at 2000g for 5min and the supernatant was decanted with the pellet resuspended 
in 1mL 4% paraformaldehyde. The adherent cells in the flasks were covered with 3mL 4% 
paraformaldehyde solution and the resuspended pellet was added with the combined mixture 
incubated at 4°C for 15min. The cells were gently dislodged with a cell scraper (Greiner) 
then transferred to a 15mL polypropylene tube with a wide tip pipette and centrifuged at 
2000g for 5min. The supernatant was discarded and the cell pellet was gently covered in 
2.5% glutaraldehyde solution. The cell pellet was submitted to the NHLS Cytology Electron 
Microscopy Unit (Tygerberg Hospital, Cape Town, South Africa) with transmission electron 
microscopy done by Mrs N. Muller. 
 
 
2.5 Protein-Protein Interactions: Matrix Metalloproteinase-2 (MMP2) 
and Recombinant Chlorotoxin (CTX) 
2.5.1 Enzyme Kinetic Analysis 
2.5.1.1 Acquisition of Chromogenic Peptide, Competitive Inhibitor of MMP2, 
Recombinant Full Length pro-MMP2 and MMP2 Activation by APMA  
The chromogenic peptide [81] was purchased from Enzo Life Sciences and was received as a 
lyophilized powder which was made up to 5mg/mL in MMP2 assay buffer. The competitive 
inhibitor of MMP2, BiPS, and recombinant pro-matrix metalloproteinase-2 was purchased 
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from Merck. Pro-MMP2 activation to mature MMP-2 was done by incubating 1mM APMA 
buffer with 1μg/mL pro-MMP2 in 1mL MMP2 assay buffer for 2-4h at 37°C. The mature 
MMP2 was purified with 10 000 MWCO concentrator tubes (Eppendorf) by centrifugation at 
16 000g for 10min in an Eppendorf 5415D bench top centrifuge (Rotor: F45-24-11) and 
resuspended in MMP2 assay buffer. The APMA activation of pro-MMP2 yields 70% active 
MMP2 [81-82].  
 
2.5.1.2 Spectrophotometric Enzyme Kinetics Analysis 
The MMP2 enzymatic activity was determined, with and without inhibitors present, to 
determine if the reported inhibition by chlorotoxin (CTX) was in the catalytic site of the 
protease enzyme. Typically MMP2 would be incubated with the chromogenic peptide and 
inhibitor, if applicable, in a 1mL cuvette for a predetermined amount of time. MMP2 
cleavage of the chromogenic peptide releases a free reduced thiol group, after which the 
sample would be heat inactivated and fractionated followed by Ellman’s (Section 2.2.1.1) 
assay for reduced thiol content in each fraction [81-82]. Here an adapted one-step assay is 
described to determine realtime MMP2 activity directly coupled to an increase in optical 
density at 412nm (OD412) in a high-throughput 96-well plate format. The typical assay 
mixture can be seen in Table 2.7. Each chromogenic peptide concentration (Table 2.7), with 
or without inhibitor present, will generate a Michaelis-Menton graph. 
 
Table 2.7: The typical composition of the MMP2 enzyme kinetic assay 
 Volume (μL) Final [ ] 
Activated MMP2 10 40ng/mL 
Ellman’s reagent (DTNB) 4 1mM  
Chromogenic peptide 6.25 0.225mM / 0.45mM / 0.9mM 
Inhibitor* 0 - 70 - 
MMP2 assay buffer 229.75 – 159.75 - 
Total 250  
*The inhibitor volumes were concentration dependent, where BiPS (commercial competitive inhibitor) 
was used at 17nM (reported IC50 [296]) and 34nM and recombinant produced chlorotoxin (CTX) was 
used at 100nM (reported IC50m [119]) and 200nM. 
 
The slope (m = 
Δy
/Δx) of the linear region of the graph will be used to determine the initial 
velocity (Vo) of the enzyme for that specific concentration of chromogenic substrate. The unit 
of time (sec, min, h) is dependent on enzyme activity as well as the affinity of the enzyme for 
the substrate. The reciprocal of the obtained velocity will be plotted on the Y-axis with the 
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corresponding reciprocal of the chromogenic peptide concentration plotted on the X-axis of a 
Lineweaver-Burke graph. The intercept of the graph with the X-axis will correspond to -
1
/Km 
where Km is an indication of the substrate binding the enzyme has for the substrate. The 
intercept of the graph with the Y-axis will correspond to 
1
/Vmax where Vmax is the maximum 
velocity of the enzyme for the substrate. Both Km and Vmax for a particular enzyme are 
dependent on the substrate, presence of inhibitors as well as the assay conditions. Differences 
in Km and Vmax describe the type of interaction an enzyme has with a substrate in the 
presence of an inhibitor. The assay was conducted on the Omega® POLARStar (BMG 
Labtech) multimodal plate reader using the discrete wavelength 412nm. The Omega® control 
software was set to absorbance for plate kinetics with 200 scans per well and a kinetic 
interval length of 2.5min for a total assay duration of 5h. Data analysis was done with 
Microsoft® Excel™ 2010. 
 
2.5.2 Wide Field Fluorescence Microscopy Investigation of Protein-Protein Co-
localization 
2.5.2.1 Propagation of pEGFP-N3-MMP2 Transfected Cells on Coverslips  
Transfected A2780 cells (Section 2.4.3) were allowed to reach ~80% confluency in a T25 
flask, trypsinized (Section 2.4.2) and propagated at 30-40% confluency (Table 2.5, Section 
2.4.2) into 6-well clear plates (Greiner) on top of an autoclaved coverslip (6mm X 6mm, 
Lasec) in each well. The cells were left to adhere overnight in a 37°C incubator with 5% CO2 
atmosphere. The spent media was pipetted off and 2mL fresh media was added per well. The 
cells were allowed to reach 50-60% confluency for further experiments. 
 
2.5.2.2 Treatment of Cells with Inducers of MMP2 
The subcellular localization of enhanced green fluorescent protein (EGFP) tagged MMP2 
was investigated with different inducers of MMP2. The inducers were prepared in the 
appropriate complete media for each of the following compounds: 100ng/mL 
lipopolysaccharide (LPS), 100ng/mL phorbol-12-myristate-13-acetate (PMA) and 2μM 
cisplatin. Cells grown on coverslips (Section 2.5.2.1) were moved to a fresh 6-well plate and 
washed twice with 1mL sterile PBS followed by the addition of 2mL complete media 
containing the appropriate inducer and incubated for 24h at 37°C with a 5% CO2 atmosphere. 
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2.5.2.3 Bioconjugation of Dansyl chloride / Rhodamine B to anti-MMP2 
Dansyl chloride (Sigma) was dissolved in tetrahydrofuran at 1mg/mL in an aqueous solution 
containing 0.02mg/mL anti-MMP2 (Pierce) and incubated at 37°C for 40-60min with gentle 
agitation. The dansylated anti-MMP2 was washed and purified with 10 000 MWCO 
concentrator tube (Millipore) by centrifugation at 6000g in a Beckman Coulter centrifuge 
(SX4750A swing rotor) precooled to 4°C. The dansylated anti-MMP2 was kept at 4°C. 
 
Rhodamine B (Sigma) was dissolved in dH2O (18.2MΩ) at 1mg/mL together with 
0.02mg/mL anti-MMP2 (Pierce) and 2mg/mL EDC. The mixture was mixed by inversion and 
left to incubate at 37°C for 40-60min. The Rhodamine B-anti-MMP2 was washed and 
purified by centrifugation and stored, as described in the previous paragraph. 
 
2.5.2.4 Staining of Cells with Chlorotoxin Conjugated Quantum Dots and 
Fluorescent Labelled anti-MMP2 
Cells grown on coverslips, prepared as described in Section 2.5.2.1, were moved to a fresh 6-
well plate and washed twice with 1mL sterile PBS followed by addition of 1mL 4% 
paraformaldehyde per well. The cells were incubated at 4°C for 15-20min with gentle 
agitation and subsequently washed twice with 1mL sterile PBS followed by addition of 1mL 
permeation buffer per well and incubated at room temperature for 20-30min. The quantum 
dots (10-500pM) and fluorescent labelled antibody (1:500-1:2000) was prepared at the 
appropriate concentration, in TBS-T20 containing 3% bovine serum albumin (BSA). The 
permeations buffer was removed from the wells and the cells were washed twice with 1mL 
sterile PBS. The appropriate fluorescent stain was added per well followed with incubation 
protected from light at room temperature for 2-3h or overnight at 4°C. The cells were washed 
gently twice with 1mL sterile PBS.  
 
2.5.2.5 Wide Field Fluorescence Microscopy 
Cells propagated on coverslips, prepared as described in Sections 2.5.2.2 or 2.5.2.4, were 
washed twice with 1mL sterile PBS and carefully dried to remove excess moisture. 
Microscopy slides (Lasec) was cleaned with 80% ethanol and dried followed by the 
application of 25μL FluoroShield® (Sigma) in the centre of the microscope slide. The 
coverslip was carefully placed face down over the solution and left to dry protected from 
light for 2-3h at 4°C. The wide field fluorescence microscopy analysis was done at the 
Fluorescence Microscopy Unit of the Central Analytical Facility (CAF) at the University of 
 
 
 
 
90 
 
Stellenbosch (Stellenbosch, Cape Town, South Africa) with assistance from Mrs L. 
Engelbrecht. The microscope system used was the Olympus Cell^R system (Olympus 
Biosystems, GmbH) equipped with a Olympus IX81 inverted fluorescent microscope; F-
view-II cooled CCD camera (Soft Imaging systems) and a Xenon-Arc burner (Olympus 
Biosystems, GmbH) as light source.  The excitation filters used was 360 nm (for blue 
staining), 492 nm (for green staining) and 572 nm (for red staining) with emission collected 
with a UBG triple-band pass emission filter cube (Chroma). Image acquisition was done with 
Cell^R® Imaging software which was set for automated background removal pre- and post-
image acquisition. Image analysis was done with ImageJ V1.46r. 
 
 
2.6 Statistical Analysis 
Statistical analysis was done with Microsoft® Excel™ 2010 utilizing the StatistiXL® (2009) 
and Excel™ 2010 Data Analysis Tools plugins. The student’s two-tailed T-test as well as 
single factor ANOVA was used, depending on the type of statistical variance in data, and was 
explicitly indicated where applied.  
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Chapter 3: The Interaction between Chlorotoxin and Matrix 
Metallproteinase-2 – Tumour Specific Targeting 
 
3.1 The Cloning, Expression and Purification of Chlorotoxin (CTX) 
3.1.1 Introduction 
Chlorotoxin (CTX) can be commercially purchased or be produced through recombinant 
molecular biology techniques. Recombinant production of CTX enabled the modification of 
the 36 amino acid residue peptide to suit different experimental requirements. A C-terminal 
hexa-histadine (6xHis) tag with a proline (pro, P) residue inserted between the tag and the 
peptide, which confers directionality of attachment to the peptide. The pro-6xHis tag enables 
the use of nickel affinity chromatography. In the following few paragraphs the cloning, 
expression and purification of CTX will be shown. CTX will be used to probe the interaction 
between itself and matrix metalloproteinase-2 (MMP2) in Sections 3.2 and 3.3. 
 
3.1.2 Cloning of Chlorotoxin 
A synthetic variant of chlorotoxin gene was designed based on the published amino acid 
sequence [118] and commercially synthesized by GenScript (GenScript Inc., New Jersey, 
USA) to be subcloned into a pGEX-6P-2 expression construct. The vector diagram of pGEX-
6P-2 can be seen in Figure 2.1 (Section 2.3.2.5). The construct was named pGEX-6P-2-CTX 
and served as a PCR template (Section 3.1.2.1) as well as to produce a protein control, which 
had no 6xHis-tag, for nitrilotriacetic acid (NTA) functionalized gold nanoparticles (Section 
3.1.4). 
 
3.1.2.1 Primer Design and PCR Amplification 
Primers (Table 3.1) were designed to amplify the full length synthetic sequence of CTX 
which included a hexa-histadine (6xHis) tag. Two sets of primers were designed and can be 
seen in Table 3.1. The first primer set included a C-terminal hexa-histadine (6xHis) tag 
sequence on the reverse primer (CTX-S1-R) flanked by an XhoI restriction recognition site. 
The second primer set also included a C-terminal 6xHis tag sequence on the reverse primer 
with a proline (pro, P) residue between the peptide and the tag (CTX-S2-R). Both primer sets 
used the same forward primer. The restriction enzyme sites, start codons, stop codons as well 
as tag sequences are indicated in Table 3.1. 
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Table 3.1: Primer sets used for Chlorotoxin PCR amplification 
CTX-S1F (5') 5’-GTTTGGATCCATGTGCATGCCG-3’ 
CTX-S1R (3') 5’-GTAACTCGAGCTATTAATGATGATGATGATGATGACGACACAGGCACTGCGG-3’ 
CTX-S2F (5') 5’-GTTTGGATCCATGTGCATGCCG-3’ 
CTX-S2R (3') 5’-GTAACTCGAGCTATTAATGGTGATGGTGATGGTGTGGACGACACAGGCACTGCGG-3’ 
Restriction enzyme sites are underlined. The start codon is in green and the stop codon in red. The C-
terminal 6xHis-tag and C-terminal Proline-6xHis tag is underlined and in italics. Si denotes primer set 
number (i = 1,2) with F – forward primer and R – reverse primer. The BamHI (GGATCC)- and XhoI 
(CTCTGAG) restriction enzyme sites are underlined. 
 
3.1.2.2 PCR Amplification of Chlorotoxin 
PCR amplification (Section 2.3.2.3a) yielded PCR products for both primer sets (Table 3.1). 
The expected size for CTX-S1 is 138bp and the expected size for CTX-S2 is 141bp. Both PCR 
products (Figure 3.1) appeared in a region on the gel between 100bp and 200bp relative to the 
DNA marker. The agarose gel electrophoresis was conducted as described in Section 2.3.2.8. 
  
                                                 
Figure 3.1: The PCR products for Amplification of synthetic Chlorotoxin (CTX). CTX-S1 – Amplicon for 
primer set 1; CTX-S2 – Amplicon primer for primer set 2; M is molecular marker; C1 and C2 are 
negative controls. The marker used is Fermentas O’Generuler 100bp Ladder. GelRed was used to stain 
DNA on a 1% agarose gel. 
 
DNA was isolated from excised agarose gel slices which contained the PCR products (Section 
2.3.2.4). The purified DNA was double digested with Fermentas FastDigest restriction 
enzymes BamHI (5') and XhoI (3') as described in Section 2.3.2.5. An empty pGEX-6P-2 
vector was similarly double digested (Section 2.3.2.5) with BamHI (5') and XhoI (3'). The 
digested DNA was ligated (Section 2.3.2.6) into the corresponding restriction sites of pGEX-
6P-2. In such a manner glutathione-S-transferase (GST) will be fused to the N-terminal of 
CTX, where the expected protein product would also include a C-terminal Pro-6xHis-tag. The 
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plasmid construct generated from the amplicon for primer set CTX-S1 was named pGEX-6P-
2-CTX-S1 and the corresponding plasmid construct for the amplicon CTX-S2 was named 
pGEX-6P-2-CTX-S2. Colony PCR (Section 2.3.2.7) with gene specific primers was used to 
screen DH5α (Section 2.3.1.1) transformants (Section 2.3.1.4) for the presence of the CTX 
gene (Figure 3.2). Nine bacterial colonies were randomly chosen per construct. The construct 
pGEX-6P-2-CTX-S1 was positive for CTX DNA in all 9 colonies (lanes 1-9, Figure 3.2) with 
the PCR product between 100bp and 200bp. Strong positive colonies as well as weak positive 
colonies were observed for the construct pGEX-6P-2-CTX-S2 (lanes 10-18, Figure 3.2). Non-
specific bands (lanes 10-14 and lanes 17-18, Figure 3.2) were observed (< 100bp) which may 
be primer dimers or amplification products of a non-specific DNA sequence. All positive 
clones were sent for sequencing and will be discussed in Section 3.1.2.3. 
 
    
Figure 3.2: The colony PCR of pGEX-6P-2-CTX-S1 (Lanes 1-9) and pGEX-6P-2-CTX-S2 (Lanes 10-18). 
The positive control (+) was chlorotoxin template DNA and negative control (-) was H2O. The marker 
used is Fermentas O’Generuler 100bp Ladder. GelRed was used to stain DNA resolved on a 1% agarose 
gel. 
 
3.1.2.3 DNA Sequence Analysis of Putative Positive Clones for Chlorotoxin 
(CTX) 
The sequence alignment of pGEX-6P-2-CTX-S1 and pGEX-6P-2-CTX-S2 relative to the 
synthetic designed CTX sequence (Section 3.1.2.1) can be seen in Table 3.2. All clones sent 
for sequencing (Section 2.3.2.10) for pGEX-6P-2-CTX-S1 and pGEX-6P-2-CTX-S2 yielded 
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identical results, respectively. A representative clone for each above mentioned construct was 
chosen at random. The 6xHis tags included on the C-terminal with primer design (Section 
3.1.2.1) were present. The sequence for CTX-S1 included an additional start codon (ATG) 
and lacked the double stop codon which was incorporated in the primer design and this was 
observed for all clones sequenced. This was most probably due to a PCR experimental error. 
Restriction enzyme recognition sites (Table 3.2, italics and underlined) and tags (Table 3.2, 
underlined) correspond to the primers designed (Table 3.2). Both stop codons (red) were 
present for pGEX-6P-2-CTX-S2. 
 
 Table 3.2: Sequence alignment of pGEX-6P-2-CTX-S1 and pGEX-6P-2-CTX-S2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Restriction enzyme sites indicated by italics and underlining. Tags are indicated by underlining. Stop 
codons are in red. Start codons are in green. The synthetic construct used as an alignment reference is 
denoted CTX. The sequences obtained for the pGEX-6P-2 expression vectors are CTX-S1 (primer set 1, 
Table 3.1) and CTX-S2 (primer set 2, Table 3.1) respectively. 
 
 
3.1.3 Recombinant Expression of Chlorotoxin  
3.1.3.1 Protein Expression and Purification 
The fusion proteins produced from the expression vectors (Section 3.1.2) were named GST-
CTX-S1 and GST-CTX-S2 for pGEX-6P-2-CTX-S1 and pGEX-6P-2-CTX-S2, respectively. 
The protein production conditions were optimized (Section 2.3.3.1) with the ArcticExpress™ 
(DE3) E.coli strain (Section 2.3.1.1). The expected fusion protein molecular weight is the 
combined weight of GST (26kDa) and CTX (4.3kDa), namely 30.3kDa. All bacterial lysates 
           -8           1                                   51 
CTX                  ATGTGCATGCCGTGTTTTACCACGGATCATCAGATGGCGCGTAAATGCGAT 
                     ||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTX-S1      GGATCCATGATGTGCATGCCGTGTTTTACCACGGATCATCAGATGGCGCGTAAATGCGAT 
        ||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTX-S2         GGATCCATGTGCATGCCGTGTTTTACCACGGATCATCAGATGGCGCGTAAATGCGAT 
 
 
      52                                                                    108 
CTX         GATTGCTGTGGCGGTAAAGGCCGCGGTAAATGTTATGGCCCGCAGTGCCTGTGTCGT 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTX-S1      GATTGCTGTGGCGGTAAAGGCCGCGGTAAATGTTATGGCCCGCAGTGCCTGTGTCGTCAT   
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTX-S2      GATTGCTGTGGCGGTAAAGGCCGCGGTAAATGTTATGGCCCGCAGTGCCTGTGTCGTCCA 
 
 
 
CTX         
 
CTX-S1      CATCATCATCATCATTAGCTCGAG   
             
CTX-S2      CCACACCATCACCATCACCATTAATAGCTCGAG 
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were obtained prepared as described in Section 2.3.3.2. The isopropyl-β-D-
thiogalactopyranoside (IPTG) protein expression screens for 10mL cultures can be seen in 
Figure 3.3. The soluble fractions of the bacterial lysates were resolved on a 16% SDS-PAGE 
gel (Section 2.3.3.4). A protein band between 26kDa and 30kDa showed an increase in 
relative intensity corresponding to increasing amounts of IPTG (red block, Figure 3.3). The 
intensity of the protein bands for the IPTG treated cultures (0.25-2mM, red block, Figure 3.3) 
was observably different than the protein band for the uninduced culture (0mM, red block, 
Figure 3.3).  Low molecular weight bands were observed in all lanes which may be indicative 
of autocleavage of CTX (4.3kDa) but was considered to be unlikely as no free GST (26kDa) 
was observed.  
         
Figure 3.3: IPTG expression screen for bacterial lysates containing GST-CTX-S2. Lysates were resolved 
on a 16% SDS-PAGE gel with Thermo PageRuler Unstained Protein Ladder as a molecular marker. The 
gel was stained with Coomassie Brilliant Blue. 
 
The bacterial lysates for 500mL cultures for GST-CTX-S1 (Figure 3.4a) and GST-CTX-S2 
(Figure 3.4b) were resolved on 16% SDS-PAGE gels after GST purification (Section 
2.3.3.3a-b). GST-CTX-S2 was more readily purified than GST-CTX-S1 under similar 
purification conditions. A prominent protein band (between 26kDa and 30kDa) was observed 
in the flow through (F)-, the first wash (W1)-, and eluted (E1-3) fractions. The above 
mentioned protein band corresponded to the protein band (between 26kDa and 30kDa) 
observed for the IPTG induction screens (Figure 3.2). The elute fractions indicate intact 
fusion protein. The eluted fractions (E1-3) were pooled for each fusion protein, respectively. 
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Figure 3.4: Purification of the GST-fusion proteins GST-CTX-S1 (a) and GST-CTX-S2 (b). M – Protein 
marker (Thermo PageRuler Unstained Protein Ladder); F – Flow through fraction; W1-3 – Wash step 
fractions; E1-3 – Eluted fractions. The protein fractions were resolved on a 16% SDS-PAGE gel with 
Thermo PageRuler Unstained Protein Ladder as a molecular marker. The gel was stained with Coomassie 
Brilliant Blue. 
 
 
The pooled GST-fusion protein eluted fractions were treated with 3C-Protease™ (Section 
2.3.3.3c) to release the peptide from the GST-fusion protein and resolved on a 16% SDS-
PAGE gel. As an example, the cleavage of CTX-S2 from GST-CTX-S2 can be seen in Figure 
3.5. The prominent band (~26kDa, Lane 1 and 2, Figure 3.5) displayed a decrease in product 
size as compared to the intact fusion protein observed in Figure 3.4 (E1-3). A green circle 
(Figure 3.4) indicates 3C-Protease™ (~46kDa). No other protein bands were observed in lane 
1 (Figure 3.5). The sample was concentrated 10-fold (Section 2.3.3.3d) to observe a diffuse 
band (red circle, lane 2) which was less than 10kDa. This low molecular weight diffuse 
protein band was expected to be CTX-S2. The sample was then fractionated to separate the 
high- and low molecular weight constituents (Section 2.3.3.3d), where both high- and low 
molecular weight fractions were desalted by buffer exchange (Section 2.3.3.3d) into PBS (pH 
7.2), concentrated (Section 2.3.3.3d) and lyophilized (Section 2.3.4). The low molecular 
weight protein band (red circle, Figure 3.5) was excised and sent for mass spectrometry 
amino acid sequence confirmation (Section 3.1.3.2). CTX-S1 was purified in a similar 
manner. 
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Figure 3.5: Cleavage of CTX-S2 from GST-CTX-S2. No CTX-S2 was observed for the protein fraction in 
lane 1. An x10 concentrate of the sample is in lane 2 where a low molecular weight protein band is 
observed (Green  – 3C-Protease™; Glutathione-S-transferase (26kDa); Red - Low molecular weight 
diffuse band). The protein fractions were resolved on a 16% SDS-PAGE gel with Thermo PageRuler 
Unstained Protein Ladder (M). The gel was stained with Coomassie Brilliant Blue. 
 
The lyophilized low molecular weight fractions obtained from the cleavage of GST-CTX-S1 
and GST-CTX-S2 as well as the fusion proteins themselves were analysed for protein content 
using the BCA protein assay (Section 2.3.3.3e). The values obtained are given in Table 3.3. 
The BCA assay confirmed the presence of protein in the low molecular weight lyophilized 
samples. 
 
Table 3.3: Protein concentrations obtained for the desalted and purified proteins 
fractions. 
Fractions Analysed Concentration  (mg/mL) 
GST-CTX-S1          0.612 ± 0.013 
CTX-S1 
(Cleaved from GST-CTX-S1) 
        0.085 ± 0.004 
GST-CTX-S2         1.936 ± 0.056 
CTX-S2 
(Cleaved from GST-CTX-S2) 
0.127 ± 0.011 
*All experiments were done in triplicate. GST-CTX-S1 – GST fusion construct for recombinant CTX-S1; 
GST-CTX-S2 – GST fusion construct for recombinant CTX-S2; CTX-S1 – Recombinant CTX peptide 
from primer set 1 (Table 3.1); CTX-S2 – Recombinant CTX peptide from primer set 2. 
 
 
3.1.3.2 Mass Spectrometry Characterization 
To confirm the identity of the low molecular weight diffuse protein band (red circle, lane 2, 
Figure 3.5) a gel slice was excised and sent for liquid chromatography (LC) tandem mass 
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spectrometry (MSMS) analysis at the Central Analytical Facility (CAF) at Stellenbosch 
University, Tygerberg Campus (2.3.3.5).  
 
The produced recombinant peptide (CTX-S2) was compared to the published amino acid 
sequence of the wild type (WT) chlorotoxin (CTX) [118, 122]. Comparative amino acid 
sequence analysis indicated three differences between the recombinant peptide and the wild 
type CTX. The N-terminal of the recombinant peptide had two additional amino acid 
residues: glycine (G) and serine (S) (green underlined, Table 3.4). These abovementioned 
residues were identified as remnants from the fusion construct cleavage site. The glycine (G) 
and arginine (R) residues, positions 24 and 25 (CTX-S2, red underlined italics, Table 3.4), 
was not detected by LC-MSMS analysis and as such their presence in CTX-S2 was not 
confirmed. The pro-6xHis tag (blue underlined italics, Table 3.4) was also not detected with 
LC-MSMS analysis. It is unknown why these 9 residues where not detected. The core 
sequence of CTX-S2 showed 34 of 36 WT amino acid residues present in the correct 
sequence. The predicted isoelectric point (pI 8.13, Table 3.4) of CTX-S2 indicates this is a 
cationic peptide. No LC-MSMS data was generated for CTX-S1 and it was decided to not 
continue with this variant of the peptide. 
 
 Table 3.4: A comparative of the amino acid sequence between the wild type (WT) CTX 
sequence and recombinant (CTX-S2) amino acid residue sequence of CTX 
 Molecular 
Weight  
(kDa) 
 
pI 
 
Amino Acid Residue Sequence 
(N' → C') 
WT  
[118, 122] 
4.0 8.5 
       M C M P C F T T D H Q M A R K C D D C C G G K G R G K C 
Y G P Q C L C R 
CTX-S2 4.1 8.13 
G S M C M P C F T T D H Q M A R K C D D C C G G K G R G K     
                             C Y G P Q C L C R P H H H H H H 
*Additional residues are depicted in green and underlined. Residues which were not detected in the core 
sequence of CTX-S2 are in red italics and underlined. The recombinant insert affinity tag of CTX-S2 is in 
navy italics and underlined. Additional and undetected residues were not taken into account for molecular 
weight prediction. 
 
An alternative method was considered to confirm the presence of the Pro-6xHis tag on the 
recombinant peptide, based on surface plasmon resonance (Section 3.1.4). 
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3.1.4 Gold Nanoparticle Assisted Surface Plasmon Resonance Investigation for the 
Presence of the Affinity tag in Recombinant Chlorotoxin (CTX-S2) 
The Pro-6xHis tag was not detected with LC-MSMS analysis of recombinant produced CTX-
S2 (Section 3.1.3). The presence of the abovementioned affinity tag was investigated by 
utilizing the surface plasmon resonance (SPR) on the surface of noble metal nanoparticles 
(Section 1.6.2.2). The change in the SPR of nitrilotriacetic acid (NTA) functionalized gold 
nanoparticles (AuNP-NTA) was utilized to confirm the presence of a 6xHis-tag in the fusion 
protein (GST-CTX-S2) as well as the cleaved peptide (CTX-S2). The AuNP-NTA synthesis 
and characterization is described in detail in Sections 4.3.4 and 4.4.2. The AuNP surface was 
designed to be functionalized with polyethyleneimine (PEI) to confer a cationic surface 
charge. Further covalent surface modification was done to have 30% PEG6-NTA 
functionalization. Optimization of the AuNP-NTA SPR interactions was done by nickel 
(Ni
2+
) titrations and protein titrations as described in Section 2.3.3.6. The nickel activated 
AuNP-NTA was used for UV- Vis spectroscopy SPR based protein interactions. The 
expression construct pGEX-6P-2-CTX (Section 3.1.2) was used to express GST-CTX fusion 
protein, which did not have a 6xHis tag, with the same conditions described in Section 
3.1.3.1. The samples used for AuNP-NTA interaction assays were GST-CTX (no affinity 
tag), GST-CTX-S2 (pro-6xHis-tag) and the latter’s cleaved variant CTX-S2 (pro-6xHis-tag). 
 
The SPR band (λSPR) showed a redshift from 525nm (red, Figure 3.6) to 530nm (green, 
Figure 3.6) upon interaction with Ni
2+
 with a minor decrease in optical density. Addition of 
GST-CTX to a final concentration of 20μg/mL caused a loss of the characteristic AuNP UV-
Vis spectra with a blueshift in the λSPR to 525nm, compared to control (green, Figure 3.6), as 
well as a pronounced increase in the optical density (light blue, Figure 3.6). The loss of UV-
Vis spectra is indicative of non-specific protein interactions on the AuNP surface as 
demonstrated for bovine serum albumin (Section CHECK) and may also indicate 
nanoparticle aggregation. The {AuNP-NTA + Ni} interaction for GST-CTX-S2 and CTX-S2 
showed an increase in optical density, a redshift from 530nm (green, Figure 3.6) to 555nm 
(purple and black, Figure 3.6) and a conserved AuNP UV-Vis spectra. The AuNP-NTA 
interaction with GST-CTX-S2 and CTX-S2 indicates directionality coordinated attachment of 
the peptide to the AuNP-NTA surface. 
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Figure 3.6: UV-Vis spectroscopy SPR investigation of changes on the AuNP-NTA surface. OD – Optical 
density; AuNP-NTA – NTA functionalized gold nanoparticles; Ni - 250μM nickel sulphate; GST-CTX 
(20μg/mL) – Fusion protein without recombinant pro-6xHis affinity tag; GST-CTX-S2 (20μg/mL) – 
recombinant fusion protein with affinity tag; CTX-S2 (20μg/mL) – recombinant peptide with affinity tag; 
λSPR – wavelength of surface plasmon resonance band. The results are representative of technical 
triplicates repeated on two different days. 
 
 
3.1.5 Discussion 
Research focused on the cloning and recombinant protein production of CTX is limited. This 
is most probably due to a US patent (held by Sontheimer and Deshane) on the wild type CTX 
gene as well as the difficulties associated with small peptide purification.  
 
The DNA sequence for pGEX-6P-2-CTX-S2 showed no mutations and contained all the 
recombinant inserted elements. The amino acid sequence however did indicate that two 
specific internal residues were absent: G (glycine, position 24, G24) and R (arginine, position 
25, R25). It is unclear if this is an experimental, instrumental or analysis error. However, in a 
site directed mutagenesis study conducted by Akcan et al in 2011 it was found that affinity of 
CTX was unaffected when lysine residues at position 15 and 23 were altered [125]. This 
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suggests that the basic nature of the peptide (pI 8.13) may not be a contributing factor to the 
cancer specific targeting activity observed in the literature. It is unclear what the effect of the 
absence of Glycine24 and Lysine25 were. 
 
DNA sequencing results indicated that the PCR cloning of the CTX gene into the pGEX-6P-2 
vector was successful and that the C-terminal 6xHis tags were incorporated into pGEX-6P-2-
CTX-S1 (6xHis) and pGEX-6P-2-CTX-S2 (Pro-6xHis). Various E.coli strains were used to 
investigate optimal soluble protein yield and the ArcticExpress™ strain was chosen. Yu et al 
produced recombinant CTX utilizing the pGEX-6P-1 plasmid and a Rosetta BL21 E.coli 
strain with protein harvesting 4h post IPTG induction [126]. This study was unable to 
produce CTX with the same expression conditions using the pGEX-6P-2 construct. This 
particular strain contains additional protein folding chaperones which are cold induced. The 
ArcticExpress™ strain exploits colder temperatures where cold induced chaperones assist in 
protein folding. Another benefit is that the colder temperatures minimalize protein 
sequestration in inclusion bodies [297]. These factors all increase maximal soluble protein 
yield for perceived toxic proteins such as CTX. However, visualization of small peptides 
such as CTX on a SDS-PAGE gel presented a new challenge. The intact fusion proteins 
(GST-CTX-S1 and GST-CTX-S2) were readily resolved on a SDS-PAGE gel. Cleavage of 
the fusion proteins released the recombinant peptides (CTX-S1 and CTX-S2) which were 
observed after concentrating the sample 10-fold as a diffuse low molecular weight protein 
band. Three different approaches were used after sample fractionation and buffer exchange. 
A sample preparation was done for the corresponding diffuse protein band and was analysed 
by BCA protein assay, mass spectrometry as well as AuNP-NTA SPR assays. The BCA 
assay confirmed the presence of protein in the low molecular weight fraction.  
  
Mass spectrometry analysis on the excised diffuse band (>10kDa, Figure 3.4) confirmed the 
presence of CTX. Also, 34 of the 36 wild type amino acid residues were present. The absence 
of glycine (G) and arginine (R) residues as well as the pro-6xHis tag cannot be explained by 
peer reviewed literature. The DNA sequencing confirms the presence of the codons for these 
residues. As such, the residues may have been cleaved and removed during sample 
preparation or that the ionization conditions used for the MALDI-QTOF MS was not optimal 
for CTX-S2 analysis. Sample preparation involved trypsin digestion. Trypsin has specificity 
for cleaving on the C-terminal of arginine (R) and lysine (K) residues [298]. As such, non-
specific cleavage was not expected. The absence of the glycine (G) and arginine (R) residues 
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can also not be explained in a similar manner. Nucleotide sequencing (Section 3.1.2.3, Table 
3.2) however indicates all residues, the Pro-6xHis tag as well as the glycine (G) and arginine 
(R), should be present. Software bias settings could have further contributed to the residues 
not being identified correctly.   
 
The presence of the pro-6xHis tag was not confirmed by protein sequencing. A method for 
probing the presence of the affinity tag was developed and was based on the surface plasmon 
resonance (SPR) on the surface on gold nanoparticles. Gold nanoparticles were 
functionalized with NTA (AuNP-NTA). AuNPs (Section 1.6.2.2) have SPR that can be 
utilized to investigate interactions on the nanoparticle surface and is a well-known 
phenomenon [140]. The flood of electrons across the nanoparticle surface will give a specific 
surface plasmon maxima wavelength (λSPR). Interactions of molecules with the gold 
nanoparticle surface will affect the pathway of the electrons resulting in a change in λSPR 
which can be observed. This assay is based on the same technology utilized in surface 
plasmon resonance (SPR) equipment such as the BiaCore systems [299-301]. Targets are 
immobilized on gold coated sample plates and a SPR signal is generated when a ligand binds 
to the target. This can be used to investigate the interaction of AuNPs with proteins or 
peptides [139-142]. The use of AuNPs gives an additional benefit as the nanoparticles will 
aggregate or flocculate if there is a non-specific adsorption onto the surface. In a non-specific 
interaction large proteins can act as “glue” which will make the nanoparticles stick to each 
other in a similar manner as when a strong counter-ion is present [302] or when 
complementary DNA strands interact [211]. The interaction between NTA and a 6xHis tag is 
activated with nickel ions (Ni
2+
) and has been demonstrated to be a highly specific interaction 
with x6His-tagged proteins during affinity chromatography [303-305]. NTA was synthesized 
(Sections 2.2.2.1-2.2.2.3) and immobilized on the surface of one-pot synthesized AuNP-PEI 
(Section 4.4.2). The NTA was covalently attached to the AuNP-PEI surface by using a 
bifunctional polyethylene glycol cross linker (SM-PEG6) which covered 30% of the primary 
amines of the PEI on the AuNP-PEI surface (Section 2.2.3.3.1). This constructed AuNP was 
named AuNP-NTA (Section 4.4.2). The high molecular weight PEI on the AuNP surface 
confers a cationic character to the nanoparticles and will repel cationic molecules based on 
charge repulsion. The SM-PEG6 reduces non-specific biomolecule interactions to a certain 
extent as shown with bovine serum albumin (BSA) in Section 4.4.2. Anionic molecules will 
however have an electrostatic attraction to the AuNP surface as demonstrated and discussed 
in Chapter 4 with citrate ions (Section 4.3.3.4). Negatively charged proteins, such as GST (pI 
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6.64) [306], bind non-specifically in an electrostatic manner to the PEI on the AuNP-NTA 
surface if no affinity tag is present on the protein. If an affinity tag is present, the GST will be 
directed away from the AuNP-NTA surface. The GST is on the N-terminus of the CTX and 
the affinity tag is on the C-terminus. GST-CTX was a negative protein control (no 6xHis-tag) 
and showed a loss of the characteristic UV-Vis spectra indicating non-specific protein 
interaction on the surface. This loss of spectra indicates that the anionic GST is interacting 
with the AuNP-NTA surface and inducing aggregation. CTX is a cationic peptide (pI 8.13, 
Table 3.4) repulsed by the cationic PEI on the AuNP-NTA surface, where interaction of 
CTX-S2 is dependent on the 6xHis-tag for directionality of attachment. GST-CTX-S2 and 
CTX-S2 showed a perceptible increase in the optical density with a redshift for λSPR, 520nm 
to 555nm, with typical AuNP-NTA UV-Vis spectra preserved which suggests an affinity tag 
is present and that there is a directional attachment of CTX-S2. Also, for GST-CTX-S2 this 
implies that the GST is directed radially away from the AuNP-NTA surface. It can be argued 
that the redshift is due to particle-to-particle interaction, but this is unlikely as only one 
affinity tag is present per peptide or fusion protein. The intact spectra as well as λSPR (Figure 
3.6) for the interactions of AuNP-NTA with GST-CTX-S2 and CTX-S2 suggested directional 
attachment of the recombinant peptides on the nanoparticle surface. The AuNP-NTA UV-Vis 
SPR interaction assay corroborates the nucleotide sequence data (Table 3.2) and confirmed 
the presence of a 6xHis-tag on CTX-S2.  
 
All CTX-MMP2 interaction studies (Section 3.3) were conducted with CTX-S2. For purposes 
of this research, no additional purification was done to ensure endotoxin removal. Endotoxin 
has not been shown to directly interact with MMP2 (EC 3.4.24.24, www.brenda.koeln.de). 
Furthermore, in vitro assay applications of CTX-S2 will be done on fixed cells and no live 
cell experiments will be conducted. 
 
 
3.2 Matrix Metalloproteinase 2 (MMP2) 
3.2.1 Introduction 
Total crude cell lysates are typically used for MMP2 based zymography and the presence of 
interfering proteins such as other matrix metalloproteinases (MMPs) could influence the 
results. Further, zymography is a cumbersome and labour intensive technique. Qualitative 
and semi-quantitative confirmation of MMP2 and other MMPs in the sample still needs to be 
done by immuno-blotting techniques. As mentioned in Section 1.4.2, Annexin A2 was 
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reported as an alternative molecular target was for CTX. This made it necessary to evaluate 
the CTX-MMP2 interaction in an experimentally controlled manner. A C-terminal enhanced 
green fluorescent protein (EGFP) tagged MMP2 construct was designed for fluorescence 
microscopy co-localization studies (Section 3.3). 
 
3.2.2 Cloning and Transfection of Matrix Metalloproteinase-2  
3.2.2.1 Primer Design and PCR Amplification from pGEM-MMP2 
A pGEM-T-Easy cDNA clone of MMP2, prepared from MCF-7 breast cancer cell line, was 
obtained from Miss Cleo Dodgen (Biotechnology Department, University of the Western 
Cape, Cape Town, South Africa) and the sequence was confirmed to be a perfect match for 
wild type full length pro-MMP2. This clone was named pGEM-T-MMP2 and was used as a 
template for PCR amplification (2.3.2.3). Primers (Table 3.5) were designed to amplify the 
full length pro-MMP2 (1983bp). The reverse primer (MMP2-R) was designed to include a 
fluorescent tag (Lumio-tag sequence, Life Technologies) on the C-terminal of MMP2. The 
forward primer included a BamHI restriction site and the reverse primer incorporated an XhoI 
restriction site to flank the 5’ and 3’ ends of the sequences respectively (Table 3.5). 
 
Table 3.5: Primer Set Used for MMP2 PCR Amplification 
MMP2-F (5’) 5’-TGCTGGATCCATGGAGGCGCTAATGGCCC-3’ 
MMP2-R (3’) 5’-TATTCTCGAGACAACAACCAGGACAACAAGGGCAGCCCAGTCG-3’ 
The BamHI and XhoI restriction sites respectively for the forward and reverse primers, respectively, are 
underlined.  A Lumio-tag sequence is in red italics. 
 
The PCR product was resolved on a 1% agarose gel (Figure 3.7) as described in Section 
2.3.2.8. The expected PCR product size appeared to correspond to the expected size of 
1983bp. Subsequent attempts to optimize the PCR yielded similar predicted amplicon sizes. A 
high fidelity hot-start Taq (HiFi™ Taq, Kapa Biosystems) was used for the large gene size 
(~2kb) as described in Section 2.3.2.3 and attempts with other Taq polymerases yielded non-
specific bands at various conditions. The PCR amplicon band was excised and purified 
(2.3.2.4) for restriction digestion (2.3.2.5) with the Fermentas FastDigest® BglII and SalI. 
The pEGFP-N3 vector was linearized by restriction digestion with FastDigest® BglII and SalI 
(Section 2.3.2.5). The digested MMP2 PCR amplicon was ligated into the pEGFP-N3 vector 
(Section 2.3.2.6) which destroyed the restriction sites. BglII is an isoschizozyme of BamHI 
and SalI is an isoschizozyme of XhoI. The transformants (Section 2.3.1.4) were screened for 
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positive clones by colony PCR (Section 2.3.2.7) which identified five positive clones (lanes 1-
5, Figure 3.8) which were sent for nucleotide sequence analysis (Section 2.3.2.10). 
 
                                            
Figure 3.7: The PCR amplification product for MMP2. Lane 1 is the MMP2 amplicon; Lanes 2 and 3 are 
negative controls; M is molecular marker (Fermentas Generuler 1kb Ladder). GelRed was used to stain 
DNA on a 1% agarose gel. 
 
 
 
Figure 3.8: A colony PCR screen to detect positive clones for pEGFP-N3-MMP2. Lanes 1-5 contain 
positive clones, Lane 6 was a negative clone, Lane 9 is a duplicate of lane 6, Lane 7 is a negative control; 
Lane 8 is the vector template as a positive control. The marker (M) used was Fermentas O’Generuler 
100bp Ladder. GelRed was used to stain DNA resolved on a 1% agarose gel. 
 
 
3.2.2.2 Amino acid Residue Sequence Alignment of pEGFP-N3-MMP2 
All clones sent for sequencing (Section 3.2.2.1, Figure 3.8) yielded identical results and a 
clone was selected at random. The reconstructed amino acid residue sequence (Table 3.6) 
indicates full length pro-MMP2 is truncated in the hemopexin domain at residue 599 (Table 
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3.6 and Figure 3.9). The 599 amino acids residues which were identified to be present 
correspond to a nucleotide sequence which is 1797bp in size. The predicted amplicon size 
was 1983bp (Section 3.2.2.1). There are 61 amino acid residues which correspond to 183bp 
nucleotides, absent from the C-terminal hemopexin domain of MMP2 in the pEGFP-N3-
MMP2 construct. The MMP2 gene sequence truncation was probably the results of BamHI or 
XhoI digestion, yet no recognition sites for these two enzymes were found in the template 
cDNA sequences. The wild type MMP2 DNA sequence however does contain a BamHI 
restriction site (Table A11, Appendix). This error was most probably attributed to incorrect 
base calling during cDNA sequence analysis. MMP2 reverse primer miss-priming may have 
taken place for the nucleotide region 1625-1680 (Table 3.7), which does not correspond to 
the verified nucleotide sequence of 1797bp, which would deliver a protein product 541-556 
amino acid residues in length. Further, the sequence alignment showed full length EGFP 
(green text, Table 3.6) was attached to the truncated C-terminal hemopexin domain at the 3' 
SalI restriction site (Figure 2.2, 2.3.2.5) of the pEGFP-N3-MMP2 construct starting at amino 
acid residue 599 (blue text, Table 3.6). The truncated protein product will be called tMMP2-
EGFP for the remainder of the text. The Lumio-tag (Table 3.5, Section 3.2.2.1) which was 
designed for insertion at the end of the hemopexin domain of MMP2 was lost due to this C-
terminal truncation. 
 
 
Figure 3.9: The conserved domains found for reconstruction of pEGFP-N3-MMP2 from sequencing data. 
PG_bindi – putative gelatin binding site; ZnMc_MMP – Conserved zinc binding pocket for matrix 
metalloproteinases; FN2 – conserved fibronectin type II domains; Peptidase – conserved peptidase zinc 
binding pocket; HX – conserved hemopexin domain; GFP – enhanced green fluorescent protein conserved 
domain. 
 
The methionine at residue locus 598 (M598) is mutated to an isoleucine (I598) (Table 3.6) 
which would not affect the hydrophobicity of the position embedded in the hemopexin 
domain. However the substrate specificity could be affected as the hemopexin domain has 
been implicated in substrate binding (Section 1.3.1). A mutation at I582 to T582 (isoleucine 
to tryptophan) in the hemopexin domain changes the residue from an aliphatic hydrophobic 
residue to an aromatic basic residue which could also affect substrate binding. The mutation 
 
 
 
 
107 
 
F80 to L80 (phenylalanine to a leucine) conserves the hydrophobicity of the position, 
although the sterical hindrance at this particular position is decreased. Mutations from 
aliphatic to aromatic residues and vice versa affects the sterical aspects of the position, as 
aromatic residues have a tendency to be physically more bulky than aliphatic residues, which 
in turn potentially changes substrate binding as well as substrate specificity. 
  
Table 3.6: Amino acid residue sequence alignment of pEGFP-N3-MMP2 with wild type 
pro-MMP2 (Genbank: NP_004521.1) sequence  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Constr – Reconstructed The start of the pEGFP-N3 sequence at the C-terminal of the truncated pro-
MMP2 is in blue font. The sequence in green indicates the first fragment of EGFP as per pEGFP-N3 
prediction. 
 
Table 3.7: Potential Site of Miss-priming of the Reverse Primer 
 
  
 
 
Constr 1    MEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELAVQYLNTFYGC  60 
WT          MEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELAVQYLNTFYGC  
 
Constr 61   PKESCNLFVLKDTLKKMQKLFGLPQTGDLDQNTIETMRKPRCGNPDVANYNFFPRKPKWD  120 
WT          PKESCNLFVLKDTLKKMQKFFGLPQTGDLDQNTIETMRKPRCGNPDVANYNFFPRKPKWD   
 
Constr 121  KNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGD  180 
WT          KNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGD   
 
Constr 181  GYPFDGKDGLLAHAFAPGTGVGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFLFN  240 
WT          GYPFDGKDGLLAHAFAPGTGVGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFLFN   
 
Constr 241  GKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGT  300 
WT          GKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGT   
 
Constr 301  SYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFTFLGNKY  360 
WT          SYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFTFLGNKY   
 
Constr 361  ESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGAL  420 
WT          ESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGAL   
 
Constr 421  MAPIYTYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGPVTPEICKQDIVFDGIAQ  480 
WT          MAPIYTYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGPVTPEICKQDIVFDGIAQ   
 
Constr 481  IRGEIFFFKDRFIWRTVTPRDKPMGPLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEY  540 
WT          IRGEIFFFKDRFIWRTVTPRDKPMGPLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEY   
 
Constr 541  WIYSASTLERGYPKPLTSLGLPPDVQRVDAAFNWSKNKKTYTFAGDKFWRYNEVKKKIDG  600 
WT          WIYSASTLERGYPKPLTSLGLPPDVQRVDAAFNWSKNKKTYIFAGDKFWRYNEVKKKM   
 
Constr 601  TAGPGSIATMVSKGEELFTGVVPILVELDGDVNGHKFSVSG……………………………………             
WT       
 
                        1625                                                                    1680 
MMP-2 (WT)                 ACTGGATCTACTCAGCCAGCACCCTGGAGCGAGGGTACCCCAAGCCACTGACCAGC 
                                 | | |||          |  |  | |      |        | 
3’ Primer (5’ to 3’)             TATTCTCGAGACAACAACCAGGACAACAAGGGCAGCCCAGTCG 
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3.2.3 Discussion 
Sequence analysis of tMMP2-EGFP shows the presence of 3 mutations and a 173bp (61 
amino acid) truncation. The truncation of MMP2 (Sections 3.2.2.1 and 3.2.2.2) in the C-
terminal pEGFP-N3-MMP2 construct was not due to restriction enzyme recognition sites 
within the gene nucleotide sequence as the truncation occurred during PCR amplification. 
Miss-priming of the reverse primer (Table 3.7) by binding to this site would have generated a 
truncated protein product (541-556 amino acid residues) which did not correspond with the 
verified truncated sequence of 599 amino acid residues (Section 3.2.2.2). Currently, the 
cDNA sequences which served as template for MMP2 amplification are being verified to 
determine the cause of the BamHI restriction site occlusion. The mutation for amino acid 
residue 598 (Table 3.6) is most probably due to the truncation of the MMP2 PCR amplicon 
and subsequent ligation into the SalI restriction site of the pEGFP-N3 vector which altered 
the codon. The mutation for residue 80 was attributed to a single base mutation in the codon 
triplet, TTT (phenylalanine) to TTA (leucine) during PCR amplification. This mutation is not 
in the catalytic domain of MMP2 and is found in the putative gelatin binding domain of the 
protein. A codon change from ATC (isoleucine) to ACC (threonine) on residue position 582 
was due to a single base mutation in the hemopexin domain of MMP2 and was most probably 
introduced during PCR amplification. The hemopexin domain is orientated in a 
transmembrane position in the event MMP2 is localized to the cytoplasmic membrane. The 
rest of the pro-MMP2 protein sequence was a good match for the wild type pro-MMP2. 
 
MMP2 has been shown to retain catalytic activity for different splice variants [307, 308] and 
the pEGFP-N3-MMP2 construct was used to create a transfected drug responsive A2780 cell 
line (Section 5.2) which expressed tMMP2-EGFP in a stable manner which will be discussed 
in Section 3.3. 
  
 
3.3 The Interaction between Chlorotoxin (CTX) and Matrix 
Metalloproteinase-2 (MMP2) 
3.3.1 Introduction 
Zymography techniques are typically employed for the detection of MMP2 in biological 
samples. This technique was also used by Deshane et al to demonstrate that CTX had a 
specific and inhibitory effect on MMP2 but offered no insight with regards to the interaction 
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mechanism between these two proteins. The direct interaction between CTX and MMP2 was 
brought into question in 2011 when Annexin A2 (Section 1.4.2) was identified as a potential 
molecular target for CTX. The interaction between CTX and MMP2 will be investigated 
using Michaelis-Menton enzyme kinetics as well as wide field fluorescence microscopy.  
 
3.3.2 Michaelis-Menton Enzyme Kinetics 
Enzyme kinetic studies were conducted in a similar manner as done by Weingarten et al [81], 
who reported MMP2 displaying Michaelis-Menton kinetics for the designed chromogenic 
peptide substrate, by using three different colorimetric peptide concentrations (Section 
2.5.1.2) to obtain the Michaelis-Menton graph (Figure 3.10a). Pro-MMP2 activation to 
mature MMP2 by organomercurial APMA was described in Section 2.5.1.1. The assay was 
developed and conducted as described in Section 2.5.1.2 (Table 2.7) with the following 
inhibitors: commercial competitive inhibitor BiPS and recombinant CTX (CTX-S2, Sections 
3.1.1.1-3.1.1.2). The assay was developed as a novel one-step realtime high-throughput 
kinetics assay. The Michaelis-Menton graph for three different chromogenic peptide 
concentrations can be seen in Figure 3.10a and was obtained as described in Section 2.5.1.2.  
The corresponding Lineweaver-Burke graph (Figure 3.10b) was obtained as described in 
Section 2.5.1.2. The kinetic parameters determined from the Lineweaver-Burke graph can be 
seen in Table 3.8. 
 
MMP2 enzyme activity (Table 3.8) delivered a Km (1.07 ± 0.01mM), Vmax (2.75 ± 
0.07μM/min) and kcat (1.38 ± 0.04) in the absence of any inhibitors. In the presence of BiPS 
(MMP2+BiPS, Figure 3.11b; Table 3.8, MMP2+I2) there is no statistical change in the Vmax 
compared to the control (MMP2, Figure 3.10 and Table 3.8). There was a statistical 
significant change in the Km value compared to the control and subsequently a change in the 
turnover number (Table 3.8). The value for MMP2+I1 was aberrant and corresponds to 
~35nM BiPS, twice the IC50 concentration. There was a statistical significant change for the 
Vmax and Km for both CTX-S2 (MMP2+CTX-S2, Figure 3.11b; Table 3.8, MMP2+CTX2) 
concentrations compared to the control. The turnover number for both concentrations of 
CTX-S2 used was significantly lower compared to control. 
 
 
 
 
 
 
 
110 
 
Table 3.8: Experimentally obtained kinetic parameters for the investigation of MMP2 
activity in the presence of a commercial inhibitor and CTX. 
 Vmax (µM/min) Km (mM) Turnover  
(kcat; M/s/mg active MMP-2) 
MMP2 
 
2.75 ± 0.07 
 
1.07 ± 0.01 
 
1.38 ± 0.04 
MMP2 + I1 
 
4.06 ± 2.80 
 
1.65 ± 1.46 
 
2.04 ± 1.40 
MMP2 + I2 
 
2.78 ± 0.43 
 
0.94 ± 0.21
†
 
 
1.39 ± 0.22 
MMP2 + CTX1 
 
1.90 ± 0.10
†
 
 
0.62 ± 0.03
†
 
 
0.95 ± 0.05
†
 
MMP2 + CTX2 
 
2.15 ± 0.15
†
 
 
0.67 ± 0.08
†
 
 
1.08 ± 0.07
†
 
All averages are the average of experimental triplicates. An amount of ~2ng active MMP2 was used in all 
kinetic experiments (MMP2 – Matrix metalloproteinase-2; I1 – Inhibitor concentration 1 (35nM); I2 – 
Inhibitor concentration 2 (17.5nM); CTX1 – Chlorotoxin (CTX-S2) concentration 1 (200nM) and CTX2 – 
Chlorotoxin (CTX-S2) concentration 2 (100nM)). All units and values are expressed as per modern 
convention (Mike Danson Lecture, 2009). † Indicates statistical significance from the corresponding value 
for MMP2. Table A1 (Appendix) shows p-values, where p < 0.05 was statistically significant. 
 
 
In seminal work Weingarten and Feder [81] developed a colorimetric assay for the global 
detection of collagenase activity in 1985. The substrate was designed as a global screen for 
collagenase activity from total crude cell lysates. As such, the cleavage site in the peptide was 
designed to be a universal matrix metalloproteinase substrate. The kinetic parameters 
reported for this thio-ester peptide was a Km = 4mM and a kcat = 370 000h
-1
 (103s
-1
). The Km 
value is an indication of the binding of an enzyme to the substrate, where a large value 
indicates slow dissociation and as such a low affinity for the substrate (Rogers and Gibon, 
2009) [309]. Vmax is the theoretical maximal catalytic velocity an enzyme can achieve when 
the substrate affinity is high (small Km) and kcat is the turnover number of the enzyme, or how 
much substrate will be converted to product per unit of time per unit of enzyme [309]. Large 
values for Vmax or kcat, predicts high theoretical catalytic velocity [309]. In comparison, the 
values experimentally obtained for the Km is 4-fold lower (Table 3.8) and the kcat value (Table 
3.8) is a hundred fold lower than reported by Weingarten for this chromogenic peptide 
substrate. This is attributed to the complex mixture of collagenase enzymes Weingarten used 
in the experimental work, compared to the pure recombinant mature MMP2 used for the 
enzyme kinetics in this study. A complex cell lysate can have many enzymes which could 
simultaneously utilize the chromogenic peptide substrate. 
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Figure 3.10: An example of the enzyme kinetic evaluation of the interaction of MMP2, BiPS and CTX-S2. 
The Michealis-Menton graph for time-dependent increase in optical density (OD) for MMP2 in the 
absence of inhibitors can be seen in (a). The Lineweaver-Burke graph (b) demonstrates the change in the 
intercept as well as gradient of the linear line in the absence and presence of inhibitors. The graphs are 
for the literature IC50 values for BiPS (17nM) and CTX-S2 (100nM).  The experiment was done in 
technical triplicates on two different days. 
 
The assay developed is novel and as such can also have an effect on the kinetic parameters. 
The IC50 value for the commercial inhibitor (MMP2 + I2, Table 3.8) shows no alteration in 
the Vmax or kcat but the Km value was statistically different which indicates a change in the 
affinity of the enzyme for the chromogenic peptide substrate in the presence of the inhibitor. 
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This is indicative of competitive inhibition [309], as the inhibitor will compete with the 
chromogenic substrate to bind to the catalytic pocket of MMP2. This corresponds to the 
designed function of the inhibitor as per manufacturer information. The 35nM concentration 
of commercial inhibitor (MMP2 + I1, Table 3.8) gave aberrant values which may suggest 
oversaturation of the substrate binding pocket because the inhibitor was used at a too high 
concentration [309, 310]. Lowered Vmax, Km and kcat values for both concentrations of CTX, 
acting as an unknown inhibitor, was obtained as opposed to the corresponding values for 
MMP2 in the absence of any inhibitors (Table 3.8). The inhibition mechanism could not be 
determined based on the kinetic data as the inhibitor curve lies above the no inhibitor curve 
[309, 310]. No crystallographic- or NMR data was obtained to indicate where CTX is located 
during the CTX-MMP2 interaction and as such the locus of CTX is left to speculation. 
 
3.3.3 Wide Field Fluorescence Microscopy Co-localization Studies of MMP2 
3.3.3.1 Differential tMMP2-EGFP  In Vitro Translocation in Response To 
Various Biochemical Stimuli 
The pEGFP-N3-MMP2 construct with the truncated hemopexin domain (tMMP2-EGFP, 
Section 3.2.2.2) was transfected (Section 2.4.4) into the drug sensitive A2780 cell line 
(Section 5.1.2) for stable fusion protein expression. All transfection attempts into the 
A2780cis (drug resistant) cell line were unsuccessful. Different biochemical stimuli, known 
to induce MMP2 membrane localization and zymogen maturation, were used to determine 
whether the EGFP fluorescence signal was specific to MMP2 intracellular localization. 
Biochemical stimulants of MMP2 maturation and subsequent translocation were used to 
determine if the translocation of EGFP was associated with MMP2 translocation, which 
would indicate whether tMMP2-EGFP was intact, as MMP2 is known to be autocatalytic 
(Section 1.3). The wide field fluorescence micrographs, obtained as described in Section 
2.5.2.5, of the pEGFP-N3-MMP2 transfected A2780 cells under different biochemical stimuli 
(Section 2.5.2.2) can be seen in Figure 3.11. The different fluorescence channels are denoted 
DAPI (nuclear stain), EGFP (EGFP associated green fluorescence) and the composite overlay 
(DAPI + EGFP).  
 
Control cells were untreated over the 24h period (Figure 3.11, Control) and showed green 
fluorescence distributed throughout the cell cytoplasm as well as in the nucleus. Cisplatin 
(Figure 3.11, 2µM cis) and PMA (Figure 3.11, 100ng/mL PMA) treated cells showed a 
decrease in overall adherent cell number as well as an observable translocation of the EGFP 
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(green) associated fluorescence emission from the cytoplasm to a cytoplasmic membrane 
compared to the control in the composite overlays. The composite overlay of the DAPI (blue) 
and EGFP (green) channels show no quenching of blue fluorescence emission (DAPI) for 
cisplatin and PMA treatment compared to the control which is suggestive of tMMP2-EGFP 
nuclear to cytoplasm/membrane translocation. Lipopolysaccharide treated cells (Figure 3.11, 
100ng/mL LPS) showed an overall increase in the adherent cell number compared to the 
control, however the translocation of the EGFP associated fluorescence emission from the 
nucleus and cytoplasm to the cell membrane was not as significant as for cisplatin and PMA. 
 
The transfected A2780 cells displayed EGFP associated fluorescence emission (Control, 
Figure 3.11) distributed throughout the cytoplasm as well as nucleus, where the green 
fluorescence was not attributed to auto-fluorescence as background subtraction was done pre- 
and post-image acquisition (2.5.2.5). The cytoplasmic and nuclear tMMP2-EGFP (Control, 
Figure 3.11) localization is attributed to the sequestration of pro-MMP2, where localization 
will be induced upon zymogen maturation (pro-MMP2 → MMP2). The EGFP associated 
fluorescence emission was confirmed to be associated with MMP2 translocation by utilizing 
biochemical stimuli reported to influence MMP2 expression levels in vitro. Sequence 
analysis (3.2.2.2) indicated that the C-terminal EGFP tagged MMP2 was truncated in the 
hemopexin domain and it was necessary to determine whether the protein product, tMMP2-
EGFP, was intact as a fusion protein. Lipopolysaccharide (LPS) (Figure 3.11, LPS) 
stimulation induces a cellular immune response by the NF-κB pro-inflammatory pathway to 
induce global matrix metalloproteinase, including MMP2, expression in cancerous and non-
cancerous cell lines [90, 102, 116, 311]. Increased cell number following LPS (a mitogen) 
treatment has been reported for mouse B cells were an increase in XBP-1 protein expression 
and alternate XPB-1 splicing was directly correlated with increased cell differentiation by 
MAPK associated kinases [312]. 
 
A decrease in adherent cell numbers was observed for the cisplatin and PMA treatment 
(Figure 3.11) with an increase in cytoplasmic volume as well as abnormal nuclear 
morphology. This is attributed to the known genotoxicity of the above mentioned compounds 
and the resultant cytoprotective response, where cisplatin chelates with DNA (1.2.3.2.1) and 
PMA is a known mutagenic carcinogen [3, 90, 116]. Roomi and co-workers demonstrated that 
PMA stimulation influences MMP9 and MMP2 expression dependent on the cell type [90]. 
Cisplatin treatment of the A2780 cell line has been reported to increase maturation of pro-
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MMP2 which is associated with acquired multi-drug resistance as well as tumour malignancy 
[53, 115, 313, 314]. The observed translocation of tMMP2-EGFP to the cytoplasmic 
membrane under these different biochemical stimuli is indicative of increased activation of 
MMP2 from the zymogen form to a mature protease.  
   
 
Figure 3.11: Wide field fluorescence micrographs of pEGFP-N3-MMP2 transfected A2780 cells under 
different biochemical stimuli. The blue colour is the nuclear stain DAPI and the green colour is enhanced 
green fluorescent protein (EGFP) associated green fluorescence emission. Control cells received no 
stimulus. The magnification is x100. 
 
The microscopy was qualitative to specifically detect tMMP2-EGFP localization as well as 
translocation and as such no account could be given for native pro-MMP2 and active MMP2 
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in the cells. The above mentioned treatments resulted in translocation of EGFP associated 
green fluorescence emission to the cytoplasmic membrane compared to the untreated control. 
This implied that (i) the expression and localization of EGFP appeared to be responsive to 
MMP2 associated biochemical stimuli, (ii) EGFP was tethered to tMMP2 and (iii) tMMP2-
EGFP displayed MMP2-like biological activity. The assumption can be made that the tMMP2 
is tethered to EGFP in tMMP2-EGFP as predicted by sequence analysis. Further, the 
truncated hemopexin domain of tMMP2-EGFP appeared to have no effect on the cell 
membrane localization of the fusion protein. As mentioned in an earlier paragraph, MMP2 
retains catalytic activity for different splice variants [308, 309] where the hemopexin domain 
was absent which served as support for the localization and translocation of tMMP2-EGFP 
observed under various biochemical stimuli.  
 
The CTX-MMP2 interaction will be investigated in Section 3.3.3.2 with the transfected 
A2780 cells under 2µM cisplatin pre-treatment. The use of cisplatin would enable the pEGFP-
N3-MMP2 cells to acquire drug resistance as well as to facilitate translocation of tMMP2-
EGFP to the cell membrane. The membrane localization of tMMP2-EGFP was used to mimic 
MMP-2 associated malignancy [53, 115, 313, 314] of the A2780(c) cells as well as to 
demonstrate the therapeutic and diagnostic potential of the CTX-MMP2 interaction for cancer 
specific targeting (Section 3.3.3.2).  
 
3.3.3.2 Wide Field Fluorescence Microscopy Co-localization Study of the 
CTX-(MMP-2) Interaction 
The pEGFP-N3-MMP2 transfected A2780 cell line showed stable expression of tMMP2-
EGFP (Section 3.3.3.1) and was kept under 2µM cisplatin treatment to keep the cell line 
multidrug resistant and have MMP2 associated malignancy (Sections 2.5.2.1 and 2.5.2.2). 
Quantum dots (QD625), peak fluorescence emission 625nm, functionalized with thiolated 
polyethyleneimine (Section 2.2.4.1) and CTX (CTX-S2) bio-conjugated on the surface 
(Section 2.2.4.2) were prepared for the investigation of co-localization of CTX with tMMP2-
EGFP to study the CTX-MMP2 interaction. Confirmation of the CTX-MMP2 co-localization 
was done by using two control experiments: (i) a goat polyclonal anti-MMP2 antibody 
(Pierce) bio-conjugated to the dansyl chloride (Sigma), as described in Section 2.5.2.3, for 
fluorescent labelling of MMP2 in untransfected A2780cis cells; and (ii) QD-PEI without 
CTX-S2 bio-conjugated to the nanoparticle surface. For ease of reading, CTX-S2 will be 
referred to as CTX in the remainder of this chapter. The cells were propagated as described in 
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Section 2.5.2.1 and stained with the fluorescent stains as described in Section 2.5.2.4. 
Micrographs were obtained as described in Section 2.5.2.5.  
 
The DAPI stain (blue) indicates the nuclei (Figure 3.12a and Figure 3.12b, DAPI) and the 
green tMMP2-EGFP (Figure 3.12a and Figure 3.12b, EGFP) appears to be localized to the 
cellular membrane with fluorescence being observed in the cytoplasm. QD625 unconjugated 
with CTX was localized in a peri-nuclear region within the cells (DAPI+QD625, Figure 3.12a) 
and no co-localization of QD625 with the MMP2-EGFP (EGFP+ QD625, Figure 3.12) 
fluorescence. A composite overlay of all the channels (DAPI+EGFP+QD625) showed the 
distinct localization of QD625, tMMP2-EGFP and the nucleus (DAPI). QD625 conjugated with 
CTX showed co-localization to a similar locus as tMMP2-EGFP (EGFP, QD625, EGFP+ 
QD625; Figure 3.12b). There was little to no localization of QD625 with the DAPI nuclear stain 
(DAPI+QD625; Figure 3.12b). An overlay of all the channels can be seen in 
DAPI+EGFP+QD625 in Figure 3.12b. CTX conjugated quantum dots (QD625) appear to alter 
the localization of QD625 from a peri-nuclear region to a cytoplasmic membrane locus, which 
suggested an interaction between CTX conjugated QD625 and tMMP2-EGFP. 
 
Dansylated anti-MMP2 antibody showed membrane specific localization (Dansyl, Figure 
3.13a and Figure 3.13b) in A2780cis cells, which did not express tMMP2-EGFP, with less 
dansyl associated fluorescence emission was observed in the cytosolic regions of the cells. 
The DAPI stained the nuclei of the cells in Figure 3.13 (DAPI, a+b). QD625 unconjugated 
with CTX was localized in a peri-nuclear region (QD625; DAPI+ QD625; Figure 3.13a) with 
minimal co-localization of the QD625 with dansyl associated fluorescence emission (QD625, 
Dansyl+QD625; Figure 3.13a). Co-localization of QD625 conjugated with CTX (Figure 3.13b; 
QD625, Dansyl+ QD625) showed co-localization to the same cellular membrane associated 
region as the dansylated anti-MMP2 antibody (DAPI+Dansyl+QD625; Figure 3.13b). The co-
localization of the CTX conjugated quantum dots with the dansylated anti-MMP2 antibody 
suggested that the peptide as well as the antibody both had similar molecular targets. 
 
The co-localization of CTX conjugated QD625 with tMMP2-EGFP (Figure 3.12b) as well as 
dansyl anti-MMP2 (Figure 3.13b) in a cellular membrane loci suggested there was a CTX-
MMP2 interaction. In the absence of CTX the QD625 localization was peri-nuclear for 
tMMP2-EGFP expressing A2780cis cells (Figure 3.12a) as well as untransfected A2780cis 
cells (Figure 3.13a).   
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Figure 3.12: Wide field fluorescence microscopy of co-localization of CTX conjugated quantum dots with 
tMMP2-EGFP expressing A2780cis cells. The quantum dots without CTX can be seen in (a) and CTX 
conjugated quantum dots can be seen in (b). DAPI – Nuclear stain; EGFP – MMP2 tagged Enhanced 
Green Fluorescent Protein tagged with; QD625 – Quantum dots (peak emission 625nm). Micrographs were 
obtained at x100 magnification. 
 
No Chlorotoxin 
Chlorotoxin 
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Figure 3.13: Wide field fluorescence microscopy of co-localization of CTX conjugated quantum dots with 
dansylated anti-MMP2 in A2780cis cells. The quantum dots without CTX can be seen in (a) and CTX 
conjugated quantum dots can be seen in (b). DAPI – Nuclear stain; Dansyl – Dansylated polyclonal anti-
MMP2 antibody; QD625 – Quantum dots (peak emission 625nm). Micrographs were obtained at x100 
magnification. 
 
No Chlorotoxin Chlorotoxin 
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Dansyl chloride labelling of antibodies (Section 2.5.2.4) was used due to instrumental 
limitations where there was significant spectral overlap for available wide-field fluorescence 
microscopy emission filters (blue, green, red) as well as commercially available fluorophores. 
Dansyl chloride fluorescence emission occurs at the same spectral window as EGFP and was 
arbitrarily depicted as yellow to avoid confusion in the micrographs. Typical organic 
fluorophores with fluorescence emission below 625nm would be quenched by QD625 (Section 
1.6.3.2, Figure 1.18). Co-localization studies suggested that the CTX-MMP2 interaction took 
place and was independent of the truncated hemopexin domain of tMMP2-EGFP for the 
transfected A2780cis cells, where CTX labelled QD625 co-localized to the cell membrane 
with tMMP2-EGFP. The CTX-MMP2 interaction gained further support with the co-
localization of dansylated anti-MMP2 with CTX conjugated QD625 at a cellular membrane 
locus in untransfected A2780cis cells. The QD625 which were unconjugated with CTX 
appeared to have a peri-nuclear localization which was attributed to the PEI polymer surface 
coating which has well known transfection and penetrative capabilities in vitro [280-283]. 
 
3.3.3.3 Discussion 
The reported interaction of CTX with Annexin A2 called the interaction of CTX with MMP2 
into question, but this study provided evidence that MMP2 was a viable molecular target for 
CTX [132]. The enzyme kinetic data of the interaction of CTX-S2 with recombinant full 
length MMP2 (Merck) provided no evidence for the CTX-MMP2 interaction. Further, 
recombinant pro-MMP2 was activated with APMA which cleaved the pro-peptide of the 
zymogen for mature MMP2 activation which ruled out the CTX-MMP2 kinetic interaction 
occurred with the pro-peptide. The hemopexin domain of mature MMP2 has been implicated 
in substrate/inhibitor binding and specificity [315] where tMMP2-EGFP was utilized for 
wide field fluorescence co-localization studies (Section 3.3.3.2). A fluorescence emission co-
localization for red QD625 (CTX conjugated) and green tMMP2-EGFP was observed which 
showed CTX-S2 interacting with MMP2. The interaction of CTX and MMP2 for this study 
was not dependent on the truncated region of the hemopexin domain of MMP2, which 
excludes amino acid residue 600-660 from interaction with CTX. A process of elimination 
ruled out the pro-peptide, catalytic site as well as the latter 61 amino acid residues of the 
hemopexin domain of MMP2. The truncation of MMP2 in the fusion construct tMMP2-
EGFP was a “happy accident” as it provided an essential piece of information which full 
length MMP2 would not have provided.  
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MMP2 is expressed in epithelial cells during tissue remodelling, especially for the case of 
aggressive metastatic cancers (Section 1.3.1, Table 1.1). The interaction of CTX with MMP2 
could be used as a diagnostic tool (Section 1.4.2) and as well as a targeting moiety to deliver 
therapeutic payloads in vivo (Section 1.4.2). It was also demonstrated that CTX was 
directionally attached to gold nanoparticles (Section 3.1.4) which demonstrated the potential 
application of using the targeted nanoparticles as drug delivery vehicles (Section 1.5, Table 
1.2). Undirected carbodiimide bioconjugation of CTX to fluorescent quantum dots (QD625) 
was demonstrated as a sensitive diagnostic tool with 10pM QD625 conjugated with CTX 
showing detectable fluorescent in vitro labelling. The QD625 surface chemistry, PEI, is similar 
to the gold nanoparticles synthesized and discussed in Chapter 4 which will was utilized in 
Chapter 5 as drug delivery vehicles. The diagnostic cancer specific targeting modality of 
CTX for nanoparticles has been demonstrated. The drug delivery modality will be discussed 
in Chapter 5. Chapter 4 will discuss the synthesis of the gold nanoparticles as well as the 
chemistries used in this chapter. 
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Chapter 4: Synthesis, Characterization and Bioconjugation of 
Gold Nanoparticles and Quantum Dots  
 
4.1 Introduction 
Various synthetic routes exist for the synthesis of gold nanoparticles and quantum dots as 
well as tailoring of their respective surface functionalization (Sections 1.6.2 and 1.6.3). Gold 
nanoparticles (AuNPs) were synthesized in an adapted one-pot synthesis for theranostic 
applications. Different AuNP synthesis conditions were evaluated such as the addition tempo 
of the reducing agent as well as the ratio of the reducing agent to gold ions in solution and 
different passivation ligands (Section 4.3). The AuNPs were evaluated for physical and 
chemical stability in solution and the most stable AuNPs were evaluated for cellular 
penetrative ability (Section 5.2.3.6) and drug delivery applications (Sections 5.2.3.2-5.2.3.5) 
after drug loading and drug release studies (Section 4.4). Further applications of the AuNPs 
were to allow for the attachment of hexa-histidine (6xHis) tagged recombinant proteins 
through nickel (Ni
2+
) affinity chromatography (Section 3.1.4). The ligands utilized for 
passivation of the AuNPs were commercially purchased and chemically altered to include 
required functional groups or freshly synthesized. The locally proprietary produced indium 
phosphide quantum dots (QDs) were functionalized with a similar surface functionality as the 
AuNPs (Section 4.5). This was done to determine if nanoparticle cellular localization was 
dependent on the nanoparticle composition or surface chemistry.  A recombinant peptide was 
also evaluated as a potential cancer targeting vector with the use of the QDs (Chapter 3). 
Ligands synthesis and modification was done by utilizing basic chemistries (Section 4.2).  
 
All syntheses and chemical modification reactions were carried out at ambient atmosphere. 
This was done to evaluate the reproducibility, labour intensity, difficulty of learning and cost 
effectiveness for applications in a developing country. Specialized laboratory equipment is 
not always readily available due to economic as well as logistic factors and it was necessary 
to determine whether the synthesis of gold nanoparticles as well as the ligands was possible 
with basic laboratory equipment to yield sufficiently pure products. The synthesis conditions 
were optimized to be as minimalistic as possible and still yield sufficiently pure drug delivery 
nanoparticles. Purity of the gold nanoparticles were assessed with energy-dispersive X-ray 
spectroscopy (EDX). Cost-effective and reproducible synthesis conditions would enable 
large-scale synthesis if so desired.  
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4.2 Ligand Synthesis and Characterization 
4.2.1 Introduction 
The chemical modified high molecular weight hyper branched polyethyleneimine (PEI-SH, 
15kDa) was used in the one-pot synthesis of AuNPs as well as modification of quantum dot 
surfaces by ligand exchange. The synthesis of SH-NTA enabled the surface modification of 
PEI-SH functionalized AuNPs for the attachment of recombinant proteins on the nanoparticle 
surface (Section 3.1.4). Techniques used for characterization of the ligands were nuclear 
magnetic resonance (NMR, Section 2.2.1.2), electron spray ionization mass spectrometry 
(ESI-MS, Section 2.2.1.8) and attenuated total reflectance infrared spectroscopy (ATR, 
Section 2.2.1.3). 
 
4.2.2 Synthesis of 6-N-2-(N-bis(carboxymethyl))-hexanoic acid (NH2-NTA) 
6-N-2-(N-bis(carboxymethyl))-hexanoic acid (Scheme 1, compound 3) was synthesized as 
described in Section 2.2.2.1 from N
6
-Cbz-L-Lysine (Scheme 1, compound 1). The reaction 
can be seen in Scheme 1. The molecular formula is C10H18N2O6. The exact mass was 
predicted to be 262.12g.mol
-1
. The product is white flocculate with a yield of 2.15g (65%). 
Characterization of 6-N-2-(N-bis(carboxymethyl))-hexanoic acid (NH2-NTA) gave the 
following: 
1
H-NMR (D2O):δ 1.07 (m, C-4), 1.56 (m, C-3), 3.38 (m, C-2, C-5, CH2), 3.54 (q, J = 
14.1Hz, C-6), 7.31 (s, NH3
+
, 3H), 8.34 (s, OH, 3H) 
MS (ESI): (M
+1
) 263.13 
ATR (ZnSe): υ(N-H) 825.4 (sh), υ(C=O) 1600.7 (s), υ(C=OH) 1627.7 (sh), υ(C-H) 2821.4 (w), υ( O-H) 
2890.8 (w), υ(O-H) 2937.1 (w). 
 
Proton resonances were not observed for all peaks due to spectral resonance overlap as 
observed for C-2/C-5. Mass spectrometry however showed an M
+1
 peak of 263.13Da gave a 
determined mass of 262.12g.mol
-1
 which confirmed the molecule was present. 
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Scheme 1: The synthesis of 6-N-2-(N-bis(carboxymethyl))-hexanoic acid (NH2-NTA) 
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Figure 4.1: ATR infrared spectrum of 6-N-2-(N-bis(carboxymethyl))-hexanoic acid (NH2-NTA) 
 
       
   Figure 4.2: 
1
H-NMR spectrum of 6-N-2-(N-bis(carboxymethyl))-hexanoic acid (NH2-NTA)                              
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4.2.3 Synthesis of 6-N-Thiobutyro-2-(N-bis(carboxymethyl))-hexanoic acid (SH-
NTA) 
                              
Scheme 2: Synthesis of 6-N-Thiobutyro-2-(N-bis(carboxymethyl))-hexanoic acid (SH-NTA) 
  
Compound 4 was synthesized as described in Section 2.2.2.2. The product was a fine yellow 
powder of 1.23g (85%) yield. The molecular formula was C14H24N2O7S with a predicted 
exact mass of 364.13g.mol
-1
. The characterizations gave the following results: 
1
H-NMR (D2O):δ 1.11 (m, C-4), 1.43 (m, C-2 / C-5 / SH / CH2), 1.68 (m, C-3), 1.84 (m, C-
9), 2.20 (m, C-8), 2.64 (t, J = 7.5Hz , C-2), 3.01 (m, C-6), 3.05 (m, C-10 / NH), 8.34 (s, OH, 
3H) 
MS (ESI): (M
+1
) 365.14 
ATR (ZnSe):  υ(C=O) 1579.4 (s), υ(C=O) 1662.4 (sh), υ(C-H) 2856.1 (w), υ(O-H) 2917.8 (w). 
 
The presence of a thiol group was not indicated by H
1
-NMR due to proton resonance overlap 
at 1.43ppm as well as at 3.01ppm. ATR also failed to indicate the presence of a thiol group 
due to instrumental limitation at 650cm
-1
 attributed to the ZnSe optical lens (Section 2.2.1.3). 
Ellman’s reagent (Section 2.2.1.1) was used to confirm the presence of a thiol group. The 
molecular weight was determined to be 364.13g.mol
-1
 from the M
+1
 mass spectrometry peak. 
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Figure 4.3: ATR Infrared spectrum of 6-N-Thiobutyro-2-(N-bis(carboxymethyl))-hexanoic acid (SH-
NTA). 
 
      
Figure 4.4: 
1
H-NMR of 6-N-Thiobutyro-2-(N-bis(carboxymethyl))-hexanoic acid (SH-NTA). 
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4.2.4  Synthesis of N-Thiobutyro-polyethyleneimine (PEI-SH) 
Commercial PEI (2kDa) was purchased from sigma and a thiol group was introduced on the 
PEI molecule at random to modify one primary amine (-NH2) as described in Section 2.2.2.3 
and shown in Scheme 3 to create compound 6. The ATR infrared spectrum of PEI and PEI-
SH can be seen in Figure 4.6. A characteristic C-S stretch (green circle, Figure 4.6) appeared 
in the infrared spectrum of PEI-SH (red, Figure 4.6) and which is absent from PEI (black, 
Figure 4.6). An S-H stretch was not observed due to instrumental limitations of the ZnSe 
crystal having maxima of absorption at 650cm
-1
. Confirmation of the presence of a thiol 
group was done by utilizing Ellman’s reagent (Section 2.2.1.1). A 10mM of PEI solution 
contained 9.81±0.03mM thiol groups, which indicated for 1mol of PEI there is ~0.98mol 
thiol (SH). The value is representative of three different PEI-SH preparations. The estimation 
made in an earlier paragraph can now be modified to the following: For each mole of PEI-SH 
there will be on average 1mol thiol, 149mol primary amines, 90mol secondary amines and 
120mol tertiary amines. 
 
 
Figure 4.6: The superimposed ATR infrared spectra of PEI (black) and SH-PEI (red). A characteristic  
C-S stretch is highlighted with a green circle. 
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Scheme 3: The thiolation of high molecular weight hyper branched polyethyleneimine (5) to produce PEI-
SH (6). 
 
4.2.5 Discussion 
The synthesis of the nitrilotriacetic acid derivatives, NH2-NTA (Section 4.2.2) and SH-NTA 
(Section 4.2.3), gave good overall yields. The 
1
H-NMR and ATR infrared data could not 
conclusively enable confirmation of the structures of the compounds. The ESI-MS gave 
perfect matches for the M
+1
 peak compared to the predicted mass of each compound. The 
synthesis of these two compounds was deemed successful. SH-NTA was used for the 
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modification of AuNP surfaces to facilitate the attachment of recombinant peptides with a 
6xHis-tag for nickel affinity chromatography (Section 3.1.4).  
 
The suggested mechanism of the synthesis of NH2-NTA can be seen in Scheme 4. The 
nucleophilic attack of the lone pair of electrons on the primary amine on the carbocation of 
the 2-bromo acetic acid generated a nitrilotriacetic acid analogue. Nucleophilic substitution of 
the acetic acid groups onto the primary amine is a SN1 reaction. The reaction time was 
decreased with increased amounts of 2-bromo acetic acid and the reaction took place in a 
polar protic solvent (H2O) at a slow rate (3h) [316]. The hydrogenation reaction took 5 days 
to complete under atmospheric conditions utilizing a palladium on carbon (5% Pd/C) catalyst. 
The mechanism for the synthesis of 6-N-Thiobutyro-2-(N-bis(carboxymethyl))-hexanoic acid 
(SH-NTA) from 6-N-2-(N-bis(carboxymethyl))-hexanoic acid (NH2-NTA) can be seen in 
Scheme 5. The suggested mechanism of nucleophilic substitution is a SN1 mechanism as 
dictated by the polar protic solvent (H2O) and a reaction tempo of 16-24h [316]. 
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Scheme 4: The mechanism of the synthesis of 6-N-2-(N-bis(carboxymethyl))-hexanoic acid (NH2-NTA). 
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Scheme 5: The mechanism of the synthesis of 6-N-Thiobutyro-2-(N-bis(carboxymethyl))-hexanoic acid 
(SH-NTA). 
 
The addition of a thiol group on the PEI to create PEI-SH was confirmed by Ellman’s reagent 
as well as ATR. ESI-MS analysis could not confirm the presence of the addition of a 
thiobutyric acid molecule due to the low relative abundance of the thiobutyro group to the 
other constituents of the PEI molecule upon fragmentation. It was estimated for 1mol 
thiolated hyperbranched polymer PEI-SH had on average 1mol thiol, 149mol primary 
amines, 91mol secondary amines and 120mol tertiary amines. The relative intensities of the 
peaks in the mass spectra will suppress the presence of the thiobutyric acid group as well as 
from NMR analysis for detection of the SH-group. The mechanism for introducing the thiol 
group onto PEI is similar to the mechanism seen in Scheme 5. The PEI-SH will be used for 
the one-pot synthesis of PEI passivated AuNPs. Synthesis and chemical modification of the 
ligands was successful and was used for various applications in AuNP synthesis (4.3), 
quantum dot (QD) aqueous functionalization (4.5) as well as generate attachment points for 
peptides (3.1.4). 
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4.3 Gold Nanoparticle Synthesis and Physico-chemical Characterization 
4.3.1 Introduction 
The AuNP synthesis was an adaptation of a method published by Zheng et al in 2004 [287]. 
In their work they demonstrated the possibility of synthesizing one-pot water soluble AuNPs. 
The synthesis was standardised to produce AuNPs with a very narrow size distribution, 
typically 6-8nm in diameter, with a water soluble ligand passivated on the surface of the 
nanoparticle. These AuNPs could readily be applied for biological applications with minimal 
chemical modifications of the surface chemistry. In this synthesis they used reduced 
glutathione (GSH) and tiopronin as model ligands for their system. The synthesis was 
adapted to produce polydisperse AuNPs diameters with different surface passivation ligands. 
Larger AuNP diameters have larger surface areas for ligand passivation and subsequent 
higher drug loading capacity. Gold nanoparticle (AuNPs) intracellular distribution is 
dependent on the size as well as surface chemistry (Section 1.6.5). An AuNP preparation with 
a wide size distribution of nanoparticles would potentially act as drug delivery vehicles for 
doxorubicin distribution to multiple sites intracellular in a simultaneous manner and was 
investigated in Section 5.2.3. A drug, such as doxorubicin, which has multiple intracellular 
loci (nuclear, cytoplasmic and mitochondria) of biochemical interactions, would potentially 
have a more potent effect if it was delivered to all these interaction sites in a near 
simultaneous manner. In this adaptation of the Zheng et al synthesis reduced glutathione 
(GSH) was used as a comparative ligand for PEI-SH (Section 4.2.4) to test whether the size 
and charge of the ligand will have an effect on the AuNPs synthesis with regards to 
nanoparticle size and shape distribution. The high nitrogen content of PEI facilitated the 
investigation of charge dependent cellular localization (Section 5.2.3.6) and the primary 
amines (-NH2) provided a high drug loading capacity (Section 4.4). The nanoparticles were 
also evaluated under various conditions for chemical stability in solution. The AuNPs which 
display the best overall stability was used for assays in Chapter 3 and Chapter 5. Techniques 
used for the characterization of the nanoparticles included ultraviolet-visible (UV-Vis, 
Section 2.2.1.6) spectrometry, high resolution transmission microscopy (HR-TEM, Section 
2.2.1.4) and attenuated total reflectance infrared spectroscopy (ATR spectroscopy, Section 
2.2.1.3). 
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4.3.2 Gold Nanoparticle Synthesis: The addition tempo of the reducing agent 
NaBH4 
The effect of the addition tempo of the reducing agent, NaBH4, was investigated. The 
solution colour in the reaction vessel had a clear rich yellow colour which was attributed to 
presence of the gold ions (Au
3+
) from the dissolved aurate salt. The synthesis was described 
in Section 2.2.3.1. Upon addition of the ligand the solution colour went from a clear rich 
yellow colour to a lighter hue of yellow within 20 minutes. Addition of the NaBH4 (aq) made 
the solution change to a black and then a tea brown colour. The development of a deep wine 
red colour took place within 5 minutes. Purification of the AuNPs is described in Section 
2.2.3.1. The AuNPs were unstable in de-ionised H2O but showed stability in phospho 
buffered saline (PBS x1, pH 7.4). The AuNPs was freeze (Section 2.3.4) dried to a black-grey 
powder and readily resuspended as needed.   
 
The solution colour for Slow A-C was variations of deep wine red. A red-brown solution 
colour was observed for Fast A-C. UV-Vis spectra were obtained as in Section 2.2.1.6. Fast 
addition of the reducing agent implies immediate addition of all of the NaBH4, while slow 
addition of the reducing agent was drop-wise addition over 30 seconds. No change was 
observed for the surface plasmon resonance band (Figure 4.7, λSPR = λmax = 518nm). Slow 
addition (Figure 4.7, Slow A-C) of the reducing agent delivered an overall increase in optical 
density for the AuNPs in comparison with the fast addition of the reducing agent (Figure 4.7, 
Fast A-C). UV-Vis spectroscopy indicated that the slow addition of the reducing agent yields 
differed significantly for different preparations (Figure 4.7, Table 4.1). Fast addition of the 
reducing agent showed no significant change in yields for different batch preparations (Figure 
4.7, Table 4.1). 
 
The average diameter per AuNP preparation was calculated as described in Section 1.6.2.2 as 
determined by Hais et al [218]. The diameters for Slow A-C were determined to be 4nm 
(Table 4.1). The Fast preparations each had a different average diameter (Table 4.1). 
Quantitative EDX analysis (Section 2.2.1.5) showed no significant differences in the 
elemental composition difference between the fast addition of the reducing agent (Table 4.1, 
Fast-A / Fast-B / Fast-C) and the slow addition of the reducing agent (Table 4.1, Slow-A / 
Slow-B / Slow-C). The average dry weight for the samples produced by slow addition of 
reducing agent was significantly higher than for the fast addition of the reducing agent. The 
average gold content (% mass) of the fast addition of the reducing agent was 52.55±2.10% 
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(60.78±4.81mg) per dry weight of sample and slow addition 43.79±7.88% (57.70±7.61mg) 
per dry weight of sample. This indicates no statistical significance in the amount of gold 
incorporated into the AuNPs for the different synthesis conditions. The other elements that 
contribute to the sample dry weight are carbon (C), nitrogen (N), oxygen (O), sodium (Na), 
phosphorus (P) and chlorine (Cl). These elements are attributed to the surface ligand as well 
as to the phospho-saline buffer (pH 7.4). The amount of gold in the aurate salt used per 
preparation was 92mg. The amount of gold utilized per AuNP preparation was calculated 
based on the dry weight % of Au (Table 4.1).  
 
 
Figure 4.7: One-pot synthesized reduced glutathione (GSH) passivated AuNPs with variation in the 
tempo of NaBH4 addition. The surface plasmon resonance (SPR) band (λmax = λSPR) is highlighted in the 
red rectangle. Optical density (OD) is directly proportional to the concentration of AuNPs in solution. 
The synthesis was done in technical triplicates for each set of experimental conditions and repeated in 
duplicate on a different day. Table A2 (Appendix) provides p-values obtained where statistical 
significance was where p < 0.05. 
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Table 4.1: AuNP diameters, dry weight and energy dispersive X-ray spectroscopy 
(quantitative EDX, 2.2.1.5) elemental analysis of AuNPs Synthesized with Differential 
Addition Tempo of NaBH4 
 Weight % (EDAX) 
Sample ASPR/A450
† Diameter 
(nm) 
 
Dry Weight 
(mg) 
C N O Na P Au Cl 
Fast A 1.29 5  125 5.07 4.96 30.69 2.10 3.12 51.76 2.30 
Fast B 1.15 4  113 4.01 2.63 26.78 2.13 6.89 55.07 2.48 
Fast C 1.09 3  109 6.99 3.27 28.28 1.69 6.60 50.83 2.34 
   Ave 115.67 5.36 3.62 28.58 1.97 5.54 52.55 2.37 
   Std 8.33 1.51 1.20 1.97 0.25 2.10 2.23 0.09 
Slow A 1.18 4  135 2.75 8.26 32.97 4.39 3.59 46.35 1.70 
Slow B 1.19 4  123 2.80 4.69 26.41 4.44 6.93 50.07 4.66 
Slow C 1.16 4  140 4.22 13.62 27.62 7.27 8.59 34.95 3.73 
   Ave 132.67 3.26 8.86 29.00 5.37 6.37 43.79 3.36 
   Std 8.74 0.83 4.49 3.49 1.65 2.55 7.88 1.52 
*p-Values can be found in Table A3 in the Appendix. †Calculated according to Hais et al [218]. 
 
There was no statistical significant difference in the utilization of gold for the fast addition as 
well as slow addition of the reducing agent (Table 4.2). The average gold utilized for the fast 
addition of reducing agent was 60.78±4.81mg (66.06±5.23%) and for the slow addition of 
reducing agent was 57.70±7.61mg (62.71±8.27%).  
 
Table 4.2: Aurate salt utilized during AuNP synthesis (based on quantitative EDX, 
2.2.1.5) 
Total Au
3+
 utilized in synthesis: 92mg / reaction 
Samples 
Au
3+
 used  
(%) 
Au
3+
 used  
(mg) 
Au
3+
 unused  
(%) 
Au
3+
 unused  
(mg) 
Fast A  70.33 64.70 29.67 27.30 
Fast B  67.64 62.33 32.36 29.77 
Fast C  60.22 55.40 39.78 36.60 
 Ave 66.06 60.78 33.94 31.22 
 Std 5.23 4.81 5.23 4.81 
Slow A  68.01 62.57 31.99 29.43 
Slow B  66.94 61.59 33.06 30.41 
Slow C  53.18 48.93 46.82 43.07 
 Ave 62.71 57.70 37.29 34.30 
 Std 8.27 7.61 8.27 7.61 
*p-Values can be found in Table A4 in the Appendix. There was no statistical difference in the average 
amount of Au
3+
 used for synthesis of AuNPs. 
 
AuNPs synthesized with fast addition of the reducing agent yielded amorphous AuNPs with 
varying sizes with observed aggregation of some of the AuNPs (Figure 4.8a). Numerous sub-
1nm gold clusters were observed in the micrograph. The size distribution histogram showed a 
skewed bell-curve distribution with bias to the smaller AuNPs (Figure 4.8c). Contribution to 
the mean AuNP diameter was set at a 3.5% cut off contribution as well as a minimum 
contribution size of ≥ 1nm for the histogram. The mean diameter of the AuNPs was 
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calculated to be 5.32±2.98nm from 2352 nanoparticle counts with ImageJ (Section 2.2.1.4b), 
which indicates ~56% variation in size distribution thus classifying the AuNPs as 
polydisperse. The numerous sub 1nm gold clusters were confirmed to contain elemental gold 
by qualitative HR-TEM EDX line-scan analysis (Figure 4.8b, red) as described in Section 
2.2.1.4a. The peaks observed for copper (Cu) and carbon (C) were attributed to the holey 
carbon copper grid. Slow drop wise addition of NaBH4 yielded near spherical AuNPs without 
any sub 1nm gold clusters observable in the micrograph (Figure 4.9a). The AuNPs do not 
appear to show any aggregation and are well dispersed from each other. The AuNP size 
distribution histogram (Figure 4.9c) indicates the mean diameters of the particles were 
12.35±4.33nm. This is a ~35% size distribution. The size distribution histogram shows a near 
perfect bell-curve distribution in AuNP size. Qualitative HR-TEM EDX line-scan (Section 
2.2.1.4b) analysis (Figure 4.9b) confirmed the elemental composition of particles was gold.  
 
UV-Vis based Beer-Lambert calculations for the determination of AuNP concentration in 
solution was not a feasible technique as discrepancies between the average diameters 
obtained from UV-Vis calculations (Table 4.1, Section 1.6.6.2) compared to the HR-TEM 
micrographs and size distribution histograms (Figure 4.8 and Figure 4.9). When the UV-Vis 
predicted diameter for Slow A-C of 4nm (Table 4.1) is compared to the size distribution 
histogram mean diameter of 12.35±4.33nm (Figure 4.9c) a distinct difference is observed. 
The Fast A-C preparations UV-Vis predicted diameter of 3-5nm (Table 4.1) diameter falls 
closer within the physical counted size distribution range of 5.32±2.98 nm (Figure 4.8c). 
Comparison of the mean diameters for the preparations predicts a redshift in the surface 
plasmon band for the Slow preparations but this was not observed. In Table 4.3 the optical 
density of the AuNPs at 450nm, the molar extinction coefficients and the corresponding 
AuNP concentrations for each AuNP preparation can be seen. The extinction coefficients are 
based on the mean diameter of the AuNPs. The concentration values (Table 4.3) for the Slow 
(A-C) preparations are lower than for the Fast (A-C) preparations, even though the optical 
density (OD) values are higher (Figure 4.7). This is however explained by taking the 
extinction coefficients into account. Comparison of the respective molar extinction 
coefficients (Table 4.3) indicate that Slow (A-C) has a higher molar extinction coefficient 
than for Fast (A-C). This corresponds to the size of the AuNPs where a larger diameter AuNP 
will have a larger extinction coefficient. As concentration is a measure of units per volume, it 
can be argued that less large diameter AuNPs are needed to have the same OD as for smaller 
diameter AuNPs. 
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Figure 4.8: Gold nanoparticle characterization data for fast addition of NaBH4 yields sub 1nm gold 
clusters as well as amorphous AuNPs with a poly-disperse size distribution. The HR-TEM micrograph 
can be seen in (a) with the corresponding EDX analysis in (b) with the gold peaks encircled in red. The 
size distribution histogram (c) shows a polydisperse size distribution (ImageJ). The data is representative 
for all AuNP preparations for this set of conditions. 
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Figure 4.9: Gold nanoparticle characterization data for slow addition of NaBH4 yields AuNPs with a 
polydisperse size distribution and no visible sub 1nm gold clusters. The HR-TEM micrograph can be seen 
in (a) with the corresponding EDX analysis in (b) with the gold peaks encircled in red. The size 
distribution histogram (c) shows a polydisperse size distribution (ImageJ). The data is representative for 
all AuNP preparations for this set of conditions. 
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Table 4.3: Concentrations for the prepared AuNPs based on the physical diameter 
counts from size distribution histograms (Figure 4.8c and Figure 4.9c). 
Sample 
Optical Density 
(450nm) 
Average Diameter 
(nm) 
ε† 
(Mol
-1
.cm
-1
) 
[ ] 
(nM) 
Slow A 0.127 
12.34 ± 4.33 1.39 x 10
8
 
0.91 
Slow B 0.237 1.71 
Slow C 0.206 1.48 
Fast A 0.116 
5.32 ± 2.98 7.20 x 10
6
 
16.11 
Fast B 0.138 19.17 
Fast C 0.196 27.22 
†Obtained from Hais et al [218] and calculated as in Section 1.6.2.2.                   
 
4.3.3 Gold nanoparticle synthesis: Different ligands with constant NaBH4:Au
3+ 
 
The effect of the ligand on AuNP formation was investigated with slow addition of the 
reducing agent at a constant ratio NaBH4:Au
3+
 (Section 4.3.2). The ligands chosen were 
reduced glutathione (GSH) and thiolated polyethyleneimine (PEI-SH). The optimal ratio for 
GSH was determined to be 0.5:1 and for PEI-SH the ratio was 0.25:1 (Figure 4.10). For all 
ratios of PEI-SH:Au
3+
 above 0.25:1 the solution didn’t change colour within 5h. Ratios of 
PEI-SH:Au
3+
 below 0.25:1 was not investigated. All GSH:Au
3+
 ratios below 0.5:1 had 
AuNPs aggregation within a short time frame (~10min) after addition of the reducing agent. 
GSH:Au
3+
 ratios above 0.5:1 made the reaction solution turn turbid yellow with no AuNP 
formation within 5h after addition of the reducing agent. An increase in optical density was 
observed for PEI-SH passivated AuNPs with a redshift in λSPR (Figure 4.10, λmax = 530nm) 
than for GSH passivated AuNPs (Figure 4.10, λmax = 518nm) under similar synthesis 
conditions.  
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Figure 4.10: Comparative UV-Vis spectra of AuNPs synthesized with a constant NaBH4:Au
3+
 (1:1) using 
GSH and PEI-SH. Identical synthesis conditions were used for both ligands. Optical density (OD) is 
directly proportional to AuNP concentration. The data is representative of technical triplicates and the 
synthesis was repeated on twice on different days. 
 
 
4.3.4 Gold nanoparticle synthesis: Differential  ratios of NaBH4:Au
3+
 and 
constant ligand:Au
3+
 ratios  
4.3.4.1 Synthesis and quantitative EDX analysis 
AuNPs were synthesized (Section 2.2.4.1) with a constant ratio of ligand:Au
3+
 (AuNP-GSH 
and AuNP-PEI, Table 4.4) and varying ratios of NaBH4:Au
3+
 (Table 4.4). The solution colour 
changes observed in Section 4.3.2 was also observed for AuNPs synthesized with differential 
amounts of NaBH4 for a constant ratio of ligand:Au
3+
. It should be noted that addition of PEI 
to the Au
3+
 solution, the solution colour changed from a rich yellow colour to a very light 
yellow, fainter than for the equivalent colour change observed for addition of GSH. This 
suggested PEI-SH reduced the gold cations in solution to a greater extent than GSH. The 
solution colour progressively turned a shade of red, dependent on the batch preparation 
conditions, within 5min post NaBH4 addition for AuNP-GSH. A near immediate wine-red 
colour was observed for all AuNP-PEI preparations upon addition of NaBH4. AuNP-GSH 
particles all displayed absorption onto the surfaces of containers made of polypropylene, 
borosilicate glass as well as silanol treated glassware. All attempts to recover the absorbed 
AuNPs were unsuccessful. Surface absorption of AuNP-PEI particles was not observed. All 
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AuNP preparations was readily lyophilized and resuspended for assays except AuNP-GSH A 
and AuNP-GSH B.  
 
AuNP-PEI particles had a significant increase in overall dry weight when compared to 
AuNP-GSH as observed in Table 4.4. There was no statistical significant change in the dry 
weight of the different AuNP-PEI preparations except for AuNP-PEI A and AuNP-PEI D. 
AuNP-GSH preparations showed a statistical difference between AuNP-GSH B and AuNP-
GSH D. There was a significant difference in the average dry weight of AuNP-PEI 
preparations compared to AuNP-GSH preparations. The AuNP-PEI particles elemental 
composition (Table 4.4) showed that carbon (C) contributed the most to the dry weight 
followed by gold (Au), chlorine (Cl) and nitrogen (N). The elemental composition of AuNP-
GSH (Table 4.4) showed that gold (Au) contributed nearly half the dry weight percentage 
with oxygen (O) contributing ~20% per preparation. The oxygen content for both AuNP-PEI- 
and AuNP-GSH preparations are attributed to synthesis under atmospheric exposure, but the 
significant contribution of oxygen to the dry weight of the AuNP-PEI preparations can be 
partly attributed to the carboxylic groups of GSH which was used in the synthesis. 
 
Table 4.4: Synthesis parameters for the preparation of AuNPs with a constant 
ligand:Au
3+
 and a varying NaBH4:Au
3+
 as well as the corresponding quantitative EDX 
(Section 2.2.1.5) elemental analysis of differential AuNP preparations 
` Weight % 
Samples 
NaBH4: 
Au
3+
 
Ligand: 
Au
3+
 
 
Dry 
Weight 
(mg) 
C N O Na P Au Cl 
AuNP-PEI 
A 
0.25:1 
0.25:1 
Ave 329.33 29.74 4.29 6.08 9.64 6.84 21.21 21.87 
Std 12.99 6.16 2.64 4.16 2.37 5.77 3.58 7.74 
AuNP-PEI 
B 
0.50:1 
Ave 319.33 35.43 11.94 10.57 5.28 5.76 18.97 12.05 
Std 21.20 4.43 1.18 1.62 0.95 1.63 1.55 0.31 
AuNP-PEI 
C 
0.75:1 
Ave 287.33 37.51 11.56 9.25 1.92 3.15 17.91 10.23 
Std 24.50 3.95 1.94 1.78 0.81 1.89 4.52 5.30 
AuNP-PEI 
D 
1:1 
Ave 286.67 44.20 12.15 11.12 4.29 5.64 11.72 10.90 
Std 10.41 1.16 0.30 0.49 0.95 0.23 1.34 0.92 
AuNP-GSH 
A 
0.25:1 
0.50:1 
Ave 100.33 4.05 4.86 25.94 12.50 5.50 27.60 19.12 
Std 12.10 1.78 0.77 6.92 0.71 0.47 2.56 5.23 
AuNP-GSH 
B 
0.50:1 
Ave 114.00 4.36 3.94 30.48 2.80 5.78 49.56 3.09 
Std 8.89 1.16 1.04 0.21 1.50 1.53 0.86 1.55 
AuNP-GSH 
C 
0.75:1 
Ave 100.00 3.23 3.16 28.18 2.12 9.26 48.48 5.57 
Std 16.09 0.59 0.91 3.30 0.08 6.65 4.13 2.05 
AuNP-GSH 
D 
1:1 
Ave 93.67 3.26 6.55 21.86 5.47 5.54 49.83 7.49 
Std 6.43 0.43 8.60 3.61 7.39 1.34 8.67 7.02 
*p-Values can be found in Table A3 in the Appendix. Statistical significance was for p < 0.05.  
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Table 4.5 summarizes the amount of gold from the aurate salt utilized for the differential 
synthesis of AuNPs, determined in a similar manner as for Table 4.1 and Table 4.2 based on 
the elemental composition of the dry weight. The AuNP-PEI D preparation utilized 
significant less gold for AuNP synthesis than the AuNP-PEI A-C preparations. AuNP-GSH A 
(Table 4.5) had significantly reduced utilization of gold when compared to preparation 
AuNP-GSH B-D. AuNP-PEI A-C and AuNP-GSH B-D did not differ statistically significant 
with gold utilization. When Table 4.4 and Table 4.5 are compared it becomes apparent that 
the contribution of gold to the dry weight of the AuNP-GSH preparations was higher than for 
the AuNP-PEI preparations. Further, the high carbon (C) contribution in dry weight for the 
AuNP-PEI preparations was attributed to the high molecular weight hyper-branched PEI 
(2kDa) which was significantly larger than GSH (307.32Da).  
 
Table 4.5:  Aurate salt utilized during the synthesis of gold nanoparticles based on EDX 
analysis from Table 4.3.                   
Total Au
3+
 utilized in synthesis: 92mg / reaction 
Samples 
Au
3+
 used 
(%) 
Au
3+
 used 
(mg) 
Au
3+
 unused 
(%) 
Au
3+
 unused 
(mg) 
AuNP-PEI A 
Ave 75.61 69.56 24.39 22.44 
Std 9.79 9.01 9.79 9.01 
AuNP-PEI B 
Ave 65.82 60.55 34.18 31.35 
Std 6.54 6.02 6.54 6.02 
AuNP-PEI C 
Ave 55.27 50.85 44.73 41.15 
Std 11.20 10.30 11.20 10.30 
AuNP-PEI D 
Ave 36.50 33.58 63.50 58.42 
Std 4.26 3.92 4.26 3.92 
AuNP-GSH A 
Ave 30.32 27.89 69.68 64.11 
Std 6.53 6.00 6.52 6.00 
AuNP-GSH B 
Ave 61.40 56.49 38.60 35.51 
Std 4.78 4.40 4.78 4.40 
AuNP-GSH C 
Ave 52.55 48.34 47.45 43.66 
Std 7.91 7.28 7.91 7.28 
AuNP-GSH D 
Ave 51.04 46.95 48.96 45.05 
Std 11.66 10.73 11.66 10.73 
*p-Values can be found in Table A4 in the Appendix. Statistical significance was for p < 0.05. 
 
4.3.4.2 Physicochemical Characterizations for Differentially Prepared AuNPs 
The ATR infrared (Section 2.2.1.3) comparative spectra for the AuNP-PEI and AuNP-GSH 
preparations can be seen in Figure 4.11. AuNP-PEI (A-D) can be seen in Figure 4.11a and 
AuNP-GSH (A-D) can be seen in Figure 4.11b. Both AuNP preparations indicate the 
disappearance of a characteristic C-S stretch for PEI-SH (Figure 4.11a, blue) and GSH to 
AuNP-GSH (Figure 4.11b, blue). Peaks of the ligands that are found on the AuNP surface is 
highlighted in red. New peaks which appeared in the spectra for the AuNPs are highlighted in 
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green. A new peak was observed in the AuNP-PEI prepared AuNP spectra below 1000cm
-1
 
(Figure 4.11a, green) which was attributed to the C-S peak observed for PEI-SH (Figure 
4.11a, blue) shifting in the spectra due to proximity to the AuNP surface. The AuNP-PEI 
spectra corresponded very well with the spectra of PEI-SH (Figure 4.11a). Changes were 
observed for all the AuNP-GSH preparations compared to GSH (Figure 4.11b) as expected. 
The spectra for AuNP-GSH B indicated a distinctive difference from the other AuNP-GSH 
preparations with the appearance of additional peaks lower than 1000cm
-1
 (Figure 4.11b, 
AuNP-GSH B). However, the AuNP-GSH spectra did not correspond well with the GSH 
spectra. The altered spectra were attributed to the proximity of the GSH, which is a small 
ligand, to the AuNP surface which influenced the vibrational states of the small ligand [318, 
319]. 
  
Figure 4.12 showed the comparative UV-Vis spectra (Section 2.2.1.6) of the differentially 
prepared AuNP-PEI (Figure 4.12a) and AuNP-GSH (Figure 4.12c) nanoparticles. The optical 
density was greatly increased of AuNP-PEI nanoparticles compared to the optical density for 
AuNP-GSH particles, being at least twice the value for AuNP-PEI as for AuNP-GSH. The 
proposed structures of the AuNPs can be seen for AuNP-PEI (Figure 4.12b) with the high 
molecular weight hyper-branched polymer on the surface and AuNP-GSH (Figure 4.12d) 
with the small zwitter ionic tri-peptide (GSH) on the surface. The structures were not drawn 
to scale. AuNP-PEI B (Figure 4.12a, red) showed a lower optical density at an equal dilution 
than the other AuNP-PEI preparations. AuNP-PEI A (Figure 4.12a, blue), AuNP-PEI B 
(Figure 4.12a, red) and AuNP-PEI D (Figure 4.12a, purple) had λmax = 530nm and AuNP-PEI 
C (Figure 4.12a, green) had λmax = 521nm. There was no clear correlation between the surface 
plasmon resonance band (λSPR = λmax) shift and the ratio of reducing agent used for synthesis 
of AuNP-PEI. AuNP-GSH A (Figure 4.12c, blue) AuNP-GSH B (Figure 4.12c, red) both 
displayed colloidal instability in solution within 30 minutes of re-suspension into solution. 
AuNP-GSH A/B had a λmax = 518nm and AuNP-GSH C/D had a λmax = 516nm, indicating a 
blueshift in the electromagnetic spectrum which appears to be correlated with increased 
amounts of reducing agent. An increase in optical density was also directly correlated to 
increased ratios of NaBH4 for AuNP-GSH (Figure 4.12c). When Table 4.5 is compared to the 
UV-Vis spectra (Figure 4.12) there appears to be a discrepancy between the optical density 
(OD) and the amount of gold utilized per AuNP preparation. 
 
 
 
 
 
 
144 
 
 
Figure 4.11: ATR infrared fingerprint spectra of AuNPs synthesized with PEI (a) and GSH (b) as capping 
agents. Peaks for AuNPs corresponding with ligand spectra are highlighted in red, novel peaks are 
highlighted in green. Fingerprint peaks are highlighted with red and peak variance is indicated in green. 
 
Optical density of gold nanoparticles in solution is directly correlated to the amount of gold 
nanoparticles in solution as determined by the Beer-Lambert law. The same amount of aurate 
salt was used for AuNP synthesis for different ligands, GSH and PEI, as well as differential 
amounts of reducing agent used. It would then be expected that the optical density of AuNP-
GSH and AuNP-PEI preparations would be similar in magnitude, however the optical density 
of the AuNP-PEI prepared nanoparticles was 2-3 fold more increased compared to AuNP-
GSH. This suggested that the optical density, as well as the surface plasmon resonance (SPR) 
band maximum (λSPR) was being affected by the ligand on the surface of the AuNPs. PEI is 
an amine rich molecule (Scheme 3) where the lone pair of electrons on the nitrogen atoms 
could significantly affect the electronic properties of the SPR and alter it.  
 
 
 
 
 
145 
 
    
 
Figure 4.12: Comparative UV-Vis spectra of differentially prepared AuNPs and their corresponding 
proposed structures. The UV-Vis spectra for GSH capped (a) and PEI capped (b) AuNPs show distinct 
differences for the different synthesis conditions. The proposed structure for the one-pot synthesized 
AuNPs can be seen for PEI-SH (b) and GSH (d) respectively and are not drawn to scale. The data is 
representative of technical triplicates and was repeated twice on different days. 
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The overall surface charge of the AuNPs was investigated by agarose gel electrophoresis as 
described in Section 2.2.19. The migration of the AuNPs on an agarose gel can be seen in 
Figure 4.15. The AuNP-PEI preparations migrated towards the anode (Figure 4.13, Lanes 7-
12 and 7-22) which indicated an overall positive surface charge. The AuNP-PEI particles 
displayed reduced electrophoretic mobility when compared to the AuNP-GSH preparations 
which indicated increased molecular mass. An experimental preparation for AuNP-PEI C 
(Figure 4.13, Lane 19) and AuNP-PEI D (Figure 4.13, Lane 21) both showed anomalous 
behaviour compared to the same experimentally prepared AuNP-PEI, migrating to the 
cathode and displaying similar electrophoretic mobility as for AuNP-GSH. Lane 21 (AuNP-
PEI D) had a very diffuse band moving towards the anode indicating the presence of a high 
molecular mass AuNP as well. AuNP-GSH A and AuNP-GSH B both displayed colloidal 
instability and disintegrated during the assay (Figure 4.13, lanes 1-6, green circle). AuNP-
GSH C and AuNP-GSH D showed the same electrophoretic ability in migration distance 
towards the cathode (Figure 4.13, Lanes 11-16) indicated an overall negative surface charge. 
The electrophoretic migration distance for the AuNP-GSH nanoparticles appeared to vary 
between different preparations and this was also observed for AuNP-PEI nanoparticles which 
suggested possible variations in the AuNP size distributions per batch. 
 
                                                                            
Figure 4.13: Electrophoretic mobility assay of differentially prepared AuNPs for qualitative charge and 
size distribution. The AuNPs were resolved on a 0.35% agarose gel for 40min at 50V. Each well 
represents an experimental preparation of the corresponding AuNPs. The anode (-) and cathode (+) is 
indicated on the gel and the centre of the wells are indicated by a black line. The green circle indicates 
AuNPs which disintegrated during electrophoresis. Lanes 1-3: AuNP-GSH A, Lanes 4-6: AuNP-GSH B, 
Lanes 11-13: AuNP-GSH C, Lanes 14-16: AuNP-GSH D, Lanes 7-9: AuNP-PEI A, Lanes 10-12: AuNP-
PEI B, Lanes 17-19: AuNP-PEI C and Lanes 20-22: AuNP-PEI D. The data is representative for all 
preparations and was repeated in technical triplicates twice on different days.  
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4.3.4.3 HR-TEM and Qualitative EDX Analysis of Selected AuNP-GSH and 
AuNP-PEI preparations 
The conditions for synthesis of the AuNPs can be found in Table 4.4. AuNP-GSH A and 
AuNP-GSH B (Section 4.3.2.3) both displayed colloidal instability making further 
physicochemical characterizations challenging. High resolution transmission electron 
microscopy (HR-TEM) and qualitative EDX analysis was done on selected prepared gold 
nanoparticle samples as described in Section 2.2.1.4.  
 
AuNP-GSH D was synthesized under the exact conditions as in Section 4.3.2.1 for the slow 
addition of the reducing agent (Table 4.1, Table 4.2, Figure 4.7 and Figure 4.9) yielded 
similar results. Preparation AuNP-GSH C showed near spherical AuNPs which are well 
dispersed from each other (Figure 4.14a) with an average size distribution of 7.32±3.90nm 
for 2049 particle counts (Figure 4.14c). This is a ~53% variation in size distribution. These 
AuNPs can be considered polydisperse in size distribution. The EDX (Figure 4.14b) confirms 
the presence of gold in the sample. 
 
AuNP-PEI A showed very well dispersed nanoparticles (Figure 4.15a) with a polydisperse 
size distribution (Figure 4.15a, c). AuNP shape discrimination and contribution to the sample 
was determined as described in 2.2.1.4. The AuNPs display mostly near spherical shapes with 
a low incidence (< 0.5%) of amorphous morphologies. The size distribution histogram 
(Figure 4.15c) indicates that AuNP-PEI A has a mean diameter of 17.38±9.05nm which is a 
~52% variation in size distribution. The size distribution was calculated by counting 2516 
particles with a cut off contribution to mean diameter of 3.5%.  
 
AuNP-PEI B showed well dispersed AuNPs with a 7%, 172 of the 2457 particles counted, 
incidence of tetrahedral shaped AuNPs (Figure 4.16a). Also, near spherical AuNPs presented 
with hexagonal shaped facets. The mean diameter was determined to be 18.19±13.30nm 
(Figure 4.16c) which is a ~73% variation in size distribution. Tetrahedral shapes did not 
contribute to the mean diameter calculation. AuNP-PEI D showed all the AuNPs were well 
dispersed from one another (Figure 4.17a) and polydisperse in size distribution (Figure 4.17c) 
with a mean diameter of 16.48±7.72nm. This is ~47% variation in size distribution for 1994 
particle counts. AuNP-PEI D showed a 42% incidence of tetrahedral AuNPs (Figure 4.17a 
and c). Tetrahedral AuNPs did not contribute to the mean diameter calculation. 
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Figure 4.14: The HR-TEM and EDX results for AuNP-GSH C. The HR-TEM micrograph (a) and size 
distribution histogram (c) (ImageJ) and indicated polydisperse GSH capped near spherical AuNPs. Only 
AuNPs which contributed 3.5% to the size distribution and spherical in shape was used for mean 
diameter calculation. The EDX (b) confirms the gold content of the AuNPs where the gold peaks are 
indicated by red circles. The data is representative for all AuNP preparations for this set of conditions.  
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Figure 4.15: The HR-TEM and EDX results for AuNP-PEI A. The HR-TEM micrograph (a) and size 
distribution plot (b) (ImageJ) indicated polydisperse PEI capped AuNPs. Only AuNPs which contributed 
3.5% to the size distribution was used for mean diameter calculation. The EDX (c) indicates the presence 
of gold confirming the composition of the AuNPs where the gold peaks are indicated with red circles. 
AuNP-PEI A and AuNP-PEI C showed highly similar AuNP properties in size and shape distribution. 
The data is representative for all AuNP preparations for this set of conditions. 
 
 
 
 
 
 
 
150 
 
 
Figure 4.16: HR-TEM and qualitative EDX results for AuNP-PEI B. The HR-TEM micrograph (a) and 
size distribution plot (c) (ImageJ) indicated polydisperse PEI capped AuNPs. Only AuNPs which 
contributed 3.5% to the size distribution and which were spherical in shape was used for mean diameter 
calculation. The EDX (c) indicates the presence of gold confirming the composition of the AuNPs where 
the gold peaks was indicated with red circles. The data is representative for all AuNP preparations for 
this set of conditions. 
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Figure 4.17: Physical parameters of the preparation of AuNP-PEI D. The HR-TEM micrographs (a, c) 
and size distribution plot (c) indicate polydisperse PEI capped AuNPs. Only AuNPs which contributed 
3.5% to the size distribution and which were spherical in shape was used for mean diameter calculation. 
The EDX (c) indicates the presence of gold confirming the composition of the AuNPs. The data is 
representative for all AuNP preparations for this set of conditions. 
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Table 4.6 draws a comparison between the UV-Vis predicted nanoparticle diameters and the 
mean diameters calculated by ImageJ assisted AuNP diameter calculations from HR-TEM 
micrographs. The diameter of the AuNPs determines the molar extinction coefficient (ε) 
which is used to calculate the concentration of the nanoparticles in solution. Differences in 
the extinction coefficients as well as the concentrations can be seen when the UV-Vis 
predicted data is compared to the ImageJ counts. AuNP-GSH A and AuNP-GSH B shows 
concentrations values magnitudes greater for the UV-Vis prediction than obtained for the 
ImageJ counts. A similar trend was observed for AuNP-GSH C, AuNP-GSH D and all the 
AuNP-PEI preparations but to a lesser extent. 
 
Table 4.6: AuNP-GSH and AuNP-PEI mean diameters and concentrations.      
 UV-Vis predicted values 
ImageJ values 
(Physical counts) 
Sample ASPR/A450
†
 
Diameter 
(nm) 
ε† 
(M
-1
.cm
-1
) 
[ ] 
(nm) 
Diameter 
(nm) 
ε† 
(M
-1
.cm
-1
) 
[ ] 
(nm) 
AuNP-GSH A 1.01 < 3 1.49 x 10
5 
3260 6.18 ± 4.53 1.26 x 10
7
 38.5 
AuNP-GSH B 0.97 < 3 1.49 x 10
5
 5850 6.60 ± 5.54 2.03 x 10
7
 43.0 
AuNP-GSH C 1.23 5 7.20 x 10
6
 491 7.32 ±3.90 2.03 x 10
7
 174.0 
AuNP-GSH D 1.19 4 3.62 x 10
6 
873 8.34 ± 3.04 3.07 x 10
7
 103.0 
AuNP-PEI A 1.63 15 2.18 x 10
8 
46.90 17.38 ± 9.05 3.23 x 10
8
 31.6 
AuNP-PEI B 1.75 22 7.31 x 10
8
 88.50 18.19 ± 13.30 3.87 x 10
8
 16.7 
AuNP-PEI C 1.58 13 1.39 x 10
8
 77.70 13.70 ± 7.52 1.76 x 10
8
 61.3 
AuNP-PEI D 1.63 15 2.18 x 10
8
 46.50 16.48 ± 7.72 2.67 x 10
8
 37.9 
†Calculated from Hais et al [218] and described in Section 1.6.2.2. 
 
4.3.4.4 Evaluation of AuNP-GSH C- and AuNP-PEI A aqueous chemical 
stability  
The biological milieu is a complex mixture of metabolites, biochemicals and macromolecules 
where each has different chemical reactivity. It was necessary to evaluate the aqueous 
stability of the prepared AuNPs for aqueous chemical stability in a wide range of buffer 
systems where the ionic strength, pH as well as chemical reactivity towards the AuNP surface 
were investigated. Selected data will be represented for NaCl and β-mercaptoethanol to 
highlight the stability in these solutions. AuNP-GSH C was representative for the AuNP-
GSH preparations and AuNP-PEI A was representative for the AuNP-PEI preparations, as 
similar results were obtained for all the AuNP-PEI particles. The stability assay evaluation 
was done as described in Section 2.2.3.2. 
 
AuNP-GSH C showed a trend in decreasing optical density associated with increased ionic 
strength of the NaCl solution with a blueshift of the surface plasmon band (Figure 4.18a, 
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λmax). The time-course stability was evaluated at an ionic strength of 1000mM NaCl for 
duration of 4 months. The data represented in Figure 4.18b showed no change in the UV-Vis 
spectra past 12h and was not included on the graph. AuNP-PEI A showed a similar 
decreasing trend in the optical density in associated with an increase in the ionic strength of 
NaCl (Figure 4.18c), however no change in the λmax was observed. As for AuNP-GSH C, the 
time course stability showed similar results (Figure 4.18d). 
 
β-mercaptethanol (BME) as a competing thiol induced colloidal instability in AuNP-GSH C 
(Figure 4.19c). There is a decrease in the optical density from 0.25mM BME without a shift 
in the λmax. At increased concentrations of BME complete colloidal instability was observed 
for AuNP-GSH C in a concentration dependent manner. The aggregation was a near 
immediate effect of suspension in the BME solution and a time-course assay was not done. 
AuNP-PEI A showed superior stability compared to AuNP-GSH C (Figure 4.19a) with no 
observable shift for λmax and a decrease in optical density. The UV-Vis spectra showed 
changes on the downward slope of the spectra (λ > λmax). It appears that the stability of 
AuNP-PEI A has a correlation to threshold concentrations of BME: for 0.25mM-1mM the 
UV-Vis spectra overlap near perfect before a perceptible decrease in optical density takes 
place. Another threshold region appears to be attained at 5mM-10mM BME. 
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Figure 4.18: Stability of selected synthesized AuNPs in NaCl solutions. Both AuNP-GSH (a) and AuNP-
PEI A (c) show very good stability up to an ionic strength of 1000mM NaCl. The time-course stability in 
1000mM NaCl This stability was observed for 8 weeks and the UV-Vis spectra can be seen up to 12h for 
both AuNPs in b and d. There was no observed difference in the UV-Vis spectra for either AuNPs past 
12h. The assay was done in triplicate and is representative for all results obtained for this assay. 
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Figure 4.19: Stability of selected synthesized AuNPs in differential concentrations of β-mercaptethanol 
(BME). The assay was done in triplicate and is representative for all for results obtained for this assay 
 
All the AuNP-PEI preparations showed colloidal instability in citrate solutions. The effect of 
ionic strength as well as time-course stability was investigated at two different pH values. 
Upon suspension of the AuNPs in the citrate solutions, at all the different concentrations, the 
solution colour went from clear wine-red to a turbid pink colour. AuNP-PEI A showed 
immediate colloidal instability for the whole range of citrate concentrations 1mM-100mM at 
pH 5 and pH 6 (Figure 4.20a and Figure 4.21a respectively). The time course stability of the 
nanoparticle was investigated at both pH values for 50mM (Figure 4.20b and Figure 4.21b) 
and 100mM (Figure 4.20c and Figure 4.21c).  The colloidal instability did not result in loss of 
the characteristic UV-Vis spectra for citrate pH 5 (Figure 4.20) and citrate pH 6 (Figure 4.21) 
presenting with a redshift from 3h-12h compared to the surface plasmon band of the control. 
A comparative blueshift was observed from 12h to 24h (Figure 4.20 and Figure 4.21) which 
was still a redshift compared to the control surface plasmon band. The colloidal instability of 
the AuNP-PEI nanoparticles appears to be a function of ionic strength and not of pH. 
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Figure 4:20: Stability of AuNP-PEI A in differential concentrations of citrate (pH 5). AuNP-PEI A 
showed a redshift in the UV-Vis spectrum (a) which was dependent on the ionic strength of the citrate in 
solution. The time course stability was evaluated for 24h in 50mM citrate (b) and 100mM citrate (c). The 
assay was done in triplicate and is representative for all results obtained for this assay. 
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Figure 4:21: Stability of AuNP-PEI A in differential concentrations of citrate (pH 6).  AuNP-PEI A 
showed a redshift in the UV-Vis spectrum (a) which was dependent on the ionic strength of the citrate in 
solution. The time course stability was evaluated for 24h in 50mM citrate (b) and 100mM citrate (c). The 
assay was done in triplicate and is representative for all results obtained for this assay.  
 
 
4.3.5 Discussion 
Typically NaBH4 reduction of aurate salts produce mono-disperse sub 10nm AuNPs. 
Depending on the size of the AuNPs required diameters of 2nm to 15nm [46, 203, 287, 320] 
can be synthesized based on the surface ligand chosen as well as the amount of NaBH4 
added. It has been reported before that using a low ratio of NaBH4:Au
3+
 produced larger 
(18nm-38nm) polydisperse aqueous AuNPs passivated by borate ions [203]. The changes in 
solution colour from dark yellow to light yellow within 10min of addition of the ligand 
indicated gold cations undergoing reduction from Au
3+
 to Au
1+
. This reduction was caused by 
the thiolate (R-S
-
) ligands forming polymeric precursors with the Au
3+
. Upon addition of the 
reducing agent, NaBH4, the polymeric aurate-thiolate precursors will further reduce the Au(I) 
to Au
0
 which induced AuNP formation with the ligand covalently attached on the surface. A 
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mechanism for this phenomenon was proposed by Brinas et al in 2007 using reduced 
glutathione (GSH) as a model ligand and is described below [213]: 
(1) Au3+ + 3GSH   → Au(I)SG + GSSG 
(2) n[Au(I)SG]   → [Au(I)SG]n 
(3) [Au(I)SG]n + NaBH4  → Au
0
[Au(I)SG]n-1 + GSH 
 
Where the cycles, m, is dependent on the amount of reducing agent added as well as 
the aurate cations in solution, 
 
(4) m cycles   → Au0[Au(I)SG]n-m + mGSH  
   
The GSH which was released per each cycle could covalently bind to the surface of Au
0
, 
where the GSH had dual roles of promoting reduction mediated growth as well as surface 
passivation of the formed AuNP [213]. The colour change in the solution upon addition of the 
reducing agent was the stepwise nucleation, seeding and growth of the AuNPs during the 
formation process as discussed in Section 1.6.2.1. The tempo of addition of the reducing 
agent played a crucial role as drop-wise addition induced nucleation, where additional 
reducing agent will then induce seeding and growth of the AuNPs. Addition of the reducing 
agent all at once resulted in the nucleation and generation of many AuNP seeds which 
exhausted the reducing, preventing subsequent growth of the AuNPs. Earlier studies for 
various synthesis techniques demonstrated similar finding such as the classic 1994 two-phase 
AuNP synthesis developed by Brust et al [212]. This result was demonstrated for the adapted 
synthesis comparing the UV-Vis spectra (Figure 4.7) and the HR-TEM micrographs (Figure 
4.8 and Figure 4.9). Fast addition of the reducing agent had significant amounts of sub 1nm 
gold clusters compared to the Slow addition of the reducing agent but no difference in the 
surface plasmon resonance band was detected as both preparations delivered a λSPR = 518nm. 
There was no significant difference in the mean diameter of the differentially prepared 
AuNPs but the phenomenon is attributed to the bathochromic shift phenomena observed for 
gold nanoparticles between the sizes of 8nm and 25nm (Section 1.5.2.2, Figure 1.22). 
 
The study by Brinas et al [213] determined that the resulting AuNP diameters will be 
dependent on the pH of the solution, where a low pH preferentially favoured formation of 
larger AuNPs and a high pH preferentially favoured the formation of smaller AuNPs. A low 
pH facilitates a denser packing of the ligands and a high pH facilitates a less dense packing of 
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ligands. This was demonstrated by GSH spatial dimensions being dependent on the pH of the 
solution. It can be further extended by speculation that if the size of the AuNP is determined 
by the size of the precursor, that a physically bigger ligand will facilitate the formation of 
larger AuNPs. This was observed when PEI-SH was used as a ligand in 4.3.3 compared to 
GSH where a significant redshift and increase in optical density was observed (Figure 4.10). 
The optimal ratio of Ligand:Au
3+
 was experimentally determined by Zheng et al [287] to be 
0.5:1, where the ligand can be a mono ligand or the sum of multiple ligands. In the seminal 
work done by Brust et al it was found that the ratio of thiol to gold is dependent on the 
reaction conditions [213]. This implied that for each type of solvent system and species of 
reducing agent, the ideal ratio of the thiol to gold would vary.  If the ratio for GSH was < 0.5 
there may not have been enough ligand to facilitate sufficient thiolate precursor formation 
and subsequent AuNP surface passivation. It has also been reported that thiolate ligands can 
also reduce the gold cations dependent on the reducing potential of the thiolate ligand [213, 
287] which may well be the case for GSH ratios > 0.5 as well as PEI-SH ratios > 0.25.  
 
For all AuNP preparation there was an overall increase in optical density for PEI-SH 
passivated AuNPs than for GSH (Figure 4.12), yet there was no significant difference in the 
amount of gold utilized for AuNP formation (Table 4.3). The increased optical density for the 
AuNP-PEI preparations is attributed to the high nitrogen content of PEI-SH. There are 360 
lone-pair electrons for 360 nitrogen atoms per mer of PEI-SH which has 149mol primary 
amines, 91mol secondary amines and 120 tertiary amines. The surface plasmon resonance 
band is the effect of electrons washing over the surface of the AuNP (Chapter 1, Figure 1.21). 
Additional electrons introduced close to the surface of the AuNP affected the surface 
plasmon resonance and as a result alter the UV-Vis spectra. Further, the size poly-dispersity 
of the AuNPs for both the GSH and PEI-SH preparations influence the validity of the Beer-
Lambert equation as one of the prerequisites for this equation is a homogenous distribution of 
an analyte species. A poly-disperse AuNP size distribution display spectroscopic properties 
which is a mean of the different molar extinction coefficients (ε), the more the variation in 
AuNP size the more inaccurate the equation will become. If the argument was extended to 
include a method, which uses the UV-Vis spectra by obtaining the ratio of the surface 
plasmon band (λSPR) to the absorption of the d/f-orbitals for noble metals at 450nm (λ450), 
such as proposed by Hais et al [218] this same effect was observed. This concept is 
demonstrated by the UV-Vis predicted AuNP diameters and concentrations in contrast to the 
values obtained from ImageJ counts (Table 4.1, Table 4.3 and Table 4.6).  These phenomena 
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as well as the bathochromic shift phenomena invalidated the use of the Beer-Lambert 
equation as well as the work done by Hais et al for determining mean diameter and 
concentration for AuNPs produced with this adapted AuNP synthesis. An adaptation of these 
methods to include a parameter(s) which described the electron density could compensate for 
the observed effect in this study. 
 
The increase of the ratio of NaBH4:Au
3+
 delivered more stable AuNP-GSH (C and D, λSPR = 
516nm) which was more stable than the unstable AuNP-GSH (A and B, λSPR = 518nm) and 
also showed higher overall concentrations and decreased size distributions from the mean 
(Table 4.6). The surface plasmon band predicted the diameter for AuNP-GSH A and AuNP-
GSH B was contradicted by the size distribution counts obtained from the micrographs 
(Table 4.6, ImageJ). The increased plasmon band for these mentioned AuNPs indicated the 
colloidal instability where smaller AuNPs were aggregating to appear larger. The ImageJ 
counts were done in the solid state and the UV-Vis spectra were done on the colloidal 
aqueous suspension. Dynamic light scattering would generate realtime data regarding 
colloidal instability under various parameters. The colloidal instability for AuNP-GSH A and 
AuNP-GSH B was indicative of inadequate quantities of NaBH4 to ensure sufficient AuNP 
maturation which left the AuNP surfaces flawed which increased the mean surface area, 
leading to increased surface chemical reactivity and subsequent etching of the AuNPs. The 
surface imperfections were a plausible explanation for the disintegration of AuNP-GSH A 
and AuNP-GSH B during the electrophoretic mobility assay (lanes 1-6, Figure 4.13). Also, 
the AuNP-GSH preparations were unstable in ultrapure water (dH2O, 18.2MΩ) and only 
displayed aqueous solubility in phospho buffered saline (PBS x1, pH 7.4) suggesting the need 
for adequate counter ions for AuNP solubility in water. AuNP-GSH C and AuNP-GSH D 
displayed good aqueous stability in differential concentrations of NaCl up to 1M but all the 
AuNP-GSH preparations showed absorption onto various glass and plasticware. The 
phosphate groups found in the component salts (K2HPO4, Na2HPO4 and NaH2PO4) could 
have facilitated the colloidal instability of the already unstable AuNP-GSH A and AuNP-
GSH B [321]. AuNP-GSH C displayed near immediate colloidal instability in the presence of 
a competing thiol, BME. In a biological milieu there are many endogenous competitive thiol 
containing small molecules as well as macromolecules such as proteins. BME was used as an 
evaluation tool to determine how susceptible the AuNP-GSH will be to a competitive thiol. 
The effect of BME as a known competitive thiol which induces irreversible aggregation of 
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alkane thiolate passivated AuNPs for the conditions where the BME affinity for the AuNP 
surface is higher than the already present passivated thiol [322].  
 
It is the first time that one-pot ligand passivated AuNPs have been synthesized using high 
molecular weight hyper branched PEI. The Au-NP PEI preparations showed no statistical 
significant difference in the mean particle diameters with increasing amounts of NaBH4. A 
combinatorial effect of using PEI-SH and NaBH4:Au
3+
 (0.5:1 and 1:1) showed a trend in 
increased tetrahedral morphology AuNPs. This was seen as a combinatorial effect as for the 
corresponding ratios of NaBH4:Au
3+
 the AuNP-GSH particles were spherical and the other 
AuNP-PEI preparations also presented with near spherical particles. It is possible that the 
high molecular weight hyper branched PEI-SH could have acted as a growth template as well 
as generating a thiolate precursor, but this needs to be investigated further. Goon et al 
demonstrated the shape and size control effect which PEI (Mw = 25 000g.mol
-1
) had on 
magnetite nanoparticles which were subsequently capped with a gold shell [323]. By 
variation of the stoichiometry between the different components in the above mentioned 
synthesis cube-, tetrahedral- as well as near spherical nanoparticles were produced. The 
tetrahedral AuNPs in this synthesis (Section 2.2.4.1) were passivated with PEI-SH in a 
covalent manner. Attempts were made to separate the different morphologies by using 
agarose electrophoresis but these attempts were unsuccessful. The AuNP-PEI particles 
showed minimal migration (Figure 4.13) from the loading wells even at agarose 
concentrations as low as 0.15%. The agarose gel was structurally unstable at such low 
agarose concentrations. Currently, two separation techniques are being standardized to enable 
shape and size enrichment of the AuNP-PEI preparations: Sucrose gradient centrifugation 
and denaturing gradient gel electrophoresis (DGGE), the latter which is a polyacrylamide 
based electrophoretic technique. Size and shape enrichment will enable further more in-depth 
physicochemical- as well as biological characterization of the AuNP-PEI prepared 
nanoparticles. The aberrant behaviour of AuNP-PEI C and AuNP-PEI D during the 
electrophoretic mobility assay, Figure 4.13, in lane 19 and lane 21 respectively is unknown. 
The AuNP-PEI preparations displayed similar high stability in NaCl as for AuNP-GSH C. 
However a superior stability in BME is attributed to one of two effects. The cationic hyper-
branched PEI-SH shields the AuNP surface sterically as well as electrostatically, effectively 
hindering the BME from interacting with the AuNP surface. The other possibility was that 
the PEI-SH had higher affinity for the AuNP surface than the BME, requiring more BME to 
outcompete the PEI-SH from the AuNP surface. Both these options remain speculative until 
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electrochemical studies can be conducted. The AuNP-PEI preparations displayed significant 
pH independent colloidal instability in differential concentration of aqueous citrate solutions. 
This was first reported by Puntes et al in 2009 [302] where they described the interactions of 
citrate with cationic and anionic functionalized AuNPs. At acidic pH the amines were 
protonated and had a positive charge. The citrate (3 carboxylic acid groups) acted as a 
counter ion for the cationic moiety on the AuNP surface as well as an inter-particle bridge. 
This will induce particle to particle electrostatic crosslinking with a redshift in the surface 
plasmon band as well as a decrease in optical density. This aggregation will take place 
regardless of the presence of polyethylene glycol on the AuNP surface [302]. 
 
The AuNP synthesis yielded poly-dispersed nanoparticles with covalent attached ligand in a 
one-pot manner. The synthesis produced AuNPs which were more stable with a high 
molecular weight cationic ligand and displayed different particle morphologies dependant on 
the amount of reducing agent used. The reproducibility for a set of synthesis conditions 
showed no statistical variance but also no statistical variance was observed for the mean size 
distribution for different synthesis conditions for the same ligand. However, a trend in 
increased mean diameter was observed as well as the formation of anisotropic nanoparticles. 
Size- and shape enrichment techniques would enable separation of the desired morphologies 
as well as sizes. AuNP-PEI A was chosen for drug loading (Section 4.4) due to the 
overwhelming particle morphology being near spherical (Section 4.3.4, Figure 4.15), the 
superior chemical stability in solution (Section 4.3.4.4) as well as having the best overall 
toxicology response of all the AuNP-PEI preparations (Section 5.2.2.2). Near spherical 
morphology for the AuNPs was deemed important as inclusion criteria as to eliminate shape 
dependent effects in the drug delivery experiments. 
 
 
4.4 AuNP-PEI A Surface Modification, Drug Loading and Drug Release 
4.4.1 Introduction 
The AuNP-PEI A gold nanoparticle preparation were covalently surface modified with 
different ratios of a commercial crosslinking polyethylene glycol (SM-PEG6) as well as SH-
NTA (Section 4.2.3) followed by covalent drug loading of doxorubicin by utilizing 
glutaraldehyde for amine-to-amine crosslinking. Total drug load as well as the in situ drug 
release was determined. The non-specific interaction of AuNP-PEI A, the PEG modified 
intermediates as well as the drug loaded variants were evaluated with isolated biomolecules 
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and complex solutions of biomolecules. The techniques utilized in this section were ATR, 
UV-Vis Spectroscopy and HPLC analysis. 
 
4.4.2 AuNP-PEI A: Drug loading and the changes in surface chemistry 
AuNP-PEI A was diluted, functionalized with differential concentrations of SM-PEG6 
(Section 2.2.3.3.1) and doxorubicin was covalently loading loaded onto the primary amines 
of the AuNP-PEI surface (Section 2.2.3.3.2). The AuNP-PEI A solution in the reaction vessel 
changed from a red-purple colour (OD ~ 0.5) to a turbid orange-red colour. Figure 4.22a 
showed a 23.8-fold increase in the optical density of the solution after doxorubicin covalent 
drug loading, as well as a significant blueshift in the λmax from 530nm to 495nm. There was a 
change in the surface plasmon band from a characteristic gold nanoparticle band (510-
550nm) to the maximum wavelength of absorption of doxorubicin (495nm). A comparison in 
the ATR “fingerprint” spectra (Figure 4.22c) for AuNP-PEI (blue), 30% PEG DOX (green) 
and DOX (red) showed that the spectra for 30% PEG DOX (green) had significant increased 
absorption for 1500-1000cm
-1
. The doxorubicin loaded variant of AuNP-PEI A, 30% PEG 
DOX, was readily lyophilized and resuspended for later use. The intermediate 
functionalization of the AuNP-PEI A surface with SM-PEG6 to create 30% PEG caused 
colloidal instability during the lyophilisation (Section 2.4.3) process. The 30% PEG particles 
showed aggregation within 72h after preparation (results not shown). The UV-Vis spectra 
showed a redshift for λmax from 530nm (Figure 4.22b, blue) to 545nm (Figure 4.22b, black) 
after functionalization with 30% PEG. There was no perceptible change in the colour of the 
nanoparticle solution for AuNP-PEI A and the 30% PEG modified solution (Figure 4.22d). 
Covalent drug loading of doxorubicin onto 30% PEG caused a significant blueshift in λmax 
from 545nm (Figure 4.22b, black) to 495nm (Figure 4.22b, green). 30% PEG (Figure 4.23a) 
as well as 30% PEG DOX (Figure 4.23b) displayed colloidal instability during HR-TEM 
analysis. The nanoparticles clustered and aggregated under the electron beam, losing their 
morphology. The proposed structures for the changes in the surface chemistry are given in 
Figure 4.24. The simplified structures indicate the shielding of the nanoparticle surface (dash 
circle) as well as the overall nanoparticle positive charge. AuNP-PEI A can be seen in Figure 
4.24a. One-pot functionalization of AuNP-PEI with the bifunctional cross linker, SM-PEG6, 
and with SH-NTA (Section 4.2.3) can be seen in Figure 4.24b. The drug loaded AuNP-PEI 
A, 30% PEG DOX, can be seen in Figure 4.24c. The proposed structure for the intermediate 
AuNP-PEI functionalization with 30% PEG (black spectra, Figure 4.22b; 30% PEG, Figure 
4.22d and Figure 4.24b) was used for nickel (Ni
2+
) titrations and subsequent surface plasmon 
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resonance (SPR) interactions with the recombinant peptide CTX-S2 in Chapter 3. This AuNP 
was referred to as AuNP-NTA for simplicity in Chapter 3 (Section 3.1.4). 
 
 
Figure 4:22: The surface modification of AuNP-PEI A with a bifunctional PEG crosslinker followed by 
drug loading of doxorubicin. Doxorubicin loading (green) onto the surface of AuNP-PEI A (blue) gave a 
significant increase in optical density as well as a blueshift in the spectrum (a). The ATR infrared 
fingerprint spectrum for AuNP-PEI A (blue) and the doxorubicin loaded 30%PEG DOX (green) can be 
seen in (c). Surface chemistry modification was monitored by UV-Vis spectroscopy (b) where shifts in λmax 
can be observed. The changes in the surface chemistry were observed in the AuNP solution colour as seen 
in (d). The data is representative for technical triplicates. 
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Figure 4.23: Colloidal instability for 30% PEG (a) and 30% PEG DOX (b) during HR-TEM analysis. The 
micrographs are representative for all preparations of nanoparticles with SM-PEG6 and subsequent drug 
loading with doxorubicin. 
 
 
Figure 4.24: The stepwise alteration in the surface chemistry of AuNP-PEI A. A simplified proposed 
structure for AuNP-PEI A can be seen in (a). 30% PEG-NTA modification of the total primary amines is 
represented in (b). Doxorubicin primary amine to primary amine crosslinking is shown in (c). 
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4.4.3 Biomolecule interaction of AuNP-PEI A, 30% PEG and 30% PEG DOX  
The interaction of the nanoparticles with biomolecules (Section 2.2.3.2) was to done to 
investigate possible non-specific surface interactions with the AuNPs, pre- and post-
doxorubicin loading. The time-points displayed were representative for detectable changes in 
the UV-Vis spectra. The interaction with a common serum protein, bovine serum albumin 
(BSA) was shown in Figure 4.25. AuNP-PEI A showed interaction with BSA from the first 
time point (Figure 4.25a, 15min) with a gradual restoration of the UV-Vis spectra at 24h. The 
spectra remain unchanged from 24h to 48h with regards to the surface plasmon band, there 
was however significant differences in the spectra from 300-450nm. The surface plasmon 
band (λmax) showed a blueshift from the control (530nm) to 24h (520nm). A similar trend was 
observed for 30% PEG with a more pronounced initial change in the spectra at 15min and a 
more rapid return to spectra which has a blueshift in the surface plasmon band at 24h. The 
24h shift was from 545nm to 520nm (Figure 4.25b), compared to control and a redshift in the 
surface plasmon band, 520nm to 525nm, from 24h to 48h (Figure 4.25b).  For the time points 
15min to 180min, both AuNP-PEI A and 30% PEG solutions was observed to turn a turbid 
colour with the disappearance of the turbidity at 24h and 48h. The doxorubicin loaded 
nanoparticle, 30% PEG DOX (Figure 4.25c), however showed a different interaction at the 
corresponding time-points than AuNP-PEI A and 30% PEG as well as a change in the optical 
densities. No significant change was observed in the λmax (495nm) for the time points for 
30% PEG DOX (Figure 4.25c). A significant decrease in the optical density was observed at 
24h and a significant increase in the optical density at 48h. 
 
Tissue culture media aims to mimic the circulatory system of an organism by providing 
essential nutrients, proteins as well as growth factors for cells grown in vitro and as such is a 
complex mixture of biomolecules which could potentially interact with nanoparticles. The 
interaction of the nanoparticles with mammalian cell culture media, RPMI1640, is shown in 
Figure 4.26. For all the time points AuNP-PEI A (Figure 4.26a), 30% PEG (Figure 4.26b) 
and 30% PEG DOX (Figure 4.26c) showed interactions with the media with altered UV-Vis 
spectra, specifically significantly increased optical densities within 48h. A permanent redshift 
in the λmax, associated with increased incubation time, was seen for all three nanoparticles. 
30% PEG DOX showed the most resistance to change in the spectra during the assay. AuNP-
PEI A had a redshift from 530nm to 545nm (Figure 4.26a), 30% PEG had a blueshift from 
545nm to 542nm (Figure 4.26b) and 30% PEG DOX had a redshift from 495nm to 555nm 
(Figure 4.26c). The solution colour for AuNP-PEI A and 30% PEG developed turbidity as 
 
 
 
 
167 
 
well as an increase in optical density at 48h. The solution colour remained clear for 30% PEG 
DOX.  
            
 
Figure 4.25: Time-course stability of AuNP-PEI A (a), 30% PEG (b) and 30% PEG DOX (c) in bovine 
serum albumin (BSA). 30%PEG DOX showed greater stability in a 1mg/mL BSA solution than its 
precursors over 48h. The data is representative for all results obtained for this assay done in triplicate. 
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Figure 4.26: Time-course stability of AuNP-PEI A (a), 30% PEG (b) and 30% PEG DOX (c) in 
RPMI1640. 30% PEG DOX showed a lessened effect in the presence of a complex biological solution 
compared to its precursors. The data is representative for all results obtained for this assay done in 
triplicate. 
 
The nanoparticle interactions with foetal bovine serum (FBS) supplemented RPMI1640 is 
shown in Figure 4.27. For all the nanoparticles there was a significant increase in the optical 
density in a time dependent manner. AuNP-PEI A showed a significant redshift from 530nm 
to 542nm within 15min (Figure 4.27a) with a further time dependent redshift to 546nm 
within 48h. 30% PEG (Figure 4.27b) showed a blueshift from 545nm to 537nm within 
15min. A time dependent redshift resulted in a surface plasmon band at 544nm within 48h. A 
similar trend in UV-Vis spectra was seen for 30% PEG DOX (Figure 4.27c) with a redshift in 
the spectra from 495nm to 554nm within 15min. This redshift remained constant for the 
duration of the 48h. 
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Figure 4.27: Time-course stability of AuNP-PEI A (a), 30% PEG (b) and 30% PEG DOX (c) in foetal 
bovine serum (FBS) supplemented RPMI1640. AuNP-PEI A showed less interaction with a complex 
biological solution than its chemical modified variants. The data is representative for all results obtained 
for this assay done in triplicate. 
 
 
4.4.4 Drug release of doxorubicin from the 30% PEG DOX AuNP-PEI A surface  
Doxorubicin release from the nanoparticle surface was done as described in Section 
2.2.3.3.3a and subsequently analysed by HPLC analysis (Section 2.2.3.3.3b). The HPLC 
overlay chromatogram can be seen for the doxorubicin standard series (serial dilution) in 
Figure 4.28a. Doxorubicin was detected at a retention time of 6.10±1.10min. The linearity of 
the standard series can be seen in Figure 4.28b. The UV-Vis spectrum of the corresponding 
chromatogram peaks confirmed the identity of the compound as doxorubicin (Figure 4.28c). 
The retention times, integration for the area under the curve and concentrations for the 
corresponding peaks can be seen in Table 4.7.  
 
As an example, the amount of doxorubicin hydrolysed after 30min of incubation in 0.1N HCl 
(Section 2.2.4.3.3a) can be seen in Figure 4.29. Four peaks were identified on the 
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chromatogram as doxorubicin associated peaks. The first identified peak (Figure 4.29a, Table 
4.7) had a retention time of 6.20min, corresponding with the expected retention time for 
doxorubicin. The additional peaks had retention times of 8.98min (Figure 4.29b, Table 4.5 – 
Unknown #1), 11.28min (Figure 4.29c, Table 4.5 – Unknown #2) and 13.97min (Figure 
4.29d, Table 4.7 – Unknown #3) respectively and where identified as doxorubicin 
metabolites by the comparing the UV-Vis spectra of the peaks with that of doxorubicin 
(Figure 4.29c). The total doxorubicin released was calculated to be 312.9nM (Table 4.7) and 
was the summation of all 4 peaks found to correspond to the UV-Vis spectra of doxorubicin. 
The peak at 11.28min contributed the most to the total doxorubicin released from the 
nanoparticle surface (129.36nM, Table 4.7 – Unknown #2). The doxorubicin peak at 6.20min 
had the second highest contribution to doxorubicin released from the nanoparticle surface 
(109.41nM, Table 4.7 – Doxorubicin). 
 
Table 4.7: HPLC analyses of drug release from the AuNP-PEI A surface after 30min. 
Peak 
Retention 
Time (min) 
Relative Area 
(mAu*min) 
Concentration 
(nM) 
Standard series (Serial 
dilution) 
Doxorubicin x1 6.02 694.76 450 
Doxorubicin x2 6.11 362.65 225 
Doxorubicin x4 6.14 174.97 112.50 
Doxorubicin x8 6.17 114.78 56.25 
 
Peak 1 Doxorubicin 6.20 168.92 109.41 
Peak 2 Unknown #1 8.98 89.27 57.82 
Peak 3 Unknown #2 11.28 199.72 129.36 
Peak 4 Unknown #3 13.97 25.18 16.31 
 312.90 
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Figure 4.28: Doxorubicin standard series utilized for acid hydrolysis based drug release assay of 
doxorubicin from the AuNP-PEI A surface. The overlay chromatograms for the serial dilution standard 
series for doxorubicin can be seen in (a). The linearity of the standard series can be seen in (b). The UV-
Vis spectrum for doxorubicin can be seen in (c). Retention times as well as integration can be seen in 
Table 4.5. The data is representative of technical triplicates and was repeated twice on different days. 
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Figure 4.29: HPLC analysis of the acid hydrolysis (0.1 N HCl) of doxorubicin from the surface of AuNP-
PEI A after 30min. Four peaks were identified which had the corresponding UV-Vis spectra for 
doxorubicin with increase in retention time (a-d). Retention times and integration can be seen in Table 
4.5. The data is representative of technical triplicates.  
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The acid hydrolysis facilitated release of doxorubicin from the nanoparticle surface was 
monitored for 24h (Figure 4.30) by HPLC analysis. After 3 hours (180min) the total 
doxorubicin release was 402nM. At 12h (720min) the total doxorubicin released was 401nM 
and at 24h (1440min) it was 405nM. The estimated concentration of 30% PEG DOX used for 
the drug release assay was calculated to be 100pM AuNP according to the method of Haiss et 
al [218] (Sections 1.6.2.2 and 2.2.1.6a). An average of 400nM doxorubicin released per 
100pM AuNP-PEI A indicates doxorubicin: AuNP-PEI A = 4000:1. On a mole to mole basis 
this means 1mmol of 30% PEG DOX AuNP-PEI A released 4mol doxorubicin.  
 
 
Figure 4:30: Time-course acid hydrolysis of doxorubicin from the AuNP-PEI A (30%PEG DOX) surface. 
The time points are indicated in coordinates (x (min), y (nM)). The data is representative for all assays. 
The p-values can be found in Table A5 in the Appendix. 
 
In Section 4.2.4 the estimation was made that for each mol PEI-SH there will be 149mol 
primary amines. The covalent attachment of doxorubicin utilizes primary amine crosslinking 
(Section 2.2.4.3.2). If the assumption is made that all the remaining primary amines are 
utilized for crosslinking for a 30% PEG AuNP-PEI functionalization with 149mol primary 
amines per 1mol PEI-SH, this implies that (0.3)(149) = 44.7mol ≈ 45mol primary amines 
unavailable for covalent drug loading. Thus 149mol – 45mol = 104mol primary amines 
available for covalent drug loading. Then for 4000mol doxorubicin this means: 
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 (4000mol doxorubicin)/(104mol primary amines)  
= 38.46mol (≈ 38.5mol) doxorubicin per 104mol PEI-SH, then x represents the amount of 
total PEI-SH per mol AuNP:    
     (38.5mol).(100%) = (70%)x 
     x = 55mol PEI-SH per 1mol AuNP 
 
The estimation was made, as shown above, that there was 55mol PEI-SH for 1mol of AuNP-
PEI. However the size poly-dispersity of the AuNPs will make this ratio vary significantly. 
  
4.4.5 Discussion 
The blueshift of the surface plasmon from 530nm to a wavelength which was not associated 
with the surface plasmon (λmax = 495nm) as well as the 23.8-fold increase in optical density 
indicated the drug loading onto the AuNP surface was sufficient enough to completely 
destroy the typical UV-Vis spectra associated with AuNPs. This high drug loading potential 
was attributed to the large number of primary amines PEI-SH provided for amine-to-amine 
crosslinking. This type of crosslinking has been used previously to covalently load 
doxorubicin onto polymers [89-91]. The typical trend in the literature is to utilize 
carbodiimide chemistry to load doxorubicin onto carboxyl functionalized AuNPs [147, 324, 
325]. Kumar et al demonstrated that 70-80 doxorubicin molecules were loaded per single 
AuNP, mediated by carbodiimide chemistry [147]. In situ drug release assays indicated that 
1mol AuNP-PEI 30% PEG DOX will release 4000mol of doxorubicin within 3 hours. The in 
situ acid hydrolysis based drug release assay aims to mimic the acidic (4 < pH < 6) conditions 
found in endosomes and lysosomes [279, 326-328]. In the event of endosome of lysosome 
sequestration of drug delivery vehicles, such as gold nanoparticles, the chemotherapeutic 
payload would be degraded or exocytosed from the cell, thus decreasing the overall 
effectiveness of the formulation.  
 
Physico-chemical characterizations of AuNP-PEI A as well as the changes in the surface 
chemistry proved challenging, with UV-Vis spectroscopy and ATR infrared spectroscopy the 
most facile methods. Electrophoretic mobility assays for qualitative evaluation of change in 
overall charge and molecular weight, per stepwise surface modification, was not be done due 
to the limitations of the current experimental setup, as mentioned in an earlier paragraph, for 
size and shape enrichment. HR-TEM analysis caused aggregation under the electron beam 
which suggests the 30%PEG and 30%PEG DOX functionalization may lower the melting 
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point of AuNP-PEI A. A similar phenomenon was reported where AuNPs aggregated under a 
200keV beam which melted the AuNPs and induced solid state aggregation [329, 330]. 
Dynamic light scattering experiments may give better insight into the colloidal stability of 
30%PEG and 30%PEG DOX and was considered as an essential component of the 
experimental workload, however this was not a feasible experiment due to logistical factors 
as well as agreement of non-disclosure which provided challenges in engaging other 
researchers. 
 
Non-specific interactions with bovine serum albumin (BSA) showed that the doxorubicin 
loaded AuNP, 30%PEG DOX, had the least amount of interaction with this serum protein. 
BSA has an isoelectric point (pI) of 4.6 and would be negatively charged at pH 7 [331] which 
was the pH of the assay. The 30%PEG DOX AuNP (Figure 4.25c) was most stable during the 
BSA assay, most likely attributed to the doxorubicin shielding the AuNP-PEI from the 
negatively charged BSA. The cationic AuNP-PEI A had electrostatic interactions with the 
anionic BSA as seen in Figure 4.25a. The 30% PEG AuNP (Figure 4.25b) displayed non-
specific interaction with the BSA and showed a UV-Vis spectra which returned to a near 
original state as well as a less pronounced change in the surface plasmon band which was 
attributed to the PEG functionalization reducing the non-specific interactions [156, 287]. 
Similar trends for 30%PEG was seen for all biomolecule interactions. Data generated in this 
study indicated that 30% surface functionalization with PEG6 (SM-PEG6) did not completely 
abolish non-specific interactions but decreased the biomolecule interactions. Complete 
abolishment of the non-specific biomolecule interactions were not seen in this study and were 
attributed to the strong cationic nature of the PEI-SH.  
 
RPMI1640 (Figure 4.26) and foetal bovine serum (FBS) supplemented RPMI1640 (Figure 
4.27) showed significant redshifts and changes in the optical density of AuNP-PEI 
interactions as well as for 30%PEG DOX. RPMI1640 is a complex biological solution which 
aims to mimic serum constituents for mammalian cell culture purposes. It contains a mixture 
of inorganic salts, vitamins and specifically reduced glutathione as indicated on the product 
information sheet provided by the supplier (Lonza). Reduced glutathione (GSH) can act as a 
competitive thiol in a similar manner to BME [332, 333] as well as act as an inter-particle 
particle-to-particle bridge by electrostatic- hydrogen bonding [334]. The addition of FBS 
further complicated the solution composition. Any number of small molecules, amino acids 
or peptides could be implicated in the reaction. Also, the pH indicator used in RPMI1640 is 
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phenol red which has a zwitter ionic charge bearing potential. Phenol red could have potential 
electrostatic interactions with the cationic AuNPs in a pH dependent manner since the assay 
conditions were done at pH 7.4, this is near the pH range (Figure 4.31) where the acid-base 
conjugate pair exists in equilibrium [335]. It has been shown for citrate capped AuNPs that 
the nanoparticles aggregated in vitro in the presence of cell culture media in a time dependent 
manner before cellular internalization occurred and as such inflicted mechanical injury to the 
cells [336]. It has not yet been reported to what extent PEG influences this interaction. The 
aggregates can cause mechanical injury to the cells or change the intrinsic composition of the 
media if vitamins or cofactors are binding to the surface of the AuNP leading to nutritional 
deficiencies for the cells.                                   
                 
                      
           Figure 4.31: The protonation of phenol red 
 
The AuNP-PEI A nanoparticle proved to have a high drug loading capacity on a comparative 
mole to mole basis. The colloidal instability of 30% PEG necessitated it to be freshly 
prepared on the day it was needed for an assay while 30% PEG DOX could be readily 
lyophilized and resuspended for later use. AuNP-PEI A and 30% PEG DOX was used to 
evaluate the drug delivery platform in multidrug sensitive- and multidrug resistant ovarian 
carcinoma cells in vitro cell based assays in Chapter 5. The proof of concept which utilized 
this PEI-SH drug delivery platform in a targeted manner was investigated by functionalizing 
nanoparticles with completely different physicochemical characteristics, namely quantum 
dots (Section 4.5), and then evaluating the nanoparticle cellular localization with the help of 
fluorescence microscopy (Section 3.3.3.2). The transfer of the PEI-SH drug delivery platform 
to quantum dots is discussed in Section 4.5.   
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4.5 Quantum Dot (QD) Surface Modification and Characterization 
4.5.1 Introduction 
The fluorescent semi-conductor quantum dots (QDs) are gaining popularity in cellular- and 
whole animal imaging applications. The intrinsic electronic semi-metallic properties of these 
nanoparticles make them superior high contrast materials for optical investigations. A major 
drawback is the inherent toxicity associated with the materials used in the synthesis of these 
nanoparticles. Propriety indium-phosphide based QDs were obtained from Mr Paul 
Mushonga [388] and these nanoparticles were investigated for the transferability of the PEI 
surface functionalization chemistry utilized for AuNP-PEI. The QDs were used to investigate 
the interaction between chlorotoxin and matrix metalloproteinase-2 in wide field fluorescence 
microscopy protein co-localization studies (Chapter 3).  
 
4.5.2 Surface Modification of palmitic acid passivated QD625 
Palmitic acid passivated QD625 was ligand exchanged (Section 2.2.4.1) from a chloroform 
solution to an aqueous solution of PEI-SH (Section 4.2.4). This resulted in aqueous soluble 
QD625 which had thiol anchored covalent attached PEI-SH on the surface. A significant 
blueshift and increase in relative fluorescence intensity was observed for QD625 during the 
phase transfer from palmitic acid passivated to PEI-SH modified (QD625-Palmitic acid to 
QD625-PEI, Figure 4.33). The QD-PEI was further modified with SM-PEG6 (Section 2.2.4.2a) 
which resulted in no observable changes in the emission maxima or in relative fluorescence 
intensity (QD625-PEI 30%PEG, Figure 4.32). The MMP2 targeting peptide, Chlorotoxin was 
covalently coupled to the QD625-PEI 30% PEG surface by carbodiimide chemistry (Section 
2.2.4.2b) without changes were observed for the quantum dot emission maxima or the 
relative fluorescence intensity for the peptide functionalized QD625 (CTX-QD625-PEI 30% 
PEG, Figure 4.32). An emission peak at 465nm was observed for QD-Palmitic acid for which 
the relative fluorescence emission intensity significantly decreased with subsequent 
functionalization with PEI and 30% PEG. There was a significant increase for this 465nm 
emission with the peptide functionalization (CTX-QD625-PEI 30% PEG, Figure 4.32) but this 
was still significantly lower than for QD625-Palmitic acid.  
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Figure 4.32: The fluorescence emission spectra of 100nM QD625 during differential functionalization of 
the nanoparticle fluorescence. 
 
The proposed change in surface chemistry is represented in Figure 4.32. The proposed 
structure for QD625-Palmitic acid (Figure 4.33a), QD625-PEI (Figure 4.33b), QD625-PEI 30% 
PEG (Figure 4.33c) and peptide functionalized CTX- QD625-PEI 30% PEG (Figure 4.33d) 
illustrates the changes in the surface chemistry of the quantum dots with modifications 
required for downstream biological fluorescence microscopy applications. 
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Figure 4.33: The proposed changes in surface chemistry of QD625 with different surface functionalization. 
 
4.5.3 Discussion 
QD sample quantity was limited. All other physicochemical characterizations were done by 
Mr Paul Mushonga [388]. Fluorescence emission spectroscopy will be presented for the 
novel surface modifications done to this palmitic acid passivated QDs. 
 
Ligand exchange (Section 2.2.4.1) of the QD625-Palmitic acid was completed within 2 hours 
and the marked change in the emission profile was observed. The phase change of the QD625 
from the chloroform to the aqueous layer indicates a change in surface chemistry. The QD625 
is altered from being lipophilic palmitic acid chelated passivated (Figure 4.33a) to covalent 
passivated by PEI-SH (Figure 4.33b) with a thiol bond. The QD625 is capped with a zinc-
selenide (ZnSe) shell. Zinc has a preferential affinity for thiol groups over amines and is such 
is the most likely bond that PEI-SH will form with the QD shell [171, 174, 230, 233]. The 
blueshift from 625nm peak emission to 600nm peak emission was observed for- and 
attributed to the PEI-SH functionalization. The high nitrogen content of the polymer provides 
lone pair electrons which altered the electronic character (similar as discussed in Section 
4.3.7) of the system and as such effected a significant change in the fluorescence character of 
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the system. The effect of amine (nitrogen) containing ligands was reported to induce a 
redshift in the fluorescence emission spectra of QDs post ligand exchange [233]. However, a 
blueshift was however observed for the indium-phosphide QDs as well as an increase in peak 
fluorescence emission intensity at 600nm, where the latter is indicative of an increased 
quantum yield which was not an effect of dilution error as all samples were at equal dilution 
during fluorescence emission spectroscopy (Section 2.2.4.1). A loss of quantum yield is 
typically predicted for QD ligand exchange reactions [161, 233, 255] from an organic 
solution to an aqueous solution due to surface imperfections created in the QD shell as atoms 
get stripped from the crystal lattice structure during ligand exchange and subsequently the 
core atoms can leak from the QD core structure [162, 292, 337]. 30% PEG showed no altered 
peak fluorescence emission maxima nor did the chemical conjugation of chlorotoxin (CTX). 
Another phenomenon was observed where a fluorescence emission peak was found at 465nm 
which differentially changed with surface functionalization. The latter phenomenon, the 
blueshift in peak emission as well as the increase in fluorescence intensity at the same QD625 
concentration during surface functionalization needs to be investigated further as these are 
novel physicochemical observations. The new observed phenomena may be specifically a 
combination of noble metal doping of the indium based QD625 as well as the use of the 
hyperbranched high molecular weight PEI-SH which introduced novel electronics to the 
proprietary QD625 (personal communication with Dr Martin Onani, Nanotechnology 
Innovation Centre (NIC), Department Chemistry, University of the Western Cape, Cape 
Town, South Africa).  
 
CTX was conjugated utilizing water soluble carbodiimide (EDC) chemistry as opposed to 
nickel affinity binding of the NTA to the recombinant 6xHis–tag on CTX due to the small 
sample quantity of QDs. The NTA group has 3 carboxyl acid groups (Figure 4.33c) which 
were used for EDC chemistry facilitated coupling of primary amine residues on CTX. 
 
The success of the functionalization of the QD625 with PEI-SH and CTX was confirmed in 
Section 3.3.3.2 with protein co-localization fluorescence microscopy studies. Shuming Nie 
suggested that PEI can be used as an efficient endosome disruptive coating for QDs using 
smaller variants of hyper branched PEI as well as linear PEI [226, 236, 255, 279, 337]. The 
functionalization of QD625 with PEI deserves more in-depth research to determine the photo-
physics as well as the electronic effects observed for this project. 
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Chapter 5: Interactive Studies of Gold Nanoparticles (AuNPs) 
with Paired Ovarian Carcinoma Cell Lines 
 
5.1 Cellular Reversion from Multi-drug Resistance to Drug Responsive: 
Biomarker Assisted Evaluation of Malignancy 
5.1.1 Introduction 
The multi-drug resistant cell line (A2780cis) was reverted to the drug responsive (A2780) 
cell line. The purpose being two-fold: Firstly, is it possible to have an aggressive cancer 
revert back to a less malignant form in vitro and secondly can a selective drug response be 
observed between drug responsive and drug resistant variants of the cell line.  The cell line 
reversion was confirmed with selected biomarkers. Cells were propagated as described in 
Section 2.4.2. 
 
5.1.2 Reversion of A2780cis to A2780: Multi-Drug Resistant (MDR) to Drug 
Sensitive 
The differences in cellular morphology between the cells cultured in the absence of cisplatin 
and presence of 2μM cisplatin (Section 2.4.3.1) can be seen in Figure 5.1a and Figure 5.1b 
respectively. Distinct white spots were visible in the cells that were under cisplatin treatment 
(Figure 5.1b) and were observed at different magnifications for the treated cells. A more 
epithelial morphology was seen for the untreated cells (Figure 5.1a) which were elongated 
and presented with larger cytoplasmic volumes. The A2780cis cells (Figure 5.1b) showed a 
more elongated morphology but some cells also presented with near-spherical or amorphous 
morphology. It was also found that the floating cells (Figure 5.1b) were still viable, since 
subculturing of these cells resulted in cellular attachment and growth. This cell line is derived 
from a very aggressive metastatic ovarian tumour. The A2780cis cells display all the 
molecular hallmarks of metastasis with increased expression of matrix metalloproteinases, 
adhesion molecules and angiogenesis associated proteins [53]. The morphological changes 
observed for the cells prompted confirmation of A2780cis reversion with immunoblotting. 
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Figure 5.1: Cellular morphology of the cisplatin responsive A2780 (a) and the resistant A2780cis cells. 
 
The protein expression patterns from passage 7 to passage 8 appeared to not have distinct 
differences (Figure 5.2a) for both cisplatin treated and untreated cells. However, passage 9 
(Figure 5.2a, p9 and p9c) showed altered protein expression for both cell types with the 
presentation of a distinctive high molecular weight protein band < 100kDa (red rectangle, 
Figure5.2a). This high molecular weight band was not the result of cisplatin treatment as it 
was present in the untreated (p9) as well as the cisplatin treated (p9c) lanes. The high 
molecular weight protein band may be associated with the duration and conditions of 
continuous sub-culturing. High passage number can result in altered protein expression and 
may not always be indicative of the disease stage as well as associated molecular events 
which have prompted the World Health Organization (WHO) to define criteria for biomarkers 
[14]. This has been a hot-topic of debate in biomarker discovery in the past few years. 
Immunoblotting (Figure 5.2b) was done to confirm the reversion of A2780cis to A2780. 
Biomarkers from different subcellular loci were chosen for this purpose.  
 
A membrane associated death receptor-death receptor ligand (CD27-CD27L) interaction 
[338-340], a mitochondrial anti-apoptotic heatshock protein (HSP60) [341-343] and a nuclear 
housekeeping protein (MLH1) [57, 344, 345] were chosen. β-actin was chosen as the 
housekeeping reference gene. Immunoblots and densiometric analysis were done as described 
in Section 2.4.3.2. The mitochondrial heatshock protein (HSP60) showed relative increased 
expression in the cisplatin treated cells for each passage compared to the untreated cells with 
regards to the immunoblot (Figure 5.2b) and the corresponding densiometric analysis (Figure 
5.2c). HSP60 is a mitochondrial chaperone protein which is predominantly found in the 
mitochondrial matrix but can also be found in the cytoplasm [342]. HSP60 plays an anti-
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apoptotic role in the mitochondria associated apoptosis pathway where it interacts with Bax 
(pro-apoptotic member of the Bcl-2 family) to prevent pore formation in the mitochondrial 
inner membrane which prevents cytochrome C release to the cytoplasm [346]. The role of 
HSP60 in acquired multi-drug resistance in ovarian cancer is still a controversial topic with 
conflicting reports in the literature. Up regulated expression of HSP60 desensitizes the cells to 
the pro-apoptotic signal and is associated with acquired drug resistance [342, 347]. 
Conversely, in the absence of cisplatin the cells displayed decreased HSP60 expression. This 
was observed at p7 to p9, indicating altered molecular pathways between the treated and 
untreated cells. MLH1 expression showed relative increased protein expression for the 
cisplatin untreated cells (Figure 5.2b and Figure 5.2c). Acquired multi-drug resistance 
presents with decreased expression of MLH1, a mismatch repair gene, for various cancers as 
well as ovarian cancers of epithelial origin [57, 348]. No direct link has yet been established 
between multi-drug resistance and altered mRNA expression of MLH1 [56] which suggests 
that MLH1 regulation is on a translational level. Evidence indicates that MLH1 is 
epigenetically repressed by methylation with acquired multidrug resistance where decreased 
expression of MLH1 results in resistance to apoptosis [55, 348, 349]. Conversely, increased 
expression of MLH1 sensitizes the cells to pro-apoptotic signals. The epigenetic silencing will 
decrease MLH1, making this an invaluable biomarker for determining cancer cell malignancy. 
Two intracellular biomarkers confirmed the reversion of the multidrug resistant cell line 
A2780cis to a drug responsive cell line, referred to as A2780.  
 
Reversion was also confirmed by flow cytometry using a third biomarker, CD27. CD27 is a 
tumour necrosis factor associated death receptor with CD70/CD27L being the binding ligand 
[340]. Qualitative flow cytometry analysis (Section 2.4.3.3) of the fluoroisothiocyanite 
(FITC) labelled CD27L ligand was evaluated for the cisplatin treated and untreated cells 
(Figure 5.3). The fluorescence shift for A2780 as compared to control (Figure 5.3, A2780) 
was not as pronounced as for A2780cis (Figure 5.3, A2780cis). It may appear contradictory 
that a multi-drug resistant cancer cell line showed increased expression of a death receptor, 
but this receptor has been shown to have immuno-modulation functionalities. CD27 is crucial 
in maintaining T-cell immunity [340], B-cell activation [350], NF-κB signal transduction and 
MAPK/JNK activation [350] as well as acting as a decoy receptor [339]. It is clear that CD27 
can modulate the overall inflammatory response. These characteristics make CD27 a 
significant contributor to avoidance of apoptosis as well as acquired multi-drug resistance. 
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Figure 5.2: The change in relative protein expression in A2780cis cells during reversion from drug 
resistant to drug responsive. The SDS-PAGE gel for whole cell lysates can be seen in (a) with the 
corresponding immunoblots for selected biomarkers MLH1 and HSP60. The densiometric analysis of the 
immunoblot was normalized to β-actin (c). Passage 7, 8 and 9 of A2780cis cells in the absence of cisplatin 
are in lanes 7, 8 and 9 respectively. Passage 7, 8 and 9 of A2780cis cell treated with 2μM cisplatin are in 
lanes 7c, 8c and 9c respectively. The cell lysates were resolved on a 14% SDS-PAGE gel using Thermo 
PageRuler Unstained Protein Ladder (M). Densiometric analysis was done with ImageJ®. 
                                                                
                             
                                 
Figure 5.3: Qualitative flow cytometric analysis of the reversion of the multi-drug resistant A2780cis at p9. 
The multidrug resistant A2780cis (green) cell line shows a shift to the right compared to control. No shift 
was observed for the drug responsive A2780 cell line. The control was unlabelled cells. A2780cis – cells 
treated with 2μM cisplatin and A2780 – cells untreated with cisplatin. A total of 10 000 cells were counted. 
 
Reversion of the multi-drug resistant A2780cis to the drug responsive A2780 cell line was 
successful. The immuno-blotting (Figure 5.2b) and flow cytometry (Figure 5.3) for known 
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biomarkers indicated molecular differences between the two cell lines. There were also 
distinct morphological differences between the two cell lines (Figure 5.1). The passive 
reversion of the cell line in the absence of cisplatin suggested that the cellular cytoprotective 
response pathways were not essential anymore which is indicative of epigenetic gene 
regulation. Epigenetic gene regulation has been suggested as the governing factor in ovarian 
carcinoma malignancy [12, 14, 16, 63], as well as for in vitro models such as the 
A2780/A2780cis paired cell lines [63, 349, 351]. The reversion of A2780cis to A2780 was to 
generate a genetic identical paired cell line for comparative analysis of cytotoxicity of 
AuNPs. A2780 and A2780cis cell lines were cultured to passage 9 for all cell based assays in 
further experiments. 
 
 
5.2 Gold Nanoparticle (AuNP) Interactions with A2780 / A2780cis Cells 
5.2.1 Introduction 
Nanotoxicology is a controversial topic in the current literature as new nanotechnology 
devices are being approved by the FDA for applications in human diagnostics and 
therapeutics. Environmental concerns have also been raised. It has become necessary to 
evaluate how nanoparticles interact with biological molecules as well as within living cells in 
vitro and in vivo. As such, the paired cell lines A2780/A2780cis were used to determine 
differential response of the cell lines to AuNPs and their drug loaded variants. The objective 
was to determine whether a drug delivery system could be developed at ultralow dosages, 
compared to current in vitro drug delivery models, which could overcome multidrug 
resistance.  
 
Tetrazolium salt cell viability and cytotoxicity assays such as the (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay have fallen out of favour for the evaluation 
of nanotechnology based treatments as a wide range of nanoparticles were reported to have 
direct interactions with the cell permeable tetrazolium salts inside the cells [256, 352]. 
Further, AuNPs have spectral overlap with the MTT assay in the range of 450nm-560nm, 
dependent on the mean size distribution of the AuNPs. WST-1 (2-[4-iodophenyl]-3-[4-
nitrophenyl]-5-[2,4-disulfophenyl]-2H-tetrazolium salt) was chosen as an alternative 
tetrazolium assay, with  a maximum absorption wavelength at 450nm where AuNPs have a 
minimum absorption wavelength. WST-1 is impermeable to the cell membrane and interacts 
with a plasma membrane bound NADH-oxidase enzyme with superoxide being the main co-
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factor for reduction of the tetrazolium salt [353, 354]. The WST-1 assay would potentially 
reduce the interference from the nanoparticles on tetrazolium assays, especially if the 
nanoparticles were internalized into the cells. Other assays that were utilized to evaluate the 
toxicity of the AuNPs determined the mechanism of cell death, oxidative stress and sub-
cellular localization associated with the nanoparticles. The assays used were based on 
colorimetric detection, luminometric detection and immunoblotting as well as electron 
microscopy techniques. In general, a time point of 24h post treatment was chosen for analysis 
as this is a commonly used exposure time for in vitro cell based assays for doxorubicin 
(DOX). 
 
5.2.2 Cytotoxicity Evaluation of the Surface Ligands and Synthesized AuNPs 
5.2.2.1 Doxorubicin (DOX) and Polyethyleneimine (PEI) 
The cytotoxicity of doxorubicin (DOX) and high molecular weight hyper branched 
polyethyleneimine (PEI, 15.4kDa) were examined on the cell lines A2780 and A2780cis 
(Figure 5.4). DOX is a known chemotherapeutic compound and was used to determine if the 
cell lines had a differential cytotoxicity response. A differential toxicity response for DOX 
would demonstrate phenotypic differences in the cell lines that were established with 
biomarkers in Section 5.1.2. PEI of various molecular weights has been reported to have 
cytotoxic effects in vitro [355, 356]. AuNPs were synthesized in a one-pot manner with PEI 
as a surface ligand (Section 4.3) which made it necessary to determine how toxic PEI was to 
the cell lines as well as if there was a differential toxicological response between the cell 
lines. The WST-1 dose response assays were done as described in Section 2.4.5.1.  
 
The A2780 cells (red, Figure 5.4a) showed high sensitivity to DOX with no statistical 
significant differences between the concentrations of DOX used. The A2780cis (red, Figure 
5.4b) cells showed statistical significant differential response to DOX from concentrations of 
32μM and lower, where no statistical significance was found between the concentrations of 
32μM, 16μM, 8μM and 4μM. This supported the reversion of A2780cis to A2780 (Section 
5.1.2), since A2780cis is expected to be resistant to DOX. Further investigation of the paired 
cell line response to DOX was not conducted at lower DOX concentrations. An approximate 
LD50 of 8μM DOX was chosen for the A2780cis cell line. 
 
High molecular weight PEI (15.4kDa) was very toxic to A2780 (yellow, Figure 5.4a) with 
statistically significant lowered toxicity at 8μM and 4μM respectively. Comparatively, PEI 
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was more toxic to A2780cis (yellow, Figure 5.4b) at 4μM PEI than for A2780. However at 
higher dosages A2780cis displayed a lessened toxic effect than A2780. It appeared that the 
approximate LD50 of PEI for both A2780 and A2780cis was 8μM.  
                                           
        
Figure 5.4: Cytotoxicity of Doxorubicin (DOX) and Polyethyleneimine (PEI, 15kDa) on paired ovarian 
carcinoma cell lines. The drug responsive A2780 (a) cell line is very sensitive to high levels of doxorubicin 
treatment as opposed to the drug resistant A2780cis cell line (b). The assay was done with WST-1 24h 
post-treatment and the optical density (OD) measured at 450nm. The assay was done in technical 
triplicates and biological duplicates. Table A6 shows p-values where p < 0.05 was statistical significant 
(Appendix). 
 
 
 
 
188 
 
5.2.2.2 Cytotoxicity of Differentially Synthesized One-pot 
Polyethyleneimine Functionalized Gold Nanoparticles 
(AuNP-PEI) 
Polyethyleneimine (PEI) functionalized AuNPs were synthesized in a one-pot manner 
(Section 4.3) and evaluated for in vitro cytotoxicity (Section 2.4.5.1) on the A2780/A2780cis 
cell lines. The cytotoxicity for the AuNPs 24h post-treatment can be seen in Figure 5.5. DOX 
(8μM) was used as a negative control as well as to evaluate relative toxicity of the AuNPs. 
The AuNPs displayed increased cytotoxicity towards the multidrug resistant cell line (Figure 
5.5b) compared to the drug responsive cell line (Figure 5.5a) on a dose-to-dose comparison. 
Comparison of the approximate LD50 values (Table 5.1) for the two cell lines showed overall 
that the AuNPs were at least twice as toxic for A2780cis than for A2780. AuNP-PEI A 
showed a trend in lowered cytotoxicity compared to the other AuNPs for both cell lines, 
where the approximate LD50 values were 500pM (Figure 5.5 and Table 5.1). AuNP-PEI A 
also showed statistical difference in decreasing concentrations from 1000pM to 125pM for 
both cell lines and was statistically significantly less toxic than the other AuNPs at 32pM for 
A2780 cells (Figure 5.5a) but only differed statistical significant at 32pM compared to AuNP-
D for A2780cis cells (Figure 5.5b). AuNP-PEI B showed statistical significant lowered 
toxicity from 1000pM to 250pM for A2780 cells (Figure 5.5a) and statistical significant 
lowered toxicity from 1000pM to 125pM for A2780cis cells (Figure 5.5b). AuNP-PEI C 
showed aberrant toxicity with a statistical significant lowered toxicity from 1000pM to 
125pM with a statistical significant increased toxicity at 63/32pM for A2780 cells. A 
statistical significant decrease in toxicity was observed for AuNP-PEI C from 100pM to 
125pM for A2780cis cells (Figure 5.5b). Cytotoxicity for AuNP-PEI D was statistical 
significant lower from 500pM to 125pM for both A2780 and A2780cis cells. At 62pM of 
AuNP-PEI D for the A2780 cells (Figure 5.5a) there was a statistical significant difference 
compared to 125pM and 32pM. All AuNPs displayed a dose-dependent trend in toxicity. 
AuNP-PEI A had the overall lowest toxicity on a dose-to-dose comparison with the other 
AuNPs. AuNP-PEI B/C/D showed dose-dependent decreased toxicity with an increased 
toxicity from 62pM and lower concentrations, most likely attributed to the irregular shaped 
AuNPs present in these preparations. AuNP-PEI A/C both have spherical in morphology 
(Section 4.3.5) where AuNP-PEI B/D nanoparticles have rod-, rectangular- and tetrahedral 
morphologies (Section 4.3.5). Different aspects of the variation in toxicity of the AuNPs will 
be discussed in the following few paragraphs. Attention will be paid to AuNP size 
distribution, surface functionalization and morphology. 
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Figure 5.5: Cytotoxicity evaluation for differentially prepared AuNP-PEI nanoparticles in paired ovarian 
carcinoma cell lines. The drug responsive cell line A2780 (a) and drug resistant cell line A2780cis (b) have 
a dose-dependent response to the AuNPs. DOX – Doxorubicin. The assay was done with WST-1 24h post-
treatment and the optical density (OD) read at 450nm. The assay was done in technical triplicates and 
biological duplicates. Doxorubicin (DOX) is the positive control. All AuNPs are in 1xPBS (pH 7.2) 
solution. Table A7 shows p-values where p < 0.05 was statistical significant (Appendix). 
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Table 5.1: Approximate LD50 values chosen for differentially prepared AuNP-PEI and 
the variance in in vitro toxicity to paired ovarian carcinoma cell lines.  
 A2780 
(pM) 
A2780cis 
(pM) 
Fold Cytotoxicity Increase to A2780cis 
(A2780/A2780cis) 
AuNP-PEI A 500 500 1 
AuNP-PEI B 500 125 4 
AuNP-PEI C 250 125 2 
AuNP-PEI D 250 32 - 125 2 – 7.8 
 *Values were chosen based on the value closest to 50% cytotoxicity. 
 
5.2.2.3 Discussion 
Doxorubicin (DOX) and Polyethyleneimine (PEI) are both known cytotoxic molecules. The 
LD50 of 8μM for DOX was near the lower recommended DOX dosage (7μM) used for patient 
treatment (Section 1.2.3.2.2). This selected concentration of 8μM DOX was used as a 
reference for further cytotoxicity cell based assays to determine comparative cytotoxicity of 
the AuNPs. The fold increased cytotoxicity of doxorubicin for A2780 compared to A2780cis 
was not investigated further as it fell outside the scope of the study. High molecular weight 
PEI polymers are cytotoxic [355, 356] due to the cationic nature of the molecule which is 
directly correlated to the amount of amines (primary, secondary and tertiary) found in the 
molecule, which act as proton acceptors. Low molecular weight PEI (<2kDa) is typically 
utilized for its well-known transfection capability of DNA [281, 357] and it was expected that 
high molecular weight PEI (2kDa) would display similar qualities. Even with a wide range of 
commercial transfection reagents available, PEI is reported to have superior transfection 
efficiency [281, 357]. Low- and high molecular weight PEI is widely used in nanotechnology 
applications as a building block for block-co-polymer nanoparticles [282, 283] as well as 
coatings on metallic nanoparticles [279, 358]. In all these reported studies, PEI facilitated 
non-viral gene delivery into cells with a very high efficiency [357]. The proton sponge effect 
would come into effect and facilitate escape from the endosomes to the cytoplasm [255].  
 
Comparative concentrations of citrate capped AuNPs used in the literature indicated dosages 
from the low nanomolar (nM) [274, 359] to mid micromolar (μM) range [274, 359] with 
values of up to up to 100μM [359] being reported. In comparison, the prepared AuNP-PEI 
appeared highly toxic (Table 5.1) with LD50 values ranging from 32-500pM. AuNP-PEI A/C 
both have near spherical nanoparticle morphologies, where toxicity is assumed to be 
attributed to the polydisperse size distribution as well as the cationic surface functionalization. 
AuNP-PEI B/D has non-spherical nanoparticle morphologies (rectangular, tetrahedral, etc) 
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which may have contributed to the observed toxicity in Figure 5.5. The toxicity of AuNP-PEI 
is governed by the following factors: size; surface functionalization; morphology and other 
possible factors. These arguments will be raised and discussed in the next few paragraphs  
 
Currently the effect of size on the toxicity of AuNPs towards cells has been investigated with 
the conclusion that smaller nanoparticles would localize towards a perinuclear region [267, 
268, 271, 359] or for the case of ultrasmall AuNPs which can enter the nucleus [271, 359] and 
even cross the blood-brain barrier [360, 361]. Bigger nanoparticles will be sequestered in the 
cytoplasm or even be membrane bound to organelles or the plasma membrane itself [267, 
268, 359]. A 2012 publication by Huang et al [268] demonstrated that smaller anionic AuNPs 
have deeper tumour penetration as well as sub-cellular penetration capabilities than larger 
anionic AuNPs. The larger AuNPs were sequestered in the cytoplasm. These AuNPs were 
functionalized with tiopronin which creates a carboxylic (-COOH) functionality on the AuNP 
surface, lending the AuNP an anionic charge. These anionic functionalized AuNPs managed 
to penetrate tumour cells and growths which have a net negative charge, demonstrating the 
ability of these nanoparticles to overcome potential electrostatic repulsion (Section 1.6.5). 
Citrate capped AuNPs have been reported to have genotoxicity [192, 275, 361, 362] and 
acting as pro-oxidants or free radical generators [193, 352, 363] which contributes to 
cytotoxicity in the cytoplasm. The AuNP-PEI nanoparticles have a polydisperse size 
distribution by design and as such the AuNPs would have various intracellular loci, ranging 
from intra-nuclear to plasma membrane bound. Cationic surface functionalized AuNPs 
showed more toxicity to cells than anionic functionalized AuNPs [210, 254, 273], but cationic 
surface functionalization for nanoparticles in general were reported to have superior cellular 
penetration, cellular retention and sub-cellular distribution [254, 255, 279]. A rough 
estimation determined that there is 55mol PEI per 1mol AuNP-PEI (Section 4.4.4). This 
means that at a concentration of 1000pM (1nM) AuNP-PEI there is 55nM (0.055μM) PEI, 
which is 72.7 fold lower than 4μM PEI (Figure 5.4). This suggested that the amount of PEI on 
the AuNP-PEI surface did not contribute significantly to the toxicity observed for AuNP-PEI 
A-D. The polydisperse size and cationic surface functionalization of the AuNP-PEI were 
considered to contribute synergistically towards the high toxicity reported in Figure 5.5 and 
Table 5.1. This may be true especially for AuNP-PEI A/C, where the nanoparticle 
morphologies were near spherical. Factors that may further contribute to the observed toxicity 
for AuNP-PEI B/D will be discussed in the next paragraph. 
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The exact role that the shapes of the AuNPs play within the cellular environment has not yet 
been clearly defined. Most studies are conducted done on rod shaped gold nanoparticles [274, 
363, 354] and spherical nanoparticles [271, 274, 363, 364], with contradictory or ill-defined 
explanations. In most studies the gold nanoparticles are CTAB functionalized and as such this 
author proposes that the surface ligand contributes to the cellular toxicity than the AuNPs 
themselves [36, 185, 271]. From a catalytic chemistry viewpoint the increased surface area to 
volume ratio makes nanoparticles ideal as catalyst [141, 365, 366]. Anisotropic (tetrahedral, 
rods, rectangles, etc.) metal nanoparticles display differential catalytic activity over the 
spherical morphologies [141, 365, 366]. The heavy metals Au, Pt and Pd display similar 
catalytic activities but each has its own specific application. Rectangular shapes will have 
reduced catalytic activity and tetrahedral shapes will display increased catalytic activity [141, 
366]. Numerous types of reactions can be catalysed by metallic nanoparticles are numerous 
and only a few will be mentioned [141, 367]: Hydrogenation, oxidation, reduction, amination 
and carbonylation. In the complex biological milieu there are many different micro- and 
macromolecules with unique chemical properties and the possibility exists that these above 
mentioned reactions could take place. Chemical modification of macromolecules such as 
nucleic acids (DNA or RNA) and proteins could alter the function of these molecules. In the 
case of DNA the nanoparticles may affect an epigenetic modification and silence a gene. For 
proteins the AuNPs could interact with the cysteine residues and bind to the thiol moiety, 
potentially impeding the protein function. This seemed to be the most reliable explanation 
why increased toxicity was found for AuNP-PEI B/D (Figure 5.5). As mentioned in Chapter 4 
(Section 4.3.4), separation of the AuNPs based on different sizes and morphologies was 
unsuccessful and needs further investigation to determine the toxicity of different AuNP 
morphologies and size distributions on the ovarian carcinoma cells.  
 
New evidence is emerging that citrate capped gold nanoparticles are not as biocompatible as 
previously assumed. Interactions with cellular thiols from small molecules as well as larger 
macromolecules have been identified (Section 1.6.5). Typically AuNPs evaluated for toxicity 
and reported in the literature get prepared by one of the following techniques: (i) Turkevich 
prepared AuNPs (Section 1.6.2.1); (ii) Brust one-pot thioalkane functionalized AuNPs 
(Section 1.6.2.1) and (iii) Inverse micelle CTAB passivated AuNPs [141]. Citrate or CTAB 
are electrostatically absorbed on the AuNP surface [141]. Bio-functionalization of these 
AuNPs requires ligand exchange (Section 1.6.2.1). When the ligand on the AuNP surface is 
electrostatically absorbed on the surface instead of attached by a covalent bond, the AuNPs 
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could display colloidal instability in the biological milieu. Electrostatic AuNP surface 
functionalization can be disrupted by NaCl or other inorganic salts such as CaCl2. This is 
utilized in nanoparticle flocculation assays to determine whether biomolecules are covalently 
or electrostatically attached to the AuNP surface [331, 368, 369]. Tissue culture media 
contains a cocktail of salts at various ionic strengths. Also, human blood is rich in inorganic 
salts. These salts can displace the electrostatic absorbed surface ligands and induce 
nanoparticle aggregation. A question comes to mind: During the cell based assays, is cell 
death induced by unstable nanoparticles or by much larger aggregates? Aggregates are not as 
homogenously dispersed as the smaller nanoparticles. The aggregates could accumulate on 
top of the cells, piercing the cell membrane or rupture the cell membrane by sheer weight of 
mechanical force. The same argument can be made in the case where electrostatic absorption 
is utilized to functionalize the AuNPs with anticancer compounds or poly-phenolic 
compounds. This question is rarely addressed in biomedical nanotechnology publications to 
date. Mirza et al demonstrated in 2011 that electrostatically adsorbed DOX on Turkevich 
prepared AuNPs aggregated in PBS (pH 7.4), acetic acid (pH 2.4) as well as HCl (pH 1) 
[370]. The only solution the AuNPs were stable in was 2-(N-morpholino)ethanesulfonic acid 
(MES) at pH 6. The stability in MES was most probably due to the sulfonic acid moiety’s 
affinity for AuNP surfaces [371] and no proof was provided that the DOX was not displaced 
from the AuNP surface by MES. AuNP-PEI A-D proved to be stable in a wide concentration 
range of NaCl (Section 4.3.6) but displayed colloidal instability in the presence of a strong 
counter-ion such as citrate (Section 4.3.6) as well as biomolecules such as bovine serum 
albumin (Section 4.4.3) and tissue culture media (Section 4.4.3). The surfaces of AuNP-PEI 
A-D was shown to not be exposed for biomolecule interactions, unlike citrate capped AuNPs, 
which was demonstrated by the high stability of the AuNP-PEI nanoparticles in the presence 
of a strong competing thiol namely β-mercaptoethanol (Section 4.3.6). Aggregation of AuNP-
PEI A-D was not induced by β-mercaptoethanol as readily as for AuNP-GSH A-D. This 
suggested PEI shielded the AuNP surface better than GSH. The PEI on AuNP-PEI interacted 
with biomolecules, demonstrated for a strong counter-ion such as citrate (Section 4.3.6), 
bovine serum albumin (Section 4.4.3), and tissue culture media (Section 4.4.3). Aggregation 
associated toxicity or unfavourable interactions with biomolecules could be a possible reason 
for the observed cytotoxicity of AuNP-PEI A-D as well. 
 
AuNP-PEI A was chosen for drug loading as it displayed the least cytotoxicity of all the 
AuNPs as well as the nanoparticles being near-spherical in morphology. This reduced the 
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factors which could influence cytotoxicity, where AuNP size distribution and surface 
functionalization was then assumed to be the main contributors. AuNP-PEI A as well as its 
drug loaded variants, 10-30% PEG, was evaluated to determine the possible causes of the 
toxicity. 
 
5.2.3 Cytotoxicity and Mechanism of Cell Death for Doxorubicin Loaded AuNP-
PEI A 
5.2.3.1 Introduction 
Covalent drug loading of doxorubicin (DOX) onto AuNP-PEI A was done as described in 
Section 2.2.4.3.2. AuNP-PEI A was modified with three polyethylene glycol concentrations 
(10-30%) as described in Section 2.2.4.3.1 and shown in Section 4.4.2. All AuNPs were in x1 
PBS (pH 7.4). As a cytotoxicity reference 8μM DOX was used for all assays. The toxicity for 
AuNP-PEI A at its LD50 value (500pM; Table 5.1 and 5.2.2) was used to compare the 
cytotoxicity of its drug loaded variants. The mechanism of cell death will be investigated as 
well as a suggested induction mechanism. The subcellular distribution of the AuNPs was also 
investigated with transmission electron microscopy. For the purposes of this section, 10-30% 
PEG DOX from Section 4.4.2 will be referred to as 10-30% PEG. 
 
5.2.3.2 Cytotoxicity of the DOX loaded AuNP-PEI A 
Cytotoxicity was determined with the WST-1 assay (Section 2.4.5.1). The A2780cis cells 
(Figure 5.6b) showed increased sensitivity to the DOX loaded AuNP-PEI on a dose-to-dose 
basis when compared to the A2780 cells (Figure 5.6a). The lowest dose of 30% PEG, 5.3pM, 
for both the A2780 cells (Figure 5.6a) and A2780cis cells (Figure 5.6b) was statistically 
significant different from the higher concentrations of 30% PEG. The other DOX loaded 
AuNPs (10% / 20% PEG) showed colloidal instability in the presence of biomolecules (results 
not shown) and were not used for any other cell biology assays. 30% PEG showed the best 
stability (Section 4.4.2). A summation of Figure 5.6 can be seen in Table 5.2. 
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Figure 5.6: Cytotoxicity differentially surface modified-DOX loaded AuNPs. The cytotoxicity for A2780 
can be seen in (a) and for A2780cis can be seen in (b). On the X-axis the value in blue is the non-drug 
loaded AuNP and the value in black indicates the concentration for DOX loaded AuNPs (PEG – 
Polyethylene glycol; DOX – Doxorubicin; 10% PEG – 10% PEG-DOX; 20% PEG – 20% PEG-DOX and 
30% PEG – 30% PEG-DOX). The assay was done with WST-1 24h post-treatment and the optical density 
(OD) read at 450nm. The assay was done in technical triplicates and biological duplicates. Table A8 shows 
p-values where p < 0.05 was statistical significant (Appendix). 
 
The fold increase in cytotoxicity of the drug loaded variants of AuNP-PEI (10-30% PEG) 
compared to DOX was calculated based on the in situ drug release assay (Section 4.4.2), 
where it was determined that 4000mol DOX was released per 1mol AuNP-PEI. The LD50 
values (Table 5.2) for the nanoparticles showed DOX loaded AuNPs had increased 
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cytotoxicity compared to AuNP-PEI. The drug loaded AuNPs (10-30% PEG, Figure 5.6) were 
23.8-fold diluted in concentration compared to AuNP-PEI A at the same optical density (OD 
~ 0.2) (Section 4.4.2). The LD50 of 5.3pM 30% PEG was ~94-fold less than the LD50 of 
500pM AuNP-PEI for A2780cis and the LD50 of 10.5pM 30% PEG was ~48-fold less than 
the LD50 of 500pM AuNP-PEI for A2780 cells. The drug resistant A2780cis cells were ~2-
fold more sensitive to the DOX loaded AuNPs than A2780 cells. The DOX loaded AuNPs 
were 190-fold more cytotoxic than 8μM DOX for the A2780 cells and 377-fold more 
cytotoxic than 8μM DOX for the A2780cis cells (Table 5.2). This fold increase in cytotoxicity 
was calculated based on the concentration of DOX on the AuNP surface where 42nM DOX is 
delivered for 10pM AuNP-PEI (A2780) and 21.2nM DOX is delivered for 5.3pM AuNP-PEI 
(A2780cis).  
 
Table 5.2: Approximate LD50 values for DOX loaded surface functionalized AuNP-PEI 
(Calculated based on 4000mol DOX per 1mol AuNP-PEI as per Section 4.4.2). 
Formulation 
LD50 
(pM) 
Fold Cytotoxicity Increase 
 
A2780 
 
 
A2780cis 
 
A2780/A2780cis 
DOX / 
A2780 
AuNP-PEI / 
A2780 
DOX / 
A2780cis 
AuNP-PEI / 
A2780cis 
AuNP-PEI 
500 500 1 - - - - 
10% PEG 
10.5 < 5.3 1.98 190 47.62 377 94.34 
20% PEG 
10.5 < 5.3 1.98 190 47.62 377 94.34 
30% PEG 
10.5 < 5.3 1.98 190 47.62 377 94.34 
DOX 
8 x 10
6
 8 x 10
6
 - - - - - 
*Values were chosen based on the value closest to 50% cytotoxicity. 
 
Gu et al (2011) designed AuNP-DOX conjugates for overcoming multidrug resistance in 
HepG2 (liver carcinoma) cells [372]. The MTT assay was used to assess toxicity after a 
treatment period of 24h. DOX (20μM) and AuNP-DOX (8μM DOX equivalent) caused 50% 
of the cells to die 24h post-treatment. This is a fold increase in dosage efficacy of x2.5 for a 
24h period. Similarities in this study indicated that the multidrug resistant cell line also 
displayed increased sensitivity towards the DOX nanoparticle conjugates. A study by Wang et 
al (2011) designed DOX tethered AuNPs to target multidrug resistant MCF7 (breast cancer) 
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cells [373]. The drug sensitive MCF7 cells showed an LD50 of 350μM 72h post-treatment. 
The multidrug resistant MCF7-AD displayed LD50 at two time points for two different 
nanoparticle-DOX conjugates. At 48h the corresponding dosage was 8.83μM DOX 
equivalents and at 72h the corresponding dosage was 3.13μM DOX equivalents. This 
represents an increase in dosage efficacy of x39.6 and x111.8 respectively. Both these cited 
studies were in vitro in nature with no direct translation to in vivo. Prabaharan et al 
synthesized folate targeted block-co-polymer passivated AuNP nanoconstructs and achieved a 
DOX load of 34μg/mL (62μM) per 10mg/mL nanoconstruct, where DOX release was 
facilitated by a pH sensitive linker [146]. The MTT assay was used to evaluate the toxicity of 
the above mentioned nanoconstruct in 4T1 (mouse mammary carcinoma) cells with 
disappointing results. DOX showed a dose-to-dose increased cytotoxicity to the cancer cells 
than the DOX loaded nanoconstruct. Further, microscopy indicated that the nanoconstructs 
were sequestered in endosomes. The labile nature of DOX makes it unstable in acidic 
environments [374] and as such endosome sequestration (4 ≤ pH ≤ 6) would release DOX 
prematurely to an acidic environment leading to drug degradation. Kim et al (2008) utilized 
pH sensitive micelles to deliver DOX to multidrug resistant A2780 cells in vitro as well as in 
vivo xenografted athymic nude mice and found the optimal dosage of DOX is ~17μM 
administered over a 24h period [375]. In this model 80% of the A2780 cells were still alive 
24h post treatment. 
 
All the above mentioned studies utilized the MTT assay as well as used monodisperse citrate 
capped AuNPs (except Kim et al) which were subsequently functionalized by ligand 
exchange and employment of further bioconjugation techniques. No reports were made for 
intracellular localization of the AuNPs (except Prabaharan et al) with cytotoxicity or cell 
viability being the only toxicity assays reported. Further, no indication was given what the 
mechanism of cell death was as DOX is known to induce topical necrosis [26, 34, 376]. DOX 
dosages delivered by the nanoparticles in the previous paragraph were all in the same range as 
the clinical dosage, 7µM to 330μM (Section 1.2.3.2.2) and although a direct comparison 
between in vitro / in vivo models and a clinically approved product cannot be drawn, the 
reported dosages were still high. DOX can present with severe cardiotoxicity, nephrotoxicity 
and hepatotoxicity at the clinical dosage (Section 1.2.3.2.2). The above mentioned studies 
showed some success with drug delivery to the drug resistant cells where 50% - 80 % of the 
cells were alive within 24h-72h of treatment. The high cellular viability 24h post-treatment 
implies that consecutive treatments were required to achieve complete cell death which could 
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lead to acquired drug resistance, especially for the ovarian carcinoma (Section 1.2.4.2) where 
consecutive treatments of doxorubicin is the prescribed treatment post-surgery (Section 
1.2.3.2.2). 
 
The DOX loaded AuNP-PEI (10%, 20% and 30%) appeared to overcome the inherent 
multidrug resistant cytoprotective mechanisms of the A2780cis cells at ultralow DOX 
concentrations with a single dosage within 24h. The A2780cis drug resistant cells were twice 
as sensitive to 30% PEG (5.3pM AuNP-PEI and 21.2nM DOX) than A2780 drug responsive 
cells (10.5pM AuNP-PEI and 42nM DOX) but the type of cell death as well as the induction 
time of cell death is unknown. The type of cell death as well as the induction time of cell 
death could potentially differ between the A2780 cell line and A2780cis cell line, but was not 
investigated due to logistical reasons. Mechanistic studies were limited to the A2780cis cell 
line. AuNP-PEI (no DOX loaded) and its drug loaded variant 30% PEG, at their respective 
LD50 values, was used to generate a model for cell death. 
 
5.2.3.3 Apoptotic Cell Death is Induced by Gold Nanoparticles 
Cytotoxicity only gives an estimate of how many cells are alive for a given time period post-
treatment. It does not elucidate any mechanisms of cell death. Further investigation was 
required to determine how cell death occurred and to propose a model for the cell death 
observed with the WST-1 cytotoxicity assay. Figure 5.7 shows the qualitative 
ApoPercentage™ (BioColor) assay (Section 2.4.5.2) to determine if apoptosis was the 
mechanism of cell death 24h post-treatment treatment with AuNP-PEI (500pM) and 30% 
PEG (5.3pM)  
 
The control cells (Figure 5.7a) show a few apoptotic cells. A significant number of cells 
treated with 8μM DOX (Figure 5.7b) stained positive for apoptosis. AuNP-PEI (Figure 5.7d) 
and 30% PEG (Figure 5.7e) treatment of the cells showed many cells stained positive for 
apoptosis. Treatment of the cells with 1mM H2O2 (Figure 5.7c) showed prominent staining 
compared to the other treatments as well as floating cells. The cellular morphology was also a 
qualitative indication of the stage of apoptosis the cells were in. The cells in Figure 5.7c 
indicated a potential early apoptotic event which ran its course over a 24h time period. Figure 
5.7b, Figure 5.7d and Figure 5.7e showed cells which were in different stages of apoptosis. 
The stages of apoptosis and the time-points of apoptosis were dependent on the dosage of the 
compound used as well as the type of compound.  
 
 
 
 
199 
 
A qualitative colorimetric assessment of the amount of cells undergoing apoptosis can be seen 
in Figure 5.8. The qualitative colorimetric ApoPercentage™ assay (Section 2.4.5.2) was 
conducted on the same cells which were used to obtain the micrographs for Figure 5.7. The 
level of apoptosis in the various treatments showed a statistical significant difference 
compared to the control (Figure 5.8a). The AuNP-PEI and DOX treatments were not 
statistically different from each other but showed a fold increase in apoptosis of ~2 and ~2.5 
compared to control  (Figure 5.8b), respectively. The treatment with 30% PEG was similar to 
that of H2O2 (Figure 5.8a), displaying a fold increase in apoptosis of ~3.7 and ~3.2 compared 
to the control (Figure 5.8b), respectively. Comparison of the cellular morphology for the 30% 
PEG and H2O2 treatments showed the cells were in different stages of apoptosis, but that the 
level of induction for 30% PEG was increased compared to AuNP-PEI and DOX alone. It is 
possible that cells detached during the assay as the qualitative colorimetric assay used an 
alkaline lysis reagent to release the dye from the cells to give a homogenous colour 
distribution in the wells.  
     
 
Figure 5.7: ApoPercentage™ (BioColor) assay for the qualitative colorimetric microscopy detection of 
apoptosis in A2780cis cells 24h post-treatment with AuNP-PEI and 30%PEG. A red-purple stain on the 
cells indicates apoptosis where: a) untreated control; b) 8μM Doxorubicin; c) 1mM H2O2; d) AuNP-PEI 
and e) 30%PEG.  Micrographs are at x20 magnification and are representative of technical triplicates and 
biological duplicates. 
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The ApoPercentage™ dye will stain cells undergoing apoptosis by being internalized 
specifically into apoptotic cells [377, 378]. The assay will not stain for necrotic cell death due 
to cellular rupture and loss of plasma membrane integrity. The apoptotic cells found in 
untreated cells (Figure 5.7a) was expected as apoptosis is a normal cellular event to maintain 
tissue homeostasis [379]. DOX is known to induce cell death by apoptosis and necrosis by 
H2O2 generation [28, 29] in a 24h time window and has been demonstrated in Section 5.2.2.1. 
The H2O2 treatment caused significant loss of cellular morphology. The manufacturer 
recommends the use of H2O2 as a positive control for apoptosis mediated by an oxidative 
stress pathway within 3h for most cells [29, 377]. Further, 30% PEG (5.3pM AuNP-PEI and 
21.2nM DOX) showed a similar level of apoptosis induction as H2O2 (1mM). This suggested 
30% PEG was a very potent inducer of apoptosis considering this is a multidrug resistant cell 
line. Comparison of the micrographs for AuNP-PEI (Figure 5.7d) and 30% PEG (Figure 5.7e) 
with the cytotoxicity data (Figure 5.6) showed a discrepancy. The micrographs indicated more 
than 50-60% of the cells are undergoing apoptosis (red stains), compared to the 50-60% 
cytotoxicity reported with the WST-1 assay (Figure 5.6) which will be discussed after the next 
paragraph. 
 
Apoptosis (Figure 5.9) is the preferred mechanism of cell death chemotherapeutic compounds 
used in cancer treatment as it is non-inflammatory to adjacent cells [380]. Apoptosis is 
mediated by the immune system [380, 381, 382] and an ATP-dependent [380, 381] process 
characterized by cell shrinkage [380, 382], membrane blebbing [380, 382], chromatin 
condensation [380, 382] and nuclear fragmentation [380, 381, 382]. Macrophages will absorb 
the cellular vesicle residue post-apoptosis [380, 382]. Necrosis (Figure 5.9) on the other hand 
is a pro-inflammatory process [383] which is an ATP-independent cellular event characterized 
by cellular and organelle swelling with no nuclear- or membrane condensation as well as 
leakage of cellular contents to the extracellular matrix with inflammation to nearby cells 
[383]. Apoptosis can be one of various pathways where the two most well established and 
studied are the intrinsic or mitochondrial pathway [380, 381] and the extrinsic or death-
receptor mediated pathway [380, 381]. The intracellular pathway is induced by intracellular 
stress such as oxidative damage [380, 384, 385] or DNA damage [380, 384, 385]. The 
extrinsic pathway is mediated by extracellular signals to cellular receptors to induce apoptosis 
[380, 384, 385].   
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Figure 5.8: ApoPercentage™ (BioColor) assay for the qualitative colorimetric detection of apoptosis 24h 
post-treatment. The relative increase in apoptosis in the A2780cis cells 24h post-treatment with the 
selected inducers can be seen compared to the control (a). An increase in optical density is directly 
correlated to the extent of apoptosis activation. The fold increase in apoptosis relative to control can be 
seen in (b). The assay was done in technical triplicates and biological duplicates.  The optical density (OD) 
was read at λ = 550nm. Table A9 shows p-values where p < 0.05 was statistical significant (Appendix). 
 
The cell morphologies (Figure 5.7) display the morphological hallmarks of apoptosis with 
Figure 5.9 as a guideline. The energy requirement of apoptosis as an active cellular process 
requires active enzymes. Dehydrogenase enzymes contribute to the production of reduced 
energy carriers, such as NADH and FADH2, which facilitate ATP production. WST-1 
undergoes enzymatic conversion by a plasma membrane bound NADH-oxidase [353, 354], 
and this enzyme can potentially be influenced by altered intracellular concentrations of 
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reduced NADH/NAD
+
. The NADH-oxidase enzyme could retain sufficient activity in the late 
stages of apoptosis and as such influence the colorimetric WST-1 reaction. It is unknown if 
the protein expression of this NADH-oxidase was altered during the apoptotic event for the 
different treatments used in this section. 
 
 
Figure 5.9: The two major forms of cell death: Apoptosis and necrosis. (Image obtained and adapted from 
http://www.icms.qmul.ac.uk/flowcytometry/uses/oncosis).  
 
AuNP-PEI and 30% PEG induced apoptotic cell death in multidrug resistant ovarian 
carcinoma cells (A2780cis) at ultralow dosages of DOX within 24h. The pathway of 
induction of apoptosis as well as the time-point of induction is still unknown and will be 
investigated in the next few sections. 
 
5.2.3.4 Caspase-3 as an Effector of Apoptosis Induced by Nanoparticle 
Cytotoxicity 
An immunoblot (Section 2.4.5.3) for procaspase-3 was done 24h post-treatment with AuNP-
PEI, 30% PEG and DOX to determine if apoptosis was induced by the mature effector 
caspase-3. The immunoblot can be seen in Figure 5.10a with the corresponding densiometric 
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analysis in Figure 5.10b. The relative expression levels of procaspase-3 showed a decreasing 
trend compared to control (Figure 5.10b) for AuNP-PEI, 30% PEG and DOX. 
 
A decrease in procaspase-3 levels correlated to activation of mature caspase-3. The antibody 
utilized for the immunoblot (Figure 5.10a) is monoclonal specific to procaspase-3 and would 
not detect caspase-3. Apoptosis was induced by caspase-3 activation for AuNP-PEI, 30% 
PEG and DOX. The time-point of procaspase-3 activation to mature caspase-3 after treatment 
with 30% PEG was investigated with a 48h time-course study (Figure 5.11). The immunoblot 
(Figure 5.11a) and the densiometric analysis (Figure 5.11b) show a decrease in procaspase-3 
compared to the control at the different time-points. The trend in decrease of procaspase-3 in 
the control cells at different time-points was expected as this is a normal cellular event with 
cells undergoing apoptosis, but was not to the same extent as for the 30% PEG treated cells 
(Figure 5.11a and Figure 5.11b). The time course activation indicated procaspase-3 was 
activated at 3h post treatment with 30% PEG in a time-dependent manner which showed 
decreased procaspase-3, with no procaspase-3 detected at 48h post treatment (Figure 5.11b). 
 
       
Figure 5.10: Immunoblot for the detection of procaspase-3 activation 24h post-treatment. The 
immunoblot can be seen in (a) and the relative normalized densiometric analysis (ImageJ) can be seen in 
(b). β-actin is the loading control for the immunoblot. Dosages used for treatment are the LD50 values 
from Table 5.2. The control was untreated. The data is representative for all assays. 
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Figure 5.11: Immunoblot for the detection of caspase-3 activity in a time-course dependent manner over 
48h. The immunoblot can be seen in (a) and the relative normalized densiometric analysis can be seen in 
(b). β-actin is the loading control for the immunoblot. Dosages used for treatment are the LD50 values 
from Table 5.2. (3, 6, 24 and 48 are the respective hours post-treatment; 0C, 3C, 24C and 48C are the 
untreated controls at the respective time points. The data is representative for all assays. 
 
Relative protein expression of procaspase-3 will decrease as it gets activated to mature 
caspase-3, the effector for the intrinsic pathway of apoptosis (Section 5.2.3.3). This suggested 
30% PEG induced apoptosis by DNA damage or oxidative stress, which corresponds to 
expected mechanisms of cellular stress associated with DOX [28, 385] and caspase-3 was 
reported as the effector caspase for DOX [28, 385]. The pathway of apoptosis induction by 
AuNP-PEI, 30% PEG and DOX was mediated caspase-3. Further, the induction time-point of 
apoptosis after treatment with 30% PEG took place within 3h at ultralow dosages of a DOX 
(21.2nM). It is unknown however whether the activation of caspase-3 is in response to 
oxidative stress or nuclear associated toxicity. This will be investigated in Sections 5.2.3.5 
and 5.2.3.6, respectively. 
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5.2.3.5 Oxidative Stress as a Cause of Apoptosis and Caspase-3 Activation 
Induced by Gold Nanoparticles 
Glutathione (GSH) is a major significant intracellular antioxidant (Section 1.2.4.2.2) which 
also plays a role in drug efflux for drug resistant cancer (Section 1.2.4.2.3). Oxidative stress is 
an indicator of cytotoxicity and can be determined by monitoring intracellular GSH levels. A 
commercial luminescence assay (Section 2.4.5.4) was utilized to determine reduced 
glutathione (GSH) and oxidized glutathione (GSSG) 24h post treatment with AuNP-PEI, 30% 
PEG, DOX and H2O2 (Figure 5.12).   
 
30% PEG showed statistically significant GSH (Figure 5.12a) and GSSG (Figure 5.12b) 
depletion compared to the untreated control, where the GSH/GSSG depletion was as 
extensive as observed for DOX or H2O2. The fold increase in GSH (Figure 5.12c) and GSSG 
(Figure 5.12d) depletion for 30% PEG is ~13.5-fold and ~15-fold compared to the control, 
respectively. The fold increase in GSH and GSSG depletion for AuNP-PEI is ~1.5-fold and 
~1.6-fold compared to the control, respectively. The treatment with 30% PEG resulted in 
more extensive intracellular depletion of GSH and GSSG than AuNP-PEI. The fold increase 
in GSH depletion for DOX and H2O2 were ~86-fold and ~63-fold compared to control, 
respectively. Also, DOX and H2O2 resulted in GSSG depletion of ~51-fold and ~46-fold 
compared to control, respectively.  
 
Reduced glutathione (GSH) plays an integral role in the cytoprotective mechanism for DOX 
induced oxidative stress [72]. The depletion of GSSG prevents the cell from recycling GSSG 
to GSH mediated glutathione reductase (GRx) [69, 387] as depicted in Figure 5.13. GSSG 
will be recycled to GSH which is dependent on reduced electron carrier NADH. The depletion 
of GSH as well as GSSG results in intracellular depletion of this antioxidant. The depletion of 
total glutathione in the cell indicates cellular efflux of GSH-conjugated electrophiles, 
catalysed by glutathione-S-transferase (GST) [69, 387]. Spontaneous nucleophilic attack of 
the thiol of GSH can also conjugate this tripeptide to reactive electrophilic species with 
subsequent cellular efflux [66]. Intracellular GSH depletion and disturbance of the 
GSH:GSSG homeostasis is known to be the major inducer of apoptosis [69]. The above 
mentioned mechanisms are reported for DOX and H2O2 [28, 29]. 
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Figure 5.12: GSH/GSSG-Glo (Promega) assay for the qualitative detection of reduced glutathione (GSH) 
and oxidised glutathione (GSSG) levels. The relative luminescence units (R.L.U.) can be seen for reduced 
glutathione (GSH) in (a) and for oxidized glutathione (GSSG) in (b). The assay was done 24h post-
treatment. The assays were done in technical triplicates and in biological duplicates. Table A10 shows p-
values where p < 0.05 was statistical significant (Appendix). 
 
 
                            
                             Figure 5.13: The glutathione recycling pathway  
 
AuNP-PEI showed significant less total glutathione depletion compared to 30% PEG, DOX or 
H2O2. Induction of oxidative stress by intracellular depletion of total glutathione is a 
suggested pathway for the induction of apoptosis by AuNP-PEI and 30% PEG. This 
corresponded to the data in Section 5.2.3.4 as oxidative stress is a known pathway for 
caspase-3 activation. The depletion of total intracellular glutathione was significant as this 
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tripeptide has been implicated as a significant contributor to the cytoprotective mechanisms of 
multidrug resistance (Section 1.2.4.2.2). The tempo of GSH- as well as GSSG depletion is 
unknown as the assay was done 24h post-treatment with AuNP-PEI and 30% PEG. The 
activation of caspase-3 was within 3h of treatment which indicated that significant oxidative 
stress had already taken place for 30% PEG. This however needs to be confirmed with more 
directed time-course assays. Caspase-3 activation was determined to be by an oxidative stress 
pathway. In the next section the subcellular localization of AuNP-PEI and 30% PEG was 
investigated. 
 
5.2.3.6 Subcellular Localization Of Gold Nanoparticles  
The subcellular localization of AuNP-PEI (Figure 5.14) and 30% PEG (Figure 5.15) in 
A2780cis cells 24h post-treatment was investigated by biological transmission electron 
microscopy (TEM) (Section 2.4.5.5). The TEM analysis was done at 24h post-treatment to 
determine the sub-cellular localization of the above mentioned AuNPs. 
 
The A2780cis cell cross sections (Figure 5.14) showed healthy cells as well as cells that were 
in various stages of apoptosis with fragmented and condensed nuclei as well as disrupted 
cytoplasmic structures. The areas in the cell cross sections which were of interest were 
highlighted in red (Figure 5.14a), blue (Figure 5.14b) and green (Figure 5.14c). In Figure 
5.14a AuNP-PEI showed cytoplasmic localization with no organelle specific association 
observed. However, AuNP-PEI nanoparticles were not individually dispersed through the 
cytoplasm and displayed near circular patterns of localization with regards to each other. 
AuNP-PEI also showed perinuclear cytoplasmic localization (Figure 5.14b and 5.14c) 
without any apparent association with particular cellular organelles or structures. Once again 
the same arrangement patterns for AuNP-PEI were observed which suggested a possible 
association with an unobserved organelle. AuNP uptake was not observed for all cells, but 
uptake appeared to be associated with aberrant nuclear morphology and size as well as 
fragmented cytoplasmic structure. Cells which showed no AuNP-PEI content presented with 
intact nuclear and cytoplasmic structures (not highlighted).  
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Figure 5.14: Biological HR-TEM micrograph of A2780cis cell cross sections 24h post-treatment with 
500pM AuNP-PEI. AuNPs are cytoplasmic localized in a cell in the late stages of apoptosis and can be 
seen in (a) indicated by the red rectangle. AuNPs in perinuclear localization can be seen in (b), indicated 
by a blue rectangle, and in (c), indicated by a green rectangle. Nuclear membranes are indicated by black 
arrows (b, c).  
 
The A2780cis cells treated with 30% PEG (Figure 5.15a and Figure 5.15b) showed a 
decrease in cell number, compared to AuNP-PEI treated cells, where most of the cells 
displayed a loss of nuclear- and cytoplasmic integrity. A significant amount of vesicles and 
cellular debris was found. The 30% PEG (Figure 5.15a, red) appear to be in a cytoplasmic 
region sequestered in organelles in close proximity to a condensed nucleus (Figure 5.15a, 
green). Figure 5.15b shows 30% PEG sequestered in organelles (Figure 5.15b, blue) in an 
extracellular localization with a fragmented plasma membrane in close proximity to a 
condensed nucleus (Figure5.15b, yellow). For Figure 5.15a and Figure 5.15b the 
morphologies of the condensed nuclei as well as the organelle specific sequestration of the 
AuNPs indicated intermediate to late stage apoptosis. 
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Figure 5.15: Biological HR-TEM micrograph of A2780cis cell cross sections 24h post-treatment with 
5.3pM 30% PEG. Different sections of the TEM copper grid can be seen in (a) and (b). Black arrows 
indicate disrupted nuclei and disrupted cytoplasmic integrity. Green (a) and yellow (b) indicates 
condensed and fragmented nuclei. Red (a) and blue (b) indicates AuNPs. 
 
AuNP-PEI demonstrated cellular retention as well as intracellular penetration in the A2780cis 
cells 24h post-treatment. This was however a qualitative assessment of the nanoparticle 
content of the cells and ICP-MS would be able to give a more quantitative answer. The 
AuNP-PEI showed cytoplasmic and nuclear localization with no observed organelle 
sequestration. This added merit to the study design where it was speculated that AuNPs 
polydisperse in size would have multiple subcellular loci. The toxicity also appeared to be 
associated with AuNP-PEI internalization, where cells which did not internalize AuNP-PEI 
appeared to present with normal morphology. The nuclear shrinkage as well as disturbed 
 
 
 
 
210 
 
cytoplasmic structures suggested that the stage of apoptosis for A2780cis cells, which 
internalized AuNP-PEI, was early to intermediate as no apoptotic vesicles were observed. 
The proximity of the AuNP-PEI to the nucleus also indicated possible nuclear toxicity but no 
AuNP-PEI was seen within the nuclei. The A2780cis cell cross-sections for 30% PEG 
treatment showed cells which were in intermediate to late stages of apoptosis 24h post-
treatment with a large number of condensed and fragmented nuclei as well as apoptotic 
vesicles. It is unknown what the sub-cellular localization of 30% PEG was as the 
nanoparticles were sequestered in organelles within apoptotic cells / apoptotic vesicles. A 
time-course experiment will be ideal to investigate this above mentioned observed 
phenomena. The type of organelles in which 30% PEG was sequestered is unknown and 
would require organelle specific immunohistology to be identified. An assumption was made 
that the unknown organelles were lysosomes as this is an organelle which has been reported 
in the literature with a peri-nuclear localization during AuNP sequestration [154]. An 
assumption was made that the 30% PEG delivered the DOX payload because the A2780cis 
cell cross sections showed evidence of significant apoptosis. Nuclear toxicity could have 
contributed to induction of apoptosis for 30% PEG in the event where it was in a perinuclear 
loci, delivering DOX to the nuclei. The assumption would be valid if 30% PEG had similar 
cytoplasmic as well as perinuclear localization as observed for AuNP-PEI. This however 
needs further investigation. 
  
5.3 Discussion 
The ideal in vitro cell line panel to evaluate a novel therapeutic would include non-cancerous 
cell lines as well as cancerous cell lines. The two cell lines used for this study were both 
cancerous, A2780 a drug responsive cell line and A2780cis a multidrug resistant cell line. 
The A2780cis ovarian carcinoma cell line was isolated from a patient who had multidrug 
resistant epithelial ovarian cancer (ECACC, Section 2.4.1). The argument was made that 
multidrug resistance is dependent on a highly similar or identical genotype, where the 
phenotype was dependent on epigenetic changes and altered protein expression which altered 
the intracellular environment. The use of a non-cancerous cell line, such as fibroblasts, would 
not have contributed to data regarding overcoming multidrug resistance in epithelial ovarian 
carcinoma. Attempts were made to obtain ovarian biopsy tissue, cancerous and non-
cancerous, to create in vitro subcultures but this was deemed logistically challenging. This 
study was conducted under an agreement of nondisclosure and created a challenge to engage 
other researchers. 
 
 
 
 
211 
 
 
The reversion of the multidrug resistant cell line (A2780cis) to the drug responsive cell line 
(A2780) was deemed successful as the cellular morphologies and biomarkers confirmed 
phenotypic differences in the cells. The cells were genetically identical. It is unknown if this 
above mentioned reversion can take place in vivo. Significant differences exist between an in 
vitro model of cancer and how cancer will behave in an in vivo environment and was 
demonstrated by the small amount of in vitro developed therapeutics which proceeds to 
clinical trials [176, 387]. This study provided strong evidence that the developed nanoparticle 
drug delivery system, AuNP-PEI (AuNP-PEI A) and 30% PEG overcame cytoprotective 
mechanisms of the A2780cis cells. Also, the drug resistant A2780cis cells were 2-fold more 
susceptible to AuNP-PEI and 30% PEG than the drug responsive A2780 cells. The 
significance becomes more apparent when it is considered that the nanoparticle concentration 
for 30% PEG (5.3pM) was ~94-fold dilute to AuNP-PEI (500pM). The 30% PEG delivered 
~21nM DOX to the A2780cis cells and induced equal or increased cell death compared to 
other in vitro AuNP studies which reported micromolar concentrations of DOX (Section 
5.2.3.2). Experimental data suggested 30% PEG induced apoptosis mediated by caspase-3 
associated with increased oxidative stress in the A2780cis cells within 3h of treatment. 
Transmission electron microscopy of the A2780cis cell cross sections showed AuNP-PEI 
nanoparticles were localized in the cytoplasm as well as in peri-nuclear regions without any 
observable organelle sequestration and 30% PEG was sequestered in post-apoptotic vesicles 
(Section 5.2.3.6). A proposed mechanistic pathway for 30% PEG can be seen in Figure 5.16: 
Treatment of multidrug resistant ovarian carcinoma cells (A2780cis) with 30% PEG resulted 
in caspase-3 activation within 3h post-treatment by oxidative stress induced apoptosis. 
 
 
Figure 5.16: A suggested pathway for the induction of apoptosis by the intrinsic mitochondrial pathway. 
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Chapter 6: General Discussion, Conclusion and Future Work 
 
6.1 General Discussion 
Ovarian cancer is difficult to diagnose where a successful diagnosis typically occurs at 
advanced stages of the disease. Acquired drug resistance attributed to successive 
chemotherapy treatment (Section 1.2.3), a high rate of disease relapse (Section 1.2.2) and a 
high incidence of diagnosis to mortality rate (Section 1.2.1) is typically expected for ovarian 
cancer in advanced disease stages, where the disease can become incurable. The need for a 
cost-effective and robust chemotherapeutic formulation which could overcome the inherent 
multidrug resistance mechanisms of ovarian cancer in a target specific manner was needed 
where increased chemotherapeutic cellular internalization as well as cellular retention would 
prove beneficial. A chemotherapeutic formulation with a multimodal functionality would 
enable diagnosis and treatment to occur simultaneously in a theranostic manner. Theranostic 
based chemotherapy enables realtime monitoring of treatment progress. Nanotechnology was 
seen as a solution where gold nanoparticles as well as quantum dots were chosen to 
demonstrate in vitro drug delivery and in vitro cancer specific targeting to ovarian carcinoma 
cells, respectively.          
 
Chlorotoxin (CTX) is assumed to be a matrix metalloproteinase-2 (MMP2) targeting peptide 
where the biomolecular interaction was called into question by recent publications in the 
literature [132]. The specific nature of the CTX-MMP2 interaction is still unknown as neither 
the kinetic data nor the fluorescence microscopy co-localization data could elucidate the 
CTX-MMP2 interaction. Kinetic data could not provide any useful information regarding the 
reported inhibition of MMP2 by CTX. There appears to be no interaction of CTX with the 
truncated region of the hemopexin domain (pEGFP-N3-MMP2, Section 3.3.3), based on wide 
field fluorescence microscopy. Further study is required to identify the residue-to-residue 
interaction for CTX-MMP2, to determine whether this peptide-protein interaction is transient 
or if the interaction locus is dependent on changes in the biological milieu. The presence of 
MMP2 in serum is directly correlated with the stage- and metastatic potential as well as a 
poor prognosis for many types of cancers (Table 1.1, Section 1.3.1). A general diagnostic 
screen which can detect these cancers could potentially improve the patient’s prognostic 
outcome. The stage of the cancer can be potentially estimated, in a similar manner to the 
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latest commercial pregnancy tests, which can improve the diagnosis of cancer. The need for 
such a type of diagnosis becomes more apparent for hard to diagnose cancers, such as ovarian 
cancer, which typically is diagnosed in late stages of the disease. The drug delivery 
applications for using CTX as a targeting moiety for gold nanoparticles was demonstrated 
with the surface plasmon resonance affinity experiment where nitrilotriacetic acid (NTA) 
functionalized gold nanoparticles displayed directionality of attachment to 6xHis-tag CTX 
(Section 3.1.4). In an undirected bioconjugation of CTX to quantum dots (Section 3.3.3), 
through the use of water soluble carbodiimide, the specificity of CTX for MMP2 appears to 
have remained unaffected. The above mentioned gold nanoparticles and quantum dots had 
similar surface chemistries as the gold nanoparticles which were used for drug delivery 
(Sections 4.4.2 and 4.5.2). Potential in vivo diagnostic techniques can exploit fluorescence 
emission, surface enhanced Raman spectroscopy (SERS) as well as X-ray imaging for CTX 
targeted nanoparticles.  
 
The one-pot polyethyleneimine (PEI) synthesized gold nanoparticles (AuNP) proved to be 
very efficient in cellular internalization and distribution to multiple subcellular loci (5.2.3.6). 
The drug loaded AuNP-PEI proved to be 2-fold more cytotoxic to drug resistant ovarian 
carcinoma cells than to the drug responsive ovarian carcinoma cells. The drug resistant 
ovarian carcinoma cells (A2780cis) are melphalan, cisplatin and doxorubicin as well as 
irradiation resistant. The increased sensitivity of A2780cis cells may be attributed to the PEI 
on the AuNP-PEI being able to overcome the multidrug resistance mechanisms where 
cellular accumulation and decreased cellular efflux is suggested to cause depletion of total 
glutathione levels. Immunodetection of procaspase-3 levels indicates that programmed cell 
death is initiated within 3h post treatment for the doxorubicin loaded AuNP-PEI (Figure 5.11, 
Section 5.2.3.4) and within 24h for non-doxorubicin loaded AuNP-PEI (Figure 5.10, Section 
5.2.3.4). The exact mechanism is unknown but a suggested global pathway was introduced in 
Section 5.3 which are based on two known mechanisms of doxorubicin induced cell death as 
well as experimental data. The doxorubicin loaded AuNP-PEI achieved programmed cell 
death within 3h at ultralow concentrations (~21nM) of doxorubicin loaded onto 5.3pM 
AuNP-PEI (Sections 5.2.3.2-5.2.3.5). No similar nanoparticle based drug delivery studies 
have reported similar findings for achieving cell death at ultralow concentrations of a 
chemotherapeutic drug up to date. Further investigation of the A2780cis cell line drug 
resistance related molecular- and cell biology is needed to understand exactly how the above 
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mentioned nanoparticles overcome the cytoprotective mechanisms as well as induce 
programmed cell death in such a fast manner.  
 
The toxicity of AuNP-PEI to non-cancerous cells is unknown as it fell outside the scope of 
this study, but needs to be investigated. Also, the efficacy of this developed drug delivery 
platform to overcome multidrug resistance as well as its cytotoxicity needs to be investigated 
with an in vivo model. The argument can be made that drug loaded AuNP-PEI functionalized 
with CTX would only target MMP2 expressing cancer cells. However the inherent toxicity of 
the AuNP-PEI, drug loaded and non-drug loaded, is an important parameter for non-
cancerous cells as to determine organ distribution and potential organ specific associated 
toxicity such as nephrotoxicity or cardiotoxicity. 
 
The synthesis of one-pot functionalized gold nanoparticles (Section 4.3) proved to be facile 
and provided size polydisperse nanoparticles which had stability based on the surface ligand 
(Section 4.3.6). Different nanoparticle shapes raised an interesting question: would 
anisotropic nanoparticles have a different in vitro toxicity profile than near spherical 
nanoparticles? The nanoparticle preparations which contained the anisotropic nanoparticles 
did display a trend in increased cytotoxicity compared to near spherical nanoparticles 
Sections (4.3.4 and 5.2.2.2). Polyethylene glycol (PEG) functionalization of the gold 
nanoparticles did display altered biomolecule interaction but this interaction was not 
completely abolished (Sections 4.4.3). Covalent drug loading of doxorubicin and subsequent 
acid hydrolysis proved to be facile and showed that 1mmol AuNP-PEI delivered 4mol 
doxorubicin (Sections 4.4.2). The gold nanoparticles, drug loaded and non-drug loaded, 
proved to be stable during the freeze-drying process and stable for long periods of time in 
lyophilized form. Further, the timeframe required for the synthesis, purification and drug 
loading of AuNPs is less than 72h. The synthesis of the gold nanoparticles proved to be cost 
effective for the development of a drug delivery vehicle. This is an important consideration 
for developing countries such as South Africa where the majority of the population live in 
rural areas with limited access to health care facilities. 
 
Ovarian cancer is typically detected in the late stages of the disease where treatments are 
either ineffective with a high rate of disease relapse or development of acquired drug 
resistance and ultimately an incurable cancer. Diagnosis and treatment can be invasive, 
expensive as well as ineffective and have to be repeated on a regular basis to monitor the 
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disease. This study demonstrated in an in vitro model the ability of nanotechnology to 
overcome the cytoprotective mechanisms of a multidrug resistant ovarian carcinoma 
(A2780cis) by delivering ultralow concentrations doxorubicin to the cells. Cell death 
initiation appears to be within 3h with only 40-50% of the cells viable after 24h with a single 
dose. The implication is a potential successful cost-effective treatment of an incurable cancer 
without the need for excessive multiple follow-up treatments which necessitates the need to 
evaluate the doxorubicin loaded AuNPs with in vivo studies. Chemotherapy associated 
symptoms such as vomiting; hair loss and lethargy can also be potentially avoided with 
ultralow dosages of doxorubicin. The inherent metallic nature of gold nanoparticles will 
make visualization of the cancer possible with X-ray imaging, and as such in vivo localization 
of the gold nanoparticles with their drug payload can be determined. Systemic toxicity can be 
overcome by targeting the drug delivery vehicle (gold nanoparticles) to cancer cells 
specifically with CTX. The drug loading can also be done for fluorescent quantum dots as the 
same surface chemistry is present as for gold nanoparticles, generating another theranostic 
nanoparticle. Quantum dots are viewed as too toxic to be utilized for diagnostics, but an 
argument can be made that current chemotherapy treatments are known to be toxic and as 
such acceptable levels of intrinsic toxicity is acceptable for a diagnostic tool which will result 
in localized cancer tissue toxicity. The question is raised: “Does the toxicity of quantum dots 
matter for the scenario where cancer specific targeting is employed to deliver a 
chemotherapeutic payload?” The case where chlorotoxin is utilized as a cancer targeting 
moiety for quantum dots (Section 3.3.3.2) serves as an illustrative consideration.    
    
 
6.2 Conclusion 
Gold nanoparticles and quantum dots proved useful for in vitro therapeutic- and diagnostic 
tools, showing potential multimodal properties. Gold nanoparticles were synthesized in a 
one-pot manner with a readily adaptable surface chemistry which overcame the 
cytoprotective mechanisms of a multidrug resistant cell line to deliver a doxorubicin payload 
and induced programmed cell death. This was achieved with ultralow dosages of doxorubicin 
compared to the typical in vitro and in vivo dosages in a comparative short time frame. The 
gold nanoparticles proved to be colloidal stable pre- and post-drug loading and cost effective 
to produce. The primary objective of the study was met in full. 
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Full length C-terminal EGFP tagged MMP2 was not successfully produced, presenting with a 
truncation in the hemopexin domain of MMP2 yet proved to be an informative mistake, 
acting as supportive evidence for the interaction of CTX-MMP2. Recombinant affinity 
tagged (6xHis-tag) chlorotoxin was successfully produced for the proof of concept for MMP2 
specific cancer targeting of multimodal nanoparticles (gold nanoparticles and quantum dots) 
which can serve as therapeutic delivery vehicles as well as high contrast imaging reagents. 
The secondary objective of the study was satisfactorily met. 
 
Nanotechnology applied in this study shows promise for the treatment and diagnosis of 
multidrug resistant ovarian cancer. 
 
 
6.3 Outputs and Future Work 
The work in this study was conducted under an agreement of non-disclosure. Aspects of the 
work, which is not in violation of the above mentioned agreement, will be submitted to peer-
reviewed journals for publication. 
 
Aspects of the research will be followed up for publication purposes. The following topics 
will receive attention: 
(i) Gold nanoparticle synthesis and characterization: 
 Physicochemical characterizations such as dynamic light scattering (DLS) 
to monitor changes in the nanoparticle surface chemistry during drug 
loading as well as in stability assays (BSA, RPMI1640, NaCl, etc.) 
 Investigation of the effect of other polyethyleneimine polymers and similar 
dendrimers on the size and shape distribution of the nanoparticles; 
 Size- and shape enrichment of the nanoparticles for more specific 
physicochemical as well as biological characterization; 
 Covalent drug loading of other chemotherapeutic agents. 
 
(ii) The CTX-MMP2 interaction: 
 Cloning and expression of full length C-terminal EGFP tagged MMP2 for 
fluorescence co-localization studies; 
 Cloning and expression of C-terminal EGFP tagged subdomains of MMP2 
for fluorescence co-localization studies; 
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 Cloning and expression of subdomains of MMP2 for NMR as well as 
crystallography studies of the CTX-MMP2 interaction. 
 
(iii) Molecular mechanisms of how the gold nanoparticles overcome multidrug 
resistance: 
 Elucidate the proposed oxidative stress pathway by immunodetection 
techniques as well as quantitative PCR; 
 Determine genotoxicity as well as potential epigenetic changes; 
 Biochemical investigation for metabolic changes in the cells. 
 
(iv) Evaluation of the developed drug delivery platform in other in vitro cancerous and 
non-cancerous cell lines; 
 
(v) Evaluation of the developed drug delivery platform in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
218 
 
REFERENCES 
 
1.  Blagoskony, M.V.  2005. Molecular Theory of Cancer, Cancer Biology & 
Therapy, 4(6):621-627. June. 
2.  Chen, Y. and Hunter, D.J.  2005. Molecular Epidemiology of Cancer, CA 
Cancer J Clin, 55:45-54. 
3.  Loeb, L.A. and Harris, C.C.  2008. Advances in Chemical Carcinogenesis – A 
Historical Review and Prospective, Cancer. Res., 68(17):6863-6872, Sept. 
4.  Wogan, G.N., Hecht, S.S., Felton, J.S., Conney, A.H. and Loeb, L.A.  2004. 
Environmental and Chemical Carcinogenesis, J. Sem. Cancer, 473-486, Jun. 
5.  Stoner, G.D., Morse, M.A. and Kelloff, G.J.  1997. Perspectives in Cancer 
Chemoprevention, Environmental Health Perspectives, 105(4):945-954. 
6.  Lee, J.T. and Herlyn, M.  2007. Old Disease, New Culprit: Tumor Stem Cells 
in Cancer, J. Cell. Physiol, 213:603-609. 
7.  Center, M., Siegel, R. and Jemal, A.  2011. Global Cancer Facts & Figures, 2nd 
Ed, American Cancer Society Inc, Atlanta. 
8.  World Healgth Organization (WHO) – Cancer, http://www.who.int/cancer/en/ 
(Accessed: 06-04-2012). 
9.  North American Centre for Disease Control (CDC) – Cancer, 
http://www.cdc.gov/cancer (Accessed: 06-04-2012). 
10.  Cvetkovic, D., Connolly, D.C. and Hamilton, T.C. 2004. Chapter 28: 
Molecular Biology and Molecular Genetics of Ovarian, Fallopian Tube, and Primary 
Peritoneal Cancer, Gynaecologic Cancer: Controversies in Management, Elsevier 
Science, 385-398. 
11.  Balkwill, F., Bast, R.C., Berek, J., Chenevix-Trench, G., Gore, M., Hamilton, 
T., Jacobs, I., Mills, G., Souhami, R., Urban, N., Ursulic, S. and Smyth, J.  2003. 
Current Research and Treatment for Epithelial Ovarian Cancer – A Position Paper 
from the Helen Harris Memorial Trust, European Journal of Cancer, 39:1818-1827. 
12.  Auersperg, N., Wong, A.S.T., Choi, K.C., Kang, S.K. and Leung, P.C.K.  
2001. Ovarian Surface Epithelium: Biology, Endocrinology and Pathology, 
Endocrine Reviews, 22(2):255-288. 
 
 
 
 
219 
 
13.  Riman, T., Persson, I. and Nilsson, S.  1998. Hormonal Aspects of Epithelial 
Ovarian Cancer: Review of Epidemiological Evidence, Clinical Endocrinology, 
49:695-707, May. 
14.  Williams, T.I., Toups, K.L., Saggese, D.A., Kalli, K.R., Cliby, W.A. and 
Muddiman, D.C.  2007. Epithelial Ovarian Cancer: Disease Etiology, Treatment, 
Detection and Investigational Gene, Metabolite and Protein Biomarkers, Journal of 
Proteome Research, 6:2936-2962, Jan. 
15.  Fathalla, M.F.  1971. Incessant Ovulation – A Factor in Ovarian Neoplasia?, 
The Lancet, 7716(298):163. 
16.  Tonin, P.  2009. Thematic Issue on the Molecular Biology of Hereditary 
Ovarian Cancer, Molecular Oncology, 3:94-96, Feb. 
17.  Gentry-Maharay, A. and Menon, U.  2011. Screening for Ovarian Cancer in 
the General Population, Best Practise & Research Clinical Obstetrics and 
Gynaecology, 26:243-256, Nov. 
18.  Van der Burg, M.E.L., Van Lent, M., Buyse, M., Kobierska, A., Colombo, N., 
Favalli, G., Lacave, A.J., Nardi, M., Renard, J. and Pecorelli, S.  1995. The Effect of 
Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced 
Epithelial Ovarian Cancer, N. Engl. J. Med., 332(10): 629-634. 
19.  Morrison, J., Swanton, A., Collins, S. and Kehoe, S.  2009. Chemotherapy 
Versus Surgery for Initial Treatment in Advanced Ovarian Epithelial Cancer, The 
Cochrane Library (Wiley & Sons), 3:1-19. 
20.  McGuire, W.P. and Markman, M.  2003. Primary Ovarian Cancer 
Chemotherapy: Current Standards of Care, British Journal of Cancer, 89(3):3-8. 
21.  Harries, M. and Gore, M.  2002. Chemotherapy for Recurrent Ovarian Cancer 
Part II: Chemotherapy for Epithelial Ovarian Cancer – Treatment of Recurrent 
Disease, Lancet Oncol., 3:537-545. Sept. 
22.  Hall, M.D. and Hambley, T.W.  2002. Platinum-(IV) Anti-tumour 
Compounds: Their Bioinorganic Chemistry, Coordination Chemistry Reviews, 
232:49-67. 
23.  Hall, M.D., Okabe, M., Shen, D.W., Liang, X.J. and Gottesman, M.M.  2007. 
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based 
Chemotherapy, Ann. Rev. Pharmacol. Toxicol., 48:495-535. 
24.  Siddik, Z.H.  2003. Cisplatin: Mode of Cytotoxic Action and Molecular Basis 
of Resistance, Oncogene, 22:7265-7279. 
 
 
 
 
220 
 
25.  Haxton, K.J. and Burt, H.M.  2009. Polymeric Drug Delivery of Platinum-
based Anticancer Agents, Journal of Pharmaceutical Sciences, 98(7):2299-2316. 
26.  Pfizer Doxorubicin CCO Formulary – Revised October 2009. 
27.  Preobrazhenskaya, M.N., Tevyashova, A.N., Olsufyeva, E.N., Huang, K.F. 
and Huang, H.S.  2006. Second Generation Drugs-derivatives of Natural Antitumour 
Anthracycline Antibiotics Daunorubicin, Doxorubicin and Carminomycin, J. Med. 
Sci., 26(4):119-128, Mar. 
28.  Thorn, C.F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeoad, H., 
Klein, T.E. and Altman, R.B.  2011. Doxorubicin Pathways: Pharmacodynamics and 
Adverse Effects, Pharmacogenet. Genomics, 21(7):440-446, Jul. 
29.  Mizutani, H., Tada-Oiakawa, S.H., Hiraku, Y., Kojima, M. and Kawanishi, S.  
2005. Mechanism of Apoptosis Induced by Doxorubicin through Generation of 
Hydrogen Peroxide, Life Sciences, 76:1439-1453. 
30.  Kostoryz, E.L. and Yourtee, D.M.  2001. Oxidative Mutagenesis of 
Doxorubicin-Fe(III)-Complex, Mutation Research, 490:131-139. 
31.  Drummond, J.T., Anthoney, A., Brown, R. and Modrich, P.  1996. Cisplatin 
and Adriamycin Resistant are Associated with MutLα and Mismatch Repair 
Deficiency in an Ovarian Tumor Cell Line, The Journal of Biological Chemistry, 
271(33):19645-19648. 
32.  Mohamed, H.E., El-Swefy, S.E. and Hagar, H. H.  2000. The Protective Effect 
of Glutathione Administration on Adriamycin-induced Acute Cardiac Toxicity in 
Rats, Pharmacological Research, 42(2): 115-121. 
33.  Sayed-Ahmed, M.M., Salman, T.M., Gaballah, H.E., El-Naga, S.A.A., 
Nicolai, R. and Calvani, M.  2001. Propionyl-L-carnitine as Protector against 
Adriamycin-induced Cardiomyopathy, Pharmcological Research, 43(6):513-520. 
34.  Boonsanit, D., Kanchanapangka, S. and Buranakarl, C.  2006. L-Carnitine 
Ameliorates Doxorubicin-induced Nephrotoxicity Syndrome in Rats, Nephrology, 
11:313-320. 
35.  Wang, G.W. and Kang, Y.J.  1999. Inhibition of Doxorubicin Toxicity in 
Cultured Neonatal Cardiomyocytes with Elevated Metallothionein Levels, The 
Journal of Pharmacology and Experimental Therapeutics, 288(3):938-944. 
36.  Dobrovolskala, M.A., Aggarwal, P., Hall, J.B. and McNeil, S.E.  2008. 
Preclinical Studies to Understand Nanoparticle Interaction with the Immune System 
 
 
 
 
221 
 
and Its Potential Effect on Nanoparticle Biodistribution, Molecular Pharmaceutics, 
5(4):487-495. 
37.  Li, S.D. and Huang, L.  2008. Pharmacokinetics and Bio-distribution of 
Nanoparticles, Molecular Pharmaceutics, 5(4):496-504. 
38.  Rowinsky, E.K.  1997. The Development and Clinical Utility of the Taxane 
Class of Antimicrotubule Chemotherapy Agents, Ann. Rev. Med., 48:353-374. 
39.  Dean, E., El-Helw, L. and Hasan, J.  2010. Targeted Therapies in Epithelial 
Ovarian Cancer, Cancers, 2:88-113. 
40.  Steeg, P.S.  2006. Tumor Metastasis: Mechanistic Insights and Clinical 
Challenges, Nature Medicine, 12:895-904, Aug. 
41.  Yang, J., Mani, S.A. and Weinberg, R.A.  2006. Exploring a New Twist on 
Tumor Metastasis, Cancer Res., 66(9): 4549-4552, May. 
42.  Schaner, M.E., Ross, D.T., Ciaravina, G., Sorlie, T., Troyanskaya. O., Diehn, 
M., Wang, Y.C., Duran, G.E., Sikic, T.L., Caldeira, S., Skomedal, H., Tu, I.P., 
Hernandez-Boussard, T., Johnson, S.W., O’Dwyer, P.J., Fero, M.J., Kristensen, 
G.B., Borresen-Dale, A.L., Hastie, T., Tibshirani, R., Van de Rijn, M., Teng, N.N., 
Longacre, T.A., Bolstein, D., Brown, P.O. and Sikic, B.L.  2003. Gene Expression 
Patterns in Ovarian Carcinomas, Molecular Biology of the Cell, 14:4376-4386. 
43.  Albini, A., Mirisola, V. and Pfeffer, U.  2008. Metastasis Signatures: Genes 
Regulating the Tumor-microenvironment Interactions Predict Metastatic Behaviour, 
Cancer Metastasis Rev., 27:75-83. 
44.  Rinker-Schaeffer, C.W., O’Keefe, J.P., Welch, D.R. and Theodorescu, D.  
2006. Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms and 
Clinical Application, Clin. Cancer Res., 12(13):3882-2889, Jul. 
45.  Feki, A., Berardi, P., Bellingan, G., Major, A., Krause, K.H., Petignat, P., 
Zehra, R., Pervaiz, S. and Irminger-Finger, I.  2009. Dissemination of Intraperitoneal 
Ovarian Cancer: Discussion of Mechanisms and Demonstration of Lymphatic 
Spreading in Ovarian Cancer Model, Critical Reviews in Oncology/Hematology, 
72:1-9. 
46.  Shield, K., Ackland, M.L., Ahmed, N. and Rice, G.E.  2009. Multicellular 
Spheroids in Ovarian Cancer Metastases: Biology and pathology, Gynecologic 
Oncology, 113:143-148. 
47.  Yoneda, J., Kuniyasu, H., Crispens, M.A., Price, J.E., Bucana, C.D. and 
Fidler, I.J.  1998. Expression of Angiogenesis-Related Genes and Progression of 
 
 
 
 
222 
 
Human Ovarian Carcinomas in Nude Mice, Journal of the National Cancer Institute, 
90(6):447-454, Mar. 
48.  Kenny, H.A., Kaur, S., Coussens, L.M. and Lengyel, E.  2008. The Initial 
Steps of Ovarian Cancer Metastasis are Mediated by MMP-2 Cleavage of 
Vitronectin and Fibronectin, The Journal of Clinical Investigation, 118(4):1367-
1379, Apr. 
49.  Zhang, L., Conejo-Garcia, J.R., Katsaros, D., Gimotty, P.A., Massobrio, M., 
Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M.N., Rubin, 
S.C. and Coukos, G.  2003. Intratumoral T Cells, Recurrence and Survival in 
Epithelial Ovarian Cancer, N. Engl. J. Med., 348:203-213. 
50.  Weihong, D., Yanhua, X. and Zehua, W.  2005. Apoptosis Rate and Objective 
Diagnosis of Drug Resistance of Ovarian Cancer Cell Lines, The Chinese-German 
Journal of Clinical Oncology, 4(5):304-308. 
51.  Hamaguchi, K., Godwin, A.K., Yakushiji, M., O’Dwyer, P.J., Ozols, R.F. and 
Hamilton, T.C.  1993. Cross-Resistance to Diverse Drugs is Associated with 
Cisplatin Resistance in Ovarian Cancer Cell Lines, Cancer Res., 53:5225-5232. 
52.  Kunjachan, S., Blauz, A., Mockel, D., Theek, B., Kiessling, F., Etrych, T., 
Ulbrich, K., Van Bloois, L., Storm, G., Bartosz, G., Rychlik, B. and Lammers, T.  
2011. Overcoming Cellular Multidrug Resistance using Classical Nanomedicine 
Formulations, European Journal of Pharmaceutical Science, 2011, Aug. 
53.  Solar, P. and Sytkowski, A.J.  2011. Differentially Expressed Genes 
Associated with Cisplatin Resistance in Human Ovarian Adenocarcinoma Cell Line 
A2780, Cancer Letters, 309:11-18, May. 
54.  Drummond, J.T., Anthony, A., Brown, R.B. and Modrich, P.  1996. Cisplatin 
and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair 
Deficiency in an Ovarian Tumour Cell Line, The Journal of Biological Chemistry, 
271(33):19645-19648, Aug. 
55.  Massey, A., Offman, J., Macpherson, P. and Karran, P.  2003. DNA Mismatch 
Repair and Acquired Cisplatin Resistance in E.coli and Human Ovarian Carcinoma 
Cells, DNA Repair, 2:73-89, Sept. 
56.  Helleman, J., Van Staveren, I.L., Dinjens, W.N.M., Van Kuijk, P.F., Ritstier, 
K., Ewing, P.C., Van der Burg, M.E.L., Stoter, G. and Berns, E.M.J.J.  2006. 
Mismatch Repair and Treatment Resistance in Ovarian Cancer, BMC Cancer, 6:201. 
 
 
 
 
 
223 
 
57.  Selvakumaran, M., Pisarcik, D.A., Bao, R., Yeung, A.T. and Hamilton, T.C.  
2003. Enhanced Cisplatin Cytotoxicity by Disturbing the Nucleotide Excision 
Repair Pathway in Ovarian Cancer Cell Lines, Cancer Res., 63:1311-1316. 
58.  Juin, P, Geneste, O., Raimbaud, E. and Hickman, J.A.  2004. Shooting at 
Survivors: Bcl-2 Family Members as Drug Targets for Cancer, Biochimica et 
Biophysica Acta, 1644:251-260. 
59.  Preston, T.J., Abadi, A., Wilson, L. and Singh, G.  2001. Mitocondrial 
Contributions to Cancer Cell Physiology: Potential for Drug Development, 
Advanced Drug Delivery Reviews, 49:45-61. 
60.  Ghavami, S., Hashemi, M., Yeganeh, B., Xiao, W. Eshragi, M., Bus, C.J., 
Kadkhoda, K., Wiechec, E., Halayko, A.J. and Los, M.  2009. Apoptosis and 
Cancer: Mutations within Caspase Genes, J. Med. Genet., 46:497-510. 
61.  Sasaki, H., Sheng, Y.L., Kotsuji, F. and Tsang, B.K.  2000. Down-Regulation 
of X-linker Inhibitor of Apoptosis Protein Induces Apoptosis in Chemiresistant 
Human Ovarian Cancer Cells, Cancer Res., 60:5659-5666. 
62.  Asselin, E., Mills, G.B. and Tsang, B.K.  2001. XIAP Regulates Akt Activity 
and Caspase-3-dependent Cleavage during Cisplatin-induced Apoptosis in Human 
Ovarian Epithelial Cancer Cells, Cancer Res., 61:1862-1868. 
63.  Roy, G., Horton, J.K., Roy, R., Denning, T., Mitra, S. and Boldogh, I.  2000. 
Acquired Alkylating Drug Resistance is Unaffected by Altered Levels of Pro- and 
Anti-Apoptotic Proteins, Oncogene, 19:141-150. 
64.  Vazquez, A., Bond, E.E., Levine, A.J. and Bond, G.L.  The Genetics of the 
p53 Pathway, Apoptosis and Cancer Therapy, Nature Drug. Disc., 7:979-987. 
65.  Reles, A., Wen, H.W., Schimder, A., Gee, C., Runnebaum, I.B., Kilian, U., 
Jones, L.A., El-Nagger, A., Minguillon, C., Schonborn, I., Reich, O., Kreienberg, R., 
Lichtenegger, W. andPress, M.F.  2001. Correlation of p53 Mutations with 
Resistance to Platinum-based Chemotherapy and Shortened Survival in Ovarian 
Cancer, Clin. Cancer Res., 7:2984-2997, Oct. 
66.  Townsend, D.M., Tew, K.D. and Tapiero, H.  2003. The Importance of 
Glutathione in Human Disease, Biomedicine & Pharmacotherapy, 57:145-155. 
67.  Mistry, P., Kelland, L.R., Abel, G., Sidhar, S. and Harrap, K.R.  1991. The 
Relationships between Glutathione, Glutathione-S-transferase and Cytotoxicity of 
Platinum Drugs and Melphalan in Eight Human Ovarian Carcinoma Cell Lines, Br. 
J. Cancer, 64:215-220. 
 
 
 
 
224 
 
68.  Godwin, A.K., Meister, A., O’Dwyer, P.J., Huang, C.S., Hamilton, T.C. and 
Anderson, M.  1991. High Resistance to Cisplatin in Human Ovarian Cancer Cell 
Lines is Associated with Marked Increase of Glutathione Synthesis, Proc. Natl. 
Acad. Sci., 89:3070-3074, Apr. 
69.  Cho, H.Y., Reddy, S.P., DeBiase, A., Yamamoto, M. and Kleeberger, S.R.  
2005. Gene Expression Profiling of NRF2-Mediated Protection against Oxidative 
Injury, Free Radical Biology & Medicine, 38:325-343, Jan. 
70.  Hayes, J.D. and McMahon, M.  2009. NRF2 and KEAP1 Mutations: 
Permanent Activation of an Adaptive Response in Cancer, Trends in Biochemical 
Sciences, 34(4):175-188, March. 
71.  Lau, A., Villeneuve, N.F., Sun, Z., Wong, P.K. and Zhang, D.D.  2008. Dual 
Roles of Nrf2 in Cancer, Pharmacological Research, 58:262-270, Sept. 
72.  Shim, G., Manandhar, S., Shin, D., Kim, T.H. and Kwak, M.K.  2009. 
Acquisition of Doxorubicin Resistance in Ovarian Carcinoma Cells Accompanies 
Activation of the NRF2 Pathway, Free Radical Biology & Medicine, 47:1619-1631, 
Sept. 
73.  Harvey, C.J., Thimmulappa, R.K., Singh, A., Blake, D.J., Ling, G., 
Wakabayashi, N., Myers, A. and Biswal, S.  2009. Nrf2-Regulated Glutathione 
Recycling Independent of Biosynthesis Survival during Oxidative Stress, Free 
Radical Biology & Medicine, 46:443-453, Jan. 
74.  Helleman, J., Burger, H., Hamelers, I.H.L., Boersma, A.W.M., De Kroon, 
A.I.P.M., Stoter, G. and Nooter, K.  2006. Impaired Cisplatin Influx in an A2780 
Mutant Cell line, Cancer Biology & Therapy, 5(8):943-949, Aug. 
75.  Gottesman, M.M., Fojo, T. and Bates, S.E.  2002. Multidrug Resistance in 
Cancer: Role of ATP-Dependent Transporters, Nature Reviews, 2:48-58, Jan. 
76.  Meijerman, I., Beijnen, J.H. and Schellens, J.H.M.  2008. Combined Action 
and Regulation of Phase II and Multidrug Resistance Proteins in Multidrug 
Resistance in Cancer, Cancer Treatment Reviews, 34:505-520, March. 
77.  Zisowsky, J., Koegel, S., Leyers, S., Devarakonda, K., Kassack, M.U., Osmak, 
M. and Jaehde, U.  2007. Relevance of Drug Uptake and Efflux for Cisplatin 
Sensitivity of Tumor Cells, Biochemical Pharmacology, 73:298-307. 
78.  Pakunlu, R.I., Cook, T.J. and Minko, T.  2003. Simultaneous Modulation of 
Multidrug Resistance and Anti-apoptotic Cellular Defence by MDR1 and BCL-2 
 
 
 
 
225 
 
Targeted Antisense Oligonucleotides Enhances the Anticancer Efficacy of 
Doxorubicin, Pharmaceutical Research, 20(3):351-359, March. 
79.  Yan, X., Yin, J., Tao, H., Mao, N., Yang, Y. and Pan, L.  2010. Increased 
Expression of Annexin A3 is a Mechanism of Platinum Resistance in Ovarian 
Cancer, Cancer Res., 70(4):OF1-OF9, Feb. 
80.  Morgunova, E., Tuuttila, A., Bergmann, U., Isupov, M., Lindqvist, Y., 
Scheinder, G. and Tryggvason, K.  1999. Structure of Human Pro-Matrix 
Metalloproteinase-2: Activation Mechanism Revealed, Science, 284:1667-1679, Jun. 
81.  Weingarten, H., Martin, R. and Feder, J.  1985. Synthetic Substrates of 
Vertebrate Collagenase, Biochemistry, 24:6730-6734, Mar. 
82.  Xia, T., Akers, K., Eisen, A.Z. and Seltzer, J.L.  1996. Comparison of 
Cleavage Site Specificity of Gelatinases A and B using Collagenous Peptides, 
Biochimica et Biophysica Acta, 1293:259-266. 
83.  Banyai, L., Tordai, H. and Patthy, L.  1994. The Gelatin-Binding Site of 
Human 72 kDa Type IV Collagenase, Biochem. J., 298:403-407. 
84.  Egeblad, M. and Werb, Z.  2002. New functions for the matrix 
metalloproteinases in cancer progression, Cancer, 2:161-174, Mar. 
85.  Wu, X., Li, H., Kang, L., Li, L., Wang, W. and Shan, B.  2002. Matrix 
Metalloproteinase-2 – A Potential Marker of Prognosis for Epithelial Ovarian 
Cancer, Gynecologic Oncology, 84:126-134. 
86.  Turpeenniemie-Hujanen, T.  2005. Gelatinases (MMP-2 and -9) and their 
Natural Inhibitors as Prognostic Indicators in Solid Cancers, Biochimie, 87:287-297, 
Jan. 
87.  Hofmann, U.B., Westphal, J.R., Van Muijen, G.N.P. and Ruiter, D.J.  2000. 
Matrix Metalloproteinases in Human Melanoma, J. Invest. Dermatol., 115:337-344, 
May. 
88.  Smyth-Templeton, N. and Stetler-Stevenson, W.G.  1991. Identification of a 
basal promotor for the Human Mr 72 000 Type IV Collagenase Gene and Enhanced 
Expression in a Highly Metastatic Cell Line, Cancer Res., 51:6190-6193, Nov. 
89.  Yamamoto, M., Mohanam, S., Sawaya, R., Fuller, G.N., Seiki, M., Sato, H., 
Gokaslan, Z.L., Liotta, L.A., Nicolson, G.L. and Rao, J.S.  1996. Differential 
Expression of Membrane-Type Matrix Metalloproteinase and Its Correlation with 
Gelatinase A Activation in Human Malignant Brain Tumors In Vivo and In Vitro, 
Cancer Res., 56:384-392, Jan. 
 
 
 
 
226 
 
90. Roomi, M.W., Monterrey, J.C., Kalinovsky, T., Rath, M. and Niedzwiecki, A.  2009. 
Patterns of MMP-2 and MMP-9 Expression in Human Cancer Cell Lines, Oncology 
Reports, 21:1323-1333, Feb. 
 
91.  Jones, J.L., Glynn, P. and Walker, R.A.  1999. Expression of MMP-2 and 
MMP-2, Their Inhibitors and the Activator MT1-MMP in Breast Carcinomas, J. 
Pathol., 189:161-168, Mar. 
92.  Sehgal, I. and Thompson, T.C.  1999. Novel Regulation of Type IV 
collagenase (Matrix Metalloproteinase-9 and -2) Activities by Transforming Growth 
Factor-β1 in Human Prostate Cancer Cell Lines, Molecular Biology of the Cell, 
10:407-416, Feb. 
93.  Brown, P.D., Levy, A.T., Margulies, I.M.K., Liotta, L.A. and Stetler-
Stevenson, W.G.  1990. Independent Expression and Cellular Processing of Mr 
72000 type IV Collagenase and Interstitial Collagenase in Human Tumorigenic Cell 
Lines, Cancer Res., 50:6184-6191, Jun. 
94.  Emmert-Buck, M.R., Roth, M.J., Zhuang, Z., Campo, E., Rozhin, J., Sloane, 
B.F., Liotta, L.A. and Stetler-Stevenson, W.G.  1994. Increased Gelatinase A 
(MMP-2) and Cathepsin B Activity in Invasive Tumor Regions of Human Colon 
Cancer Samples, Am. J. Pathol., 145:1285-1290, Dec. 
95.  Giambernardi, T.A., Grant, G.M., Taylor, G.P., Hay, R.J., Maher, V.M., 
McCormick, J.J. and Klebe, R.J.  1997. Overview of Matrix Metalloproteinase 
Expression in Cultured Human Cells, Matrix Biology, 16:483-496. 
96.  Cheung, P.Y., Sawicki, G., Wozniak, M., Wang, W., Radomski, M.W. and 
Schulz, R.  2000. Matrix Metalloproteinase-2 Contributes to Ischemia-Reperfusion 
Injury in the Heart, Circulation, 101:1833-1839, Jan. 
97.  Kwan, J.A., Schulze, C.J., Wang, W., Leon, H., Sariahmetoglu, M., Sung, M., 
Sawicka, J., Sims, D.E., Sawicki, G., and Schulz, R.  2004. Matrix 
metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is 
capable of cleaving poly(ADP-ribose) polymerase (PARP) in vitro, FASEB J., 
18:690-692. 
98.  Elkington, P.T.G., O’Kane, C.M. and Friedland, J.S.  2005. The Paradox of 
Matrix Metalloproteinases in Infectious Disease, Clinical and Experimental 
Immunology, 142:12-20, Apr. 
 
 
 
 
 
227 
 
99.  Rumbaugh, J., Turchan-Cholewo, J., Galey, D., St Hillaire, C., Anderson, C., 
Conant, K. and Nath, A.  2006. Interaction of HIV Tat and Matrix Metalloproteinase 
in HIV Neuropathogenesis: A New Host Defense Mechanism, FASEB J., 20:E1114-
E1123. 
100.  Fridman, R., Fuerst, T.R., Bird, R.E., Hoyhtya, M., Oelkuct, M., Kraus, S., 
Komarek, D., Liotta, L.A., Berman, M.L. and Stetler-Stevenson, W.G.  1992. 
Domain Structure of Human 72-kDa Gelatinase/Type IV Collagenase, The Journal 
of Biological Chemistry, 257(22):15398-15405, Aug. 
101.  Bernardo, M.M. and Fridman, R.  2003. TIMP-2 (Tissue Inhibitor of Matrix 
Metalloproteinase-2) Regulates MMP-2 (Matrix Metalloproteinase-2) Activity in the 
Extracellular Environment after pro-MMP-2 activation by MT1 (Membrane Type 
1)-MMP, Biochem J., 374: 739-745. 
102.  Brooks, P.C., Stromblad, S., Sanders, L.C., Von Schalscha, T., Aimes, R.T., 
Stetler-Stevenson, W.G., Quigley, J.P. and Cheresh, D.A.  1996. Localization of 
Matrix Metalloproteinase-2 (MMP-2) to the Surface of Invasive Cells by Interaction 
with Integrin αvβ3, Cell, 85:683-693, May. 
103.  Howard, E.W. and Banda, M.J.  1991. Binding of Tissue Inhibitor of 
Metalloproteinase 2 to Two Distinct Sites on Human 72-kDa Gelatinase, The 
Journal of Biological Chemistry, 266(27):17972-17977, May. 
104.  Hernandez-Barrantes, S., Toth, M., Bernardo, M.M., Yurkova, M., Gervasi, 
D.C., Raz, Y., Sang, Q.X.A. and Fridman, R.  2000. Binding of Active (57kDa) 
Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) to Tissue Inhibitor of 
Metalloproteinase (TIMP)-2 Regulates MT1-MMP Processing and Pro-MMP2 
Activation, The Journal of Biological Chemistry, 275(16):12080-12089, Jan. 
105.  Sariahmetoglu, M., Crawford, B.D., Leon, H., Sawicka, J., Li, L., Ballerman, 
B.J., Holmes, C., Berthiaume, L.G., Holt, A., Sawicki, G. and Schulz, R.  2007. 
Regulation of Matrix Metalloproteinase-2 (MMP-2) Activity by Phosphorylation, 
FASEB, J., 21:2486-2495, Jul. 
106.  Munshi, H.G., Wu, Y.I., Mukhopadhyay, S., Ottaviano, A.J., Sassano, A., 
Koblinski, J.E., Platanias, L.C. and Stack, M.S.  2004. Differential Regulation of 
Membrane Type-1 Matrix Metalloproteinase Activity by ERK 1/2 – and p38 
MAPK-modulated Tissue Inhibitor of Metalloproteinase 2 Expression Controls 
Transforming Growth Factor-β1-induced Pericellular Collagenolysis, The Journal of 
Biological Chemistry, 279(37):39042-39050, Jul. 
 
 
 
 
228 
 
 
107.  Nelson, K.K., Ranganatham, A.C., Mansouri, J., Rodriguez, A.M., 
Providence, K.M., Rutter, J.L., Pumiglia, K., Bennett, J.A. and Melendez, J.A.  
2003. Elevated Sod2 Activity Augments Matrix Metalloproteinase Expression: 
Evidence for the Involvement of Endogenous Hydrogen Peroxide in Regulating 
Metastasis, Clin. Cancer Res., 9:424-432, Jan. 
108.  Van de Wiele, C. and Oltenfreiter, R.  2006. Imaging Probes Targeting Matrix 
Metalloproteinases, Cancer Biotheraphy & Radiopharmaceuticals, 21:409-417, 
Nov. 
109.  Cai, W., Rao, J., Gambhir, S.S. and Chen, X.  2006. How Molecular Imaging 
is Speeding up Antiangiogenic Drug Development, Mol. Cancer Ther., 5:2624-2633, 
Nov. 
110.  Pirila, E., Maisi, P., Salo, T., Koivunen, E. and Sorsa, T.  2001. In Vivo 
Localization of Gelatinases (MMP-2 and -9) by In Situ Zymography with a Selective 
Gelatinase Inhibitor, Biochemical and Biophysical Research Communications, 
287:766-774, Aug. 
111.  Snoek-van Beurden, P.A.M. and Von den Hoff, J.W.  2005. Zymographic 
Techniques for the Analysis of Matrix Metalloproteinases and their Inhibitors, 
Biotechniques, 38:73-83, Jan. 
112.  Leber, T.M. and Balkwill, F.R.  1997. Zymography: A Single-step Staining 
Method for Quantification of Proteolytic Activity on Substrate Gels, Anal. Biochem., 
249:24-28, Jan. 
113.  Medina, O.P., Haikola, M., Tahtinen, M., Simpura, I., Kaukinen, S., Valtanen, 
H., Zhu, Y., Kuosmanen, S., Cao, W., Reunanen, J., Nurminen, T., Saris, P.E.J., 
Smith-Jones, P., Bradbury, M., Larson, S. and Kairemo, K.  2011. Liposomal Tumor 
Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands, 
Journal of Drug Delivery, 2011:1-9, Jan. 
114.  Medina, O.P., Soderlund, T., Laakkonen, L.J., Tuominen, E.K.J., Koivunen, 
E. and Kinnunen, P.K.J.  2001. Binding of Novel Peptide Inhibitors of Type IV 
Collagenases to Phospholipid Membranes and Use in Liposome Targeting to Tumor 
Cells In Vitro, Cancer Res., 61:3978-3985, May. 
115.  Davidson, B., Goldberg, I., Gotlieb, W.H., Kopolovic, J., Ben-Baruch, G., 
Nesland, J.M., Berner, A., Bryne, M. and Reich, R.  2000. High Levels of MMP-2, 
 
 
 
 
229 
 
MMP-9, MT1-MMP and TIMP-2 mRNA correlate with Poor Survival in Ovarian 
Carcinoma, Clinical & Experimental Metastasis, 17:799-808, Feb. 
116.  Shen, S.C., Lin, C.W., Lee, H.M., Chien, L.L. and Chen, Y.C.  2006. 
Lipopolysaccharide Plus 12-O-Tetradecanoylphorbol-13-acetate Induction of 
Migration and Invasion of Glioma Cells In Vitro and In Vivo, Neuroscience, 
140:477-489, Feb. 
117.  Konstantinopoulos, P.A., Spentzos, D., Fountzilas, E., Francoeut, N., 
Sanisetty, S., Grammatikos, A.P., Hecht, J.L. and Cannistra, S.A.  2011. Keap1 
Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer, Cancer Res., 
OnlineFirst:1-9, Jun. 
118.  DeBin, J. A., and Strichartz, G. R.  1991. Chloride Channel Inhibition by the 
Venom of the Scorpion Leiurus quinqeustriatus, Toxicon, 29:1403–1408. 
119.  Lippens, G., Najib, J., Wodsk, S.J. and Tartar, A.  1995. NMR Sequential 
Assignments and Solution Structure of Chlorotoxin, a Small Scorpion Toxin That 
Blocks Chloride Channels, Biochemistry, 34:13-21, Sept. 
120.  Landon, C., Cornet, B., Bonmatin, J.M., Kopeyan, C., Rochat, H., Vovelle, F. 
and Ptak, M.  1996. 
1
H-NMR-derived Secondary Structure and the Overall Fold of 
the Potent Anti-mammal Anti-insect toxin III from the Scorpion Leiurus 
quinqeustriatus quinquestriatus, Eur. J. Biochem., 236:395-404, Sept. 
121.  Tamaoki, H., Miura, R., Kusunoki, M., Kyogoku, Y., Kobayashi, Y. and 
Moroder, L.  1998. Folding Motifs Induced and Stabilized by Distinct Cysteine 
Frameworks, Protein Engineering, 11(8):649-659. 
122.  Deshane, J., Garner, C.C. and Sontheimer, H.  2002. Chlorotoxin Inhibits 
Glioma Cell Invasion via Matrix Metalloproteinase-2, Journal of Biological 
Chemistry, 278:4136-4144, Feb. 
123.  Sontheimer, H.  2008. An Unexpected Role for Ion Channels in Brain Tumor 
Metastasis, Exp. Biol. Med., 233:779-791. 
124.  Wiranowska, M., Colina, L.O.and Johnson, J.O.  2011. Clathrin-mediated 
Entry and Cellular Localization of Chlorotoxin in Human Glioma, Cancer Cell 
International, 11:27-40. 
125.  Akcan, M., Stroud, M.R., Hansen, S.J., Clark, R.J., Daly, N.L., Craik, D.J. and 
Olson, J.M.  2010. Chemical Re-engineering of Chlorotoxin Improves 
Bioconjugation Properties for Tumor Imaging and Targeted Therapy, J. Med. 
Chem., 54:782-787, Aug. 
 
 
 
 
230 
 
 
126.  Yu, X.F., Sun, Z., Li, M., Xiang, Y., Wang, Q.Q., Tang, F., Wu, Y., Cao, Z. 
and Li, W.  2010. Neurotoxin-conjugated Upconversion Nanoprobes for Direct 
Visualization of Tumors Under Near-infrared Irradiation, Biomaterials, 31:8724-
8731, Aug. 
127.  Veiseh, O., Kievit, F.M., Gunn, J.W., Ratner, B.D. and Zhang, M.  2009. A 
Ligand-mediated Nanovector for Targeted Gene Delivery and Transfection in 
Cancer Cells, Biomaterials, 30:649-667, Nov. 
128.  Veiseh, M., Gabikian, P., Bahrami, S.B., Veiseh, O., Zhang, M., Hackman, 
R.C., Ravanpay, A.C., Stroud, M.R., Kusuma, Y., Hansen, S.J., Kwok, D., Munoz, 
N.M., Sze, R.W., Grady, W.M., Greenberg, N.M., Ellenbogen, R.G. and Olson, J.  
2007. Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative 
Visualization of Cancer Foci, Cancer Res., 67(14):6882-6888, Jul. 
129.  Mamelak A.N., Rosenfeld S., Bucholz R., Raubitschek A., Nabors L.B., 
Fiveash J.B., Shen S., Khazaeli M.B., Colcher D., Liu A., Osman M., Guthrie B., 
Schade-Bijur S., Hablitz D.M., Alvarez V.L. and Gonda M.A. 2006. Phase I Single-
Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults with 
Recurrent High-Grade Glioma, J. Clin. Oncol., 24(22):3644–50. 
130.  Lyons, S.A., O'Neal, J. and Sontheimer, H.  2002. Chlorotoxin, A Scorpion 
Derived Peptide, Specifically Binds to Gliomas and Tumors of Neuroectodermal 
Origin, Glia, 39:162-173. 
131.  Jacoby, D.B., Dyskin, E., Yalcin, M., Kesavan, K., Dahlberg, W., Ratliff, J., 
Johnson, E.W. and Mousa, S.A.  2010. Potent Pleiotropic Anti-angiogenic Effects of 
TM601, a Synthetic Chlorotoxin Peptide, Anticancer Research, 30:39-46. 
132.  Kesavan , K., Ratliff, J., Johnson, E.W., Dahlberg, W., Asara, J.M., Misra. P., 
Frangioni, J.V. and Jacoby, D.B.  2010. Annexin A2 is a Molecular Target for 
TM601, a Peptide with Tumor-targeting and Anti-angiogenic Effects, The Journal of 
Biological Chemistry, 285(7):4366-4374, Jan. 
133.  Veiseh, O., Sun, C., Gunn, J., Kohler, N., Gabikian, P., Lee, D., Bhattarai, N., 
Ellenbogen, R., Sze, R., Hallahan, R., Olson, J. and Zhang, M.  2005. Optical and 
MRI Multifunctional Nanoprobe for Targeting Gliomas, Nano Lett., 5(6):1003-1008, 
Mar. 
 
 
 
 
231 
 
134.  Kievit, F.M., Veiseh, O., Fang, C., Bhattarai, N., Lee, D., Ellenbogen, R.G. 
and Zhang, M.  2010. Chlorotoxin Labeled Magnetic Nanovectors for Targeted 
Gene Delivery to Glioma, ACS Nano, 4(8):4587-4594, Aug. 
135.  Fu, Y., An, N., Li, K., Zheng, Y. and Liang, A.  2012. Chlorotoxin-conjugated 
nanoparticles as potential glioma-targeted drugs, J. Neurooncol., 107:457-462, Jan. 
136.  Veiseh, O., Kieivt, F.M., Ellenbogen, R.G. and Zhang, M.  2011. Cancer Cell 
Invasion: Treatment and Monitoring Opportunities in Nanomedicine, Advanced 
Drug Delivery Reviews, 63:582-596. 
137.  Lee, S., Xie, J. and Chen, X.  2010. Peptide-Based Probes for Targeted 
Molecular Imaging, Biochemistry, 49:1364-1376, Jan. 
138.  Chandrawati, R., Hosta-Rigau, L., Vanderstraaten, D., Lokuliyana, S.A., 
Stadler, B., Albericio, F. and Caruso, F.  2010. Engineering Advanced Capsosomes: 
Maximizing the Number of Subcompartments, Cargo Retention and Temperature-
Triggered Reaction, ACSNano, 4(3):1351-1361. 
139.  Rodriguez-Lorenzo, L., De la Rica, R., Alvarez-Puebla, R.A., Liz-Marzan, 
L.M. and Stevens, M.M.  2012. Plasmonic Nanosensors with Inverse Sensitivity by 
Means of Enzyme-Guided Crystal Growth, Nature Materials, 11:604-607. 
140.  Ghosh, S.K. and Pal, T.  2007. Interparticle Coupling Effect on the Surface 
Plasmon Resonance of Gold Nanoparticles: From Theory to Applications, Chem. 
Rev., 107:4797-4862, Jan. 
141.  Daniel, M.C. and Astruc, D.  2004. Gold Nanoparticles: Assembly, 
Supramolecular Chemistry, Quantum-Size-Related Properties, and Applications 
towards Biology, Catalysis and Nanotechnology, Chem. Rev., 104:293-346, Jan. 
142.  Cao. C. and Sim, S.J.  2006. Signal Enhancement of the Surface Plasmon 
Resonance Immunoassay using Enzyme Precipitation-Functionalized Gold 
Nanoparticles: A Femto-molar Level Measurement of Anti-glutamic acid 
Decarboxylase Antibody, Biosensors & Bioelectronics, 22:1874-1880, Aug. 
143.  Kneipp, J., Kenipp, H., McLaughlin, M., Brown, D. and Kneipp, K.  2006. In 
Vivo Molecular Probing of Cellular Compartments with Gold Nanoparticles and 
Nanoaggregates, Nano Lett., 6(10):2225-2231, Sept. 
144.  Xie, J., Zhang, Q., Lee, J.Y. and Wang, D.I.C.  2008. The Synthesis of SERS-
Active Gold Nanoflower Tags for In Vivo Applications, ACSNano, 2(12):2473-2480. 
 
 
 
 
232 
 
145.  Hainfeld, J.F., Slatkin, D.N., Focella, T.M. and Smilowitz, H.M.  2006. Gold 
Nanoparticles: A New X-Ray Contrast Agent, The British Journal of Radiology, 
79:248-253, Mar. 
146.  Prabaharan, M., Grailer, J.J., Pilla, S., Steeber, D.A. and Gong, S.  2009. Gold 
Nanoparticles with a Monolayer of Doxorubicin-conjugated Amphiphilic Block 
Copolymer for Tumor-targeted Drug Delivery, Biomaterials, 30:6065-6075, Aug. 
147.  Kumar, S.A., Peter, Y.A., Nadeau, J.L.  2008. Facile Biosynthesis, Separation 
and Conjugation of Gold Nanoparticles to Doxorubicin, Nanotechnology, 
19:495101, Nov. 
148.  Chanda, N., Kattumuri, V., Shukla, R., Zambra, A., Katti, K., Upendran, A., 
Kulkarni, R.R., Kan, P., Fent, G.M., Casteel, S.W., Smith, C.J., Boote, E., 
Robertson, J.D., Cutler, C., Lever, J.R., Katti, K.V. and Kannan, R.  2009. Bombesin 
Functionalized Gold Nanoparticles Show In vitro and In vivo Cancer Receptor 
Specificity, Proc. Natl. Acad. Sci., 1072(10):1-6, Nov. 
149.  Cheng, Y., Samia, A.C., Meyers, J.D., Panagopoulos, I., Fei, B. and Burda, C.  
2008. Highly Efficient Drug Delivery with Gold Nanoparticle Vectors for In Vivo 
Photodynamic Therapy of Cancer, J. Am. Chem. Soc., 130:10643-10647, Jul. 
150.  Agasti, S.S., Chompoosor, A., You, C.C., Ghosh, P., Kim, C.K. and Rotello, 
V.M.  2009. Photoregulated Release of Caged Anticancer Drugs from Gold 
Nanoparticles, J. Am. Chem. Soc., 131:5728-5729, Jan. 
151.  Gibson, J.D., Khanal, B.P.and Zubarev, E.R.  2007. Paclitaxel-Functionalized 
Gold Nanoparticles, J. Am. Chem., 129:11653-11661, Aug. 
152.  Lee. S., Cha, E.J., Park, K., Lee, S.Y., Hong, J.K., Sun, I.C., Kim, S.Y., Choi, 
K., Kwon, I.C., Kim, K. and Ahn, C.H.  2008. A Near-Infrared-Fluorescence-
Quenched Gold Nanoparticle Imaging Probe for In Vivo Drug Screening and 
Protease Activity Determination, Angew. Chem. Int. Ed., 47:2804-2807, May. 
153.  Craig, G.E., Brown, S.D., Lamprou, D.A., Graham, D. and Wheate, N.J.  
2012. Cisplatin-Tethered Gold Nanoparticles That Exhibit Enhanced 
Reproducibility, Drug Loading and Stability: A Step Closer to Pharmaceutical 
Approval?, J. Am. Chem. Soc., 51(6):3490-3497, Mar. 
154.  Brown, S.D., Nativo, P., Smith, J.A., Stirling, D., Edwards, P.R., Venugopal, 
B., Flint, D.J., Plumb, J.A., Graham, D. and Wheate, N.J.  2010. Gold Nanoparticles 
for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin, 
J. Am. Chem. Soc., 132:4678-4684, Mar. 
 
 
 
 
233 
 
155.  Weston, S.D., Daniel, W.L., Giljohann, D.A., Mirkin, C. A., Lippard, S.J.  
2009. Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery 
Vehicles for Platinum(IV) Warheads, J. Am. Chem. Soc., 131:14652-14653, Aug. 
156.  Shenoy, D., Fu, W., Li, J., Crasto, C., Jones, G., DiMarzio, C., Sridhar, S. and 
Amiji, M.  2006. Surface Functionalization of Gold Nanoparticles using Hetero-
bifunctional Polyethylene Glycol Spacer for Intracellular Tracking and Delivery, 
International Journal of Nanomedicine, 1(1):51-57. 
157.  Yigit, M.V. and Medarova.  2012. In Vivo and Ex Vivo Applications of Gold 
Nanoparticles for Biomedical SERS Imaging, Am. J. Nucl. Med. Mol. Imaging, 
2(2):232-241, Apr. 
158.  Kemp, M.M., Kumar, A., Mousa, S., Dyskin, E., Yalcin, M., Ajayan, P., 
Linhardt, R.J. and Mousa, S.A.  2009. Gold and Silver Nanoparticles Conjugated 
with Heparin Derivative Possess Anti-angiogenic Properties, Nanotechnology, 
20:455104. 
159.  Ghosh, P.S., Kim, C.K., Forbes, N.S. and Rotello, V.M.  2008. Efficient Gene 
Delivery Vectors by Tuning the Surface Charge Density of Amino Acid-
Functionalized Gold Nanoparticles, ACSNano, 2(11):2213-2218. 
160.  Han, G., Ghosh, P. and Rotello, V.M.  2007. Functionalized Gold 
Nanoparticles for Drug Delivery, Nanomedicine, 2(1):113-123. 
161.  Derfus, A.M., Chan, W.C.W. and Bhatia, S.N.  2004. Probing the Cytotoxicity 
of Semiconductor Quantum Dots, Nano Lett., 4(1):11-18, Feb. 
162.  Drobohlavova, J., Adam, V. Kizek, R. and Hubalek, J.  2009. Quantum Dots – 
Characterization, Preparation and Usage in Biological Systems, Int. J. Mol. Sci., 
10:656-673, Feb. 
163.  Hardman, R. 2006. A Toxicologic Review of Quantum Dots: Toxicity 
Depends on Physicochemical and Environmental Factors, Environmental Health 
Perspectives, 114(2):165-172, Sept. 
164.  Liu, H.Y. and Vu, T.Q.  2007. Identification of Quantum Dot Bioconjugates 
and Cellular Protein Co-localization by Hybrid Gel Blotting, Nano Lett., 7(4):1044-
1049, Mar. 
165.  Wu, X., Liu, H., Liu, J., Haley, K.N., Treadway, J.A., Larson, J.P., Ge, N., 
Peale, F. and Bruchez, M.P.  2002. Immunofluorescent Labeling of Cancer Marker 
Her2 and other Cellular Targets with Semiconductor Quantum Dots, Nature 
Biotech., 21:41-46, Jan. 
 
 
 
 
234 
 
166.  Chattopadhyay, P.K., Price, D.A., Harper, T.F., Betts, M.R., Yu, J., Gostick, 
E., Perfetto, S.P., Goepfert, P., Koup, R.A., De Rosa, S.C., Bruchez, M.P. and 
Roederer, M.  2005. Quantum Dots Semiconductor Nanocrystals for 
Immunophenotyping by Polychromatic Flow Cytometry, Nature Med., 12(8):972-
977, Aug. 
167.  Kaji, N., Tokeshi, M. and Baba, Y.  2007. Single-Molecule Measurements 
with a Single Quantum Dot, The Chemical Accord, 7:295-304, Aug. 
168.  Gao, X., Cui, Y., Levenson, R.M., Chung, L.W.K. and Nie, S.  2004. In Vivo 
Cancer Targeting and Imaging with Semiconductor Quantum Dots, Nature Biotech., 
22(8):969-976, Aug. 
169.  Weng, K.C., Noble, C.O., Paphadjopoulos-Sternberg, B., Chen, F.F., 
Drummond, D.C., Kirpotin, D.B., Wang, D., Hom, Y.K., Hann, B. and Park, J.W.  
2008. Targeted Tumor Cell Internalization and Imaging of Multifunctional Quantum 
Dots-Conjugated Immunoliposomes In Vitro and In Vivo, Nano Lett., 8(9):2851-
2857, Jul. 
170.  Walling, M.A., Novak, J.A. and Shepard, J.R.E.  2009. Quantum Dots for Live 
Cell and In Vivo Imaging, Int. J. Mol. Sci. 10:441-491, Feb. 
171.  Guzelian, A.A., Katari, J.E.B., Kadavanich, A.V., Banin, U., Hamad, K., 
Juban, E. and Alivisatos.  1996. Synthesis of Size-selected, Surface-Passivated InP 
Nanocrystals, J. Phys. Chem., 100:7212-7219, Feb. 
172.  Ryu, E., Kim, S., Jang, E., Jun, S., Jang, H., Kim, B. and Kim, S.W.  2009. 
Step-wise Synthesis of InP/ZnS Core-Shell Quantum Dots and the Role of Zinc 
Acetate, Chem. Mater., 21(4):573-575, Feb. 
173.  Gao, X., Yang, L., Petros, J.A., Marshall, F.F., Simons, J.W. and Nie, S.  
2005. In Vivo Molecular and Cellular Imaging with Quantum Dots, Anal. Biochem., 
16:63-72. 
174.  http://www.cytimmune.com/go.cfm?do=Page.View&pid=26 (Accessed: 12-
06-2012) 
175.  http://www.nanospectra.com/clinicians/aurolasetherapy.html (Accessed: 12-
06-2012) 
176.  Etheridge, M.L., Campbell, S.A., Erdman, A.G., Haynes, C.L., Wolf, S.M., 
McCullough, J.  2012. The Big Picture on Nanomedicine: The State of 
Investigational and Approved Nanomedicine Products, Nanomedicine, 9(1):1-14, 
Jun. 
 
 
 
 
235 
 
177.  Ahn, C.H., Chae, S.Y., Bae, Y.H. and Kim, S.W.  2002. Biodegradable 
Poly(ethylenemine) for Plasmid DNA Delivery, Journal of Controlled Release, 
80:273-282, Nov. 
178.  Gao, J. and Xu, B.  2009. Applications of Nanomaterials inside Cells, Nano 
Today, 4:37-51, Oct. 
179.  Mohan, P. and Rapoport, N.  2010. Doxorubicin as a Molecular 
Nanotheranostic Agent: Effect of Doxorubicin Encapsulation in Micelles or 
Nanoemulsions on the Ultrasound-mediated Intracellular Delivery and Nuclear 
Trafficking, Molecular Pharmaceutics, 7(6):1959-1973, Oct. 
180.  Kim, G.B. and Kim, Y.P.  2012. Analysis of Protease Activity Using Quantum 
Dots and Resonance Energy Transfer, Theranostics, 2(2):127-138, Feb. 
181.  Veiseh, O., Kievit, F.M., Ellenbogen, R.G. and Zhang, M.  2011. Cancer Cell 
Invasion: Treatment and Monitoring Opportunities in Nanomedicine, Advanced 
Drug Delivery Reviews, 63:582-596, Feb. 
182.  Nystrom, A.M. and Wooley, K.L.  2011. The Importance of Chemistry in 
Creating Well-Defined Nanoscopic Embedded Therapeutics: Devices Capable of the 
Dual Functions of Imaging and Therapy, Accounts of Chemical Research, 
44(10):969-978, Mar. 
183.  Lovestam, G., Rauscher, H., Roebben, G., Kluttgen, B.S., Gibson, N., Putaud, 
J.P. and Stamm, H.  2010. Considerations on a Definition of Nanomaterial for 
Regulatory Purposes, EU JRC Reference Reports. 
184.  Shenhar, R. and Rotello, V.M.  2003. Nanoparticles: Scaffolds and Building 
Blocks, Acc. Chem. Res., 36:549-561, Jan. 
185.  Thakor, A.S., Jokerst, J., Zavaleta, C., Massoud, T.F. and Gambhir, S.S.  
2011. Gold Nanoparticles: A Revival in Precious Metal Administration to Patients, 
Nano Lett., 11:4029-4036, Aug. 
186.  McNeil, S.  2005. Nanotechnology for the Biologist, Journal of Leukocyte 
Biology, 78:585-594, Sept. 
187.  Eustis, S. and El-Sayed, M.A.  2005. Why Gold Nanoparticles are more 
Precious than Pretty Gold: Noble Metal Surface Plasmon Resonance and its 
Enhancement of the Radiative and Non-radiative Properties of Nanocrystals of 
Different Shapes, Chem.Soc. Rev., 35:209-217, Nov. 
 
 
 
 
236 
 
188.  Bunz, U.H.F. and Rotello, V.M.  2010. Gold Nanoparticle-Fluophore 
Complexes: Sensitive and Discerning “Noses” for Biosystems Sensing, Angew. 
Chem. Int. Ed., 49:3268-3279, Jun. 
189.  Tiwari, P.M., Vig, K., Dennis, V.A. and Singh, S.R.  2011. Functionalized 
Gold Nanoparticles and Their Biomedical Applications, Nanomaterials, 1:31-63, 
Jun. 
190.  Jain, P.K., Lee, K.S., El-Sayed, I.H. and El-Sayed, M.A.  2006. Calculated 
Absorption and Scattering Properties of Gold Nanoparticles of Different Size, Shape 
and Composition: Applications in Biological Imaging and Biomedicine, J. Phys. 
Chem., 110:7328-7248, Feb. 
191.  Xu, C., Xu, K., Gu, H., Zhong, X., Guo, Z., Zheng, R., Zhang, X. and Xu, B.  
2003. Nitrilotriacetic Acid-Modified Magnetic Nanoparticles as a General Agent to 
Bind Histadine Tagged Proteins, J. Am. Chem. Soc., 126:3392-3393, Dec. 
192.  Singh, N., Manshian, B., Jenkins, G.J.S., Griffiths, S.M., Williams, P.M., 
Maffeis, T.G.G., Wright, C.J. and Doak, S.H.  2009. Nanogenotoxicology: The 
DNA Damaging Potential of Engineered Nanomaterials, Biomaterials, 30(23):3891-
3914, Apr. 
193.  Xia, T., Li, N. and Nel, A.E.  2009. Potential Health Impact of Nanoparticles, 
Annu. Rev. Public Health, 30:137-150, Jan. 
194.  Pathak, Y. and Thassu, D.  2009. Drug Delivery Nanoparticle Formulation and 
Characterization, Vol 191, Informa Healthcare, New York. 
195.  Skirtach, A.G., Karageorgiev, P., Bedard, M.F., Sukhorukov, G.B. and 
Mohwald, H.  2008. Reversible Permeable Nanomembranes of Polymeric 
Microcapsules, J. Am. Chem. Soc., 130:11572-11573, Apr. 
196.  Morawska, L., Ristovski, Z., Jayaratne, E.R., Keogh, D.U. and Ling, X.  2008. 
Ambient Nano and Ultrafine Particles from Motor Vehicle Emissions: 
Characteristics, Ambient Processing and Implications on Human Exposure, 
Atmospheric Environment, 42:8113-8138, Jul. 
197.  Kulmala, M., Vehkamaki, H., Petaja, T., Del Maso, M., Lauri, A., Kerminen, 
V.M., Birmili, W. and McMurry, P.H.  2004. Formation and Growth Rates of 
Ultrafine Atmospheric Particles: A Review of Observations, Aerosol Science: 
35:143-176. 
198.  Stern, S. and McNeil, S.E.  2007. Nanotechnology Safety Concerns Revisited, 
Tox. Sci. Advance, 1-59, Jun. 
 
 
 
 
237 
 
199.  Turkevich, J.  1985. Colloidal Gold Part I: Historical and Preparative Aspects, 
Morphology and Structure, Gold Bull., 18(3):86-91. 
200.  Kimling, J., Maier, M., Okenve, B., Kotaidis, V., Ballot, H. and Plech, A.  
2006. Turkevich Method for Gold Nanoparticle Synthesis Revisited, J. Phys. Chem. 
B., 110:15700-15707, May. 
201.  Polte, J., Ahner, T.T., Delissen, F., Sokolov, S., Emmerling, F., Thunermann, 
A.F. and Kraehnert, R.  2010. Mechanism of Gold Nanoparticles Formation in the 
Classical Citrate Synthesis Method Derived from Coupled In Situ XANES and 
SAXS Evaluation, J. An. Chem. Soc., 132:1296-1301, Aug. 
202.  Ji, X., Song, X., Li, S., Bai, Y., Yang, W. and Peng, X.  2007. Size Control of 
Gold Nanocrystals in Citrate Reduction: The Third Role of Citrate, J. Am. Chem. 
Soc., 129:13939-13948, Jun. 
203.  Jana, N.R., Gearheart, L. and Murphy, C.J.  2001. Evidence for Seed-
Mediated Nucleation in the Chemical Reduction of Gold Salts to Gold 
Nanoparticles, Chem. Mater., 13:2313-2322, May. 
204.  Frens, G.  1973. Controlled Nucleation for the Regulation of the Particle Size 
in Monodisperse Gold Suspensions, Nat. Phys. Sci., 241:20–22. 
205.  Jana, N.R.J., Gearheart, L. and Murphy, C.J.  2001. Seeding Growth for Size 
Control of 5-40nm Diameter Gold Nanoparticles, Langmuir, 17:6782-6787, Aug. 
206.  Jana, N.R.  2005. Gram-Scale Synthesis of Soluble, Near-Monodisperse Gold 
Nanorods and Other Anisotropic Nanoparticles, Small, 1(89):875-882. 
207.  Narayanan, R. and El-Sayed, M.A.  2005. Catalysis with Transition Metal 
Nanoparticles in Colloidal Solution: Nanoparticle Shape Dependence and Stability,  
J. Phys. Chem., 109:12663-12676, Apr. 
208.  Brown. L.O. and Hutchinson, J.E.  1999. Controlled Growth of Gold 
Nanoparticles During Ligand Exchange, J. Am. Chem. Soc., 121:882-883, Oct. 
209.  Basiruddin, S.K., Saha, A., Pradhan, N. and Jana, N.R.  2010. Advances in 
Coating Chemistry in Deriving Soluble Functional Nanoparticles, J. Phys. Chem., 
114:11009-11017, Apr. 
210.  Sperling, R.A. and Parak, W.J.  2010. Surface Modification, Functionalization 
and Bioconjugation of Colloidal Inorganic Nanoparticles, Phil. Trans. R. Soc., 
268:1333-1383, Feb. 
 
 
 
 
238 
 
211.  Lee, O.S., Prytkova, T.R. and Schatz, G.C.  2010. Using DNA to Link Gold 
Nanoparticles, Polymers and Molecules: A Theoretical Perspective, J. Phys. Chem. 
Lett., 1:1781-1788, May. 
212.  Brust, M., Walker, M., Bethell, D., Schiffrin, D.J. and Whyman, R.  1994. 
Synthesis of Thiol-derivatised Gold Nanoparticles in a Two-phase Liquid-Liquid 
System, Chem. Soc., Chem. Commun., 801-802, Dec. 
213.  Brinas, R.P., Hu, M., Qian, L., Lymar, E.S. and Hainfeld, J.F.  2007. Gold 
Nanoparticle Size Controlled by Polymeric Au(I) Thiolate Precursor Size, J. Am. 
Chem. Soc., 130:975-982, Aug. 
214.  Maye, M.M., Zheng, W., Leibowitz, F.L., Ly, N.K. and Zhong, C.J.  2000. 
Heating Induced Evolution of Thiolate-Encapsulated Gold Nanoparticles: A Strategy 
for Size and Shape Manipulations, Langmuir, 16:490-497, Sept. 
215.  Chen, Y., Preece, J.A. and Palmer, R.E.  2008. Processing and 
Characterization of Gold Nanoparticles for Use in Plasmon Probe Spectroscopy and 
Microscopy of Biosystems, Ann. N. Y. Acad. Sci., 1130:201-206. 
216.  Link, S. and El-Sayed, M.A.  1999. Spectral Properties and Relaxation 
Dynamics of Surface Plasmon Electronic Oscillations in Gold and Silver Nanodots 
and Nanorods, J. Phys. Chem. B., 103:8410-8426, Aug. 
217.  He, Y.Q., Liu, S.P., Kong, L. and Liu, Z.F.  2005. A Study on the Sizes and 
Concentrations of Gold Nanoparticles by Spectra of Absorption, Resonance 
Rayleigh Scattering and Resonance Non-Linear Scattering, Spectrochimica Acta 
Part A, 61:2861-2866, Oct. 
218.  Haiss, W., Thanh, N.T.K., Aveyard, J. and Fernig, D.G.  2007. Determination 
of Size and Concentration of Gold Nanoparticles from UV-Vis Spectra, Anal. 
Chem., 79:4215-4221, Jun. 
219.  Link, S. and El-Sayed, M.A.  1999. Size and Temperature Dependence of the 
Plasmon Absorption of Colloidal Gold Nanoparticles, J. Phys. Chem. B., 103:4212-
4217, Apr. 
220.  Chang, E., Miller, J.S., Sun, J., Yu, W.W., Colvin, V.L., Drezek, R. and West, 
J.L.  2005. Protease-activated Quantum Dot Probes, Biochemical and Biophysical 
Research Communications, 334:1317-1321, Jul. 
221.  Medintz, I.L. and Mattousi, H.  2008. Qunatum Dot-Based Resonance Energy 
Transfer and its Growing Application in Biology, Phys. Chem. Chem. Phys., 11:17-
45, Nov. 
 
 
 
 
239 
 
222.  Riegler, J., Ditengou, F., Palme, K. and Nann, T.  2008. Blue Shift of 
CdSe/ZnS Nanocrystal-Labels Upon DNA-Hybridization, Journal of 
Nanobiotechnology, 6(7). 
223.  Hezinger, A.F.E., Teβmar, J. and Gopferich, A.  2007. Polymer Coating of 
Qunatum Dots – A Powerful Tool Toward Diagnostics and Sensorics, European 
Journal of Pharmaceutics and Biopharmaceutics, 68:138-152, Jun. 
224.  Michalet, X., Pinaud, F.F., Bentolila, L.A., Tsay, J.M., Doose, S., Li, J.J., 
Sundaresan, G., Wu, A.M., Gambhir, S.S. and Weiss, S.  2005. Quantum Dots for 
Live Cells, In Vivo Imaging and Diagnostics, Science, 307(5709):538-544, Jan. 
225.  Li, L., Daou, J., Texier, I., Chi, T.T.K., Liem, N.Q. and Reiss, P.  2009. 
Highly Luminescent CuInS2/ZnS Core/Shell Nanocrystals: Cadmium-Free Quantum 
Dots for In Vivo Imaging, Chem. Mater., 21:2422-2429, Apr. 
226.  Smith, A.M., Duan, H., Mohs, A.M. and Nie, S.  2008. Bioconjugated 
Quantum Dots for In Vivo Molecular and Cellular Imaging, Advanced Drug Delivery 
Reviews, 60:1226-1240, Apr. 
227.  Reiss, P., Bleuse., J. and Pron, A.  2002. Highly Luminescent CdSe/ZnSe 
Core/Shell Nanocrystals of Low Size Dispersion, Nano Lett., 2(7):781-784, May. 
228.  Guyot-Sionnest, P. and Hines, M.A.  1996. Synthesis and Characterization of 
Strongly Luminescing ZnS-Capped CdSe Nanocrystals, J. Phys. Chem., 100:468-
471, Jan. 
229.  Wang, T., Chen, J.Y., Zhen, S., Wang, P.N., Wang, C.C., Yang, W.L. and 
Peng, Q.  2009. Thiol-Capped CdTe Quantum Dots with Two-Photon Excitation for 
Imaging High Autofluorescence Background Living Cells, J. Fluoresc., 19:615-621, 
Dec. 
230.  Zheng, J., Zhang, C. and Dickson, R.M.  2004. Highly Fluorescent, Water-
Soluble, Size-Tunable Gold Quantum Dots, Physical Review Letters, 93(7):077402. 
231.  Volpe, M.V., Longo, A., Pasquini, L., Casuscelli, V. and Carotenuto, G.  
2003. Synthesis and Characterization of Gold-based Quantum Dots, Journal of 
Materials Science Letters, 22:1679-1699. 
232.  Zheng, J., Nicovich, P.R. and Dickson, R.M.  2007. Highly Fluorescent 
Noble-Metal Quantum Dots, Annu. Rev. Phys. Chem., 58:409-431, Nov. 
233.  Dubois, F., Mahler, B., Dubertret, B., Doris, E. and Mioskowski, C.  2006. A 
Versatile Strategy for Quantum Dot Ligand Exchange, J. Am. Chem. Soc., 129:482-
483, Oct. 
 
 
 
 
240 
 
234.  Alivisatos, A.P.  1996. Semiconductor Clusters, Nanocrystals, and Quantum 
Dots, Science, 271:933-937. 
235.  Nirmal, M. and Brus, L.E.  1999. Luminescence Photophysics in 
Semiconductor Nanocrystals, Acc. Chem. Res., 32:407-414. 
236.  Chan, W.C.W., Maxwell, D.J., Gao, X., Bailey, R.E., Han, M. and Nie, S.  
2002. Luminescent Quantum Dots for Multiplexed Biological Detection and 
Imaging, Anal. Biotech., 13:40-46, Feb. 
237.  Resch-Genger, U., Grabolle, M., Cavaliere-Jaricot, S., Nitschke, R. and Nann, 
T.  2008. Quantum Dots Versus Organic Dyes as Fluorescent Labels, Nature Meth., 
5(9):763-775, Sept. 
238.  Adiseshaiah, P.P., Hall, J.B. and McNeil, S.E.  2009. Nanomaterial Standards 
for Efficacy and Toxicity Assessment, WIREs Nanome. Nanibiotech., 2:99-112. 
239.  Malik, M.Y., Hashim, M.A., Nabi, F. and Malik, M.A.  2011. Nanotoxicity: 
Dimensional and Morphological Concerns, Advances in Phys. Chem., 2011:450912, 
Jan. 
240.  Dixit, V., Van den Bossche, J., Sherman, D.M., Thompson, D.H. and Andres, 
R.P.  2006. Synthesis and Grafting of Thiocotic Acid-PEG-Folate Conjugates onto 
Au Nanoparticles for Selective Targeting of Folate Receptor-Positive Tumour Cells, 
Bioconjugate Chem., 17:603-609, Feb. 
241.  Byrne, J.D., Betancourt, T. and Brannon-Peppas, L.  2008. Active Targeting 
Schemes for Nanoparticle Systems in Cancer Therapeutics, Advanced Drug Delivery 
Reviews, 60:1615-1625, Sept. 
242.  Zitsmann, S., Kramer, S., Mier, W., Hebling, U., Altmann, A., Rother, A., 
Berndorff, D., Eisenhut, M. and Haberkom, U.  2007. Identification and Evaluation 
of a New Tumor Cell-Binding Peptide, FROP-1, J. Nucl. Med., 48(6):965-972. 
243.  Shadidi, M. and Sioud, M.  2003. Selective Targeting of Cancer Cells Using 
Synthetic Peptides, Drug Resistance Updates, 6:363-371, Nov. 
244.  Aina. O.H., Liu, R., Sutcliffe, J.L., Marik, J., Pan, C.X. and Lam, K.S.  2007. 
From Combinatorial Chemistry to Cancer-Targeting Peptides, Molecular 
Pharmaceutics, 4(5):631-651, Jul. 
245.  Levy, R., Thanh, N.T.K., Doty, R.C., Hussain, I., Nichols, R.J., Schiffrin, D.J., 
Brust, M. and Fernig, D.G.  2004. Rational and Combinatorial Design of Peptide 
Capping Ligands for Gold Nanoparticles, J. Am. Chem. Soc., 126:10076-10054, 
Mar. 
 
 
 
 
241 
 
246.  Wang, Z., Levy, R., Fernig, D.G. and Brust, M.  2005. The Peptide Route to 
Multifunctional Gold Nanoparticles, Bioconjugate Chem., 16:497-500, Apr. 
247.  Krpetic, Z., Nativo, P., Porta, F. and Brust, M.  2009. A Multidentate Peptide 
for Stabilization and Facile Bioconjugation of Gold Nanoparticles, Bioconjugate 
Chem., 20:619-624, Jan. 
248.  Zitsman, S., Ehemann, V. and Schwab, M.  2002. Arginine-Glycine-Aspartic 
Acid (RGD)-Peptide Binds to Both Tumor and Tumor-endothelial Cells In Vivo, 
Cancer Res., 62:5139-5143, Sept. 
249.  Stern, M. and Herrmann, R.  2005. Overview of Monoclonal Antibodies in 
Cancer Therapy: Present and Promise, Critical Reviews in Oncology/Hematology, 
54:11-29, Oct. 
250.  Gulloti, E. and Yeo, Y.  2009. Extracellularly Activated Nanocarriers: A New 
Paradigm of Tumor Targeted Drug Delivery, Molecular Pharmaceutics, 6(4):1041-
1051, Apr.  
251.  Weiner, L.M.  2006. Fully Human Therapeutic Monoclonal Antibodies, 
Journal of Immunotherapy, 29(1):1-9, Feb. 
252.  Fitzpatrick, D.P.G., You, J.S., Bemis, K.G., Wery, J.P., Ludwig, J.R. and 
Wang, M.  2007. Searching for Potential Biomarkers of Cisplatin Resistance in 
Human Ovarian Cancer using label-free LC/MS-based Protein Quantification 
Method, Proteomics Clin. Appl., 1:246-263, Nov. 
253.  Solar, P. and Sytkowski, A.J.  2011. Differentially Expressed Genes 
Associated with Cisplatin Resistance in Human Ovarian Adenocarcinoma Cell Line 
A2780, Cancer Letters, 309:11-18, May. 
254.  You, C.C., Verma, A. and Rotello, V.M.  2006. Engineering the Nanoparticle-
Biomacromolecule Interface, Soft Matter, 2:190-204, Jan. 
255.  Yezhelyev, M.V., Qi, L., O’Regan, R.M., Nie, S. and Gao, X.  2008, Proton-
Sponge Coated Quantum Dots for siRNA Delivery and Intracellular Imaging, J. Am. 
Chem. Soc., 130:9006-9012, Jan. 
256.  Wurle-Knirch, J.M, Pulskamp, K. and Krug, H.F.  2006. Oops they did it 
Again! Carbon Nanotubes Hoax Scientists in Viability Assays, Nano Lett., 
6(6):1261-1268, Mar. 
257.  El-Ansary, E. and Al-Daihan, S.  2009. On the Toxicity of Therapeutically 
used Nanoparticles: An Overview, Journal of Toxicology, 2009:754810. 
 
 
 
 
242 
 
258.  Liu, Z., Chen, K., Davis, C., Sherlock, S., Cao, Q.Z., Chen, X.Y., Dai, H.J.  
2008. Drug Delivery with Carbon Nanotubes for In Vivo Cancer Treatment, Cancer 
Res., 68:6652–6660. 
259.  Pisanic, T.R., Blackwell, J.D., Shubayev, V.I., Finones, R.R. and Jin, S.  2007. 
Nanotoxicity of Iron Oxide Nanoparticle Internalization in Growing Neurons, 
Biomaterials, 28(16):2572–2581. 
260.  De Paoll Lacerda, S.H., Park, J.J., Meuse, C., Pristinki, D., Becker, M.L., 
Karim, A. and Douglas, J.F.  2010. Interaction of Gold Nanoparticles with Common 
Human Blood Proteins, ACSNano, 4(1):365-379, Dec. 
261.  Li, J.J., Zou, L., Hartono, D., Ong, C.N., Bay, B.H., Lanry-Yung, L.Y.  2008. 
Gold Nanoparticles Induce Oxidative Damage in Lung Fibroblasts In Vitro, Adv. 
Mater., 20:138–42. 
262.  Sudeep, P.K., Joseph, S.T.S, and Thomas, K.G.  2005. Selective Detection of 
Cysteine and Glutathione Using Gold Nanorods, J. Am. Chem. Soc., 127:6516-6517, 
Feb. 
263.  Gao, W., Xu, K., Ji, L. and Tang, B.  2011. Effect of Gold Nanoparticles on 
Glutathione Depletion-Induced Hydrogen Peroxide Generation and Apoptosis in 
HL7702 Cells, Toxicology Letters, 205:86-95, May. 
264.  Kong, B., Seog, J.H., Graham, L.M. and Lee, S.B.  2011. Experimental 
Considerations on the Cytotoxicity of Nanoparticles, Nanomedicine, 6(5):929-941. 
265.  Love, S.A., Maurer-Jones, M.A., Thompson, J.W., Lin, Y.S. and Haynes, C.L.  
2012. Assessing Nanoparticle Toxicity, Annu. Rev. Anal. Chem., 5:181-205, Apr.  
266.  Kandasamy, K., Choi, C.S. and Kim, S.  2010. An Efficient Analysis of 
Nanomaterial Cytotoxicity Based on Bioimpedance, Nanotechnology, 21:375501. 
267.  Chithrani, B.D and Chan, W.C.W.  2007. Elucidating the Mechanism of 
Cellular Uptake and Removal of Protein Coated Gold Nanoparticles of Different 
Sizes and Shapes, Nano Lett., 7(6):1542-1550, Mar. 
268.  Huang, K., Ma, H., Liu, J., Huo, S., Kumar, A., Wei, T., Zhang, X., Jin, S., 
Gan, Y., Wang, P.C., He, S., Zhang, X. and Liang, X.J.  2012. Size-Dependent 
Localization and Penetration of Ultrasmall Gold Nanoparticles in Cancer Cells, 
Multicellular Spheroids and Tumors In Vivo, 6(5):4483-4493, Apr. 
269.  Aillon, K.L., Xie, Y., El-Gendy, N., Berkland, C.J. and Forrest, M.L.  2009. 
Effects of Nanomaterial Physicochemical Properties on In Vivo Toxicity, Advanced 
Drug Delivery Reviews, 61:457-466, Apr. 
 
 
 
 
243 
 
270.  Patra, H.K., Banerjee, S., Chaudhuri, U., Lahiri, P. and Dasgupta, A.K.  2007. 
Cell Selective Response to Gold Nanoparticles, Nanomedicine: Nanotechnology, 
Biology and Medicine 3, 3:111-119, Mar. 
271.  Soenen, S.J., Manshian, B., Montenegro, J.M., Amin, F., Meermann, B., 
Thiron, T., Cornelissen, M., Vanhaecke, F., Doak, S., Parak, W.J., De Smedt, S. and 
Braeckmans, K.  2011. Cytotoxic Effects of Gold Nanoparticles: A Multiparametric 
Study, ACSNano, 6(7):5767-5783, Dec. 
272.  Arvizo, R.R., Miranda, O.R., Thompson, M.A., Pabelick, C.M., Bhattacharya, 
R., Robertson, J.D., Rotello, V.M., Prakash, Y.S. and Mukherjee, P.  2010. Effect of 
Nanoparticle Surface Charge at the Plasma Membrane and Beyond, Nano Lett., 
10:2543-2548, Jun. 
273.  Goodman, C.M., McCusker, C.D., Yilmaz, T. and Rotello, V.M.  2004. 
Toxicity of Gold Nanoparticles Functionalized with Cationic and Anionic Side 
Chains, Bioconjugate Chem., 15:897-900, Mar. 
274.  Murphy, C.J., Gole, A.M., Stone, J.W., Sisco, P.N., Alkilany, A.M., 
Goldsmith, E.C. and Baxter, S.C.  2008, Gold Nanoparticles in Biology: Beyond 
Toxicity to Cellular Imaging, Account of Chemical Research, 41(12):1721-1730, 
Feb. 
275.  Albanese, A., Tang, P.S. and Chan, W.C.W.  2012. The Effect of Nanoparticle 
Size, Shape, and Surface Chemistry on Biological Systems, Annu. Rev. Biomed. 
Eng., 14:1-16, Apr. 
276.  Rzigalinkski, B.A. and Strobl, J.S.  2009. Cadmium-containing Nanoparticles: 
Perspectives on Pharmacology and Toxicology of Quantum Dots, Toxicology and 
Applied Pharmacology, 238:280-288, Apr. 
277.  Ballou, B., Ernst, L.A., Andrenko, S., Harper, T., Fitzpatrick, J.A.J., 
Waggoner, A.S. and Bruchez, M.P.  2007. Sentinel Lymph Node Imaging Using 
Quantum Dots in Mouse Tumor Models, Bioconjugate Chem., 18:389-396, Nov. 
278.  Yu, W.W., Chang, E., Drezek, R. and Colvin, V.L.  2006. Water-soluble 
Quantum Dots for Biomedical Applications, Biochemical and Biophysical Research 
Communications, 348:781-786, Aug. 
279.  Duan, H. and Nie, S.  2006. Cell-Penetrating Quantum Dots Based on 
Multivalent and Endosome-Disrupting Surface Coatings, J. Am. Chem. Soc., 
129:3333-3338, Nov. 
 
 
 
 
244 
 
280.  Xia, T., Kovochich, M., Liong, M., Meng, H., Kabehle, S., George, S., Zink, 
J.I. and Nel, A.E.  2009. Polyethyleneimine Coating Enhances the Cellular Uptake 
of Mesoporous Silica Nanoparticles and Allows for Safe Delivery of siRNA and 
DNA Constructs, ACSNano, 3(10):3273-3286, Aug. 
281.  Yue, Y., Jin, F., Chen, Y., Kung, H.F., Lin, M.C.M. and Wu, C.  2009. Revisit 
the Complexation of PEI and DNA – How to Make Low Cytotoxic and Highly 
Efficient PEI Gene Transfection Non-viral Vectors with a Controllable Chain 
Length and Structure?, Journal of Controlled Release, 140:40-46, Jul. 
282.  Tian, H.Y., Deng, C., Lin, H., Sun, J., Deng, M., Chen, X. and Jing, X.  2005. 
Biodegradable Cationic PEG-PEI-PBLG Hyperbranched Block Copolymer: 
Synthesis and Micelle Characterization, Biomaterials, 26:4209-4217, Dec. 
283.  Liang, B., He, M.L., Xiao, Z.P., Li, Y., Chan, C.Y., Kung, H.F., Shuai, X.T. 
and Peng, Y.  2008. Synthesis and Characterization of Folate-PEG-Grafted-
Hyperbranched-PEI for Tumor-targeted Gene Delivery, Biochemical and 
Biophysical Research Communications, 367:874-880, Jan. 
284.  Riddles, P.W., Blakeley, R.L. and Zerner, B.  1979. Ellman’s Reagent:5,5’-
Dithiobis(2-nitrobenzoic acid) – A re-examination, Anal. Biochem., 94:75-81, Jul. 
285.  Eyer, P., Worek, F., Kiderlen, D., Sinko, G., Stuglin, A., Simeon-Rudolf, V. 
and Reiner, E.  2003. Molar Absorption Coefficients for the Reduced Ellman 
Reagent: Reassessment, Anal. Biochem., 312:224-227, Aug. 
286.  Xu, C., Xu, K., Gu, H., Zhong, X., Guo, Z., Zheng, R., Zhang, X. and Xu, B.  
2004. Nitrilotriacetic Acid-Modified Magnetic Nanoparticles as a General Agent to 
Bind Histidine-Tagged Proteins, J. Am. Chem. Soc., 126:3392-3393, Feb. 
287.  Zheng, M., Li, Z. and Huang, X.  2004. Ethylene Glycol Monolayer Protected 
Nanoparticles: Synthesis, Characterization, and Interactions with Biological 
Molecules, Langmuir, 20:4226-4235, Feb. 
288.  Pierce Biotechnology.  2006. Crosslinking Reagents Technical Handbook. 
289.  Leo, E., Vandelli, M.A., Cameroni, R. and Forni, F.  1997. Doxorubicin-
loaded Gelatin Nanoparticles Stabilized by Glutaraldehyde: Involvement of the Drug 
in the Cross-linking Process, International Journal of Pharmaceutics, 155:75-82, 
May. 
290.  Migneault, I., Dartinguenave, C., Bertrand, M.J. and Waldron, K.C.  2004. 
Glutaraldehyde: Behavior in Aqueous Solution Reaction with Proteins, and 
Application to Enzyme Crosslinking, BioTechniques, 37:790-802, Nov. 
 
 
 
 
245 
 
291.  Etrych, T., Chytil, P., Mrkvan, T., Sirova, M., Rihova, B. and Ulbrich, K.  
2008. Conjugates of Doxorubicin with Graft HPMA Copolymers for Passive Tumor 
Targeting, Journal of Controlled Release, 132:184-192, Apr. 
292.  Pong, B.K., Trout, B.L. and Lee, J.Y.  2008. Modified Ligand-Exchange for 
Efficient Solubilisation of CdSe/ZnS Quantum Dots in Water: A Procedure Guided 
by Computational Studies, Langmuir, 24:5270-5276, Feb. 
293.  Dubois, F., Mahler, B., Dubertret, B., Doris, E. and Mioskowski.  2006. A 
Versatile Strategy for Quantum Dot Ligand Exchange, J. Am. Chem. Soc., 129:482-
483, Oct. 
294.  Susumu, K., Uyeda, H.T., Medintz, I.L., Pons, T., Delehanty, J.B. and 
Mattoussi, H.  2007. Enhancing the Stability and Biological Functionalities of 
Quantum Dots via Compact Multifunctional Ligands, J. Am. Chem. Soc., 
129:13987-13996, Jul. 
295.  Fischer, S.J., Benson, L.M., Fauq, A., Naylor, S. and Windebank, A.J.  2008. 
Cisplatin and Dimethyl Sulfoxide React to Form an Adducted Compound with 
Reduced Cytotoxicity and Neurotoxicity, NeuroToxicology, 29:444-452, Mar. 
296.  Tamura, Y., Watanabe, F., Nakatani, T., Yasui, K., Fuji, M., Komurasaki, T., 
Tsuzuki, H., Maekawa, R., Yoshioka, T., Kawada, K., Sugita, K. and Ohtani, M.  
1998. Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-
9 and MMP-2): N-Sulfonylamino Acid Derivatives, J. Med. Chem., 41:640-649, 
Nov. 
297.  Stratagene. ArcticExpress™ Competent Cells and ArcticExpress™ (DE3) 
Competent Cells Instruction Manual, Rev. 050061. 
298.  Salisbury, C.M., Maly, D.J. and Ellman, J.A.  2002. Peptide Microarrays for 
the Determination of Protease Substrate Specificity, J. Am. Chem. Soc., 124:14868-
14870, Jun. 
299.  Keller, T.A., Duschi, C., Kroger, D., Sevin-Landais, A.F. and Vogel, H.  1995. 
Reversible Oriented Immobilization of Histidine-Tagged Proteins on Gold Surfaces 
Using a Chelator Thioalkane, Supremolecular Science, 2:155-160, Apr. 
300.  Lee, J.K., Kim, Y.G., Chi, Y.S., Yun, W.S. and Choi, I.S.  2004. Grafting 
Nitrilotriacetic Groups onto Carboxylic Acid-Terminated Self-Assembled 
Monolayers on Gold Surfaces for Immobilization of Histidine-Tagged Proteins, J. 
Phys. Chem., 108:7665-7673, Mar. 
 
 
 
 
246 
 
301.  Cao, C. and Sim, S.J.  2007. Signal Enhancement of Surface Plasmon 
Resonance Immunoassay Using Enzyme Precipitation-Functionalized Gold 
Nanoparticles: A Femto Molar Level Measurement of Anti-Glutamic Acid 
Decarboxylase Antibody, Biosensors and Bioelectronics, 22:1874-1880, Aug. 
302.  Ojea-Jimenez, I. and Puntes, V.  2009. Instability of Cationic Gold 
Nanoparticle Bioconjugates: The Role of Citrate Ions, J. Am. Chem. Soc., 
131:13320-13327, Aug. 
303.  Ueda, E.K.M., Gout, P.W. and Morganti, L.  2003. Current and Prospective 
Applications of Metal Ion-Protein Binding, Journal of Chromatography A, 988:1-23, 
Dec. 
304.  Gaberc-Porekar, V. and Menart, V.  2001. Perspectives of Immobilized-Metal 
Affinity Chromatography, J. Biochem. Biophy. Methods, 49:335-360. 
305.  Chaga, G.S.  2001. Twenty-five Years of Immobilized Metal Ion Affinity 
Chromatography: Past, Present and Future, J. Biochem. Biophys. Methods, 49:313-
334. 
306.  Armstrong, R.N.  1991. Glutathione-S-Transferase: Reaction Mechanism, 
Structure, and Function, Chem. Res. Toxicol., 4(2):131-140, Apr. 
307.  Murphy, G., Stanton, H., Cowell, S., Butler, G., Knauper, V., Atkinson, S. and 
Gavrilovic, J.  1999. Mechanisms for Pro-Matrix Metalloproteinase Activation, 
APMIS, 107:38-44. 
308.  Olson, M.W., Gervasi, D.C., Mobashery, S. and Fridman, R.  1997. Kinetic 
Analysis of the Binding of Human Matrix Metalloproteinase-2 and -9 to Tissue 
Inhibitor of Metalloproteinase (TIMP)-1 and TIMP-2, The Journal of Biological 
Chemistry, 272(47):29975-29983, Sept. 
309.  Rogers, A. and Gibon, Y.  2009. Chapter 4: Enzyme Kinetics - Theory and 
Practise, Plant Metabolic Networks (Springer). 
310.  Eisenthal, R. and Danson, M.  2002. Enzyme Assays: A Practical Approach, 
2
nd
 Ed. Oxford: Oxford University Press, 283p. 
311.  Li, Q., Withoff, S. and Verma, I.M.  2005. Inflammation-Associated Cancer: 
NF-κB is the Lynchpin, TRENDS in Immunology, 26(6):318-325, Jun. 
312.  Iwakoshi, N.N., Lee, A.H., Vallabhajosyula, P., Otipoby, K.L., Rajewsky, K. 
and Glimcher, L.H.  2003. Plasma Cell Differentiation and the Unfolded Protein 
Response Intersect at the Transcription Factor XBP-1, Nature Immunology, 
4(4):321-329, Mar. 
 
 
 
 
247 
 
313.  Yang, J.M., Xu, Z., Wu, H., Zhu, H., Wu, X. and Hait, W.N.  2003. 
Overexpression of Extracellular Matrix Metalloproteinase Inducer in Multidrug 
Resistant Cancer Cells, Mol. Can. Res., 1:420-427, Apr. 
314.  Davidson, B., Goldberg. I., Gotlieb, W.H., Kopolovic, J., Risberg, B., Ben-
Baruch, G. and Reich, R.  2003. Coordinated Expression of Integrin Subunits, 
Matrix Metalloproteinases (MMP), Angiogenic Genes and ETS Transcription 
Factors in Advanced Stage Ovarian Carcinoma: A Possible Activation Pathway?, 
Cancer and Metastasis Reviews, 22:102-115. 
315.  Visse, R. and Nagase, H.  2003. Matrix Metalloproteinases and Tissue 
Inhibitors of Metalloproteinases: Structure, Function and Biochemistry, Circ. Res., 
92:827-839, Mar. 
316.  Phan, T.B., Nolte, C., Kobayashi, S., Oflal, A.R. and Mayr, H.  2009. Can One 
Predict Changes from SN1 to SN2 Mechanisms?, J. Am. Chem. Soc., 131:11392-
11401, Apr. 
317.  Yemul, O. and Imae, T.  2008. Synthesis and Characterization of 
Polyethyleneimine Dendrimers, Colloid. Polym. Sci., 286:747-752, Jan. 
318.  Badia, A.B., Cuccia, L., Demers, L., Morin, F. and Lennox, R.F.  1997. 
Structure and Dynamics in Alkanethiolate Monolayers Self-Assembled on Gold 
Nanoparticles: A DSC, FT-IR, and Deuterium NMR Study, J. Am. Chem. Soc., 
119:2682-2692, Oct. 
319.  Shibu, E.S., Muhammed, M.A.H., Tsukuda, T. and Pradeep, T.  2008. Ligand 
Exchange of Au25SG18 Leading to Functionalized Gold Clusters: Spectroscopy, 
Kinetics and Luminescence, J. Phys. Chem., 112:12168-12176, Apr. 
320.  Templeton, A.C., Chen, S., Gross, S.M. and Murray, R.W.  1999. Water-
soluble, Isolable Gold Clusters Protected by Tiopronin and Coenzyme-A 
Monolayers, Langmuir, 15:66-76, Nov. 
321.  Du, S., Kendall, K., Toloueinia, P., Mehrabadi, Y., Gupta, G. and Newton, J.  
2012. Aggregation and Adhesion of Gold Nanoparticles in Phosphate Buffered 
Saline, J. Nanopart. Res., 14:758, Jan. 
322.  Zhao, W., Lin, J. and Hsing, I.M.  2009. Rapid Synthesis of DNA-
Functionalized Gold Nanoparticles in Salt Solution Using Mononucleotide-Mediated 
Conjugation, Bioconjugate Chem., 20(6):1218-1222, Apr. 
 
 
 
 
248 
 
323.  Goon, I.Y., Lai, L.M.H., Lim, M., Munroe, P., Gooding, J.J. and Amal, R.  
2009. Fabrication and Dispersion of Gold-Shell-Protected Magnetite Nanoparticles: 
Systematic Control using Polyethyleneimine, Chem. Mater., 21:673-681, Dec. 
324.  Lee, J.Y., Choi, Y.S., Suh, J.S., Kwon, Y.M., Yang, V.C., Lee, S.J., Chung, 
C.P. and Park, Y.J.  2011. Cell-Penetrating Chitoson/Doxorubicin/TAT Conjugates 
for Efficient Cancer Therapy, Int. J. Cancer, 128:2470-2480. 
325.  King, H.D., Yurgaitis, D., Willner, D., Firestone, R.A., Yang, M.B., Lasch, 
S.J., Hellstrom, K.E. and Trail, P.A.  1999. Monoclonal Antibody Conjugates of 
Doxorubicin Prepared with Branched Linkers: A Novel Method for Increasing the 
Potency of Doxorubicin Immunoconjugates, Bioconjugate Chem., 10:279-288, Dec. 
326.  Tomlinson, R., Heller, J., Brocchini, S. and Duncan, R.  2003. Polyacetal-
Doxorubicin Conjugates Designed for pH-Dependent Degradation, Bioconjugate 
Chem., 14:1096-1106, Aug. 
327.  Torchilin, V.P.  2006. Multifunctional Nanocarriers, Advancecd Drug 
Delivery Reviews, 58:1532-1555, Sept. 
328.  Breunig, M., Bauer, S. and Goepferich, A.  2007. Polymers and Nanoparticles: 
Intelligent Tools for Intracellular Targeting?, European Journal of Pharmaceutics 
and Biopharmaceuticals, 68:112-128, Jun. 
329.  Chen Y., Palmer R.E. and Wilcoxon J.P.  2006. Sintering of Passivated Gold 
Nanoparticles under the Electron Beam, Langmuir, 22, 2851 – 2855. 
330.  Mafuné F., Kohno J., Takeda Y., and Kondow T.  2002. Nanoscale Soldering 
of Metal Nanoparticles for Construction of Higher-Order Structures, J. Am. Chem. 
Soc., 125, 1686 - 1687. 
331.  Brewer, S.H., Glomm, W.R., Johnson, M.C., Knag, M.K. and Franzen, S.  
2005. Probing BSA Binding to Citrate-Coated Gold Nanoparticles and Surfaces, 
Langmuir, 21:9303-9307, Jun. 
332.  Sykora, D., Kasicka, V., Miksik, I., Rezanka, P., Zaruba, K., Matejka, P. and 
Kral, V.  2010. Application of Gold Nanoparticles in Separation Sciences, Journal of 
Separation Science, 33(3):372-387, Feb. 
333.  Cai, H.H., Wang, H., Wang, J., Wei, W., Yang, P.H. and Cai, J.  2011. Naked 
Eye Detection of Glutathione in Living Cells Using Rhodamine B-Functionalized 
Gold Nanoparticles Coupled with FRET, Dyes and Pigments, 92:778-782, Jun. 
 
 
 
 
249 
 
334.  Lim, I.S., Mott, D., Ip, W., Njoki, P.N., Pan, Y., Zhou, S. and Zhing, C.J.  
2008. Interparticle Interactions in Glutathione Mediated Assembly of Gold 
Nanoparticles, Langmuir, 24:8857-8863, May. 
335.  Sendray, J. and Rodkey, F.L.  1961. Apparent Dissociation Constant of Phenol 
Red as Determined by Spectrophotometry and by Visual Colorimetry, Clin. Chem., 
7(6):646-654. 
336.  Giljohann, D.A., Seferos, D.S., Daniel, W.L., Massich, M.D., Patel, P.C. and 
Mirkin, C.A.  2010. Gold Nanoparticles for Biology and Medicine, Angew. Chem. 
Int. Ed., 49:3280-3294, Apr.  
337.  Smith, A.M., Ruan, G., Rhyner, M.N. and Nie, S.  2006. Engineering 
Luminescent Quantum Dots for In Vivo Molecular and Cellular Imaging, Annals of 
Biomedical Engineering, 34(1):3-14, Feb. 
338.  Schneiderman, D., Kim, J.M., Senterman, M. and Tsang, B.K.  1999. 
Sustained Supression of Fas Ligand Expression in Cisplatin-Resistant Human 
Ovarian Surface Epithelial Cancer Cells, Apoptosis, 4(4):271-282. 
339.  Bertazza, L. and Mocellin, S.  2008. Tumor Necrosis Factor (TNF) Biology 
and Cell Death, Frontiers in Bioscience, 13:2736-2743, Jan. 
340.  Aggarwal, S., He, T., Fitz-Hugh, W., Rosenthal, K., Field, B., Heidbrink, J., 
Mesmer, D., Ruben, S.M. and Moore, P.A.  2009. Immune Modulator CD70 as a 
Potential Cisplatin Resistance Predictive Marker in Ovarian Cancer, Gynecologic 
Oncology, 115:430-437, Oct. 
341.  Abu-Hadid, M., Wilkes, J.D., Elakawi, Z., Pendyala, L. and Perez, R.P.  1997. 
Relationship between Heat Shock Protein 60 (HSP60) mRNA Expression and 
Resistance to Platinum Analogues in Human Ovarian and Bladder Carcinoma Cell 
Lines, Cancer Letters, 119:63-70, Apr. 
342.  Shen, D.W., Akiyama, S.I., Schoenlein, P., Pastan, I. and Gottesman, M.M.  
1995. Characterization of High-Level Cisplatin-Resistant Cell Lines Established 
from a Human Hepatoma Cell Line and Human Adenocarcinoma Cells: Cross-
Resistance and Protein Changes, British Journal of Cancer, 71:676-683. 
343.  Ciocca, D.R. and Calderwood, S.K.  2005. Heat Shock Proteins in Cancer: 
Diagnostic, Prognostic, Predictive, and Treatment Implications, Cell Stress & 
Chaperones, 10(2):86-103. 
344.  Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B. and Brown, R.  2000. 
Reversal of Drug Resistance in Human Tumor Xenografts by 2'-Deoxy-5-
 
 
 
 
250 
 
azacytidine-Induced Demethylation of the hMLH1 Gene Promotor, Cancer Res., 
60:6039-6044, Nov. 
345.  Blasi, M.F., Ventura, I., Aquilina, G., Degan, P., Bertario, L., Bassi, C., 
Radice, P. and Bignami, M.  2006. A Human Cell-Based Assay to Evaluate the 
Effects of Alterations in the MLH1 Mismatch Repair Gene, Cancer Res., 
66(18):9036-9044, Sept. 
346.  Ghosh, J.C., Dohi, T., Kang, B.H. and Altieri, D.C.  2008. Hsp60 Regulation 
of Tumor Cell Apoptosis, The Journal of Biological Chemistry, 283(8):5188-5194, 
Feb. 
347.  Cicchillitti, L., Michele, M.D., Urbani, A., Ferlini, C., Donati, M.B., Scambia, 
G. and Rotillo, D.  2008. Comparative Proteomic Analysis of Paclitaxel Sensitive 
A2780 Epithelial Ovarian Cancer Cell Line and its Resistant Counterpart A2780TC1 
by 2D-DIGE: The Role of ERp57, Journal of Proteome Research, 8:1902-1912, 
Oct. 
348.  Ding, X., Mohd, A.B., Huang, Z., Baba, T., Bernardini, M.Q., Lyerly, H.K., 
Berchuck, A., Murphy, S.K., Buermeyer, A.B. and Devi, G.R.  2009. MLH1 
Expression Sensitises Ovarian Cancer Cells to Cell Death Mediated by XIAP 
Inhibition, British Journal of Cancer, 101:269-277, Jun. 
349.  Matei, D.E. and Nephew, K.P.  2010. Epigenetic Therapies for 
Chemoresensitization of Epithelial Ovarian Cancer, Gynecologic Oncology, 
116:195-201, Oct. 
350.  Caamano, J. and Hunter, C.A.  2002. NF-κB Family of Transcription Factors: 
Central Regulators of Innate and Adaptive Immune Functions, Clin. Microbiol. Rev., 
15(3):414-429, Jul. 
351.  Asadollahi, R., Hyde, C.A.C. and Zhong, X.Y.  2010. Epigenetics of Ovarian 
Cancer: From the Lab to the Clinic, Gynecologic Oncology, 118:81-87, Apr. 
352.  Kroll, A., Pillukat, M.H., Hahn, D. and Schnekenburger, J.  2009. Current In 
Vitro Methods in Nanoparticle Risk Assessment: Limitations and Challenges, 
European Journal of Pharmaceutics and Biopharmaceutics, 72:370-377, Aug. 
353.  Berridge, M.V. and Tan, A.S.  1998. Trans-Plasma Membrane Electron 
Transport: A Cellular Assay for NADH- and NADPH-oxidase Based on 
Extracellular, Superoxide-Mediated Reduction of the Sulfonated Tetrazolium Salt 
WST-1, Protoplasma, 205:74-82, Aug. 
 
 
 
 
251 
 
354.  Lewinski, N., Colvin, V. and Drezek, R.  2007. Cytotoxicity of Nanoparticles, 
Small, 4(1):26-49, May. 
355.  Sethuraman, V.A., Na, K. and Bae, Y.H.  2006. pH-Responsive 
Sulfonamide/PEI System for Tumor Specific Gene Delivery: An In Vitro Study, 
Biomacromolecules, 7:64-70, Oct. 
356.  Kabaniv, A.V. 2006. Polymer Genomics: An Insight into Pharmacology and 
Toxicology of Nanomedicines, Advanced Drug Delivery Reviews, 58:1597-1621, 
Oct. 
357.  Nimesh, S., Goyal, A., Pawar, V., Jayaraman, S., Kumar, P., Chandra, R., 
Singh, Y. and Gupta, K.C.  2006. Polyethyleneimine Nanoparticles as Efficient 
Transfecting Agents for Mammalian Cells, Journal of Controlled Release, 110:457-
468, Oct. 
358.  Thomas, M. and Klibanov, A.M.  2002. Conjugation to Gold Nanoparticles 
Enhances Polyethyleneimine’s Transfer of Plasmid DNA into Mammalian Cells, 
Proc. Natl. Acad. Sci., 100(16):9138-9143, Aug.  
359.  Alkilany, A.M. and Murphy, C.J.  2010. Toxicity and Cellular Uptake of Gold 
Nanoparticles: What we have learned so far?, J. Nanopart. Res., 12:2313-2333, Nov. 
360.  Sonavane, G., Tomoda, K. and Makino, K.  2008. Biodistribution of Colloidal 
Gold Nanoparticles after Intravenous Administration: Effect of Particle Size, 
Colloids and Surfaces B: Biointerfaces, 66:274-280, Jul. 
361.  Mailander, V. and Landfester, K.  2009. Interaction of Nanoparticles with 
Cells, Biomacromolecules, 10:2379-2400, May. 
362.  Rieznichenko, L.S., Dybkova, S.M., Gruzina, T.G., Ulberg, Z.R., Todor, I.N., 
Lukyanova, N.Y., Shpyleva, S.I. and Chekhun, V.F.  2012. Gold Nanoparticles 
Synthesis and Biological Activity Estimation In Vitro and In Vivo, Exp. Oncol., 
34(1):25-28, Jan. 
363.  Wani, M.Y., Hashim, M.A., Nabi, F., Malik, M.A.  2011. Nanotoxicity: 
Dimensional and Morphological Concerns, Advances in Physical Chemistry, 
2011(450912):15p. 
364.  Jain, P.K., El-Sayed, I. and El-Sayed, M.A.  2007. Gold Nanoparticles Target 
Cancer, NanoToday, 2(1):18-29, Feb. 
365.  Jia, C.J. and Schuth, F.  2011. Colloidal Metal Nanoparticles as a Component 
of Designed Catalyst, Phys. Chem. Chem. Phys., 13:2457-2487, Jan. 
 
 
 
 
252 
 
366.  Narayanan, R. and El-Sayed, M.A.  2005. Catalysis with transition Metal 
Nanoparticles in Colloidal Solution: Nanoparticle Shape Dependence and Stability, 
J. Phys. Chem. B., 109:12663-12676, Apr. 
367.  Astruc, D. 2008. Chapter 1: Transition-Metal Nanoparticles in Catalysis: From 
Historical Background to the State-of-the-Art, Nanoparticles and Catalysis (Wiley), 
1-48. 
368.  Grabar, K.C., Brown, K.R., Keating, C.D., Stranick, S.J., Tang, S.L. and 
Natan, M.J.  1997. Nanoscale Characterization of Gold Colloid Monolayers: A 
Comparison of Four Techniques, Anal. Chem., 69:471-477, Feb. 
369.  Weisbecker, C.S., Merrit, M.V. and Whitesides, G.M.  1996. Molecular Self-
Assembly of Aliphatic Thiols on Gold Colloids, Langmuir, 12:3763-3772, Sept. 
370.  Mirza, A.Z. and Shamshad, H.  2011. Preparation and Characterization of 
Doxorubicin Functionalized Gold Nanoparticles, European Journal of Medicinal 
Chemistry, 46:1857-1860, Feb.  
371.  Shon, Y.S., Gross, S.M., Dawson, B., Porter, M. and Murray, R.W.  2000. 
Alkanethiolate-Protected Gold Clusters Generated from Sodium S-
Dodecylthiosulfate (Bunte Salts), Langmuir, 16:6555-6561, May. 
372.  Gu, Y.J., Cheng, J., Man, C.W.Y., Wong, W.T. and Cheng, S.H.  2011. Gold-
Doxorubicin Nanoconjugates for Overcoming Multidrug Resistance, Nanomedicine, 
8:204-211, Jun. 
373.  Wang, F., Wang, Y.C., Dou, S., Xiong, M.H., Sun, T.M. and Wang, J.  2011. 
Doxorubicin-Tethered Responsive Gold Nanoparticles Facilitate Intracellular Drug 
Delivery for Overcoming Multidrug Resistance in Cancer Cells, ACSNano, 
5(5):3679-3692, Apr. 
374.  Beijnen, J.H., Van der Houwen, O.A.G.J., Voskuilen, M.C.H. and Underberg, 
W.J.M.  1986. Aspects of the Degradation Kinetics of Doxorubicin in Aqueous 
Solution, International Journal of Pharmaceutics, 86:90215-2. 
375.  Kim, D., Lee, E.S., Park, K., Kwon, I.C. and Bae, Y.H.  2008. Doxorubicin 
Loaded pH-sensitive Micelle: Antitumoral Efficacy against A2780/DOX Tumor, 
Pharm. Res., 25(9):2074-2082, Dec. 
376.  Brenner, D.E., Wiernik, P.H., Wesley, M. and Bachur, N.R.  1984. Acute 
Doxorubicin Toxicity: Relationship to Pretreatment Liver Function, Response, and 
Pharmacokinetics in Patients with Acute Nonlymphocytic Leukemia, Cancer, 
53:1042-1048. 
 
 
 
 
253 
 
377.  Biocolor Life Science Assays Internet Manual. Downloaded 11-01-2012 
(www.biocolor.co.uk). 
378.  Meyer, M., Essack, M., Kanyanda, S. and Rees, J.G.  2008. A Low-cost Flow 
Cytometric Assay for the Detection and Quantification of Apoptosis using an 
Anionic Halogenated Fluorescein Dye, BioTechniques, 45:317-320, Sept. 
379.  Sjostrom, J. and Makela, T.  2006. Chapter 1: Apoptosis and the Cell Cycle in 
Human Disease, Encyclopaedia of Life Sciences, Wiley, 1-6. 
380.  D’Amelio, M., Tino, E. and Cecconi, F.  2008. The Apoptosome: Emerging 
Insights and New Potential Targets for Drug Design, Pharmaceutical Research, 
25(4):740-751, Aug. 
381.  Liu, J.R., Opipari, A.W., Tan, L., Jiang, Y., Zhang, Y., Tang, H. and Nunez, 
G.  2002. Dysfunctional Apoptosome Activation in Ovarian Cancer: Implications for 
Chemoresistance, Cancer Res., 62:924-931, Feb. 
382.  Lowe, S.W. and Lin, A.W.  2000. Apoptosis in Cancer, Carcinogenesis, 
21(3):485-495. 
383.  Ullrich, E., Bonmort, M., Mignot, G., Kroemer, G. and Zitvogel, L.  2008. 
Tumor Stress, Cell Death and the Ensuing Immune Response, Cell Death and 
Differentiation, 15:21-28, Nov. 
384.  Zhou, J., Zhang, S., Ong, C.N. and Shen, H.M.  2006. Critical Role of Pro-
apoptotic Bcl-2 Family Members in Andrographolide-induced Apoptosis in Human 
Cancer Cells, Biochemical Pharmacology, 72:132-144, Apr. 
385.  Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S., Konorev, E. and 
Kotamraju, S.  2002. Doxorubicin-induced Apoptosis: Implications in 
Cardiotoxicity, Mol. Cell. Biochem., 234:119-124. 
386.  Hancock, J.T., Desikan, R. and Neill, S.J.  2001. Role of Reactive Oxygen 
Species in Cell Signalling Pathways, Biochemical Society Transactions, 29(2):345-
350, Sept. 
387.  Kim, B.Y.S., Rutka, J.T., and Chan, W.C.W.  2010. Nanomedicine, N. Engl. J. 
Med., 363:2434-2443, Dec. 
388.  Mushonga, P., Onani, M.O., Madiehe, A.M. and Meyer, M.  2013. One-pot 
Synthesis and Characterization of InP/ZnSe Semiconductor Nanocrystals, Matt. 
Lett., 95:37-39, Jan. 
 
 
 
 
 
 
254 
 
APPENDIX 
 
Table A1: p-Values calculated for the Lineweaver-Burke obtained enzyme kinetic 
parameters (Section 3.3.2, Table 3.8)                                      
                                 
            *p-Values calculated with student’s two-tailed T-test T-test.  
              p < 0.05 indicates statistical signifigance. 
 
Table A2: p-Values calculated for the UV-Vis Spectra of AuNPs synthesized with 
different additon tempos (Section 4.3.2, Figure 4.7) 
                                      
                                     *p-Values calculated with student’s two-tailed T-test T-test.  
                                       p < 0.05 indicated statistical signifigance 
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Table A3: p-Values calculated for the EDX analysis of AuNPs synthesized with different 
additon tempos (Section 4.3.2, Table 4.1) as well as different amounts of NaBH4 (Section 
4.3.3, Table 4.4) 
 
*p-Values calculated with student’s two-tailed T-test T-test. p < 0.05 indicated statistical signifigance. 
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Table A4: p-Values calculated determined for different % aurate salt used during 
AuNP synthesis (Sections 4.3.2 and 4.3.3, Table 4.2 and Table 4.5) 
                                       
                                *p-Values calculated with student’s two-tailed T-test T-test.  
       p < 0.05 indicated statistical signifigance. 
 
 
Table A5: p-Values calculated for the time-based DOX release from AuNP-PEI A 
surface (Section 4.4.4, Figure 4.30) 
                                                              
   *p-Values calculated with student’s two-tailed T-test T-test.  
     p < 0.05 indicated statistical signifigance. 
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Table A6: p-Values calculated for A2780/A2780cis response to PEI and DOX dose-
response assays (Figure 5.4, Section 5.2.2.1) 
                         
                             *p-Values calculated with student’s two-tailed T-test. p < 0.05 indicated   
    statistical signifigance. 
 
Table A7: p-Values calculated for A2780/A2780cis dose-response to differentially 
synthesized AuNPs (Figure 5.5, Section 5.2.2.2) 
                      
            *p-Values calculated with ANOVA (single factor). p < 0.05 indicated   
                            statistical signifigance. 
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Table A8: p-Values calculated for A2780/A2780cis dose-response DOX loaded AuNPs 
(Figure 5.6, Section 5.2.3.2) 
                          
                 *p-Values calculated with ANOVA (single factor). p < 0.05 indicated   
                                statistical signifigance. 
 
Table A9: p-Values calculated for A2780cis apoptosis in response to various stimulants 
(Figure 5.8, Section 5.2.3.3) 
                                                 
                                               *p-Values calculated with ANOVA (single factor).  
           p < 0.05 indicated statistical signifigance. 
 
Table A10: p-Values calculated for A2780cis GSH/GSSG deplation in response to 
various stimulants (Figure 5.12, Section 5.2.3.5) 
                                            
        *p-Values calculated with ANOVA (single factor). 
                        p < 0.05 indicated statistical signifigance. 
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Table A11: Sequence alignment of wild type MMP2 (Genbank Accession: 
NM_004530.4) with the utilized cDNA seq (BamHI is highlighted)  
                                  Score Expect Identities Gaps Strand 
                                       1595 bits(1768) 0.0 1432/1797(80%) 0/1797(0%) Plus/Plus 
Query* 1     ATGGAGgcgctgatggcgcgcggcgcgctgaccggcccgctgcgcgcgctgtgcctgctg  60 
             ||||||||||| ||||| || |||||||| || || || ||| | ||||| || || ||| 
Sbjct† 312   ATGGAGGCGCTAATGGCCCGGGGCGCGCTCACGGGTCCCCTGAGGGCGCTCTGTCTCCTG  371 
 
Query  61    ggctgcctgctgAGCCATGCGGCGGCGGCGCCGAGCCCGATTATTAAATTTCCGGGCGAT  120 
             ||||||||||||||||| || || || ||||||   || || || || || || |||||| 
Sbjct  372   GGCTGCCTGCTGAGCCACGCCGCCGCCGCGCCGTCGCCCATCATCAAGTTCCCCGGCGAT  431 
 
Query  121   GTGGCGCCGAAAACCGATAAAGAACTGGCGGTGCAGTATCTGAACACCTTTTATGGCTGC  180 
             || || || ||||| || |||||  |||| ||||| || ||||||||||| ||||||||| 
Sbjct  432   GTCGCCCCCAAAACGGACAAAGAGTTGGCAGTGCAATACCTGAACACCTTCTATGGCTGC  491 
 
Query  181   CCGAAAGAAAGCTGCAACCTGTTTGTGCTGAAAGATACCCTGaaaaaaaTGCAGAAACTG  240 
             || || || ||||||||||||||||||||||| || || || || || ||||||||  |  
Sbjct  492   CCCAAGGAGAGCTGCAACCTGTTTGTGCTGAAGGACACACTAAAGAAGATGCAGAAGTTC  551 
 
Query  241   TTTGGCCTGCCGCAGACCGGCGATCTGGATCAGAACACCATTGAAACCATGCGCAAACCG  300 
             ||||| ||||| ||||| || ||||| || ||||| ||||| || |||||||| || ||  
Sbjct  552   TTTGGACTGCCCCAGACAGGTGATCTTGACCAGAATACCATCGAGACCATGCGGAAGCCA  611 
 
Query  301   CGCTGCGGCAACCCGGATGTGGCGAACTATAACTTTTTTCCGCGCAAACCGAAATGGGAT  360 
             |||||||||||||| |||||||| ||||| ||||| || || ||||| || || |||||  
Sbjct  612   CGCTGCGGCAACCCAGATGTGGCCAACTACAACTTCTTCCCTCGCAAGCCCAAGTGGGAC  671 
 
Query  361   AAAAACCAGATTACCTATCGCATTATTGGCTATACCCCGGATCTGGATCCGGAAACCGTG  420 
             || |||||||| || ||  | || |||||||| || || |||||||| || || || ||| 
Sbjct  672   AAGAACCAGATCACATACAGGATCATTGGCTACACACCTGATCTGGACCCAGAGACAGTG  731 
 
Query  421   GATGATGCGTTTGCGCGCGCGTTTCAGGTGTGGAGCGATGTGACCCCGCTGCGCTTTAGC  480 
             |||||||| ||||| || || || || || ||||||||||||||||| ||||| |||    
Sbjct  732   GATGATGCCTTTGCTCGTGCCTTCCAAGTCTGGAGCGATGTGACCCCACTGCGGTTTTCT  791 
 
Query  481   CGCATTCATGATGGCGAAGCGGATATTATGATTAACTTTGGCCGCTGGGAACATGGCGAT  540 
             || || |||||||| || || || || ||||| ||||||||||||||||| ||||||||| 
Sbjct  792   CGAATCCATGATGGAGAGGCAGACATCATGATCAACTTTGGCCGCTGGGAGCATGGCGAT  851 
 
Query  541   GGCTATCCGTTTGATGGCAAAGATGGCCTGCTGGCGCATGCGTTTGCGCCGGGCACCGGC  600 
             || || || ||||| || || || || || ||||| ||||| || || || ||||| ||  
Sbjct  852   GGATACCCCTTTGACGGTAAGGACGGACTCCTGGCTCATGCCTTCGCCCCAGGCACTGGT  911 
 
Query  601   GTGGGCGGCGATAGCCATTTTGATGATGATGAACTGTGGACCCTGGGCGAAGGCCAGGTG  660 
             || || || ||   |||||||||||| ||||| || |||||| |||| |||||||| ||| 
Sbjct  912   GTTGGGGGAGACTCCCATTTTGATGACGATGAGCTATGGACCTTGGGAGAAGGCCAAGTG  971 
 
Query  661   GTGCGCGTGAAATATGGCAACGCGGATGGCGAATATTGCAAATTTCCGTTTCTGTTTAAC  720 
             || || ||||| ||||| ||||| ||||| || || ||||| || || ||  |||| ||  
Sbjct  972   GTCCGTGTGAAGTATGGGAACGCCGATGGGGAGTACTGCAAGTTCCCCTTCTTGTTCAAT  1031 
 
Query  721   GGCAAAGAATATAACAGCTGCACCGATACCGGCCGCAGCGATGGCTTTCTGTGGTGCAGC  780 
             ||||| || || ||||||||||| ||||||||||||||||||||||| || ||||||  | 
Sbjct  1032  GGCAAGGAGTACAACAGCTGCACTGATACCGGCCGCAGCGATGGCTTCCTCTGGTGCTCC  1091 
 
Query  781   ACCACCTATAACTTTGAAAAAGATGGCAAATATGGCTTTTGCCCGCATGAAGCGCTGTTT  840 
             |||||||| |||||||| || |||||||| || ||||| || || |||||||| |||||  
Sbjct  1092  ACCACCTACAACTTTGAGAAGGATGGCAAGTACGGCTTCTGTCCCCATGAAGCCCTGTTC  1151 
 
Query  841   ACCATGGGCGGCAACGCGGAAGGCCAGCCGTGCAAATTTCCGTTTCGCTTTCAGGGCACC  900 
             ||||||||||||||||| ||||| ||||| ||||| ||||| || ||||| ||||||||  
Sbjct  1152  ACCATGGGCGGCAACGCTGAAGGACAGCCCTGCAAGTTTCCATTCCGCTTCCAGGGCACA  1211 
 
Query  901   AGCTATGATAGCTGCACCACCGAAGGCCGCACCGATGGCTATCGCTGGTGCGGCACCACC  960 
               |||||| ||||||||||| || |||||||| |||||||| |||||||||||||||||  
Sbjct  1212  TCCTATGACAGCTGCACCACTGAGGGCCGCACGGATGGCTACCGCTGGTGCGGCACCACT  1271 
 
Query  961   GAAGATTATGATCGCGATAAAAAATATGGCTTTTGCCCGGAAACCGCGATGAGCACCGTG  1020 
             || || || || ||||| || || |||||||| ||||| || ||||| |||  ||| ||  
Sbjct  1272  GAGGACTACGACCGCGACAAGAAGTATGGCTTCTGCCCTGAGACCGCCATGTCCACTGTT  1331 
 
Query  1021  GGCGGCAACAGCGAAGGCGCGCCGTGCGTGTTTCCGTTTACCTTTCTGGGCAACAAATAT  1080 
             || || |||   ||||| || || || || || || || || || ||||||||||||||| 
Sbjct  1332  GGTGGGAACTCAGAAGGTGCCCCCTGTGTCTTCCCCTTCACTTTCCTGGGCAACAAATAT  1391 
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Query  1081  GAAAGCTGCACCAGCGCGGGCCGCAGCGATGGCAAAATGTGGTGCGCGACCACCGCGAAC  1140 
             || |||||||||||||| |||||||| || || || |||||||| |||||||| || ||| 
Sbjct  1392  GAGAGCTGCACCAGCGCCGGCCGCAGTGACGGAAAGATGTGGTGTGCGACCACAGCCAAC  1451 
 
Query  1141  TATGATGATGATCGCAAATGGGGCTTTTGCCCGGATCAGGGCTATAGCCTGTTTCTGGTG  1200 
             || |||||||| ||||| |||||||| ||||| || || || || |||||||| || ||| 
Sbjct  1452  TACGATGATGACCGCAAGTGGGGCTTCTGCCCTGACCAAGGGTACAGCCTGTTCCTCGTG  1511 
 
Query  1201  GCGGCGCATGAATTTGGCCATGCGATGGGCCTGGAACATAGCCAGGATCCGGGCGCGCTG  1260 
             || || || || |||||||| || ||||| ||||| ||   ||| || || || || ||| 
Sbjct  1512  GCAGCCCACGAGTTTGGCCACGCCATGGGGCTGGAGCACTCCCAAGACCCTGGGGCCCTG  1571 
 
Query  1261  ATGGCGCCGATTTATACCTATACCAAAAACTTTCGCCTGAGCCAGGATGATATTAAAGGC  1320 
             ||||| || ||||| ||||| ||||| ||||| || |||  ||||||||| || || ||| 
Sbjct  1572  ATGGCACCCATTTACACCTACACCAAGAACTTCCGTCTGTCCCAGGATGACATCAAGGGC  1631 
 
Query  1321  ATTCAGGAACTGTATGGCGCGAGCCCGGATATTGATCTGGGCACCGGCCCGACCCCGACC  1380 
             |||||||| || ||||| ||    || || ||||| || ||||||||||| ||||| ||  
Sbjct  1632  ATTCAGGAGCTCTATGGGGCCTCTCCTGACATTGACCTTGGCACCGGCCCCACCCCCACG  1691 
 
Query  1381  CTGGGCCCGGTGACCCCGGAAATTTGCAAACAGGATATTGTGTTTGATGGCATTGCGCAG  1440 
             |||||||| || || || || || ||||||||||| ||||| ||||||||||| || ||| 
Sbjct  1692  CTGGGCCCTGTCACTCCTGAGATCTGCAAACAGGACATTGTATTTGATGGCATCGCTCAG  1751 
 
Query  1441  ATTCGCGGCGAAAtttttttttttAAAGATCGCTTTATTTGGCGCACCGTGACCCCGCGC  1500 
             || || || || || || || || || || || || |||||||| || ||||| || ||  
Sbjct  1752  ATCCGTGGTGAGATCTTCTTCTTCAAGGACCGGTTCATTTGGCGGACTGTGACGCCACGT  1811 
 
Query  1501  GATAAACCGATGGGCCCGCTGCTGGTGGCGACCTTTTGGCCGGAACTGCCGGAAAAAATT  1560 
             || || || ||||| || ||||||||||| || || ||||| || || |||||||| ||| 
Sbjct  1812  GACAAGCCCATGGGGCCCCTGCTGGTGGCCACATTCTGGCCTGAGCTCCCGGAAAAGATT  1871 
 
Query  1561  GATGCGGTGTATGAAGCGCCGCAGGAAGAAAAAGCGGTGTTTTTTGCGGGCAACGAATAT  1620 
             |||||||| || || || || ||||| || || || ||||| ||||| || || |||||  
Sbjct  1872  GATGCGGTATACGAGGCCCCACAGGAGGAGAAGGCTGTGTTCTTTGCAGGGAATGAATAC  1931 
 
Query  1621  TGGATTTATAGCGCGAGCACCCTGGAACGCGGCTATCCGAAACCGCTGACCAGCCTGGGC  1680 
             ||||| ||    || ||||||||||| || || || || || || ||||||||||||||  
Sbjct  1932  TGGATCTACTCAGCCAGCACCCTGGAGCGAGGGTACCCCAAGCCACTGACCAGCCTGGGA  1991 
 
Query  1681  CTGCCGCCGGATGTGCAGCGCGTGGATGCGGCGTTTAACTGGAGCaaaaacaaaaaaaCC  1740 
             ||||| || ||||| ||||| |||||||| || |||||||||||||||||||| || ||  
Sbjct  1992  CTGCCCCCTGATGTCCAGCGAGTGGATGCCGCCTTTAACTGGAGCAAAAACAAGAAGACA  2051 
 
Query  1741  TATACCTTTGCGGGCGATAAATTTTGGCGCTATAACGAAGTGaaaaaaaaaaTGGAT  1797 
             || | |||||| || || ||||| ||| | || || || ||||| || ||||||||| 
Sbjct  2052  TACATCTTTGCTGGAGACAAATTCTGGAGATACAATGAGGTGAAGAAGAAAATGGAT  2108 
* cDNA MMP2 
† Wild type MMP2 
 
 
 
 
 
